1 Curriculum Vitae October, 2016 PETER ANTHONY CROOKS, MSc, PhD, DSc (Manc), FRSC, FRPharmS, CSci, CChem Simmons Chair in Cancer Research Professor and Chairman Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W. Markham St., #522-3 Little Rock, AR 72205-7199 Email: [email protected]Tel. (501)686-6495 Fax (501)686-8136 Emeritus Professor Department of Pharmaceutical Sciences College of Pharmacy University of Kentucky Lexington, KY 40356 I. General Information Home Address: 22 Ridgefield Cove, Little Rock, AR 72223 Telephone: (859) 321-6001 Email [email protected]Licensure: Registered Pharmacist Year Certified: 1969 Name of Speciality Board: Royal Pharmaceutical Society of Great Britain State/Country: Great Britain II. Education 1958-1966 Sir Percy Jackson Grammar School, Doncaster, Yorkshire, United Kingdom 1966 University of Manchester, United Kingdom B.Sc. (Hons) First Class in Pharmacy 1967 University of Manchester, United Kingdom M.Sc. in Pharmacy 1970 University of Manchester, United Kingdom Ph.D. in Pharmacy 2011 University of Manchester, United Kingdom D.Sc., Faculty of Medical and Human Sciences
Transcript
1
Curriculum Vitae October, 2016
PETER ANTHONY CROOKS, MSc, PhD, DSc (Manc), FRSC, FRPharmS, CSci, CChem
Simmons Chair in Cancer Research Professor and Chairman
Department of Pharmaceutical Sciences College of Pharmacy
University of Arkansas for Medical Sciences 4301 W. Markham St., #522-3
Name of Speciality Board: Royal Pharmaceutical Society of Great Britain
State/Country: Great Britain
II. Education 1958-1966 Sir Percy Jackson Grammar School, Doncaster, Yorkshire, United Kingdom 1966 University of Manchester, United Kingdom
B.Sc. (Hons) First Class in Pharmacy 1967 University of Manchester, United Kingdom
M.Sc. in Pharmacy 1970 University of Manchester, United Kingdom Ph.D. in Pharmacy 2011 University of Manchester, United Kingdom D.Sc., Faculty of Medical and Human Sciences
2
III. Professional Experiences 1966-1967 Preregistration pharmacy training, University of Manchester, UK
IV. Academic Appointments
1966-1967 Laboratory Demonstrator (full time),
University of Manchester, United Kingdom
1968-1970 Assistant Lecturer in Pharmacy (full time),
University of Manchester, United Kingdom
1969-1972 Assistant Warden and Tutor-in-residence,
Moberly Tower, Graduate Student Hall of Residence,
University of Manchester Campus, United Kingdom
1970-1980 Lecturer in Pharmacy (with tenure) (full time),
Drug Form Design, (PHR 944), (3 credit course), University of Kentucky College of Pharmacy,
primary responsibility.
Topics in Pharmaceutical Sciences: Drug Targets and Actions, (PHR 760-008, 3 credit course),
University of Kentucky College of Pharmacy, secondary responsibility.
Special Topics in Pharmaceutical Sciences: Drug Design (FAGG 6213, 2 credit course, Fall
2004), School of Pharmacy, University of Puerto Rico San Juan, primary responsibility.
Topics in Pharmaceutical Sciences: Molecular Neurobiology of Abused Drugs, (PHR 760-008, 3
credit course, Fall semester), University of Kentucky College of Pharmacy, secondary
responsibility.
Biosynthesis of Natural Products (PHR 620, 3 credit course, Fall semester), University of
Kentucky College of Pharmacy, secondary responsibility.
Design of Molecules with Drug-like Properties (PHS 760-019, 3 credit course, Fall semester),
University of Kentucky College of Pharmacy, primary responsibility.
Good Regulatory Practices (PHSC 6043, 3 credit course, Spring semester), College of
Pharmacy, University of Arkansas for Medical Sciences, primary responsibility.
5
VI. Supervision of Graduate Students, Post-doctoral Fellows and Visiting Scientists
Major Professor for the following students who have graduated with the degree of Ph.D. or M.S.
Ph.D. Students Graduation Year
Howard E. Rosenberg (University of Cambridge, U.K.) 1975 Richard Szyndler (University of Manchester, U.K.) 1976 Trevor Deeks (University of Manchester, U.K.) 1979 Peter Burn (University of Manchester, U.K.) 1981 Eric Benghiat (University of London, U.K.) 1982 Mohamad S. Shaker (University of Jordan) 1983 Kenneth C. Cundy (University of Manchester, U.K.) 1984 Abdul Al-Ghani Hoodi (University of Bagdhad, Iraq) 1986 Samirah Hassan (University of Baghdad, Iraq) 1987 Chukwemeka G. Nwosu (University of Pennsylvania, U.S.A.) 1987 Riad Awad (University of Jordan) 1987 William F. Pool (University of California, San Diego, U.S.A.) 1987 C. Steven Godin (University of Massachusetts, U.S.A.) 1988 Hana Dannan (University of Damascus, Syria) 1988 Santosh C. Kottayil (University of Poona, India) 1993 Supinan Na-Phuket (University of the Phillipines) 1997 Jyothi Matharu (University of Bombay, India) 1997 Omar Ghosheh (University of Jordan) 2000 Michelle Howard-Sparks (University of Kentucky, U.S.A.) 2000 Aimee Bence (Houghton College, U.S.A.) 2001 Joshua R. Ring (Georgia Tech., U.S.A.) 2006 Joshua T. Ayers (Dartmouth College, U.S.A.) 2006 Aaron Haubner (University of Kentucky, U.S.A.) 2008 Harpreet K. Dhooper (Delhi University, New Delhi, India) 2010 Ujjwal Chakraborty (Delhi University, New Delhi, India) 2011 Joshua Eldridge (Kentucky State University, USA) 2013 John Culver (Western Kentucky University, USA) 2014 Nikhil Reddy Madadi (Eastern Kentucky University) 2014 Jai Shankar Yadlapalli (Andhra University, Andhra Pradesh, India) 2015 Zheng Chen (Brandeis University) 2015 M.S. Students Graduation Year
Trevor Deeks (University of Manchester, UK) 1976 Nabil N. Daoud (University of Baghdad, Iraq) 1981 Jeffrey Leigh (University of Manchester, UK) 1982 Amal N. A. Al-Taae (University of Baghdad, Iraq) 1983 Shyamala Chandrasekaran (University of Poona, India) 1993 Min Li (University of Beijing, People’s Republic of China) 1996 David Worthen (St. Johns University, U.S.A.) 1997 Jason Swango (Berea College, U.S.A.) 1997
6
SungHee Park (South Korea) 2011 Research Supervision of the following Post-doctoral Fellows, Visiting Scientists, and Scholars:
Postdoctoral Fellows Graduation Year
Dr. Francesco DeSimone (University of Naples, Italy) 1974,1975 Dr. Eliseo Ramundo (University of Naples, Italy) 1975 Dr. Antonio Dini (University of Naples, Italy) 1975 Dr. E. Huq (Bangladesh) 1976 - 1977 Dr. Michio Sato (Japan) 1982 - 1983 Dr. Abdulghani A. Houdi (University of Manchester, United Kingdom) 1985 - 1986 Dr. Terence Tita (University of Kentucky, U.S.A.) 1987 Dr. Chen-Yie Chien (U.S.A.) 1986 - 1988 Dr. Anita Rathore (India) 1989 - 1991 Dr. Balwinder Bhatti (India) 1990 - 1999 Dr. Alain Ravard (France) 1991 - 1995 Dr. Naranjan Deo (Clemmson University, U.S.A.) 1992 - 1995 Dr. Grazyna Cynkowska (Poland) 1993 - 2000 Dr. Tadeusz Cynkowski (Poland) 1993 - 2000 Dr. Latch Trifonov (Bulgaria) 1994 - 1995 Dr. Chongxi Yu (USA) 1995 - 1996 Dr. Muhammad Qureshi (Pakistan) 1996 - 1998 Dr. Haeil Park (South Korea) 1996 - 1998 Dr. Srishailkumar B. Hadimani (India) 1996 - 1999 Dr. Raj Puri (India) 1997 - 1998 Dr. Wenkui Li (Hong Kong) 1998 - 1999 Dr. Xu- Rui (People’s Republic of China) 1998 - 2001 Dr. Xiaochen Wei (University of Kentucky, U.S.A.) 1999 - 2005 Dr. Vijayakumar Sonar (India) 2000 - 2008 Dr. Marhaba Hojahmat (Japan) 2000 - 2002 Dr. Neelakantan Sundar (India) 2000 - 2009 Dr. Guangrong Zheng (People's Republic of China) 2000 - 2011 Dr. Jianjun Gao (Japan) 2000 - 2001 Dr. Xiao Ming Yu (People's Republic of China) 2002 - 2003 Dr. Jianhong Chen (People's Republic of China) 2002 - 2006 Dr. Abeer M. Al Ghananeem (University of Kentucky, U.S.A.) 2002 - 2007 Dr. Mohamed Hamad (University of Sudan) 2002 - 2006 Dr. Timothy Benson (University of Manchester, U.K.) 2003 Dr. Fang Zheng (People’s Republic of China) 2003 - 2008 Dr. Zhenfa Zhang (People’s Republic of China) 2004 - 2009 Dr. Ahmad Malkawi (University of Jordan) 2004 - 2011 Dr. Shama Nasim (University of Karachi) 2004 - 2010 Dr. Venkatraj Muthusamy (Bharathidasan University, India) 2005 - 2006 Dr. Zaineb Fadhel (University of Bhagdad, Iraq) 2005 - present Dr. Buchi N. Nalluri (Andhra University, India) 2005 - 2007 Dr. Ashish Vartak (University of Minnesota, U.S.A) 2006 - 2009 Dr. Thirupathi Reddy (National Institute of Technology, Warangal, India) 2006 - 2011 Dr. Vipin Purushothaman Nair (South Africa) 2006 - 2008 Dr. Syed Raziullah Hussaini (University of Oxford, UK) 2006 - 2007 Dr. Vijender R. Adelli (Indian Institute of Chemical Technology) 2007
7
Dr. Narismha R. Penthala (National Institute of Technology, Warangal, India) 2007 - present Dr. Purushothama Rao Ponugoti (Indian Institute of Chemical Technology, Hyderabad, India) 2009 - 2011 Dr. Derong Ding (Shanghai Institute of Materia Medica; CAS) 2010 - 2011 Dr. Raghotham Reddy Pinninti (National Institute of Technology, Warangal, India) 2010 - 2011 Dr. J. Venu Madhav (National Institute of Technology, Warangal, India) 2012 - present Dr. Shoban Babu Bommagani 2013 - present Dr. Shyamsunder R. Joolakanti 2013 – 2015 Dr. Punnamchandar Ramidi 2016 Dr. Soma Shekar Dachavaram 2016 - present Visiting Scientists Dr. Jerzy W. Krechniak (Poland) 1984 - 1985 Dr. Lyaquatali A. Damani (University of Manchester, U.K.) 1985 - 1986 Dr. Zhao-Xia Fang (People's Republic of China) 1988 - 1991 Dr. Talal A. Aburjai (University of Jordan) 2004 Dr. Bavntula Rajitha (National Institute of Technology, Warangal, India) 2008, 2012 Dr. Yucel Kadioglu (Ataturk University, Turkey) 2009 - 2010 Dr. Adejuwon Adewale Adeneye (Fulbright Scholar; University of Lagos, Africa) 2010 - 2011
Current Chairman or Member of the Following Ph.D. Dissertation Committees: (University of Kentucky, University of Arkansas for Medical Sciences, University of Colorado): Mike Clark (Member) Yibin Qiu (Member) Jay Shanker Yadlappalli (Chairman) Zheng Chen (Chairman) Kevin Howk (Chairman) Trey Curtis-Lowery (Chairman) Anqi Wan (Chairman) Gauri Lamture (Chairman) Maroof K. Zafar (Member) Daesong Jang (Member) Jessica Ponder (Member) Past Chairman or Member of the following Ph.D. dissertation committees (University of Kentucky): K. Abdul-Nabi Ali, Pharmaceutical Sciences (Member) Michael B. Maurin, Pharmaceutical Sciences (Member) William Rencher, Pharmaceutical Sciences (Member) George Garbolis, Pharmaceutical Sciences (Member) Kenneth Cundy, Pharmaceutical Sciences (Chairman) Prince Hinson, Pharmaceutical Sciences (Member) Rong Fong Shen, Pharmaceutical Sciences (Member) Lee Young Chau, Chemistry (Member) Carl Niehaus, Pharmaceutical Sciences (Member) David Wells, Pharmaceutical Sciences (Member)
8
Ralph Bouvette, Pharmaceutical Sciences (Member) Fatima Tawfig, Pharmaceutical Sciences (Member) Riad Awad, Pharmaceutical Sciences (Co-Chairman) Samirah Hassan, Pharmaceutical Sciences (Chairman) Chukwuemeka Nwosu, Toxicology (Chairman) William Pool, Toxicology (Chairman) Steven Godin, Pharmaceutical Sciences (Chairman) Hana Dannan, Pharmaceutical Sciences (Co-Chairman) Nurul Islam, Chemistry (Member) Chang-Jin Wang, Pharmaceutical Sciences (Member) Margaret Britto, Pharmaceutical Sciences (Member) Janan Jona, Pharmaceutical Sciences (Member) Santosh C. Kottayil, Chemistry (Co-Chairman) Paul Yeary, Chemistry (Member) Trupti Deshmukh, Pharmaceutical Sciences (Member) Zhinan Xia, Pharmaceutical Sciences (Member) Bin-Sun, Chemistry (Co-Chairman) Danita M. Saxon, Nutritional Sciences (Member) Randy Finch, Pharmaceutical Sciences (Member) Shrong-Shi Lin, Pharmaceutical Sciences (Member) Danny Kao, Pharmaceutical Sciences (Member) Donna Isbell, Biochemistry (Member) Yi Li, Chemistry, Chemistry (Member) Min Li, Toxicology (Chairman) Robert Trupp, Chemistry (Member) Bassam Tashtoush, Pharmaceutical Sciences (Member) Ashraf Traboulsi, Pharmaceutical Sciences (Member) Prakash N. Nair, Toxicology (Member) Mohammed S. Siddiqui, Chemistry (Member) LiHong Teng, Toxicology (Member) David Worthen, Pharmaceutical Sciences (Chairman) Supinan Na Phuket, Pharmaceutical Sciences (Chairman) Jyothi Matharu, Pharmaceutical Sciences (Chairman) Chris Lockwood, Pharmaceutical Sciences (Member) Mark Strohm, Pharmaceutical Sciences (Member) Jason Swango, Pharmaceutical Sciences (Chairman) Melissa Varner, Chemistry (Member) Jaber Qasem, Pharmaceutical Sciences (Member) Chinh Vu, Pharmaceutical Sciences (Member) Omar Ghosheh, Pharmaceutical Sciences (Chairman) Michelle Howard-Sparks, Pharmaceutical Sciences (Chairman) Freddie Hughes, Jr., Chemistry (Member) Marlon Jones, Chemistry (Chairman) Xiaochen Wei, Agronomy (Member) Alison Anderson, Pharmaceutical Sciences (Co-Chairman) Aimee Bence, Pharmaceutical Sciences (Chairman) Lincoln Wilkins, Pharmaceutical Sciences (Member) Dong Zhang, Pharmaceutical Sciences (Co-Chairman) Joshua R. Ring, Pharmaceutical Sciences, (Chairman) Lisa Middleton, Pharmaceutical Sciences (Member) Chandra Patel, Pharmaceutical Sciencs (Co-Chairman) Joshua T. Ayers, Pharmaceutical Sciences (Chairman) Tao Liu, Pharmaceutical Sciences (Member) Korie G. Sell, Pharmaceutical Sciences (Chairman)
9
Joseph Medendorp, Pharmaceutical Sciences (Member) Paul Kiptoo, Pharmaceutical Sciences (Member) Stan Banks, Pharmaceutical Sciences (Member) Aaron Haubner, Pharmaceutical Sciences (Chairman) Yik Ho, Pharmaceutical Sciences (Member) Hapreet K. Dhooper (Chairman) Mikolaj Milewski (Member) Yolanda Williams (Member) Ujjwal Chakraborty (Chairman) David Horton (Member) Cao Zheng (Member) Joshua Eldridge (Chairman) Asif Pathan (Member) Nisha Nanaware (Member) John Culver (Chairman) Nikhil Reddy Madadi (Chairman) Zheng Chen (Chairman)
VII. Administrative Activity and University Service At the University of Manchester
Staff-Student Committee, Department of Pharmacy 1968 - 1970
Member of the Board of the Faculty of Science 1970 - 1981
Secretary, Safety Committee, Department of Pharmacy 1978 - 1981
Member of Convocation, University of Manchester 1978 - present
Co-ordinator for Research Seminars 1978 - 1981
Senate Watchdog Committee (member) 1979 - 1980
Member of Postgraduate Committee, Faculty of Science 1980 - 1981
Postgraduate Admissions Officer, Department of Pharmacy 1980 - 1981
At the University of Kentucky College Student Affairs Committee (Member) 1981 - 1982
Graduate Program Committee (Member) 1981 - 1986
Curriculum Committee (Member) 1982 - 1985
Honors and Recognition Committee (Member) 1982 - 1984
Library Committee (Chairman) 1982 - 1985
Research and Seminar Committee (Member 1983-1984, 1983 - 1988
Moderator and Symposium Organizer, Medicinal Chemistry and Natural Products/Biotechnology
Symposium: "Functional Genomics in Drug Discovery." 1999 Southeast Regional Meeting of the
American Association of Pharmaceutical Scientists, June, 1999, Durham, NC.
Expert Witness for the Patented Medicine Prices Review Board, Government of Canada, Ottawa,
Canada, June, 2000.
External Examiner (Dossier Evaluation) for Promotion of a Faculty member to Associate
Professor, Applied Sciences University, Amman, Jordan, September, 2000.
External Examiner for the Ph.D. degree, Organic Chemistry, Indian Institute of Technology,
Bombay, India, 2000-present.
Nominated and Elected by the AAPS Membership as Vice-Chair Elect, Drug Design and
Discovery Section, American Association of Pharmaceutical Scientists, November, 2001.
16
Reviewer, National Institute on Drug Abuse - Cutting-Edge Basic Research Awards (NIDA-
CEBRA), 2002.
Vice-Chair, Drug Design and Discovery Section, American Association of Pharmaceutical
Scientists, 2002.
Member, American Association of Pharmaceutical Scientists 2003 Annual Meeting Program
Committee (AMPC), 2003.
Member, American Association of Pharmaceutical Scientists Fellows Selection Committee,
2004-on.
Member, American Association of Pharmaceutical Scientists 2004 Annual Meeting Program
Committee (AMPC), 2004.
Member, American Association of Pharmaceutical Scientists Program Coordination Committee
(PPC), 2003-2005.
Member, American Association of Pharmaceutical Scientists Strategic Visioning Committee
(SVC), 2003-2005.
Member, American Association of Pharmaceutical Scientists Membership Strategic Oversight
Committee (MSOC), 2004-2006.
Member, American Association of Pharmaceutical Scientists National Biotechnology Conference
2005 Planning Committee, 2004-2005.
Chair Elect, Drug Design and Discovery Section, American Association of Pharmaceutical
Scientists, November, 2003
Chair, Drug Design and Discovery Section, American Association of Pharmaceutical Scientists,
May, 2004-November 2005.
Member, National Institutes of Health Study Section, Special Emphasis Panel – National
Cooperative Drug Discovery groups for the Treatment of Mood Disorders or Nicotine Addiction
(NIMH/NIDA ZMH1 BRB-S (09)), 2004. Moderator and Symposium Co-Organizer, “Naturceuticals (Natural Products), Nutraceuticals, Herbal Botanicals, and Psychoactives: Drug discovery and Drug-Drug Interactions”, NIDA-AAPS Symposium, November 5-7, 2004, Baltimore, MD. Moderator and Symposium Organizer, “Neuronal Nicotinic Receptors and Ligands: New Targets for Medications Development” AAPS Symposium, November 8th, 2004, Baltimore, MD. Moderator and Symposium Co-Organizer, “Predictive Intestinal Drug Absorption” AAPS Symposium, November 10th, 2004, Baltimore, MD. Member, American Association of Pharmaceutical Scientists, Nominations Committee, 2005-6.
17
Member, Canadian Institutes of Health, Drug Development Initiative: Research Resource Grants Study Section, CIHR Research Translation Programs – Commercialization Program, 2005-2006. Member, American Association of Pharmaceutical Scientists, 2006 Fellows Committee. Member, American Association of Pharmaceutical Scientists, Awards Committee, 2006-2007. Member, American Association of Pharmaceutical Scientists, Content Advisory Committee, 2006-2007. Moderator and Symposium Organizer, “Bacterial Biofilm as a New target in the Discovery of New Antibiotic Drugs” AAPS Symposium, October 31st, 2006, San Antonio, TX. Moderator and Symposium Organizer, “AAPS Graduate Student Symposium in Drug Design and Discovery” AAPS Symposium, October 31st, 2006, San Antonio, TX. Moderator and Round Table Organizer, “Solid State Chemical Reactions of Significance in the Formulation and Stability of Solid Dosage Forms” AAPS Round Table, October 31st, 2006, San Antonio, TX. Member, American Association of Pharmaceutical Scientists, 2007 Fellows Committee. Moderator and Sunrise Session Organizer, “Targeted Prodrug Design” AAPS Sunrise Session, November 2nd, 2006, San Antonio, TX. Nominated and Elected by the AAPS Membership as Member-at-Large, AAPS Executive Committee, 2007. Member, National Institutes of Health Study Section, Special Emphasis Panel, “Drug Design for the Neurological Sciences” [ZRG1 MDCN-G(91) Review Committee], 2007. Member, American Association of Pharmaceutical Scientists, Drug Discovery and Delivery Interface (D3I) Planning Committee, 2008. Member, American Association of Pharmaceutical Scientists, Program Content Committee (PCC), 2008. Member, Quebec Intergrative Research Group (IRG), Research Hospital Fund (RHF)-Large-Scale Institutional Endeavours (LSIE) Review Board, Canada Foundation for Innovation, Montreal, Canada, February, 2008. Chairman, Graduate Program Review Committee, College of Pharmacy, Department of Medicinal Chemistry, University of Gainesville, Florida, March, 2008. External Examiner for the Ph.D. degree, Organic Chemistry, National Institute of Technology,
Department of Chemistry, Warangal, India, 2008-present.
Member, National Advisory Committee, National Symposium on Recent Trends in Organic
Medicinal Chemistry, Department of Chemistry, National Institute of Technology, Warangal,
India, January, 2009.
Member, National Institute on Drug Abuse Study Section, NIH – GMP Synthesis of Bulk Drug
Lexington Herald Leader, lead article: "Plant Possible Addiction Treatment", Oct. 30th, 2000, page C5. http://www.kentuckyconnect.com/health/stories/features/1030lobeline.htm Lexington Herald Leader, article: “It’s All About the e’s”, Section C, January 27th, 2003. National Institute on Drug Abuse: “Director’s Report to the National Advisory Council on Drug Abuse”, February, 2003. http://www.drugabuse.gov/Dirreports/Dirrep203/DirectorReport1.html Lexington Herald Leader, lead article: “Cures and Currency: Success Story Inspires Hope for UK-Business Partnerships”, March 9th, 2003, page A13. http://www.kentucky.com/mld/heraldleader/5351696.htm Tobacco Tech: Looking to the Future of Tobacco. “New Pharmaceutical Company to use Natural Compounds from Plants.” Kentucky Tobacco Research and Development Center, University of Kentucky, Issue 7, May, 2003. University of Kentucky: Odyssey Online Exclusive. “Faculty Entrepreneurs Linda Dwoskin and Peter Crooks: Research Findings to Crow About”. October 14th, 2003. http://www.rgs.uky.edu/ca/odyssey/exclusive/index.html
Louisville Courier Journal: “Kentucky Puts Hopes in Natural-Products Sector”. November 9th,
Lexington Herald Leader, front page story: "UK Gets $6 Million to Help Kick Nicotine: Grant Award is Boost for College ", November 13th, 2003. http://www.kentucky.com/mld/kentucky/news/7259103.htm The Louisville Courier Journal, front page story: “UK Effort on Quitting Smoking Wins Grant: Researchers’ Drug Aims to Stop Craving Without Nicotine”, November 13th, 2003. http://www.courier-journal.com/localnews/2003/11/14ky/met-front-grant1114-5650.html Kentucky Kernel: “Researchers get Record Grant: $6 Million Grant Helps College of Pharmacy Study Nicotine, Tobacco”, November 13th, 2003. http://www.kykernel.com/ UK News: “Pharmacy gets Record Grant”, November 24th, 2003. http://www.uky.edu/PR/UK_News/welcome.html
UK News: UKResearch-Spotlight, November 29th, 2004.
Expert Witness for the Patented Medicine Prices Review Board, Government of Canada,
Ottawa, Canada, June, 2000 in the case against Hoechst Marion Roussel Canada, Inc.
Expert Witness, Vanderbilt University, TN, January, 2008 in the case against Icos Corporation.
Expert Witness, for Apotex, Inc. and the Government of Canada, Ministry of Health, July, 2015 in
the case against Pfizer Canada, Inc., and Pfizer Products, Inc.
27
Invited Research Seminars "Analysis of polyoxyethylene sorbitan esters by proton magnetic resonance and mass
spectrometry," Pharmaceutical Society of Great Britain, Pharmaceutical Analysis Group Meeting,
May, 1973, Bloomsbury Square, London, UK. "Some aspects of the chemistry of aromatic triones," Research Seminar, April, 1975, University
of Naples, Department of Pharmaceutical Chemistry and Toxicology, April, 1975, Italy.
"Structure-activity studies in a series of conformationally restricted phenethylamines," University
of Yale, Sterling Hall of Medicine, Department of Pharmacology, Research Seminar, December,
1977, Connecticut, USA.
"Metabolism of catecholamines in cell culture systems," Gordon Research Conferences, August,
1977, New Hampshire, USA. "S-Tubercidinylhomocysteine - A metabolically stable inhibitor of S-adenosylmethionine-
dependent methyltransferases," University of London, School of Pharmacy, Research Seminar,
November, 1979, London, UK.
"In Vitro metabolism of metyrapone to an alpha-pyridone metabolite in the rat," United Kingdom
Drug Metabolism Group, Research Paper, November 1980, Manchester, UK.
"Mechanism of methyl group transfer in the catechol-O-methyltransferase reaction," University of
Bradford, School of Pharmacy, Research Seminar, February, 1981, Bradford, UK.
"Inhibition of S-adenosylmethionine-dependent methyltransferases in cultured cell systems,"
University of Wales, Institute of Science and Technology, Department of Pharmacy, Research
Seminar, March, 1981, Cardiff, UK.
"In Vivo metabolism of pyridine - species variation," United Kingdom Drug Metabolism Group,
Research Paper, April, 1981, St. Mary's Hospital, London, UK.
"Progress in the rational design of specific inhibitors of S-adenosyl-methionine dependent
methyltransferases," University of Kentucky, College of Pharmacy, Research Seminar, June,
1981, Lexington, KY, USA.
"Inhibitors of RNA methyltransferases as potential chemotherapeutic agents," University of
Kentucky Research Foundation, Mini-Forum on Anti-Tumor`Drugs and Drug DNA interactions,
May, 1981, Lexington, KY, USA. "Rationally designed inhibitors of transmethylases," University of Kentucky, Department of
Chemistry, Research Seminar, October, 1982, Lexington, KY, USA.
"Recent studies on the mechanism and inhibition of biological methylation reactions," University
of Louisville, Department of Pharmacology and Toxicology, March, 1983, Louisville, KY, USA.
"Rigid Analogs of Phenethylamines," Addiction Research Center, National Institute on Drug
Abuse, Department of Health and Human Services, March, 1983, Lexington, KY, USA.
28
"S-Adenosylmethionine-Dependent N-Methyltransferases." Section on Enzymes and Cellular
Biochemistry, National Institutes of Arthritis, Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Bethesda, Maryland, October, 1984. "Stereo-specific Nicotine Metabolism in the Guinea Pig." Department of Pharmacy, University of
Aston in Birmingham, Birmingham, Great Britain, April, 1984. "Biotransformation of Nicotine in the Guinea Pig," Department of Pharmacy, University of
Manchester, Manchester, Great Britain, April, 1984.
"N-Methylation as a Route of Xenobiotic Metabolism". University of Toronto, Faculty of
Pharmacy, Toronto, Canada, September, 1985. "The Formation of Quaternary N-Methylated Biotransformation Products -Studies Using Nicotine
as a Model Xenobiotic", Department of Pharmacology, Medical Center, University of Kentucky,
Lexington, Kentucky, February, 1986. "Recent Studies on the Metabolism of Nicotine", R.J. Reynolds Tobacco Company, Winston-
Salem, North Carolina, June, 1986.
"Mechanism-based Methyltransferase Inhibitors", G.D. Searle and Company, Research and
Development Division, Skokie, Illinois, August, 1986. "Stereochemistry of Drugs and Drug Metabolism", 40th National Meeting of the Association of
Official Racing Chemists, Lexington, Kentucky, April, 1986. "Effect of Nicotine on Histamine Metabolism in the Guinea Pig", National Institutes of Health,
National Heart, Lung and Blood Institute, Workshop on the Effects of Tobacco Smoke on
Pulmonary Cells and Synthesis and Regulation of Pulmonary Macromolecules, Bethesda,
Maryland, May, 1986.
"One-Carbon Transfer Reactions in Xenobiotic Metabolism", Graduate Center for Toxicology,
University of Kentucky, Lexington, KY, November 1987.
"Chirodiastaltic Effects in Radiotracer Studies", Bristol Myers Co., Drug Metabolism and
Pharmacokinetics Division, Syracuse, NY, USA, May, 1988. "Metabolic Rates and Processes in the Lung", Invited Speaker, Symposium on Respiratory Drug Delivery, University of Kentucky, Lexington, KY, USA, May, 1988. "Sulphonium Salts", Invited Keynote Speaker, First International Symposium on Sulphur
Xenobiochemistry, London, UK, September, 1988.
"Methyltransferases: Mechanisms, Inhibitor Design, and Role in Drug Metabolism", Department
of Pharmacology, Medical Center, University of Kentucky, Lexington, KY, USA, September,
1988.
"Methyltransferases: Enzyme Mechanism, Inhibitor Design, and Opportunities for Drug
Discovery", Department of Pharmacy, University of Sydney, New South Wales, Australia,
November, 1988.
29
"Mechanism-Based Approach to Methyltransferase Inhibition", Southern Research Institute,
Birmingham, AL, USA, January, 1989.
"Peptidases of the Nasal and Respiratory Tracts". Invited Speaker, Department of
Pharmaceutics - New Product Development, Rorer Pharmaceuticals, Fort Washington, PA, USA,
March, 1989.
"The Role of Peptidases of the Nasal and Respiratory Tract in the Bioavailability of Nasally
Administered Peptides". Invited Speaker, Eighth Annual Robert S. Roxman Memorial
Symposium, Drug Metabolism Discussion Group, Fort Washington, PA, June 1989.
"Lung Peptidases and their Activities". Invited Speaker, Second International Symposium on
Respiratory Drug Delivery, Keystone, CO, U.S.A., March, 1990.
NIDA-Supported National Cooperative Drug Discovery Groups Symposium. Building
Translational Research in Medication Development in Academia: Issues, Strategies and Tactics,
Quebec City, Canada, June, 2007.
“The Search for More Selective Neuronal Nicotinic Acetylcholine Receptor Antagonists as
Smoking Cessation Agents”. Invited speaker, Symposium on Molecular Diversity in Drug Design,
Discovery and Delivery, University of South Florida, Tampa, FL, October, 2007.
“Recent Developments in the Search for More Selective Neuronal Nicotinic Acetylcholine
Receptor Antagonists as Smoking Cessation Agents”. Invited speaker, James K. Coward
Symposium, University of Michigan, College of Pharmacy, Ann Arbor, MI, January, 2008.
“Decamethonium Analogs as Brain Deliverable Neuronal Nicotinic Acetylcholine Receptor
Antagonists for Nicotinic Addiction”. Invited speaker, Fourteenth International Pharmaceutical
Technology Symposium: Overcoming Biological Barriers in Innovative Delivery Systems,
Antalya, Turkey, September, 2008.
Keynote Address, Golden Jubilee Celebrations of the National Institute of Technology, Warangal,
India, January, 2009.
“Hybrid Drugs (Codrugs)”. Plenary Speaker, National Symposium on Recent Trends in Organic
and Medicinal Chemistry, Department of Chemistry, National Institute of Technology, Warangal,
India, January, 2009.
Freshman Address, National Institute of Pharmaceutical Sciences (NIPS), Warangal, India,
January, 2009.
“The Journey of Yaupon Therapeutics”. Invited Case Study Panelist, Wharton Entrepreneurship
Conference, 2009: Carrying Ideas to Success, Philadelphia, PA, February, 2009.
“Parthenolide and DMAPT (LC-1)”. Developmental Therapeutics Program, Markey Cancer
Center, University of Kentucky, Lexington, KY, December, 2009.
“Parthenolide and its Analogs as Novel Anticancer Agents”, Tumor Board, Markey Cancer
Center, University of Kentucky, Lexington, KY, January, 2010.
“So You Want to Start a Company?”. Young Scientist Seminar, Panel Member, Association of
Pharmaceutical Scientists, University of Kentucky College of Pharmacy Student Chapter,
Lexington, KY, March, 2010.
“Drug Discovery and Development in an Academic Environment: Translational Efforts and
Successes”, Translational Pharmaceutical Sciences: Drug Discovery and Development: Center
for Clinical and Translational Science (CCTS) 5th Annual Spring Conference, Lexington, KY,
March, 2010.
“Novel Neuronal Nicotinic Acetylcholine Receptor Antagonists as Potential Smoking Cessation
Agents”, 2010 Ronald F. Borne Distinguished Lecture in Medicinal Chemistry, University of
Mississippi School of Pharmacy, Department of Medicinal Chemistry, Oxford, MS, March, 2010.
“Nicotinic Acetylcholine Receptor Antagonists as Potential Smoking Cessation Agents”, Invited
34
Research Seminar, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, April, 2010. “Brain Bioavailability of a bis-Quaternary Ammonium Compound as a Potential Smoking Cessation Agent”, Invited Presentation, Fifth National Analytical Chemistry Congress, Ataturk University, Erzurum, Turkey, June, 2010. “HPLC/MS/MS Analysis and Pharmacokinetic Profile of Opiate-Cannabinoid Codrugs for Pain Modulation”, Invited Presentation, National Symposium on Chromatographic Methods, Ataturk University, Erzurum, Turkey, June, 2010. “A Novel Approach to the Discovery of Smoking Cessation Agents: Inhibition of Nicotine-Evoked Dopamine Release”. Invited Research Seminar, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, August, 2010. Research Achievement Award Seminar in Drug Design and Discovery, American Association of Pharmaceutical Scientists, “Nicotinic Acetylcholine Receptors as Novel Targets for Drug Discovery”. Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, New Orleans, LA, November, 2010. “Entrepreneurial Adventures in an Academic Environment”, Invited Keynote Speaker, Summit on Drug Discovery, Chemical Biology, and Drug Delivery: Innovation and Entrepreneurship Translational Science Institute, Wake Forest School of Medicine, Winston-Salem, NC, June, 2011. “Drug Discovery Successes in an Academic Environment”. College of Pharmacy, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, August, 2011. “New nAChR Targets and the Development of Drug Abuse and Pain Therapeutics”. College of Medicine, Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, September, 2011. “Funding Drug Discovery in an Academic Environment: Is it a Good Investment?”. Chancellor’s Forum: New Frontiers in Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, November, 2011. “Novel Drug Molecules for the Treatment of Psychostimulant Abuse”. College of Medicine, Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR, November, 2011. “Investigative Studies for Drug Therapies”. Chancellor’s Forum, University of Arkansas for Medical Sciences, Little Rock, AR, November, 2011. “Discovery of Novel nAChR Antagonists as Drug Abuse and Pain Therapeutics”. D.Sc. Award Lecture, School of Pharmacy, University of Manchester, Manchester, England, December, 2011. “Translational Research Efforts and Successes”, Translational Research Institute Rainmaker Symposium on Drug and Biologic Development, Clinton Presidential Center, Little Rock, AR, March, 2012. “Nicotinic Acetylcholine Receptors as Targets for the Development of Novel Therapeutic Agents”. College of Pharmacy, Department of Pharmaceutical Sciences, University of Hawaii at Hilo, Hilo, HI, April, 2012. “Role of Tocoflexols in Radiation Protection”. Keynote Speaker, Rice Processing Program: Industry Alliance Meeting, University of Arkansas, Fayetteville, AR, May 23rd, 2012.
35
“Design of Molecules with Drug-like Properties”, Center for Drug Discovery and Therapeutics Retreat, Morgantown, West Virginia University School of Pharmacy, WV, June, 2012. “The Patent Application Process”. Center for Drug Discovery and Therapeutics Retreat, Morgantown, West Virginia University School of Pharmacy, WV, June, 2012. “Development of Novel Smoking Cessation Agents Through Inhibition of Nicotine-Evoked Dopamine Release”. National Center for Toxicological Research, Pine Bluff, AR, August, 2012. “Development of Nicotinic Receptor Antagonists as Agents for Treating Nicotine Addiction”. Invited Speaker, Plenary Symposium: “Tobacco Addiction: From Basic Science to Policy”, Meeting on Behavior, Biology, & Chemistry: Translational Research in Addiction, March, 2013, San Antonio, TX. “Development of Nicotinic Receptor Antagonists as Agents for Treating Nicotine Addiction”. Invited lecture, Drug Addiction: Science & Society Symposium; jointly sponsored by the Translational Research Institute (TRI), the Psychiatric Research Institute (PRI), the T32 National Institute on Drug Abuse (NIDA), theT32 Training Grant, and the Department of Pharmacology & Toxicology, UAMS, Little Rock, AR, April, 2013. Panelist, “Drug Discovery and Clinical Trials”, Science Café, Little Rock, AR, April, 2013. “A Career in Pharmaceutical Sciences - Challenges and Opportunities”. Keynote Speaker, PharmForum ’13, Nanomedicine and Translational Experimental Therapeutics: Going Small and Aiming Big!, University of Arkansas for Medical Sciences, Little Rock AR, May, 2013. “Drug Discovery in the Crooks’ Laboratory”. Special Guest Speaker; The UAMS Winthrop P. Rockefeller Cancer Institute Foundation, Holiday Luncheon to Honor the Board of Directors and Dedicated Supporters, Little Rock, AR, December, 2013. “Increasing the Efficacy of a Promising Chemotherapeutic Agent Utilizing a Nanodelivery Approach”. Plenary Speaker, 5th Annual Nanotechnology for Health Care Conference, Winthrop Rockefeller Conference Center, Petit Jean Mountain, AR, April, 2014. “Natural Products and their Analogs as Anticancer Agents: Nature and Biomedical Science at its Best”. Plenary Speaker, Drug Discovery and Development Colloquium 2014, Keynote Presentation, Little Rock, AR, June, 2014. “How We Did It – Stories From Faculty-driven University Start-ups”. Invited Speaker/Panelist: Arkansas Commercialization Retreat, Winthrop Rockefeller Conference Center, Petit Jean Mountain, AR, June, 2014. “Natural Products and Chemotherapy: From Plant Shoots to Cancer Roots!” The Medicines from Nature 10th Annual Lecture, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock Arkansas, October, 2014. “Can Anti-leukemic Sesquiterpene Drugs Treat Solid Tumors Effectively?”. Winthrop P. Rockefeller Cancer Institute Grand Rounds, University of Arkansas for Medical Sciences, Little Rock, AR, January, 2015. “Development of Therapeutics for Treatment of Methamphetamine Abuse”. Invited research seminar, Hendrix College, Conway, AR, March, 2015.
36
“Computer-aided Techniques in Drug Discovery”. Invited session-featured speaker, Mid-South Computational Biology and Bioinformatics (MCBIOS) XII Annual Conference, Little Rock, AR, March, 2015. “Reflections on 30 years as a UK College of Pharmacy Faculty Member: Great Students, Talented Colleagues and Good Science! Swintosky Distinguished Lecture, Invited Presentation, University of Kentucky College of Pharmacy, Lexington, KY, 2015. “Progress Towards the Preclinical Development of a VMAT-2 Inhibitor for Treatment of Methamphetamine Abuse”. Invited featured speaker, Drug Discovery and Development Colloquium 2016, Birmingham, AL, June, 2016. “Chemical Modification of Cellulose Surfaces”, EPSCOR: Center for Advanced Surface Engineering (CASE), Annual Meeting, Little Rock, AR, June, 2016.
37
XII. Publications
Original Research Articles Published in Peer-Reviewed Journals [articles cited 10 or more times (Advanced Google Scholar; October 13th, 2015) are indicated in parentheses; number of total citations – 10,345; h-index 49].
1. "Thermal Indolisation of 4-Pyrimidylhydrazones and 4-Pyridylhydrazones". By Peter A.
Crooks and Brian Robinson, Chemistry and Industry (London), 1967, 547-548.
2. "Isolation and Structure of an Indole Alkaloid of Biogenetic Interest from Tabernamontana
cumminsii". By Peter A. Crooks, Brian Robinson and George F. Smith, J. Chem. Soc.,
Chem. Comm., 1968, 1210.
3. "Azaindoles. Part I. The Synthesis of 5-aza- and 5,7-Diazaindoles by the Non-catalytic
Thermal Indolisation of 4-Pyridyl- and 4-Pyrimidylhydrazones, respectively". By Peter A.
Crooks and Brian Robinson, Can. J. Chem.,1969, 47, 2061-2067 [15 citations].
4. "The Isolation and Identification of Quininone from Cinchona ledgeriana". By Peter A. Crooks
and Brian Robinson, J. Pharm. Pharmacol., 1970, 22, 469-470.
5. "The Isolation and Identification of Jollyanine from Tabernamontana cumminsii". By Peter A.
Crooks and Brian Robinson, J. Pharm. Pharmacol. 1970, 22, 471-474.
6. "The Isolation and Identification of (-)-Apparicine from Tabernamontana cumminsii". By Peter
A. Crooks and Brian Robinson, J. Pharm. Pharmacol., 1970, 22, 799-800.
7. "Conopharyngine Pseudoindoxyl, a New Alkaloid from Tabernamontana pachysiphon Stapf.
var. cumminsii (Stapf.) H. Huber". By Peter A. Crooks and Brian Robinson, J. Pharm.
Pharmacol., 1973, 25, 820-823.
8. "Effects of Amphetamine, 2-Aminoindane and 2-Aminotetralin on the Concentration of Whole
Brain Noradrenaline, Dopamine, 5-Hydroxytryptamine and 5-Hydroxyindoleacetic Acid in the
Mouse". By Peter A. Crooks, Hilary J. Little and John M. H. Rees, J. Pharm. Pharmacol.,
1973, 25, 124P.
9. "Synthesis of -Amino Alcohols via Spiro-Oxiran Intermediates". By Peter A. Crooks and Richard Szyndler, Chemistry and Industry (London), 1973, 1111-1112 [32 citations].
10. "The Determination of the Hydrophile-Hydrophobe Proton Ratio in a Series of
Polyoxyethylene Sorbitan Esters". By Peter A. Crooks, John H. Collett and Roger
50. "Species Differences in the Metabolic C- and N-Oxidation, and N-Methylation of [14C]-
Pyridine In Vivo". By Lyaquatali A. Damani, Peter A. Crooks, Mamhoud S. Shaker, John
Caldwell, J. D'Souza and R. L. Smith, Xenobiotica, 1982, 12, 527-534 [29 citations].
51. "Synthesis of 7-Deazaguanine-(2-amino-3, 7-dihydropyrrolo[2,3-d]pyrimidin-4-one)
analogues substituted at C-8". By Eric Benghiat and Peter A. Crooks, Chemistry and
Industry (London), 1982, 661-662.
52. "Synthesis of 2, 3, 3a, 8a-Tetrahydroindeno[2,1-b]pyrrole Derivatives". By Peter A. Crooks,
Francesco DeSimone and Eliseo Ramundo, J. Heterocyclic Chem., 1982, 19, 1433-1436.
53. "Preparation of S-(3-Indolemethyl) Derivatives of Mercaptoamino Acids". By Eric Benghiat
and Peter A. Crooks, Synthesis, 1982, 12, 1033-1036 [11 citations].
54. "Determination of Benzalkonium Chloride by Chemical Ionization Mass Spectroscopy". By
Nabil N. Daoud, Peter A. Crooks, Richard Speak and Peter Gilbert, J. Pharm. Sci., 1983, 72,
290-292.
55. "Synthesis and Analgesic Properties of Two Leucine-Enkephalin Analogues Containing a
Conformationally Restrained N-Terminal Tyrosine Residue. By Trevor Deeks, Peter A.
Crooks and Roger D. Waigh, J. Medicin. Chem., 1983, 26, 762-765 [41 citations].
56. "Synthesis of S-3-Indolemethyl Derivatives of 5'-Deoxy-5'-thioadenosine". By Eric Benghiat
and Peter A. Crooks, J. Heterocyclic Chem., 1983, 20, 423-425.
57. "Synthesis of S-5-Pyrrolo[2,3-b]pyridinemethyl and S-5- and S-6-Pyrrolo[2,3-
d]pyrimidinemethyl Derivatives of 5'-Deoxy-5'-thioadenosine". By Eric Benghiat and Peter A.
Crooks, J. Heterocyclic Chem., 1983, 20, 677-680.
58. "-2-Adrenoceptor Agonist Properties of Exo- and Endo-isomers of 2-Amino-6, 7-
dihydroxybenzonorbornenes Designed as Rigid Catecholamines". By Peter Hicks, Christopher Waldron, Peter Burn and Peter A. Crooks, J. Pharm. Pharmacol., 1983, 35, 94-99 [14 citations].
59. "Multisubstrate Adducts as Potential Inhibitors of S-Adenosylmethionine Dependent
Methylases: Inhibition of Indole N-Methyltransferase by (5'-Deoxyadenosyl)[3-(3-
indolyl)prop-1-yl]methylsulfonium and (5'-Deoxyadenosyl)[4-(3-indolyl)but-1-yl]methyl-
sulfonium Salts". By Eric Benghiat and Peter A. Crooks, J. Medicin. Chem., 1983, 26, 1470-
1477 [18 citations].
60. "Reaction of 2-Acetamido-3, 7-dihydropyrrolo[2,3-d]pyrimidin-4-one with Dimethylamine and
Formaldehyde. Formation of Two Isomeric Mannich Bases" By Eric Benghiat and Peter A.
Crooks, J. Heterocyclic Chem., 1983, 20, 1023-1025.
61. "Synthesis of Endo- and Exo-2-Amino-6-hydroxybenzonorbornenes - Rigid Analogues of
Tyramine". By Peter A. Crooks and Peter Burn, Chemistry and Industry (London), 1983,
644-645.
42
62. "Unexpected Phenomenon in the High-Performance Liquid Chromatographic Analysis of
Racemic 14C-Labeled Nicotine: Separation of Enantiomers in a Totally Achiral System". By
Kenneth C. Cundy and Peter A. Crooks, J. Chromatography, 1983, 281, 17-23 [98 citations].
63. "Differential Metabolism of [2'-14C]-Nicotine and [N-14CH3]-Nicotine in the Guinea Pig". By
Kenneth C. Cundy and Peter A. Crooks, J. Pharm. Pharmacol., 1983, 35, 75P.
64. "Leucine Enkephalin Analogues Containing a Conformationally Restrained N-Terminal Amino
Acid Residue". By Trevor Deeks, Peter A. Crooks and Roger D. Waigh, J. Pharm. Sci., 1984, 73, 457-460 [10 citations].
65. "High-Performance Liquid Chromatographic Method for the Determination of N-Methylated
Metabolites of Nicotine". By Kenneth C. Cundy and Peter A. Crooks, J. Chromatogr.
Biomed. Appl., 1984, 306, 291-301 [50 citations].
66. "Leu-Enkephalin Provokes Naloxone-Insensitive Pulmonary Vasoconstriction". By Mark N.
Gillespie, Bruce D. Bowdy, Carol N. Reinsel, Edgar T. Iwamoto and Peter A. Crooks, Life
Sciences, 1984, 34, 1177-1183 [15 citations].
67. "Synthesis and Stereochemical Analysis of 2-Amino-1, 2, 3, 4-tetrahydro-1, 4-
methanonaphthalene-2-carboxylic acid, a Conformationally Rigid Phenylalanine Derivative".
By W. John Layton, Stanford L. Smith, Peter A. Crooks, Trevor Deeks and Roger D. Waigh,
J. Chem. Soc., Perkin Trans. I, 1984, 1283-1287.
68. "Reaction of Dimethyloxosulphonium Methylide with Aromatic Methoxylated 1, 2, 3, 4-
Tetrahydronaphthalene-1-ones". By Peter A. Crooks and Richard Sommerville, Chemistry
and Industry (London), 1984, 351-352.
69. "Inhibition of Bacterial DNA Cytosine-5-methyltransferase by S-Adenosyl-L-homocysteine
and Some Related Compounds". By Peter A. Crooks, Malcolm J. Tribe and Richard J.
Pinney, J. Pharm. Pharmacol., 1984, 36, 85-89 [20 citations].
70. "Structure-Activity Evidence against Opiate Receptor Involvement in Leu5-Enkephalin-
Induced Pulmonary Vasoconstriction". By Peter A. Crooks, Bruce D. Bowdy, Carol N.
Reinsel, Edgar T. Iwamoto and Mark N. Gillespie, Biochemical Pharmacol., 1984, 33, 4095-
4098.
71. "Evidence of Stereospecificity in the In Vivo Methylation of [14C]-()-Nicotine in the Guinea
Pig". By Kenneth C. Cundy, C. Steven Godin and Peter A. Crooks, Drug Metab. Disposit.,
1984, 12, 755-759 [16 citations].
72. "Stereospecific In Vitro N-Methylation of Nicotine in Guinea Pig Tissues by an S-
Adenosylmethionine-Dependent N-Methyltransferase" By Kenneth C. Cundy, C. Steven
Godin and Peter A. Crooks, Biochemical Pharmacol., 1985, 34, 281-284 [31 citations].
73. "Stereospecific In Vivo N-Methylation of Nicotine in the Guinea Pig". By Kenneth C. Cundy,
Michio Sato and Peter A. Crooks, Drug Metab. Disposit,, 1985, 13, 175-185 [31 citations].
74. "N-Methylnornicotinium Ion, a New In Vivo Metabolite of R-(+)-Nicotine". By Michio Sato and
Peter A. Crooks, Drug Metab. Disposit., 1985, 13, 348-353 [18 citations].
43
75. "Synthesis and Pharmacological Evaluation of Aromatic Dihydroxylated Spiro[indan-1, 3'-
pyrrolidine] and Spiro[indan-2, 2'-pyrrolidine] Derivatives". By Richard Sommerville, Howard
E. Rosenberg, and Peter A. Crooks, J. Pharm. Sci., 1985, 74, 553-555.
76. "Pulmonary Metabolism of Exogenous Enkephalins in Isolated Perfused Rat Lungs". By
Mark N. Gillespie, Jerzy W. Krechniak, Peter A. Crooks, Jack W. Olson and Ralph J. Altiere,
J. Pharmacol. Exp. Therap., 1985, 232, 675-681 [40 citations].
77. "Remarkable Substrate-Inhibitor Properties of Nicotine Enantiomers towards a Guinea Pig
Lung Aromatic Azaheterocycle N-Methyltransferase". By Kenneth C. Cundy, Peter A. Crooks
and C. Steven Godin, Biochem. Biophys. Res. Commun., 1985, 128, 312-316 [24 citations].
78. "High-Performance Liquid Chromatographic Analysis of Pulmonary Metabolites of Leu- and
Met-Enkephalins in Isolated Perfused Rat Lung". By Peter A. Crooks, Jerzy W. Krechniak,
Mark N. Gillespie and Jack W. Olson, J.Pharm. Sci., 1985, 74, 1010-1012.
79. "Reaction of 5, 6-Benzobicyclo[2.2.1]hepta-2, 5-diene with Thallium(III) Nitrate." By W. John
Layton, Carolyn P. Brock, Peter A. Crooks, Stanford L. Smith and Peter Burn, J. Org. Chem.,
1985, 50, 5372-5375.
80. "In Vitro Characteristics of Guinea Pig Lung Aromatic Azaheterocycle N-Methyltransferase".
By Kenneth C. Cundy and Peter A. Crooks, Drug Metab. Disposit., 1985, 13, 658-663 [12
citations].
81. "Biotransformation of Primary Nicotine Metabolites. I: In Vivo Metabolism of R-(+)-[14C-
NCH3]-N-Methylnicotinium Ion in the Guinea Pig". By William F. Pool and Peter A. Crooks,
Drug Metab. Disposit., 1985, 13, 578-581 [13 citations].
82. "Effect of Nicotine and N'-Nitrosonornicotine on Rat Lung and Trachea Ornithine
Decarboxylase Activity". By Jack W. Olson and Peter A. Crooks, Carcinogenesis, 1985, 6,
1517-1519.
83. "High-Performance Liquid Chromatography with Electrochemical Detection for the
Determination of Nicotine and N-Methylnicotinium Ion". By Shaker Mousa, Abdulghani Al-
Houdi, Glen R. Van Loon and Peter A. Crooks, J. Chromatogr., 1985, 347, 405-410 [23
citations].
84. "Inhibition of Vaccinia RNA Guanine 7-methyltransferase by Compounds Designed as
Multisubstrate Adducts". By Eric Benghiat, Peter A. Crooks, Raymond Goodwin and Fritz
Rottman, J. Pharm. Sci., 1986, 75, 142-145.
85. "N-Methylation and Quaternization of Pyridine In Vitro by Rabbit Lung, Liver and Kidney N-
Methyltransferases: an S-Adenosyl-L-Methionine-Dependent Reaction". By Lyaquatali A.
Damani, Mamhoud S. Shaker, Peter A. Crooks, C. Steven Godin, and Chukwuemka G.
89. "A Serendipitous Synthesis of 2-Amino-cis-bicyclo[4.3.0]nonane". By Peter A. Crooks,
Chemistry and Industry (London), 1986, 462-463.
90. "Isolation and Characterization of N-Methyl-N'-oxonicotinium ion, A New Urinary Metabolite of
R-(+)-Nicotine in the Guinea Pig". By William F. Pool, Abdulghani A. Houdi, Lyaquatali A.
Damani, W. John Layton, and Peter A. Crooks, Drug Metab. Disposit., 1986, 14, 574-579 [18
citations].
91. "Synthesis of 2-Amino-1, 2, 3, 4-tetrahydro-6, 7-dihydroxy-1, 4-methanonaphthalen-2-
carboxylic Acid- a Conformationally Rigid Analogue of 3, 4-Dihydroxyphenylalanine (DOPA)".
By Everett J. Horn, W. John Layton, Stanford L. Smith and Peter A. Crooks, Chemistry and
Industry (London), 1986, 615-616.
92. "In Vitro Inhibition of Histamine Metabolism in Guinea Pig Lung by S-(-)-Nicotine". By C.
Steven Godin and Peter A. Crooks, J. Pharm. Sci., 1986, 75, 949-951.
93. "Synthesis and Antinociceptive Properties of a Series of Exo- and Endo-6-hydroxy-2-
aminobenzonorbornenes". By Peter A. Crooks, Peter Burn, Robert D.E. Sewell, and Neil
Upton, J. Pharm. Sci., 1986, 75, 1010-1013.
94. "S-Acylation of Cysteine by O-Acetylsalicylic Anhydride - A Possible Mechanism for Aspirin
Hypersensitivity?" By Hana Dannan, M. N. Khawam, Joseph B. Bogardus, Anwar A. Hussain
and Peter A. Crooks, J. Pharm. Sci., 1986, 75, 1081-1084.
95. "N-Methylation of Phenylpyridines and Bis-pyridyls as a Potential Toxication Route: Tissue
Distribution of Azaheterocycle N-Methyltransferase Activity in the Rabbit." By C. Steven
Godin, Peter A. Crooks and Lyaquatali A. Damani, Toxicol. Lett., 1986, 34, 217-222.
96. "Biotransformation of Primary Nicotine Metabolites II. Metabolism of 3H-S-(-)-Cotinine in the
Guinea Pig: Determination of In Vivo Urinary Metabolites by High-Performance Liquid
Radiochromatography". By Kenneth C. Cundy and Peter A. Crooks, Xenobiotica, 1987, 17,
785-792 [12 citations].
97. "Perturbation of S-Adenosylhomocysteine and S-Adenosylmethionine Levels, and Inhibition
of Histamine Metabolism in the Guinea Pig, By Nicotine", Tobacco Smoking and Health,
International Symposium, Lexington, Kentucky, December, 1985; in Tobacco Smoking and
Nicotine: A Neurobiological Approach, edited by William R. Martin, Glen R. Van Loon, Edgar
T. Iwamoto, and Layten Davis, p. 500, Plenum Press, New York and London, 1987.
45
98. "In Vitro and In Vivo Biomethylation of Nicotine Enantiomers", Tobacco Smoking and Health,
International Symposium, Lexington, Kentucky, December, 1985; in Tobacco Smoking and
Nicotine: A Neurobiological Approach, edited by William R. Martin, Glen R. Van Loon, Edgar
T. Iwamoto, and Layten Davis, p. 499, Plenum Press, New York and London, 1987.
99. "Stereospecific N-Methylation of Nicotine by Intact Guinea Pig Pulmonary Alveolar
Macrophages", Tobacco Smoking and Health, International Symposium, Lexington,
Kentucky, December, 1985; in Tobacco Smoking and Nicotine: A Neurobiological Approach,
edited by William R. Martin, Glen R. Van Loon, Edgar T. Iwamoto, and Layten Davis, p. 497,
Plenum Press, New York and London, 1987.
100. "A Simple and Sensitive Determination of Histamine and N-Methylhistamine in Biological
Fluids by High-Performance Liquid Chromatography with Electrochemical Detection".
Abdulghani Al-Houdi, Peter A. Crooks, Glen R. Van Loon, and Cathryn A. W. Schubert, J.
Pharm. Sci., 1987, 76, 398-401 [10 citations].
101. "High Performance Liquid Chromatography of Radiolabeled Nicotine Enantiomers and their
Metabolism in the Guinea Pig to N-Methylated Products". By Peter A. Crooks and Kenneth
C. Cundy, invited chapter in "Flow-Through Radioactive Detectors in HPLC". Progress in
HPLC, Vol. 4, Edit. H. Parvez, M. Kessler and S. Parvez, V.N.U. International Science Press,
Utrecht, Holland, 1988, pp 129-147.
102. "N-Methylation of Nicotine Enantiomers by Human Liver Cytosol". By Peter A. Crooks and C.
Steven Godin, J. Pharm. Pharmacol., 1988, 40, 153-154 [24 citations].
103. "High Performance Liquid Chromatography with Electrochemical Detection for the Determination of Nicotine in Plasma". By Chen-Yie Chien, John N. Diana and Peter A. Crooks, J. Pharm. Sci., 1988, 77, 277-279.
104. "Determination of Plasma Nicotine by High Performance Liquid Chromatography with
Electrochemical Detection". By Chen-Yie Chien, John N. Diana and Peter A. Crooks, LC-
GC, Mag. Liq. Gas Chromatogr., 1988, 6, 53-55.
105. "Formation of Quaternary Amines by N-Methylation of Azaheterocycles with Homogenous
Amine N-Methyltransferases." By Peter A. Crooks, C. Steven Godin, Lyaquatali A. Damani,
Sherry S. Ansher and William B. Jakoby, Biochem. Pharmacol., 1988, 37, 1673-1677 [24
citations].
106. "N-Methyl-N'-oxonicotinium Ion: Synthesis and Stereochemistry." By Peter A. Crooks,
William F. Pool, Lyaquatali A. Damani and Stephen A. Winkle, Chemistry and Industry
(London), 1988, 95-96.
107. "Inhibition of Histamine N-Methyltransferase Activity in Guinea Pig Pulmonary Alveolar
Macrophages by Nicotine". By Chandrachuranan Gairola, C. Steven Godin, Abdulghani Al
Houdi, and Peter A. Crooks, J. Pharm. Pharmacol., 1988, 40, 724-726.
108. "Stereoselectivity in the N'-Oxidation of Nicotine Isomers by Flavin-Containing
Monooxygenase". By Lyaquatali A. Damani, William F. Pool, Peter A. Crooks, R. Keith
Kaderlik, and Daniel M. Ziegler, Mol. Pharmacol., 1988, 33, 702-705 [46 citations].
46
109. "Equilibrium Binding of Spermine and Histamine to Salmon Sperm DNA and Poly(dGdC)".
By Stephen A. Winkle and Peter A. Crooks, J. Pharm. Pharmacol., 1988, 40, 809-811.
110. "Response of Plasma Arginine Vasopressin to Nicotine in Normal Man". By Steven R.
Goldsmith, Adriana Katz and Peter A. Crooks, Clin. Pharmacol. Ther., 1988, 44, 478-481.
111. "Effect of Continuous Nicotine Administration on Urinary Histamine and N-Methylhistamine Levels in the Guinea Pig". By Abdulghani A. Houdi, C. Steven Godin and Peter A. Crooks, Toxicol. Letters, 1988, 44, 161-166.
112. "Biotransformation of Primary Nicotine Metabolites, III. Metabolism of R-(+)-[3H-N'-CH3;
14C-N-CH3]-N-methylnicotinium Acetate - The Use of Double Isotope Studies to Determine the In Vivo Stability of the N-Methyl Groups of N-Methylnicotinium Ion". By William F. Pool and Peter A. Crooks, J. Pharm. Pharmacol., 1988, 40, 758-762.
113. "Species Variation and Stereoselectivity in the Metabolism of Nicotine Enantiomers". By
Chukwuemeka G. Nwosu and Peter A. Crooks, Xenobiotica, 1988, 18, 1361-1372 [42
citations].
114. "Enantioselective Metabolism During Continuous Administration of S-(-)- and R-(+)-Nicotine
Isomers in Guinea Pigs". By Chukwuemeka G. Nwosu, C. Steven Godin, Abdulghani A.
Houdi, Lyaquatali A. Damani and Peter A. Crooks, J. Pharm. Pharmacol., 1988, 40, 862-869
[19 citations].
115. "Kinetics and Mechanism of the Reactions of Hypochlorous Acid and Monochloramine with
N-Acetylcysteine". By Prakash Kulkarni, Anwar A. Hussain, and Peter A. Crooks, Proc. Fourth Conference on Prog. Chem. Disinfection, 1988, 399-407.
116. "Metabolism of the Sulphonamido Group." By Peter A. Crooks, invited chapter in "Sulphur
Drugs and Related Organic Chemicals - Chemistry, Biochemistry and Toxicology", Chapter 7, Edit. Lyaquatali A. Damani, Vol. 1, Part B, Ellis Horwood Limited, Chichester, U.K., 1989, pp 181-194.
117. "Sulphonium Salts." By Peter A. Crooks, invited chapter in "Sulphur Drugs and Related
Organic Chemicals - Chemistry, Biochemistry and Toxicology", Edit. Lyaquatali A. Damani,
243. "The Antiproliferative and Immunotoxic Effects of L-Canavanine and L-Canaline". By Aimee
K. Bence, David R. Worthen, Val R. Adams, and Peter A. Crooks, Anti-Cancer Drugs, 2002,
13, 313-320 [28 citations].
244. "N-n-Alkylnicotinium Analogs, a Novel Class of Nicotinic Receptor Antagonist: Inhibition of
S(-)-Nicotine-Evoked [3H]Dopamine Overflow from Superfused Rat Striatal Slices". By
Lincoln H. Wilkins, Jr., Aaron Haubner, Joshua T. Ayers, Peter A. Crooks, and Linda P
Dwoskin, J. Pharmacol. Exp. Therap., 2002, 301, 1088-1096 [38 citations].
245. "Synthesis and Evaluation of Conformationally Restricted Pyridino N-Alkylated Nicotine
Analogs as Neuronal Nicotinic Acetylcholine Receptor Antagonists". By Rui Xu, Linda P.
58
Dwoskin, Vladimir P. Grinevich, Aaron Haubner, and Peter A. Crooks, Drug Development
Res., 2002, 55, 173-186 [23 citations].
246. “Epilepsy - A Review of the Recent Patent Literature”. By Peter A. Crooks, Joshua Ring, and
Aaron Haubner, IDrugs, 2002, 5, 990-999.
247. “bis-Azaaromatic Quaternary Ammonium Analogues: Ligands for 42* and α7* Subtypes of Neuronal Nicotinic Receptors". By Joshua T. Ayers, Linda P. Dwoskin, A. Gabriela Deaciuc, Vladimir P. Grinevich, Jun Zhu, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2002, 12, 3067-3071 [47 citations].
248. “Meso-transdiene, a Potent, Selective Antagonist at alpha3*-containing Nicotinic Receptors”.
By Linda P. Dwoskin, Dennis K. Miller, Guangrong Zheng, Seth D. Norrholm, Vladimir P. Grinevich, and Peter A. Crooks, Drug and Alcohol Dependence, 2002, 64, 38.
249. “8-Hydroxyl Esterification of Lobeline Increases Selectivity for the alpha4beta2* Subtype of
Nicotinic Receptor, While Increasing Affinity for Dopamine and Serotonin Transporters”. By Seth D. Norrholm, Dennis K. Miller, Marhaba Hojahmat, Peter A. Crooks, and Linda P. Dwoskin. Drug and Alcohol Dependence, 2002, 64, 25.
250. “The Bis-picolinium Salt, bPiDDB, is a Potent and Selective Antagonist at Nicotinic
Acetylcholine Receptors Mediating Nicotine-evoked Dopamine Release in Rat Striatum”. By Peter A. Crooks, Joshua T. Ayers, Aaron J. Haubner, Vladimir P. Grinevich, Sangeetha P. Sumithran, A. Gabriela Deaciuc and Linda P. Dwoskin. Drug and Alcohol Dependence, 2002, 64, 38.
251. “L-Canavanine as a Radiosensitization Agent for Human Pancreatic Cancer Cells.” By Aimee
K. Bence, Val R. Adams, and Peter A. Crooks, Mol. Cell. Biochem., 2003, 244, 37-43 [19
citations].
252. "Plasma Cotinine, 3’-Hydroxycotinine and their Glucuronides in Caucasian and African American Smokers”. By Jose de Leon, Francisco J. Diaz, Thea Rogers, Debra Browne, Lori Dinsmore, Omar A. Ghosheh, Linda P. Dwoskin, and Peter A. Crooks, J. Clin. Psychopharmacol., 2003, 23(2), 209-211.
253. "A Pilot Study of Plasma Caffeine Concentrations in a U.S. Sample of Smokers and
Nonsmokers". By Jose de Leon, Francisco Diaz, Thea Rogers, Debra Browne, Lori Dinsmore, Omar A. Ghosheh, Linda P. Dwoskin, and Peter A. Crooks, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2003, 27, 165-171 [78 citations].
254. "N-n-Alkylnicotinium Analogs, a Novel Class of Nicotinic Receptor Antagonists: Interaction
with 42* and 7* Neuronal Nicotinic Receptors". By Lincoln H. Wilkins, Peter A. Crooks,
and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., 2003, 304, 400-410 [38 citations].
255. "Drug Targeting to the Lung: Chemical and Biochemical Considerations". By Peter A.
Crooks and Abeer M. Al-Ghananeem, Invited Chapter in "Pharmaceutical Inhalation Aerosol Technology. Second Edition", Edit. Anthony Hickey, Marcel Dekker, Inc., NY, Chapter 4, pp 89-154, 2003.
256. “N,N-Disubstituted Piperazines: Synthesis and Affinities at 42* and 7* Neuronal Nicotinic
Acetylcholine Receptors”. By Jianhong Chen, Seth Norrholm, Linda P. Dwoskin, Peter A. Crooks, and Donglu Bai, Bioorganic and Medicinal Chemistry Letters, 2003, 13, 97-100.
59
257. “Active Transport of High Affinity Choline and Nicotine Analogs into the Central Nervous System by the Blood-Brain Barrier Choline Transporter”. By David D. Allen, Paul R. Lockman, Karen E. Roder, Linda P. Dwoskin, and Peter A. Crooks, J. Pharmacol. Exp. Therap., 2003, 304, 1268-1274 [56 citations].
258. “An In Vivo Evaluation of the Antiseizure Activity and Acute Neurotoxicity of Agmatine.” By
Aimee K. Bence, David R. Worthen, James P. Stables and Peter A. Crooks, Pharmacol.
265. "N-n-Alkylnicotinium and N-n-Alkylpyridinium Analogs Inhibit Dopamine Transporter Function:
Selectivity as Nicotinic Receptor Antagonists". By Jun Zhu, Peter A. Crooks, Joshua T.
Ayers, Sangitha P. Sumithran, and Linda P. Dwoskin, Drug Development Res., 2003, 60,
270-284.
266. “(Z)-2-Thiophen-3-ylmethylene-1-aza-bicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2003, E59, o1464-o1466.
267. “(Z)-2-(3-Hydroxy-4-methoxybenzylidene)-1-aza-bicyclo[2.2.2]octane-3-one”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2003, C59, o647-o649.
268. “(Z)-2-Benzo[b]thiophen-3-ylmethylene-1-aza-bicyclo[2.2.2]-octan-3-one”. By Vijayakumar N.
Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2003, E59, o1726-o1728.
60
269. “(Z)-2-(2,4-Dimethoxybenzylidene)-1-aza-bicyclo[2.2.2]octan-3-ol”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2003, E59, o2010-o2012.
270. “The Preparation of 2-Arylmethylidene-8-methyl-8-azabicyclo[3.2.1]octane-3-ones”. By
Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, Synth. Comm., 2004, 34(11), 1931-
1942.
271. “Toxicity of Dipyridyl Compounds and Related Compounds”. By Shenggang Li, Peter A.
Crooks, Xiaochen Wei, and Jose de Leon, Crit. Rev. Tox., 2004, 34, 447-460 [46 citations].
272. “Subtype-Selective Nicotinic Receptor Antagonists: Potential as Tobacco Use Cessation
Agents”. By Linda P. Dwoskin, Sangeetha Sumithran, Jun Zhu, A. Gabriela Deaciuc, Joshua
T. Ayers and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2004, 14, 1863-1867 [46 citations].
273. “Development of Subtype-Selective Ligands as Antagonists at Nicotinic Receptors Mediating
Nicotine-Evoked Dopamine Release”. By Peter A. Crooks, Joshua T. Ayers, Xu Rui,
Sangeetha P. Sumithran, Vladimir P. Grinevich, Lincoln Wilkins, A. Gabriela Deaciuc, David
D. Allen and Linda P. Dwoskin, Bioorg. Med. Chem. Lett., 2004, 14, 1869-1874 [32 citations].
274. “(Z)-2-(1H-Indol-3-ylmethylene)-1-aza-bicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o6-o8.
275. “Two isomers of 2,4-dibenzyl-8-azabicyclo[3.2.1]octane-3-ol”. By Guangrong Zheng, Sean
Parkin, Linda P. Dwoskin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o9-o11.
276. “Elimination of Alkaloids from Plant-Derived Human Monoclonal Antibody”. Kisung Ko, Xiaochen Wei, Peter A. Crooks, Hilary Koprowski, Journal of Immunological Methods, 2004, 286, 79-85 [17 citations].
Isomerization of the Z isomer to the E isomer”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, J. Chem. Crystallogr., 2004, 34, 239-244.
278. “Molecular Pathway for Thymoquinone-Induced Cell Cycle Arrest and Apoptosis in
Neoplastic Keratinocytes”. By Hala U. Gali-Muhtasib, Wassim G. Abou Kheir, Lynn A. Kheir, and Peter A. Crooks, Anticancer Drugs, 2004, 15(40), 389-399 [120 citations].
279. “(Z)-3-(1-Methyl-1H-indol-3-yl)-2-(thiophen-3-yl)acrylonitrile”. By Vijayakumar N. Sonar, Sean
Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o217-o218 [11 citations].
280. “A Duplex “Gemini” Prodrug of Naltrexone for Transdermal Delivery”. By Dana C. Hammell,
Mohamed O. Hamad, H. Kumar Vaddi, Peter A. Crooks, and Audra L. Stinchcomb, J. Controlled Release, 2004, 97, 283-290 [38 citations].
281. “Physicochemical Evaluation, In Vitro Human Skin Diffusion and Concurrent
Biotransformation of O-3-Alkylcarbonate Prodrugs of Naltrexone”. By Omathanu Pillai, Mohamed O. Hamad, Peter A. Crooks, and Audra L. Stinchcomb. Pharm. Research, 2004, 21, 1146-1152 [32 citations].
61
282. “Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular
Monoamine Transporters and Diminished Activity at 42 and 7 nAChRs”. By Dennis K. Miller, Peter A. Crooks, Guangrong Zheng, Vladimir P. Grinevich, Seth Norrholm, and Linda P. Dwoskin, J. Pharmacol. Exper. Therap., 2004, 310, 1035-1045 [57 citations].
283. "1-(2, 5-Dichloro-phenyl)-3-methyl-5-phenyl-1H-pyrazole". By Vijayakumar N. Sonar, Sean
Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o547-o549.
284. "(E)-N-Benzo[b]thiophen-3-ylmethylene-N-(2, 5-dichloro-phenyl) hydrazine". By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o550- o551,
285. “(Z)-2-(1-Phenylsulfonyl-1H-indol-3-ylmethylene)-1-aza-bicyclo[2.2.2]octan-3-one and
(±)-(Z)-2-(1-Phenylsulfonyl-1H-indol-3-ylmethylene)-1-aza-bicyclo[2.2.2]octan-3-ol”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2004, C60, o659-o661 [31 citations].
286. “4-Benzo[b]thiophen-3-yl-1-methyl-piperidine-4-carbonitrile”. By Vijayakumar N. Sonar, Sean
Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2004, E60, o1533-o1534.
287. “Indirect Trapping of the Retro-Conjugate Addition Reaction Intermediate Involved in Lobeline Epimerization: Application to the Synthesis of (-)-Sedamine”. By Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, J. Org. Chem., 2004, 69, 8514-8517 [20 citations].
288. “(Z)-3-(1H-Indol-3-yl)-2-thiophen-3-yl-acrylonitrile and (Z)-3-[1-(4-tert-Butyl-benzyl)-1H-indol-
3-yl]-2-thiophen-3-yl-acrylonitrile”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2005, C61, o78-o80 [17 citations].
289. “In Vivo Evaluation of 3-O-Alkyl Ester Transdermal Prodrugs of Naltrexone in Hairless
Guinea Pigs”. By Satyanarayana Valiveti, Dana C. Hammell, Kalpana S. Paudel, Mohamed O. Hamad, Peter A. Crooks, and Audra L. Stinchcomb, J. Controlled Release, 2005, 102, 509-520 [30 citations].
290. “Bioconversion of Naltrexone and Its 3-O-Alkyl Ester Prodrugs in a Human Skin Equivalent”.
By Dana C. Hammell, Elzbieta I. Stolarczyk, Mitch Klausner, Mohamed O. Hamad, Peter A. Crooks, and Audra L. Stinchcomb, J. Pharm. Sci., 2005, 94, 828-826 [22 citations].
291. “(Z)-2-Thiophen-3-yl-3-(3, 4, 5-trimethoxy-phenyl)acrylonitrile”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, o933-o935.
292. “Introduction of Unsaturation into the N-n-Alkyl Chain of the Neuronal Nicotinic Receptor Antagonists, NONI and NDNI: Effect on Affinity and Selectivity”. By Sangeetha P. Sumithran, Peter A. Crooks, Rui Xu, Jun Zhu, Agripina G. Deaciuc, Lincoln H. Wilkins, and Linda P. Dwoskin, AAPS Journal: AAPS-NIDA Symposium, Frontiers in Science: Drug Addiction: From Basic Research to Therapeutics, 2005, 7(1). E201-217 [10 citations].
293. “Molecular Modeling of Mono- and Bis-Quaternary Ammonium Salts as Ligands at the α4β2* Nicotinic Acetylcholine Receptor Subtype Using Non-Linear Techniques”. By Joshua T. Ayers, Aaron Clauser, Jeffrey D. Schmitt, Linda P. Dwoskin and Peter A. Crooks, AAPS
62
Journal: AAPS-NIDA Symposium, Frontiers in Science: Drug Addiction: From Basic Research to Therapeutics, 2005, 7(3), E678-E685 [16 citations].
294. “Human Skin Permeation of Branched Chain 3-O-Alkyl Ester and Carbonate Prodrugs
of Naltrexone”. By Haranath K. Vaddi, Mohamed O. Hamad, Jianhong Chen, Stan L. Banks, Peter A. Crooks, and Audra L. Stinchcomb, Pharm. Research, 2005, 22, 758- 765 [36 citations].
295. “In Vitro Release Studies on Matrix Type Transdermal Drug Delivery Systems of Naltrexone
and its Acetyl Prodrug”. By Buchi N. Nalluri, Caitlin Milligan, Jianhong Chen, Peter A. Crooks, and Audra L. Stinchcomb, Drug Development and Industrial Pharmacy, 2005, 31, 871-877 [22 citations].
296. “3D-QSAR Study of bis-Azaaromatic Quaternary Ammonium Analogs at the Blood-Brain
Barrier Choline Transporter”. By Werner J. Geldenhuys, Paul R. Lockman, Tiffany H. Nguyen, Cornelis J. Van der Schyf, Peter A. Crooks, Linda P. Dwoskin, and David D. Allen, Biorg. Med. Chem., 2005, 13, 4253-4261 [26 citations].
297. “In Vitro/In Vivo Correlation of Transdermal Naltrexone Prodrugs in Hairless Guinea Pigs”. By
Satyanarayana Valiveti, Kalpana S. Paudel, Dana C. Hammell, Mohamed O. Hamad, Jianhong Chen, Peter A. Crooks, and Audra L. Stinchcomb, Pharm. Research., 2005, 22, 981-989 [36 citations].
298. “A General Procedure for the Enantioselective Synthesis of the CNS-active Minor Tobacco
Alkaloids: Nornicotine, Anabasine and Anatabine”. By Joshua T. Ayers, Rui Xu, Linda P.
Dwoskin, and Peter A. Crooks, AAPS Journal: AAPS-NIDA Symposium, Frontiers in Science:
Drug Addiction: From Basic Research to Therapeutics, 2005, 7(3), E752-E758 [13 citations].
299. “Lobeline Analogues as Novel Ligands for the Vesicular Monoamine Transporter”. By Guangrong Zheng, Linda P. Dwoskin, Agripina G. Deaciuc, Seth D. Norholm, Marlon D. Jones, and Peter A. Crooks, Bioorganic Med. Chem., 2005, 13, 3899-3909 [32 citations].
300. “Evaluation of O3-, O21-DI-(N1-Methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl)17-
hydroxy-5-pregnan-20-one as a Novel Potential Antiangiogenic Codrug”. By Michelle Howard-Sparks, Abeer M. Al-Ghananeem, Andrew P. Pearson, and Peter A. Crooks, J. Enzyme Inhibit. Med. Chem., 2005, 20, 417-428 [10 citations].
301. “Defunctionalized Lobeline Analogues: Structure-Activity of Novel Ligands for the Vesicular
Monoamine Transporter”. By Guangrong Zheng, Linda P. Dwoskin, A. Gabriela Deaciuc, Seth D. Norrholm, and Peter A. Crooks, J. Medicin. Chem., 2005, 48, 5551-5560 [51 citations].
302. “Transdermal Delivery of Naltrexone and its Active Metabolite 6-beta-Naltrexol in Human
Skin In Vitro and Guinea Pigs In Vivo”. By Kalpana S. Paudel, Nalluri B Naidu, Paul Kiptoo, Dana Hammell, Mohamed O. Hamad, Satyanarayana Valiveti, Peter A. Crooks, and Audra L. Stinchcomb, J. Pharm. Sci., 2005, 94, 1965-1975 [34 citations].
303. “Novel Antiglaucoma Prodrugs and Codrugs of Ethacrynic Acid”. By Grazyna Cynkowska,
Tadeusz Cynkowski, Abeer A. Al-Ghananeem, Hong Guo, Paul Ashton, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2005, 15, 3524-3527 [29 citations].
63
304. “The Characterization of a Novel α7-selective nAChR Agonist and the Modulation of Agonist Properties by Boron Inclusion”. By Roger L. Papke, Linda Dwoskin, Nicole A. Horenstein, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2005, 15, 3874-3880 [11 citations].
305. “N-(2, 5-Dichlorophenyl)-N’-[(E)-3-thienyl-methylene]hydrazine”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, 01907-o1909.
306. “Modeling Multiple Species of Nicotine and Deschloroepibatidine Interacting with α4β2 Nicotinic Acetylcholine Receptors: From Microscopic binding to Phenomenological Binding Affinity”. By Xiaoqin Huang, Fang Zheng, Peter A. Crooks, Linda P. Dwoskin and Chang-Guo Zhan, J. Amer. Chem. Soc., 2005, 127, 14401-14414 [49 citations].
307. “6-Acetoxy-4, 5-epoxy-3-methoxy-17-methyl-morphin-7-ene”. By Vijayakumar N. Sonar, Sean
Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, o2579-2581.
308. “(E)-2-Methyl-3-(2-methyl-2-nitrovinyl)-1H-indole and (E)-3-(2-Methyl-2-nitrovinyl)-2-phenyl-1H-indole”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2005, C61, o527-o530.
309. “A 1R, 2R, 5R-(+)-2α-hydroxypinan-3-one Ketimine”. By Joshua T. Ayers, Vijayakumar N.
Sonar, Sean Parkin, Linda P. Dwoskin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, o2682-o2684.
310. “Synthesis and Evaluation of a Series of Tropane Analogues as Novel Vesicular Monoamine
Transporter-2 Ligands”. By Guangrong Zheng, Linda P. Dwoskin, Agripina G. Deaciuc, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2005, 15, 4463-4466.
311. “Identification and Synthesis of Novel Alkaloids from the Root System of Nicotiana tabacum:
Affinity for Neuronal Nicotinic Acetylcholine Receptors". By Xiaochen Wei, Sangeetha P. Sumithran, A. Gabriela Deaciuc, Harold R. Burton, Lowell P. Bush, Linda P. Dwoskin and Peter A. Crooks, Life Sciences: Special Issue, National Institutes of Health (NIDA) Symposium on Naturceuticals and Nutraceuticals, 2005, 78, 495-505 [48 citations].
312. “(Z)-2-(3-Methoxybenzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2005, C61, o660-o661.
313. “(Z)-2-(3-Nitro-benzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, o3254-o3256.
314. “(2E,4E)-8-Methyl-2,4-bis-thiophen-3-ylmethylene-8-azabicyclo[3.2.1]octan-3-one”. By
Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2005, E61, o3445-o3446.
315. “Effect of a Novel Nicotinic Receptor Antagonist, N,N’-dodecane-1,12-diyl-bis-picolinium
dibromide (bPiDDB), on Nicotine Self-Administration and Hyperactivity in Rats”. By Nicole M.
Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin and Michael T. Bardo,
316. "N-Alkylnicotinium Analogs, a Novel Class of Antagonists at α4β2* Nicotinic Acetylcholine
Receptors: Inhibition of Nicotine-Evoked 86Rb+ Efflux from Rat Thalamic Synaptosomes". By
Lincoln H. Wilkins, Jr., Dennis K. Miller, Joshua T. Ayers, Peter A. Crooks, and Linda P.
64
Dwoskin, AAPS Journal: AAPS-NIDA Symposium, Frontiers in Science: Drug Addiction:
From Basic Research to Therapeutics, 2006, 7(4), Article 90, E922-E930.
317. “QSAR Modeling of mono- and bis-Quaternary Ammonium Salts that Act as Antagonists at Neuronal Nicotinic Acetylcholine Receptors Mediating Dopamine Release”. By Fang Zheng, Ersin Bayram, Sangeetha P. Sumithran, Joshua T. Ayers, Chang-Guo Zhan, Jeffrey D. Schmitt, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic Medicinal Chem., 2006, 14, 3017-3037 [44 citations].
318. “Synthesis and Stability of Two Indomethacin Prodrugs”. By Shyamala Chandrasekaran,
Abeer M. Al-Ghananeem, Robert M. Riggs, and Peter A. Crooks, Biorg. Med. Chem. Lett., 2006, 16, 1874-1879 [17 citations].
319. “(Z)-2-(2-Methoxy-benzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N.
Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o393-o395.
320. “(Z)-2-(4-Methoxy-benzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o396-o397.
321. “Effect of pH on Sublingual Absorption of Oxycodone Hydrochloride”. By Abeer M. Al-
Ghananeem, Ahmad Malkawi, and Peter A. Crooks, AAPS PharmSciTech, 2006, 7(1), E163-E167 [23 citations].
one” By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr. Section E, 2006, E62, o623-o625.
323. “1-(1H-Indol-3-ylcarbonyl)-N-(4-methoxybenzyl)-formamide”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2006, C62, o153-o154.
324. “Methyl (E)-2-cyano-3-(1H-indol-3-yl)acrylate”. By Vijayakumar N. Sonar, Sean Parkin,
and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o1077-o1078.
325. “N, N-Disubstituted Piperazines and Homopiperazines: Synthesis and Affinities at 42*
and 7* Neuronal Nicotinic Acetylcholine Receptors”. By Jianhong Chen, Agripina G. Deaciuc, Linda P. Dwoskin, Donglu Bai and Peter A. Crooks, J. Enz. Inhibit. Med. Chem., 2006, 21(6), 667-680.
326. “Enhancement of Transdermal Delivery of 6--Naltrexol via a Codrug Linked to
Hydroxybupropion”. By Paul K. Kiptoo, Mohamed, O. Hamad, Peter A. Crooks, and Audra L. Stinchcomb, J. Controlled Release, 2006, 113, 137-145 [38 citations].
327. “Opiate Receptor Binding Properties of Morphine-, Dihydromorphine-, and Codeine-6-O- Sulfate Ester Congeners”. By Peter A. Crooks, Santosh Kottayil, Abeer M. Al- Ghananeem, Stephen R. Byrn, and D. Alan Butterfield, Bioorg. Med. Chem. Lett., 2006, 16, 4291-4295 [15 citations].
328. “Synthesis and Hydrolytic Behavior of Two Novel Tripartate Codrugs of Naltrexone and 6β-Naltrexol with Hydroxybupropion as Potential Alcohol Abuse and Smoking Cessation
65
Agents”. By Mohamed O. Hamad, Paul K. Kiptoo, Audra L. Stinchcomb, Peter A. Crooks, Bioorg. Med. Chem., 2006, 14, 7051-7061 [41 citations].
329. “1-(4-Methoxybenzyl)-1H-indole-3-carbaldehyde”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o3231-o3232.
330. “Vesicular Monoamine Transporter 2: Role as a Drug Target for Ligand Development”. By
Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, AAPS Journal: NIDA -AAPS Symposium on Drugs of Abuse: Mechanisms of Toxicity, Toxicokinetics and Medical Consequences of Drugs of Abuse", 2006, 8(4), Article 78, E682-E692 [98 citations].
331. “(E)-1-Benzyl-3-(2-nitrovinyl)-1H-indole”. By Vijayakumar N. Sonar, Sean Parkin, and
Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o3328-o3330.
332. “1-(4-tert-Butylbenzyl)-1H-indole-3-carbaldehyde”. By Vijayakumar N. Sonar, Sean
Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o3380-o3381.
333. “Des-keto Lobeline Analogs with Increased Potency and Selectivity at Dopamine and
Serotonin Transporters”. By Guangrong Zheng, David Horton, Agripina G. Deaciuc,
Linda P. Dwoskin, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters,
2006, 16, 5018-5021.
334. “(Z)-2-Thiophen-2-ylmethylene-1-azabicyclo[2.2.2]octan-3-one”. By
Vijayakumar N. Sonar, M. Venkatraj, Sean Parkin, and Peter A. Crooks, Acta
Crystallogr., Section E, 2006, E62, o5869-o5870.
335. “1-Azepan-1-yl-2-(1H-indol-3-yl)ethane-1,2-dione”. By Vijayakumar N. Sonar,
Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62,
o3744-o3746.
336. “Assessment of Nasal Drug Delivery in Humans Using Radionuclide Imaging Techniques”.
By Abeer M. Al-Ghananeem and Peter A. Crooks, Pharmaceutical Formulation and
Quality, 2006, 8(4), 38-43.
337. “Translation in Tobacco and Drug Abuse Prevention Research”, By M. A. Pentz, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Eval. Health Prof., 2006, 29, 246-271.
338. “(Z)-2-(Cyclohexylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N.
Sonar, M. Venakataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2006, E62, o5576-5577.
339. “Nornicotine Inhibition of Dopamine Transporter Function in Striatum via Nicotinic Receptor Activation”. By Lisa S. Middleton, Peter A. Crooks, Peter J. Wedlund, Wayne A. Cass, and Linda P. Dwoskin, Synapse, 2006, 61(3), 157-165.
340. “(Z)-2-(1, 3-Benzodioxol-5-ylmethylene)-1-azabicyclo[2.2.2]octan-3-one”. By
Vijayakumar N. Sonar, M. Venkataraj, Sean Parkin, and Peter A. Crooks, Acta
Crystallogr., Section E, 2006, E62, o5742-o5744.
341. “(Z)-2-(2-Methylbenzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By
66
Vijayakumar N. Sonar, M. Venkataraj, Sean Parkin, and Peter A. Crooks, Acta
Crystallogr., Section E, 2006, E62, o5738-o5739.
342. “Modeling Subtype-Selective Agonists Binding with α4β2 and α7 Nicotinic Acetylcholine
Receptors: Effects of Local Binding and Long-Range Electrostatic Interactions”. By Xiaoqin Huang, Xi Chen, Fang Zheng, Peter A. Crooks, Linda P. Dwoskin, and Chang Guo Zhan, J. Medicin. Chem., 2006, 49, 7661-7674 [48 citations].
343. “(Z)-2-(4-Methylbenzylidene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N.
Sonar, M. Venkataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr.,
Section E, 2006, E62, o5740-o5741.
344. “Effects on Nornicotine Enantiomers on Intravenous S(-)-Nicotine Self-
Administration and Cardiovascular Function in Rats”. By Dustin J. Stairs, Nicole M. Neugebauer, Xiaochen Wei, C. Boustany, Marhaba Hojahmet, Lisa A. Cassis, Peter A. Crooks, and Linda P. Dwoskin, Michael T. Bardo, Psychopharmacology, 2007, 190, 145-155. 345. “Novel Chemical Enhancers of Heat Shock Increase Thermal Radiosensitization Through a Mitotic Catastrophe Pathway”. By Konjeti R Sekhar, Vijayakumar N. Sonar, Venkatraj Muthusamy, Soumya Sasi, Andrei Laszlo, Jamil Swani, Nobuo Horikoshi, Ryji Higashikubo, Robert G. Bristow, Michael J. Borrelli, Peter A. Crooks, James R. Lepock, Joseph L. Roti Roti, and Michael L. Freeman, Cancer Res., 2007, 67, 695-701 [34 citations]. 346. “Scopolamine Sublingual Spray: An Alternative Route of Delivery for the Treatment of
Motion Sickness”. By Abeer Al-Ghananeem, Ahmad H. Malkawi, and Peter A. Crooks,
Drug Development and Industrial Pharmacy, 2007, 33, 577-582. 347. “A Novel Chemical Delivery System Comprising an Ocular Sustained Release
Formulation of 3α, 17α, 21-Trihydroxy-5-pregnan-20-one-BIS-5-fluorouracil Codrug. By Michelle Howard-Sparks, Abeer M. Al-Ghananeem, Andrew P. Pearson, and Peter
A. Crooks, Drug Development and Industrial Pharmacy, 2007, 33, 677-682. 348. “The Effects of a Novel Nicotinic Receptor Antagonist N, N-Dodecane-1, 12-diyl-bis-
picolinium dibromide (bPiDDB) on Acute and Repeated Nicotine-induced Increases in Extracellular Dopamine in Rat Nucleus Accumbens”. By Shafiq Rahman, Nicole M. Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Neuropharmacology, 2007, 52, 755-763 [35 citations].
349. “Tablet Formulation Studies on Nimesulide- and Meloxican-Cyclodextrin Binary Systems”. Buchi N. Nalluri, K. P. R. Chowdary, K. V. R. Murthy, G. Becket, and Peter A. Crooks, AAPS PharmSciTech, 2007, 8(2), Article 36, E1-E7 [27 citations].
350. “A Pharmacokinetic Study on 3-(N-Benzylindole-3-yl)methylenequinuclidin-3-ol; a Novel
Radiosensitization Agent”. By Abeer M. Al-Ghananeem, Zaineb Al-Beyati, Ahmad Malkawi, Vijayakumar Sonar, and Peter A. Crooks, Cancer Chemother. Pharmacol., 2007, 60, 915-919.
351. “(Z)-2-(1-Benzyl-5-nitro-1H-indol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-one”. By Vijayakumar N. Sonar, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section C,
67
2007, C63, o135-o136.
352. “The Pharmacological Activity of Nicotine and Nornicotine on nAChR Subtypes: Relevance to Nicotine Dependence and Drug Discovery”. By Roger L. Papke, Linda P. Dwoskin, and Peter A. Crooks, J. Neurochemistry, 2007, 101, 160-167 [46 citations].
353. “(E)-1-(2-Methoxyphenyl)methyleneaminoguanidine monohydrochloride. By Vijayakumar N. Sonar, Sundar Neelakantan, Maxime Siegler and Peter A. Crooks, Acta Crystallogr., Series E, 2007, E63, o535-536. 354. “Computational Neural Network Analysis of the Affinity of Lobeline and Tetrabenazine Analogs for the Vesicular Monoamine Transporter-2”. By Fang Zheng, Guangrong Zheng, A. Gabriela Deaciuc, Chang-Guo Zhan, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem., 2007, 15, 2975-2992 [21 citations]. 355. “(E)-1-(2-Chlorophenyl)methyleneaminoguanidine hydrochloride”. By Vijayakumar N. Sonar, Joshua R. Ring, Maxime Siegler and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o974-o975. 356. “Rac-(Z)-2-Thiophen-2-ylmethylene-1-azabicyclo[2.2.2]octan-3-ol”. By Vijayakumar N.
Sonar, M. Venkataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C,
2007, C63, o493-o495.
357. “(Z)-2-[(Phenylsulfonyl-1H-indol-3-yl)methylene]-1-azabicyclo[2.2.2]octan-3-one Semicarbazone”. By Vijayakumar N. Sonar, M. Venkataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section C, 2007, C63, o277-o279. 358. “Supression of Pancreatic Tumor Growth by Combination Therapy with Sulindac and LC-1 is Associated with Cyclin D1 Inhibition In Vivo”. By Michele T. Yip-Schneider, Huangbing Wu, Matthew Ralstin, Constantin Yiannoutsos, Peter A. Crooks, Sundar Neelakantan, Steven Noble, Harikrishna Nakshatri, Christopher J. Sweeney, and C. Max Schmidt, Mol. Cancer Therapeutics, 2007, 6(6):1736-1744 [39 citations]. 359. “Phase I and Phase II Ocular Metabolic Activities and the Role of Metabolism in Ophthalmic Prodrug and Codrug Design and Delivery”. By Abeer M. Al-Ghananeem and Peter A. Crooks, Molecules, 2007, 12, 373-388. [20 citations]. 360. “(4-Methoxy-3-nitrobenzylidenamino)guanidine Hydrochloride”. By Joshua R. Ring, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section C, 2007, C63, o392-o394. 361. “Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer”. By Reid C. Vegeler, Michele T. Yip-Schneider, Matthew Ralstin, Huangbing Wu, Peter A. Crooks, Sundar Neelakantan, Harikrishna Nakshatri, Christopher J. Sweeney, and C. Max Schmidt, Journal of Surgical Research, 2007, 143, 169-176. 362. “Benzyl 2, 6-Dihydroxy-3-nitrobenzoate”. By Vijayakumar N. Sonar, M.
Venkataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E,
2007, E63, o3226.
363. “Methyl 2, 6-dihydroxy-3-nitrobenzoate”. By Vijayakumar N. Sonar, M.
Venkataraj, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E,
68
2007, E63, o3227.
364. “Discovery of a Novel Nicotinic Receptor Antagonist for the Treatment of
Dibromide (TMPD)”. By Linda P. Dwoskin, Barry M. Joyce, Guangrong Zheng,
Nichole M. Neugebauer, Vamshi K. Manda, Paul Lockman, Roger L. Papke,
Michael T. Bardo, and Peter A. Crooks, Biochemical Pharmacology, 2007, 74,
1271-1282 [10 citations].
365. “An HPLC Method for the Simultaneous Determination of Neurotoxic Dipyridyl
Isomers in Human Plasma”. By Ahmad Malkawi, Abeer Al-Ghananeem,
Shama Naseem, Xiaochen Wei, Jose de Leon, and Peter A. Crooks, J.
Pharm. Biomed. Anal., 2007, 45, 120-124.
366. "Lobelane Decreases Methamphetamine Self-administration in Rats”. By Nicole M.
Neugebauer, Steven B. Harrod, Dustin J. Stairs, Peter A. Crooks, Linda P. Dwoskin,
and Michael T. Bardo, European Journal of Pharmacology, 2007, 571, 33-38
[49 citations].
367. “The Radiosensitization Effect of Parthenolide in Prostate Cancer Cells is Mediated by NF-кB Inhibition and Enhanced by the Presence of PTEN”. By Yulan Sun, Daret K. St. Clair, Fang Fang, Graham W. Warren, Vivek M. Rangnekar, Peter A. Crooks, and William H. St. Clair, Molecular Cancer Therapeutics, 2007, 6(9), 2477-2486 [61 citations. 368. “An Orally Biovailable Parthenolide Analog Selectively Eradicates Acute Myelogenous Leukemia Stem Cells and Progenitor Cells”. By Monica L. Guzman, Randall M. Rossi, Sundar Neelakantan, Xiaojie Li, Cheryl Corbett, Duane C. Hassane, Michael W. Becker, John M. Bennet, Edmund Sullivan, Joshua L. Lachowicz, Christopher Sweeney, William Matthews, Martin Carroll, Peter A. Crooks, and Craig T. Jordan, Blood, 2007, 110, 4427- 4435 [308 citations]. 369. “rac-(Z)-2-(2,4-Dichlorobenzylidene)-1-azabicyclo[2.2.2]octan-3-ol”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o3907. 370. “rac-(Z)-2-(Naphthalen-1-ylmethylene)-1-azabicyclo[2.2.2]octan-3-ol”. By Vijayakumar N. Sonar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o3915. 371. “(11R)-13-(Benzylamino)-4,5-epoxy-11,13-dihydrocostunolide”. By Shama Nasim, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o3922. 372. “(Z)-3-[1-(4-Chlorobenzyl)-1H-indol-3-yl]-2-(3-thienyl)acrylonitrile”. Vijayakumar N. Sonar,
Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o3979.
373. “bis-Azaaromatic Quaternary Ammonium Salts as Antagonists at Nicotinic Receptors
Mediating Nicotine-Evoked Dopamine Release: An Investigation of Binding Conformation”.
By Guangrong Zheng, Zhenfa Zhang, Marharyta Pivavarchyk, Agripina G. Deaciuc, Linda
P. Dwoskin and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, 2007, 17,
6734-6738 [11 citations].
69
374. “tris-Azaaromatic Quaternary Ammonium Salts: Novel Templates as Antagonists at
Nicotinic Receptors Mediating Nicotine-Evoked Dopamine Release”. By Guangrong
Zheng, Sangeetha P. Sumithran, Agripina G. Deaciuc, Linda P. Dwoskin and Peter A.
Benzylindol-3-ylmethylene)quinuclidin-3-ol Derivatives as Potent Thermal Sensitizing
Agents”. By Vijayakumar N. Sonar, Y. Thirupathi Reddy, Konjeti R. Sekhar, Soumya Sasi,
Michael L. Freeman, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters,
2007, 17, 6821-6824 [22 citations].
376. “(11R)-13-(Naphthylmethylamino)-4, 5-epoxy-11,13-dihydrocostunolide”. By Shama Nasim, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E63, o4274. 377. “(E)-3-(Benzo[b]thiophen-2-yl)-2-(3,4,5-trimethoxyphenyl)acrylonitrile and (Z)-3- (benzo[b]thiophen-2-yl)-2-(3,4-dimethoxyphenyl)acrylonitrile”. By Vijayakumar N. Sonar, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section C, 2007, C63, o743-o745. 378. “3-Ethyl-2-methyl-5-methylene-6,7-dihydroindol -4(5H)-one”. By Vijayakumar N. Sonar, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2007, E64, 0158.
379. “Carrrier Mediated Transport at the Blood-Brain Barrier for the Quaternary Ammonium
Nicotinic Receptor Antagonist, N, N’-Dodecyl-bis-picolinium bromide (bPiDDB)”. By Paul R. Lockman, Werner J. Geldenhuys, Vamshi Manda, Fancy Thomas, Peter A. Crooks, Linda P. Dwoskin and David D. Allen, J. Pharmacol. Exp. Therap., 2008, 324, 244-250 [19 citations].
380. “Modern Instrumental Methods for Studying Mechanisms of Toxicology.” By Peter A. Crooks, David R. Worthen, Gary D. Byrd, J. Donald deBethizy, and William S. Caldwell, Invited Chapter in: Principles and Methods of Toxicology, Fifth Edition, Ed. A. Wallace Hayes, Taylor & Francis, Philadelphia, 2008, Chapter 41, pp 2041-2112. 381. “Region-specific Effects of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB) on Nicotine-induced Increase in Extracellular Dopamine In Vivo”. By Shafiqur Rahman, Zhenfa Zhang, Roger L. Papke, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Brit. J. Pharmacol., 2008, 153, 792-804 [18 citations]. 382. “(11R), (13R)-1-aminotetralino)-4,5-epoxy-11,13-dihydrocostunolide”. By Shama Nasim, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2008, E64, o639. 383. “(11R)-13-(4-Hydroxyphenylethylamino)-4,5-epoxy-11,13-dihydrocostunolide”. By Shama Nasim, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2008, 64E, o644. 384. “Tetrabenzylpyrophosphate: An Efficient Catalyst for the Synthesis of Carboxamides from Carboxylic Acids and Amines”. By Y. Thirapathy Reddy, P. Narsimha Reddy, P. Raghotham Reddy, and Peter A. Crooks, Chem. Lett., 2008, 37(5), 528-529. 385. “Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery". By Ahmad Malkawi, Abeer M. Al- Ghananeem, and Peter A. Crooks, AAPS Journal, 2008, 10, 261-267 [22 citations].
70
386. “In Vivo Evaluation of a Transdermal Codrug of 6-Beta-Naltrexol linked to Hydroxybupropion in Hairless Guinea Pigs”. By Paul K. Kiptoo, Kalpana S. Paudel, Dana C. Hammell, Mohamad O. Hamad, Peter A. Crooks, and Audra L. Stinchcomb, Europ. J. Pharm. Sci., 2008, 33, 371-379 [24 citations]. 387. “Sulfamic Acid: An Efficient, Cost-effective and Reusable Solid Acid Catalyst for the Synthesis of 1, 8-Naphthyridines Under Solvent-free Heating and Microwave Irradiation”. By Y. Thirupathi Reddy, P. Raghotham Reddy, B. Rajitha, M. Nikhil Reddy, and Peter A. Crooks, Synth. Comm., 2008, 38, 3201-3207. 388. “CuPy2Cl2: A Novel and Efficient Catalyst for Synthesis of Propargylamines under Conventional Method and Microwave Irradiation”. By J. Venu Madhav, B. Suresh Kuarm, P. Someshwar, B. Rajitha, Y.Thirupathi Reddy and Peter A. Crooks, Synth. Comm., 2008, 32, 3215-3223. 389. “Effect of Celecoxib and the Novel Anti-cancer Agent Dimethylamino-parthenolide in a Developmental Model of Pancreatic Cancer”. By Michele Yip-Schneider, Huangbing Wu, Victor Njoku, Matthew Ralstin, Bryan Holcomb, Peter Crooks, Sundar Neelakantan, Christopher Sweeney, and C. Max Schmidt, Pancreas, 2008, 37, e45-53 [19 citations]. 390. “Ceric Ammonium Nitrate (CAN): An Efficient Catalyst for Coumarin Synthesis via Pechmann Condensation using Conventional Heating and Microwave Irradiation”. By Y. Thirupathi Reddy, Vijayakumar N. Sonar, Peter A. Crooks, Pavan K. Dasari, P. Narsimha Reddy, and B. Rajitha, Synth. Comm., 2008, 38(12), 2082-2088 [30 citations]. 391. “The NF-κB Subunit, Rel A, is Associated with In Vitro Survival and Clinical Disease Progression in Chronic Lymphocytic Leukemia and Represents a Promising Therapeutic Target”. By Saman Hewamana, Suhair Alghazal, Thet Thet Lin, Mathew Clement, Chris Jenkins, Monica Guzman, Craig T. Jordan, Sundar Neelakantan, Peter A. Crooks, Alan K. Burnett, Guy Pratt, Chris Fegan, Clare Rowntree, Paul Brennan and Chris Pepper, Blood, 2008, 111, 4681-4689 [144 citations]. 392. “The Radiosensitizing Effects of L-Canavanine”. By David R. Worthen and Peter A. Crooks, In: Herbal Radiomodulators: Applications in Medicine, Homeland Defence and Space. Edit. Rajesh Arora, Chapter 18, pp 255-269, CABI Publishing, UK, 2008. 393. “Extending the Analysis of Nicotinic Receptor Antagonists with the Study of Alpha6 Nicotinic Receptor Subunit Chimeras”. By Roger L. Papke, Linda P. Dwoskin, Clare Stokes, Guangrong Zheng, Zhenfa Zhang, J. Michael McIntosh, and Peter A. Crooks, Neuropharmacology, 2008, 54, 1189-1200 [53 citations]. 394. “Flux Across Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol In Vitro”. By Stan L. Banks, Harvinder S. Gill, Mark R. Prausnitz, Peter A. Crooks, and Audra L. Stinchcomb, Pharm. Research., 2008, 25, 1677-1685 [45 citations]. 395. “Synthesis of 2-(Pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(Pyridin-3-yl)-1-azabicyclo- [2.2.2]octane, and 2-(Pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a Class of Potent Nicotinic Acetylcholine Receptor–Ligands”. By Balwinder S. Bhatti, Jon-Paul Strachan, Scott R. Breining, Craig H. Miller, Persida Tahiri, Peter A. Crooks, Niranjan Deo, Cynthia S. Day, and William S. Caldwell, J. Org. Chem., 2008, 73, 3497-3507.
71
396. “Dipyridine Cobalt Chloride: a Novel Catalyst for the Synthesis of Coumarins via
Pechmann Condensation”. J. Venu Madhav, B. Suresh Kuarm, P. Someshwar, B. Rajitha, Y. Thirupathi Reddy, and Peter A. Crooks, J. Chem. Research, 2008, No. 4, 232-234.
397. “N,N’-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-induced Dopamine Release and Hyperactivity”. By Linda P. Dwoskin, Thomas E. Wooters, Sangeetha P. Sumithran, Kiran B. Siripurapu, B. Matthew Joyce, Paul R. Lockman, Vamshi K. Manda, Joshua T. Ayers, Zhenfa Zhang, J. Michael McIntosh, Peter A. Crooks and Michael T. Bardo, J. Pharmacol. Exp. Therap., 2008, 326, 563-576 [33 citations]. 398. “Effects of Norketamine Enantiomers in Rodent Models of Persistent Pain”. By Joseph R. Holtman, Jr., Peter A. Crooks, Jamie K. Johnson, Marhaba Hojahmat, Mark Kleven and Elzbieta P. Wala, Pharm. Biochem. Behav., 2008, 90, 676-685 [42 citations]. 399. “Smoking Risk and the Likelihood of Quitting Among African American Female Light and Heavy Smokers”. By Anita Fernander, Mitzi Schumacher, Xiaochen Wei, Peter Wedlund, and Peter A. Crooks, J. National Medical Assoc., 2008, 100, 1199-1206. 400. “Interaction Between Morphine and Norketamine Enantiomers in Rodent Models of Nociception”. By Joseph R. Holtman, Peter A. Crooks, Jaime Johnson and Elzbieta P. Wala, Pharmacol. Biochem. Behavior, 2008, 90, 769-777 [19 citations]. 401. “Pharmacokinetics of the Novel Nicotinic Receptor Antagonist, N,N’-dodecane-1,12-diyl- bis- picolinium dibromide (bPiDDB)”. By Zaineb A. Fadhel Albayati, Linda P. Dwoskin, and Peter A. Crooks, Drug Metabolism and Disposition, 2008, 36, 2024-2029 [11 citations]. 402. “Antileukemic Activity of Aminoparthenolide Analogs”. By Shama Nasim and Peter A. Crooks, Bioorganic and Med. Chem. Letters, 2008, 18, 3870-3873 [36 citations]. 403. “Synthesis of Symmetrical 2,6-Disubstituted Granatanines”. By Ashish P. Vartak, Linda P. Dwoskin, and Peter A. Crooks, Tetrahedron Lett., 2008, 49, 6330-6333. 404. “tetrakis-Azaaromatic Quaternary Ammonium Salts: Novel Subtype-selective Antagonists at Neuronal Nicotinic Receptors that Mediate Nicotine-evoked Dopamine Release”. By Zhenfa Zhang, Guangrong Zheng, Marharyta Pivavarchyk, A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic Med. Chem. Letters, 2008, 18, 5753- 5757. 405. “bis-Pyridinium Cyclophanes: Novel Ligands with High Affinity for the Blood-Brain Barrier
Choline Transporter”. By Zhenfa Zhang, Paul R. Lockman, Rajender K. Mittapalli, David D. Allen, Linda P. Dwoskin and Peter A. Crooks, Bioorganic Med. Chem. Lett., 2008, 18, 5622-5625. [10 citations].
406. “(Z)-4-[(3-((3-Oxoquinuclidin-2-ylidene)methyl]-1H-indol-1-yl)methylbenzonitrile”. By Thirupathi Reddy Yerram Reddy, Narsimha Reddy Penthala, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2008, E64, o2049. 407. “(Z)-Methyl 4-{[3-(3-oxoquinuclidin-2-ylidene)methyl-1H-indol-1-yl]methyl}benzoate”. By Thirupathi Reddy Yerram Reddy, Narsimha Reddy Penthala, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2008, E64, o2050.
72
408. “The Novel Nicotinic Receptor Antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium Dibromide Decreases Nicotine-induced Dopamine Metabolism in Rat Nucleus Accumbens”. By Shafiqur Rahman, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, European Journal of Pharmacology, 2008, 601, 103-105. 409. “(Z)-4-({3-[2,5-dioxoimidazolidin-4-ylidene)methyl]-1H-indol-1-yl}methyl)benzonitrile”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerram Reddy, Sean Parkin and Peter A. Crooks, Acta Crystallogr. E, 2008, E64, o2122. 410. “Synthesis and Evaluation of a Series of Homologous Analogues of Lobelane at the Vesicular Monoamine Transporter-2”. By Guangrong Zheng, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2008, 18, 6509-6512 [20 citations].
411. “Nuclear Factor-Bas a Potential Therapeutic Target for the Novel Cytoxic Agent LC-1 in Acute Myeloid Leukaemia”. By Christopher Jenkins, Saman Hewamana, Amanada Gilkes, Sundar Neelakantan, Peter A. Crooks, Ken Mills, Chris Pepper, and Alan Burnett, Br. J. Haematol. 2008, 143, 661-671 [30 citations].
412. “Synthesis and Biological Evaluation of Novel Substituted N1-[1-Benzyl-3-(3-tert- butylcarbamoyl-octahydroisoquinolin-2-yl)-2-hydroxypropyl]-2-[(2-oxo-2H-chromene-3- carbonyl)amino]succinamide Analogs as Anti-Viral and Anti-HIV Agents”. By Y. Thirupathi Reddy, P. Narsimha Reddy, Peter A. Crooks, Erik De Clercq, G. V. Panakala Rao, and B. Rajitha, Heterocyclic Communications, 2009, 14 (6), 419-426.
413. “Cellulose Sulfuric Acid: An Efficient Biodegradable and Recyclable Solid Acid Catalyst for the One-pot Synthesis of Aryl-14H-dibenzo[a.j]xanthenes Under Solvent-free Conditions”. By J. Venu Madhav, Y. Thirupathi Reddy, P. Narsimha Reddy, M. Nikhil Reddy, Suresh Kuarm, Peter A. Crooks, and B. Rajitha, Journal of Molecular Catalysis-A, 2009. Chemical 304, 85-87 [74 citations]. 414. “Sulfamic Acid Catalyzed One-pot Synthesis of 2,5-Diaryl-1,3,4-Oxadiazoles Under Microwave Irradiation and Conventional Heating”. By J. Venu Madhav, Y. Thirupathi Reddy, P. Narsimha Reddy, Peter. A. Crooks, V. Naveen Kumar and B. Rajitha, J. Heterocyclic Chemistry, 2009, 46, 289-293. 415. “Cellulose Sulfuric Acid: An Efficient Biodegradable and Recyclable Solid Acid Catalyst for the One-pot Synthesis of 3,4-Dihydropyrimidine-2(1H)-ones”. By Penthala Narsimha Reddy, Y. Thirupathi Reddy, M. Nikhil Reddy, Bavntula Rajitha, and Peter. A. Crooks, Synth. Comm., 2009, 39, 1257-1263 [34 citations]. 416. “Human Skin Permeation of 3-O-Alkyl Carbamate Prodrugs of Naltrexone”. By Haranath K. Vaddi, Stan L. Banks, Jianghong Chen, Dana C. Hammell, Peter A. Crooks, and Audra L. Stinchcomb, J. Pharm. Sci., 2009, 98, 2611-2625 [17 citations].
417. “A Scalable, Enantioselective Synthesis of the α2-Adrenergic Agonist, Lofexidine”. By Ashish P. Vartak and Peter A. Crooks, Organic Process Research and Development, 2009, 13, 414-418. 418. “N-Chlorosuccinimide is a Convenient Oxidant for the Synthesis of 2,4-Disubstituted 1,2,4- Thiadiazolidine-3,5-diones”. By Shama Nasim and Peter A. Crooks, Tetrahedron Letters, 2009, 50, 257-259 [10 citations].
73
419. “(Z)-Methyl-4-({3-[2,5-dioxoimidazolidin-4-ylidene)methyl]-1H-indol-1-yl}methyl)- benzoate” By Narsimha Reddy Penthala, Thirupathi Reddy Yerram Reddy, Sean Parkin and Peter A. Crooks, Acta Crystallogr. E, 2009, E65, o62-o63. 420. “Nicotine Exposure can be Detected from LC-MS Analysis of Cerebrospinal Fluid from Active and Passive Smokers”. By Ahmad Malkawi, Abeer Al-Ghananeem, Jose de Leon,and Peter A. Crooks, Pharm. Biomed. Anal., 2009, 49, 129-132 [11 citations]. 421. “Transdermal Delivery of Bupropion and its Active Metabolite, Hydroxybupropion: A Prodrug Strategy as an Alternative Approach”. By Paul K. Kiptoo, Kalpana S. Paudel, Dana C. Hammell, Raghotham Reddy Pinninti, JianHong Chen, Peter A. Crooks, and Audra L. Stinchcomb, J. Pharm. Sci, 2009, 98, 583-594 [22 citations]. 422. “Synthesis and Antitubercular Activity of a Series of Hydrazone and Nitrovinyl Analogs Derived from Heterocyclic Aldehydes”, By Vijayakumar N. Sonar and Peter A. Crooks. J. Enz. Inhibit. Medicin. Chem., 2009, 24(1), 117-124 [19 citations]. 423. “Targeting Reward-Relevant Nicotinic Receptors in the Discovery of Novel
Pharmacotherapeutic Agents to Treat Tobacco Dependence”. By Linda P. Dwoskin,
Marharyta Pivavarchyk, Barry M. Joyce, Nichole M. Neugebauer, Guangrong Zheng,
Zhenfa Zhang, Michael T. Bardo, and Peter A. Crooks, invited chapter, 55th Annual
Nebraska Symposium on Motivation: The Motivational Impact of Nicotine and its Role in
424. “Computational Neural Network Analysis of the Affinity of N-n-Alkylnicotinium Salts for the α4β2* Nicotinic Acetylcholine Receptor”. By Fang Zheng, Chang-Guo Zhan, Linda P. Dwoskin, and Peter A. Crooks, J. Enz. Inhibit. Med. Chem., 2009, 24 (1), 157-168. 425. “3-(2-Amino-1-methyl-4-oxo-4,5-dihydro-1H-imidazole-5-yl)-3-hydroxyindolein-2-one Monohydrate”. By Narismha Reddy Penthala, Thirupathi Reddy Yerram Reddy, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2009, E65, o552. 426. “Cis-2,6-Dibenzylcyclohexanone”. By John P. Culver, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2009, E65, o551. 427. “Indolyl-quinuclidinols Inhibit ENOX Activity and Endothelial Cell Morphogenesis While Enhancing Radiation-mediated Control of Tumor Vasculature”. Ling Geng, Girish Rachakonda, D. James Morré, Dorothy M. Morre, Peter A. Crooks, Vijayakumar N. Sonar, Joseph L. Roti Roti, Buck E. Rogers, Suellen Greco, Fei Ye, Kenneth J. Salleng, Soumya Sasi, Michael L. Freeman, and Konjeti R. Sekhar, The FASEB Journal, 2009, 23, 2986-2995 [10 citations]. 428. “The Novel Nicotinic Receptor Antagonist, N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB), Inhibits Nicotine-Evoked [3H]Norepinephrine Overflow from Rat Hippocampal Slices”. By Andrew M. Smith, Gurpreet K. Dhawan, Zhenfa Zhang, Kiran B. Siripurapu, Peter A. Crooks and Linda P. Dwoskin, Biochemical Pharmacology, 2009, 78, 889-897. . 429. “Nicotinic Receptor-based Therapeutics and Candidates for Smoking Cessation”. By Linda P. Dwoskin, Andrew M. Smith, Thomas E. Wooters, Zhenfa Zhang, Peter A. Crooks, and Michael T. Bardo, Biochemical Pharmacology, 2009, 78, 732-743. [44 citations].
74
430. “QSAR Study on Maximal Inhibition (Imax) of Quaternary Ammonium Salts for S-(-)- Nicotine–evoked Dopamine Release from Dopaminergic Terminals in Rat Striatum”. By Fang Zheng, Mathew McConell, Chang-Guo Zhan, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic Medicinal Chemistry, 2009, 17, 4477-4485. 431. “Aminoparthenolides as Novel Anti-leukemic Agents: Discovery of the NF-B Inhibitor, DMAPT (LC-1)”. By Sundar Neelakantan, Shama Nasim, Monica Guzman, Craig T. Jordan and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2009, 19, 4346-4349. [99 citations]. 432. “rac- and (+)-[4,4’,5,5’-2H4]-2-(2’,6”-Dichlororphenoxy]-ethyl)-2-imidazoline (Lofexidine)”. By Ashish P. Vartak, Vijayakumar Sonar, and Peter A. Crooks, J. Labelled Comp. Radiopharmaceuticals, 2009, 52, 431-434. 433. “Selective Inhibition of Acetylcholine-evoked Responses of 7 Neuronal Nicotinic
Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists”. By Gretchen Y. López-Hernández, Jeffrey S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda. P. Dwoskin, and Roger L. Papke, Mol. Pharmacol., 2009, 76, 652-666 [16 citations].
434. “(11R)-13-[Dimethylamino]-4,5-epoxy-11,13-dihydrocostunolide Monofumarate Salt”. By Neelakantan Sundar, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., E., 2009, E65, o1569. 435. “Stereocontrolled Synthesis and Pharmacological Evaluation of cis-2,6-Diphenethyl-1- azabicyclo[2.2.2]octanes as Lobelane Analogues”. By Guangrong Zheng, Linda P. Dwoskin, Agripina G. Deaciuc, Peter A. Crooks, J. Org. Chem., 2009, 74, 6072-6076. 436. “In vivo Evaluation of Diaminodiphenyls: Anticonvulsant Agents with Minimal Acute Neurotoxicity”. By David R. Worthen, Aimee K. Bence, James P. Stables, and Peter A. Crooks, Bioorganic Med. Chem. Lett., 2009; 19, 5012-5015. 437. “rac-2-(2-Amino-4-oxo-4,5-dihydrothiazol-5-yl)-2-hydroxy-1H-indene-1,3-dione”. By Narsimha R. Penthala, Thirupathi R. Y. Reddy, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., E, 2009, E65, o1877. 438. “Pyrrolidine Analogs of Lobelane: Relationship of Affinity for the Dihydrotetrabenazine Binding Site with Function of the Vesicular Monoamine Transporter 2 (VMAT2)”. By Ashish P. Vartak, Justin R. Nickell, Jaturaporn Chagkutip, Linda P. Dwoskin, and Peter A. Crooks, J. Med. Chem., 2009, 52, 7878-7882 [15 citations]. 439. “Synthesis of Novel Isoluminol Probes and their Use in Rapid Bacterial Assays”. By Sundar Neelakantan, Iwan Surjawan, Huseyin Karacelik, Clair L. Hicks and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2009, 19, 5722-5726. 440. “First Principles Determination of Molecular Conformations of Indolizidine (-)-235B’ in Solutions”. By Fang Zheng, Linda P. Dwoskin, Peter A. Crooks, and Chang-Guo Zhan, Theor. Chem. Acc., 2009, 124, 269-278. 441. “Mecamylamine, Dihydro-beta-erythroidine, and Dextromethorphan Block Conditioned Responding Evoked by the Conditional Stimulus Efects of Nicotine”. By Amanda M. Struthers, Jamie L. Wilkinson, Linda P. Dwoskin, Peter A. Crooks, and Rick A. Bevins, Pharm. Biochem. Behav., 2009; 94, 319-328 [20 citations].
75
442. “3-(2-Amino-1-methyl-4-oxo-4,5-dihydro-1H-imidazol-5-yl)-3-hydroxy-1-phenylindolin-2-one Ethanol solvate”. By Narisimha R. Penthala, Thirapathi R. Y. Reddy, Sean Parkin, and Peter A. Crooks, Acta Cryst., Section E, 2009, E65, o2909-o2910. 443. “3-(2-Amino-1-methyl-4-oxo-4,5-dihydro-1H-imidazol-5-yl)-5-fluoro-3-hydroxy 1-pheny- lindolin-2-one Methanol hemisolvate”. By Narisimha R. Penthala, Thirapathi R. Y. Reddy, Sean Parkin, and Peter A. Crooks, Acta Cryst., Section E, 2009, E65, o2439-02440. 444. “Targeting Nicotinic Receptor Antagonists as Novel Pharmacotherapies for Tobacco Dependence and Relapse”. By Linda P. Dwoskin, Peter A. Crooks, and Michael T. Bardo, Neuropsychopharmacology, 2009, 34(1), 244-246; DOI: 10.1038/npp.2008.157 [13 citations]. 445. “Expeditious Pechman Condensation by Using Biodegradable Cellulose Sulphuric Acid as Solid Acid Catalyst”. By J. Venu Madhav, Thirupathi R. Y. Reddy, Peter A. Crooks and Bavntula Rajitha Synthetic Communications, 2010, 40, 3358-3364 [15 citations]. 446. "Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2”. By Justin R. Nickell, Sairam Krishnamurthy, Seth Norrholm, Gabriela Deaciuc, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin, J. Pharm. Exp. Therap., 2010, 332, 612-621 [45 citations]. . 447. “The Analgesic and Toxic Effects of Nornicotine Enantiomers Alone and in Interaction with Morphine in Rodent Models of Acute and Persistent Pain”. By Joseph R. Holtman, Peter A. Crooks, Jaime K. Johnson-Hardy, Elzbieta P. Wala, Pharm. Biochem. Behav., 2010, 94, 352-362 [10 citations]. 448. “Improved and Scalable Synthetic Route to the Synthon 17--(2-carboxyethyl)-1,3,5- estratriene: an Important Intermediate in the Synthesis of Bone-Targeting Estrogens”. By Shama Nasim, William M. Pierce, Jr., K. Grant Taylor, and Peter A. Crooks, Synth. Comm., 2010, 40(5), 772-781. 449. “A Convenient and Scalable Process for the Preparation of Bupropion Hydrochloride via Efficient Bromination using N-Bromosuccinimide”. By Y. Thirupathi Reddy, P. Narsimha Reddy, M. Nikhil Reddy, B. Rajitha and Peter A. Crooks, Synth. Comm., 2010, 40, 1566- 1573. 450. “Microwave Assisted Synthesis and In Vitro Cytotoxicities of Substituted (Z)-2-Amino-5-(1- benzyl-1H-indol-3-yl) methylene-1-methyl-1H-imidazol-4(5H)-ones Against Human Tumor Cell Lines. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, and Peter A Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 591-593 [17 citations].
451. “Novel substituted (Z)-5-((N-Benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5- ((N-Benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as Potent Radio- sensitizing Agents” By Y. Thirupathi Reddy, Konjeti R. Sekhar, Nidhish Sasi, P.Narsimha Reddy, Michael L. Freeman, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 600-602 [33 citations]. 452. “Aplysinopsin Analogs: Synthesis and Anti-proliferative Activity of Novel Substituted (Z)-5- (N-benzylindol-3-ylmethylene)imidazolidine-2,4-diones”. By Y. Thirupathi Reddy, P. Narsimha Reddy, Srinivas Koduru, Chendil Damodaran, and Peter A. Crooks, Bioorg. Med. Chem., 18, 3570-3574, 2010, 453. “1-Methyl-2,6-cis-distyrylpiperidine”. Guangrong Zheng, Sean Parkin, Linda P. Dwoskin
76
and Peter A. Crooks, Acta Cryst., Section E, 2010, E66, o77. 454. “1-Methyl-2S,6S-trans-distyrylpiperidinium chloride”. Guangrong Zheng, Sean Parkin, Linda P. Dwoskin and Peter A. Crooks, Acta Cryst., Section E, 2010, E66, o78. 455. “Lobeline Esters as Novel Ligands for Neuronal Nicotinic Acetylcholine Receptors and Neurotransmitter Transporters”. By Marhaba Hojahmat, David Horton, Seth D. Norrholm, A. Gabriela Deaciuc, Vladimir Grinevich, Dennis K. Miller, Linda P. Dwoskin, and Peter A. Crooks, Bioorg. Med. Chem., 2010, 18, 640-649. 456. “Transdermal Delivery of Naltrexol and Skin Permeability Lifetime after Microneedle Treatment in Hairless Guinea Pigs In Vivo”. Stan L. Banks, Raghotham R. Pinninti, Harvinder S. Gill, Peter A. Crooks, Mark R. Prausnitz, and Audra L. Stinchcomb, J. Pharm. Sci., 2010, 99, 3072-3080 [44 citations]. 457. “Novel bis-2,2,5,5-Tetramethylpiperidine and bis-Mecamylamine Antagonists at Neuronal Nicotinic Receptors that Mediate Nicotine-evoked Dopamine Release”. By Zhenfa Zhang, Marharyta Pivavarchyk, Karunai Leela Subramanian, A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 1420-1423. 458. “Predictive Screening Model for Potential Vector-Mediated Transport of Cationic Substrates at the Blood-Brain Barrier Choline Transporter”. By Werner J. Geldenhuys, Vamshi K. Manda, Rajender K. Mittapalli, Cornelis J. Van der Schyf, Peter A. Crooks, Linda P. Dwoskin, David D. Allen and Paul R. Lockman, Bioorg. Med. Chem. Lett., 2010, 20, 870- 877 [13 citations]. 459. “A Water Soluble Parthenolide Analogue Suppresses In Vivo Prostate Cancer Growth by Targeting NF-κB and Generating Reactive Oxygen Species”. By Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng, Peter A. Crooks, Sundar Neelakantan, William Matthews, Harikrishna Nakshatri, and Christopher J. Sweeney, The Prostate, 2010, 70, 1074-1086 [42 citations]. 460. “A NADPH Oxidase-Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer Cells”. By Yulan Sun, Daret St Clair, Yong Xu, Peter A. Crooks, and William St Clair, Cancer Research, 2010, 70, 2880-2890 [73 citations]. 461. “N-Methyl-2,6-(E)-distyrylpyridinium iodide”. By Narsimha Reddy Penthala, Joshua Eldridge, Thirupathi Reddy Yerram Reddy, Sean Parkin and Peter A. Crooks, Acta Cryst., Section E, 2010, E66, o1793. 462. “Repeated Nicotine Administration Robustly Increases bPiDDB Inhibitory Potency at 62-containing Nicotinic Receptors Mediating Nicotine-evoked Dopamine Release”. By Andrew M. Smith, Marharyta Pivavarchyk, Tom E. Wooters, Zhenfa Zhang, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo and Linda P. Dwoskin, Biochemical Pharmacology, 2010, 80, 402-409. 463. “Z-2-Amino-5-[2,4-dimethoxy-6-(4-methoxystyryl)benzylidene]thiazol-4(5H)-one Methanolate”. By Nikhil Reddy Madadi, Thirupathi Reddy Yerram Reddy, Narsimha Reddy Penthala, Sean Parkin, and Peter A. Crooks, Acta Cryst., Section E, 2010, E66, o1792. 464. “In Vitro Permeation of a Pegylated Naltrexone Prodrug Across Microneedle-treated Skin”. By Mikolaj Milewski, Thirupathi Reddy Yerramreddy, Priyanka Ghosh, Peter A. Crooks, and
77
Audra L. Stinchcomb, J. Controlled Release, 2010, 146, 37-44 [36 citations]. 465. “Regiospecific and Conformationally Restrained Analogs of Melphalan and DL-2-NAM-7 and their Affinities for the Large Neutral Amino Acid Transporter (System L)”. By Jyothi Matharu, Jun Oki, Quentin R. Smith, David R. Worthen, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 3688-3691. 466. ”The NF-κB Inhibitor LC-1 has Single Agent Activity in Multiple Myeloma Cells and Synergises with Bortezomib”. By Elisabeth Walsby, Guy Pratt, Saman Hewamana, Peter A. Crooks, Alan Burnett, Chris Fegan, Chris Pepper. Molecular Cancer Thrapeutics, 2010, 9, 1574-1582. 467. “Novel 3-O-Pegylated Carboxylate and 3-O-Pegylated Carbamate Prodrugs of Naltrexone for Microneedle-Enhanced Transdermal Drug Delivery”. By Thirupathi Reddy Yerramreddy, Mikolaj Milewski, Narsimha Reddy Penthala, Audra L. Stinchcomb, and Peter A. Croooks, Bioorg. Med. Chem. Lett., 2010, 20, 3280-3283. 468. “bis-Azaaromatic Quaternary Ammonium Salts as Ligands for the Blood-brain Barrier CholineTransporter”. By Guangrong Zheng, Zhenfa Zhang, Paul R. Lockman, Werner J. Geldenhuys, David D. Allen, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 3208-3210. 469. “Quinlobelane: a Water-soluble Analog of Lobelane with VMAT2 Inhibitory Properties”. By Ashish P. Vartak, Agripina G. Deaciuc, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 3584-3587. 470. “Antinociceptive Effects and Toxicity of Morphine-6-O-sulfate Sodium Salt in Rat Models of Pain”. By Joseph R. Holtman, Jr., Peter A. Crooks, Jamie Johnson-Hardy, and Elzbieta P. Wala, Europ. J. Pharmacol., 2010, 648, 87-94 [16 citations]. 471. “Synthesis and In Vitro Evaluation of N-Alkyl-3-hydroxy-3-(2-imino-3-methyl-5- oxoimidazolidin-4-yl)indolin-2-ones as Potential Anticancer Agents”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, M. Nikhil Reddy and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 4468-4471 [25 citations]. 472. “The Novel Pyrrolidine nor-Lobelane Analog, UKCP-110 (cis-2,5-di-(2-Phenethyl)-pyrrolidine Hydrochloride) Inhibits VMAT2 Function, Methamphetamine-evoked Dopamine Release, and Methamphetamine Self-administration in Rats”. By Joshua S. Beckmann, Kiran B. Siripurapu, Justin R. Nickell, David B. Horton, Emily D. Denehy, Ashish Vartak, Peter A. Crooks, Linda P. Dwoskin, Michael T. Bardo. J. Pharmacol. Exp. Therap., 2010, 335, 841- 851 [18 citations]. 473. “Chemical Genomic Screening Reveals Synergism between Parthenolide and Inhibitors of the PI-3 Kinase and mTOR Pathways”. Duane C. Hassane, Siddhartha Sen, Randall M. Rossi, Cheryl A. Corbett, Marlene Balys, Liping Wei, Peter A. Crooks, Monica L. Guzman, and Craig T. Jordan, Blood, 2010, 116, 5983-5990 [56 citations]. 474. “3-O-Phosphate Ester Conjugates of 17--O-{1-[2-Carboxy-(2-hydroxy-4-methoxy-3- carboxamido)anilido]ethyl}1,3,5(10)-estratriene as Novel Bone-Targeted Agents”. By Shama Nasim, Ashish P. Vartak, William M. Pierce, Jr., K. Grant Taylor, Ned Smith and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2010, 20, 7450-7453. 475. “Antiangiogenic Properties of Substituted (Z)-(±)-2-(N-Benzylindol-3-ylmethylene)-
quinuclidin-3-ol/one Analogs and their Derivatives”. By Amudhan Venkateswaran, Y.
78
Thirupathi Reddy, Vijaykumar N. Sonar, Venkatraj Muthusamy, Peter A. Crooks, Michael L. Freeman, and Konjeti R. Sekhar, Bioorg. Med. Chem. Lett., 2010, 20, 7323-7326.
476. “3-[Benzimidazo- and Benzothiadiazoleimidazo-(1,2-c)quinazolin-5-yl]-2H-chromene-2-ones as Potent Anti-microbial Agents”. B. Suresh Kuarm, Y. Thirupathi Reddy, J. Venu Madhav,
Peter A. Crooks, and B.Rajitha, Bioorg. Med. Chem. Lett., 2011, 21, 524-527 [52 citations]. 477. “Bioavailability of 9-Tetrahydrocannabinol Following Intranasal Administration of a Mucoadhesive Gel Spray Delivery System in Conscious Rabbits”. By Abeer M. Al-Ghananeem, Ahmad H. Malkawi, and Peter A. Crooks, Drug Development and Industrial Pharmacy, 2011, 37, 329-334 [10 citations]. 478. “Phenyl Ring-Substituted Lobelane Analogs: Inhibition of [3H]Dopamine Uptake at the Vesicular Monoamine Transporter-2”. By Justin R. Nickell, Guangrong Zheng, Gabriela A. Deaciuc, Peter A. Crooks and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., 2011, 336, 724-733. 479. “Cellulose Sulfuric Acid: Novel and Efficient Biodegradable and Recyclable Acid Catalyst for the Solid State Synthesis of Thiadiazolo Benzimidazoles”. By B. Suresh Kuarm, J. Venu Madhav, Bavntula Rajitha, Y.Thirupathi Reddy, P. Narsimha Reddy, and Peter A. Crooks, Synth. Commun., 2011, 41(5), 662-669 [13 citations]. 480. “Improving the Use of Drug CombinationsThrough the Codrug Approach”. By Peter A. Crooks, Harpreet K. Dhooper and Ujjwal Chakravorty, in Prodrugs and Targeted Delivery. Towards Better ADME Properties, Edit. Jarkko Rautio, Invited Chapter, Methods and Principles in Medicinal Chemistry, Volume 47, Part Three, Chapter 13, pp 347-383; Wiley- VCH Verlag GmbH & Co. New York, 2011; ISBN: 978-3-527-32603-7. 481. “Design, Synthesis and Interaction at the Vesicular Monoamine Transporter-2 of Lobeline Analogs: Potential Pharmacotherapies for the Treatment of Psychostimulant Abuse”. Peter A. Crooks, Guangrong Zheng, Ashish Vartak, John Culver, Fang Zheng, David B. Horton, and Linda P. Dwoskin, Current Topics in Medicinal Chemistry, 2011, 11(9), 1103- 1127 [14 citations]. 482. “bPiDI: A Novel, Selective 62* Nicotinic Receptor Antagonist and Preclinical Candidate for Treatment for Nicotine Abuse”. By Thomas E. Wooters, Andrew M. Smith, Marharyta Pivavarchyk, Kiran B. Siripurapu, J. Michael McIntosh, Zhenfa Zhang, Peter A. Crooks, Michael T. Bardo and Linda P. Dwoskin, British Journal of Pharmacology, 2011, 163, 346-357 [20 citations]. 483. “Indolizidine (-)-235B’ and Related Structural Analogs: Antagonists at 62-Containing Nicotinic Receptors Mediating Nicotine-evoked [3H]Dopamine Release”. By Marharyta Pivavarchyk, Andrew M. Smith, Naoki Toyooka, Hiroshi Tsuneki, Toshi yasu Sasaoka, Zhenfa Zhang, J. Michael McIntosh, Peter A. Crooks, and Linda P. Dwoskin, European J. Pharmacology, 2011, 658(2-3), 132-139. 484. “meso-Transdiene Analogs Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-evoked Dopamine Release”. By David B. Horton, Kiran B. Siripurapu, Seth D. Norrholm, John P. Culver, Marhaba Hojahmat, Joshua S. Beckmann, Steven B. Harrod, Agripina G. Deaciuc, Michael T. Bardo, Peter A. Crooks and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., 2011, 336, 940-951 [17 citations]. 485. “Novel bis-, tris-, and tetrakis-Tertiary Amine Antagonists as Antagonists at Neuronal
Nicotinic Receptors that Mediate Nicotine-evoked Dopamine Release”. By Zhenfa Zhang,
79
Guangrong Zheng, Marharyta Pivavarchyk, A. Gabriela Deaciuc, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2011, 21, 88-91.
486. “Melampomagnolide: a New Antileukemic Sesquiterpene”. By Shama Nisam, ShanShan Pei, Fred Hagen, Craig T. Jordan, and Peter A. Crooks, Bioorg. Med. Chem., 2011, 19, 1515-1519 [18 citations]. 487. Cis-2,5-bis-(2-Fluoro-5-methoxyphenylethyl)pyrrolidine Formate”. By Purushothama Rao Ponugoti, Narsimha Reddy Penthala, Linda P. Dwoskin, Sean Parkin, and Peter A. Crooks, Acta Crystallogr. Section E, 2011, E67(3), o737. 488. “(S)-2-Amino-2-(2-chlorophenyl)cyclohexanone D-Tartrate Salt” By Marahba Hojhamat, Guangrong Zheng, Max Siegler, Sean Parkin, Manfred Biermann, Peter A. Crooks, Acta Crystallogr. Section E, 2011, E67(3), o736. 489. “(2Z,3E)-2-((1-(4-Chlorobenzyl)-1H-Indol-3-yl)methylene)quinuclidine-3-one Oxime”. By Narsimha Reddy Penthala, Thirupathi Reddy Yeramreddy, Sean Parkin, and Peter A.Crooks, Acta Crystallogr. Section E, 2011, E67(3), o735. 490. “Synthesis and In Vitro Screening of Novel N-Benzyl Aplysinopsin Analogs as Potential Anticancer Agents”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2011, 21, 1411-1413. [10 citations].
491. “Cellulose Sulfuric Acid: An Efficient Biodegradable and Recylable Solid Catalyst for the Synthesis of 1-Oxo-hexahydroxanthene”. By B. Suresh Kuarm, J. Venu Madhav, S. Vijaya Laxmi, Bavntula Rajitha, Y. Thirupathi Reddy, P. Narsimha Reddy, and Peter A. Crooks, Synth. Commm., 2011, 41(12), 1719-1724.
492. “Cis-1-Benzylpyrrolidine-2,5-dicarbonitrile”. By Purushothama Rao Ponugoti, Narsimha Reddy Penthala, Linda P. Dwoskin, Sean Parkin and Peter A. Crooks, Acta Crystallogr. Section E, 2011, E67, o747. 493. “(S)-2-Amino-2-(2-chlorophenyl)cyclohexanone Free Base”. By Manfred Biermann, Kenneth I. Hardcastle, Nikolai V. Moskalev and Peter A. Crooks, Acta Crystallogr. Section E, 2011, E67, o936. 494. "A Water Soluble Parthenolide Analogue Suppresses In Vivo Tumor Growth of Two Tobacco Associated Cancers, Lung and Bladder Cancer, by Targeting NF-B and Generating Reactive Oxygen Species". By Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng, Peter A. Crooks, Sundar Neelakantan, Tyler Peat, James Klaunig, William Matthews, Harikrishna Nakshatri, and Christopher J Sweeney, International Journal of Cancer, 2011, 128(10), 2481-2494 [36 citations]. 495. “Discovery of Non-Peptide, Small Molecule Antagonists of 910 Nicotinic Acetylcholine Receptors as Novel Analgesics for Treatment of Neuropathic and Tonic Inflammatory Pain”. By Guangrong Zheng, Zhenfa Zhang, Cheryl Dowell, Elzbieta Wala, Linda P. Dwoskin, Joseph R. Holtman, Jr., J. Michael McIntosh, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2011, 21, 2476-2479 [15 citations]. 496. “Expeditious Synthesis of cis-1-Methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo-[3,2h]iso- quinoline/[2,3-f]quinoline via Azomethine Ylidine-alkene [3+2] Cycloaddition”. By Zhenfa Zhang, Linda P. Dwoskin and Peter A. Crooks, Tetrahedron Letters, 2011, 52, 2667-2669.
80
497. “The Novel Small Molecule 910 Nicotinic Acetylcholine Receptor Antagonist ZZ-204G is Analgesic”. By Joseph R. Holtman, Linda P. Dwoskin, Cheryl Dowell, Elzbieta P. Wala, Peter A. Crooks and J. Michael McIntosh, Europ. J. Pharmacol., 2011, 339, 500- 508 [17 citations]. 498. “Synthesis and Evaluation of Chromenyl Barbiturates and Thiobarbiturates as Potential
Antituberculosis Agents”. By S. Vijayalaxmi, Y. Thirupathi Reddy, B. Suresh Kuarm, P. Narsimha Reddy, J. Venu Madhav, Peter A. Crooks, and B. Rajitha, Bioorg. Med. Chem. Lett., 2011, 21, 4329-4331 [28 citations].
499. “Inhibition of NF-B and DNA Double Strand Break Repair by DMAPT Senitizes Non Small Cell Lung Cancers to X-rays”. By Neil C. Estabrook, Helen Chin-Sinex, Anthony J. Borgmann, Ryan M. Dhaemers, Ronald H. Shapiro, David Gilley, Nazmul Huda, Peter A. Crooks, Christopher Sweeney, and Marc S. Mendonca. Free Radical Biology and Medicine, 2011, 51, 2249-2258. 500. “The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to the Sites of DNA Damage, Suppressing Repair of DNA Double Strand Breaks, and Enhancing Radio-sensitization”. By Konjeti R. Sekhar, Yerramreddy T Reddy, Peter A. Crooks, Amudhan Venkateswaran, Hayes, W. McDonald, Ling Geng, Souma Sasi, Robert P. Van Der Waal, Joseph L. Roti Roti, Ken J. Salleng, and Michael L. Freeman, Clin. Cancer Research, 2011, 17, 6490-6499. 501. “Discovery of 1,2,4-Thiadiazolidine-3,5-dione Analogs that Exhibit Unusual and Selective Rapid Cell Death Kinetics against MV-411 Acute Myelogenous Leukemia Cells in Culture”. By Shama Nasim, Monica L. Guzman, Craig T. Jordan, and Peter A. Crooks, Bioorg Med. Chem. Lett., 2011, 21, 4879-4883. 502. “Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-evoked Dopamine Release”. By David
B. Horton, Kirin B. Siripurapu, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., 2011, 339, 286-297 [18 citations].
503. “Dimethylamino Parthenolide Enhances the Inhibitory Effects of Gemcitabine in Human Pancreatic Cancer Cells” By Bryan K. Holcomb, Michele T. Yip-Schneider, Joshua A. Waters, Joal D. Beane, Peter A. Crooks, and C. Max Schmidt, Journal of Gastrointestinal Surgery, 2012, 16, 1330-1340; DOI: 10.1007/s11605-012-1913-7; PMID 22618517.
504. “Synthesis and In Vitro Screening of Novel Heterocyclic Compounds as Potential Breast Cancer Agents”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, Nikhil Reddy Madadi, Vijayakumar Sonar, and Peter A Crooks, In Breast Cancer Cells/Book 3, Breast Cancer-Current and Alternative Therapeutic Modalities, Edit. E. Gunduz, Chapter 14, pp 283-294, 2012, Intech Publishing Company, Vienna, Austria; ISBN: 978-953-307-776-5; DOI: 10.5772/21838. 505. “Polyamine Modulation of NMDR as a Mechanism to Reduce Effects of Alcohol Dependence”. By Susan Barron, Ben Lewis, Kristen Wellmann, Megan Carter, Justin Farook, Joshua Ring, Dennis T. Rogers, Robert Holley, Peter A. Crooks and John Littleton, Recent Patents on CNS Drug Discovery, Bentham Ebooks, Bentham Science Publishers, Ltd., 2012, 7, 129-144; DOI: 10.2174/157488912800673128; PMID: 22574674. 506. “Isolation and Structure Elucidation of a New Indole Alkaloid, Ernidine, from Hunteria umbellata Seeds”. By Adejuwon A. Adeneye, Peter A. Crooks, Anne-Frances Miller, Jack Goodman, Adeyemi O. Olufunmilayo, and Agbaje O. Esther, Pharmacologia,
2012, 3(7), 204-214. 507. “Xanthan Sulfuric Acid: an Efficient Biodegradable Solid Acid Catalyst for the Synthesis of 14-Aryl-14H-dibenzo[a,i]xanthene-8,13-diones”. By B. Suresh Kuarm, Peter A. Crooks and A. Rajitha, Adv. Appl. Sci. Research., 2012, 3, 1-5.
508. “The Effect of a Novel VMAT2 Inhibitor, GZ-793A, on Methamphetamine Reward in Rats”. By Joshua S. Beckmann, E. D. Denehy, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Psychopharmacology, 2012, 220, 395-403; DOI: 10.1007/s00213-011-2488-9; PMID: 22638813 [17 citations]. 509. “L-Proline Catalyzed Efficient Multicomponent One-Pot Synthesis of Poly Substituted Pyridines”. By B Janardhan, V. Ravibabu, Peter A. Crooks, and Bavanthula Rajitha, Org. Commun., 2012, 5(4), 186-195. 510. “Xanthan Sulfuric Acid: An Efficient Bio-supported and Recyclable Solid Acid Catalyst for the Synthesis 2-Aryl Thiadiazolobenzimidazoles". By B. Suresh Kuarm, B. Janardan, Peter
A. Crooks, and B. Rajitha, Chinese Journal of Chemistry, 2012, 30, 947-950; DOI: 10.1002/cjoc.201100137
511. “(Z)-3-Benzofuran-2-yl-2-(3,4,5-trimethoxyphenyl)acrylonitrile”. By Narsimha Reddy Penthala, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2012, E68, o731. 512. “(Z)-3-Indol-3-yl)-2-(3,4,5-trimethoxyphenyl)acrylonitrile”. By Narsimha Reddy Penthala, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2012, E68, o729. 513. “(Z)-2-(2,4-Dimethoxy-6-(E-4-methoxystyryl)benzylidene)quinuclidin-3-one”. By Nikhil Reddy Madadi, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2012, E68, o730. 514. “Novel Small Molecule 910 Nicotinic Receptor Antagonist Prevents and Reverses Chemotherapy-Evoked Neuropathic Pain in the Rat”. By Elzbieta P. Wala, Peter A. Crooks, J. Michael McIntosh, and Joseph R. Holtman, Jr., Anesthesia and Analgesia, 2012, 115, 713-720; DOI: 10.1213/ANE.0b013e31825a3c72; PMID: 22610850 [20 citations]. 515. “The Effect of VMAT2 Inhibitor GZ-793A on the Reinstatement of Methamphetamine- seeking in Rats”. By Kristin M. Alvers, Joshua S. Beckmann, Guangrong Zheng, Peter A.
Crooks, Linda P. Dwoskin, and Michael T. Bardo, Psychopharmacology, 2012, 224, 255-262, DOI: 10.1007/s00213-012-2748-3; PMID 22634741.
516. “Polyvinylsulfonic Acid: an Efficent and Recyclable Bronsted Acid Catalyst for Pechman Condensation”. By B. Suresh Kuarm, Peter A. Crooks, and Bavanthula Rajitha, Int. J. Res. Pharm. Biomed. Sci., 2012, 3, 50-53. 517. “Oxycodone N-Oxide”. By Vijayakumar N. Sonar, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section C, 2012, C68, o436-o438; DOI: 10.1107/S01082701120401882012; PMID: 23124457. 518. “The Effect of Hydrogen Bonding on the Conformation of 2-(1H-Indol-3-yl)-2-oxoacetamide and 2-(1H-Indol-3-yl)-N,N-dimethyl-2-oxoacetamide”. By Vijayakumar N. Sonar, Sean Parkin and Peter A. Crooks, Acta Crystallographica, Section C, 2012, C68, o405-o407; DOI: 10.1107/S01082701120383222012; PMID: 23007543.
82
519. “rac-Z-Methyl 1-Benzyl-3-[(3-hydroxyquinuclidin-2-ylidene)methyl]-1H-indole-6-carboxylate”. By Narsimha Reddy Penthala, Purushotham Rao Ponugoti, Sean Parkin and Peter A. Crooks, Acta Crystallographica, Section E, 2012, 68(11), o3111; DOI: 10.1107/S1600536812040731; PMID: 23284437. 520. “Effect of Recrystallization on the Pharmaceutical Properties of Valsartan for Improved Therapeutic Efficacy”. By Buchi N. Nalluri, Ramya Krishna M. Rao, T. P. Rao, and Peter A. Crooks, J. Applied. Pharm. Sci., 2012, 2, 126-132. 521. “Poly(4-vinylpyridinium) Hydrogen Sulfate: An Efficient and Recyclable Bronsted Acid Catalyst for the Synthesis of Fused 3,4-Dihydropyrimidin-2(1H)-ones and Thiones". By
Janardhan, B. Rajitha and Peter A. Crooks, J. Saudi Chemical Society, 2012, 6pp, published on-line, November 7th, http://dx.doi.org/10.1016/j.jscs.2012.10.007.
522. “The Novel Antiangiogenic VJ115 Inhibits the NADH Oxidase ENOX1 and Cytoskeleton- Remodeling Proteins”. A. Venkateswaran, D. B. Friedman, A. J. Walsh, M. C. Skala, S. Sasi, G. Rachakonda, P. A. Crooks, M. L. Freeman, and K. R. Sekhar, Invest. New Drugs, 2013, 31, 535-544; DOI: 1101007/s 10637-012-9884-9; PMID: 23054211. 523. “rac-5-Bromo-N-benzylisatincreatinine Ethanol Solvate”. By Narsimha Reddy Penthala and Peter A. Crooks, Acta Crystallogr., Section E, 2013, E69(2), o288-o289; DOI: 10.1107/160053681300038X; PMID: 23424559. 524. “5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as Potential Anticancer Agents with Anti-inflammatory Properties”. By Narsimha Reddy Penthala, Purushothama Rao Ponugoti, Vinod Kasam, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2013, 23, 1442-1446, DOI: pii: S0960-894X(12)016472.10.1016/j.bmcl. 2012.12.053; PMID: 23339966. 525. “Improving the Inhibitory Activity of Arylideaminoguanidine Compounds at the N-methyl-D- aspartate Receptor Complex from a Recursive Computational-experimental Structure- Activity Relationship Study”. By Joshua R. Ring, Fang Zheng, Aaron J. Haubner, John M. Littleton, and Peter A. Crooks, Bioorg. Med. Chem., 2013, 21, 1764-1774; DOI: 10.1016/j.bmc.2013.01.051, 2013; PMID: 23465801. 526. “Solvent Specific C-N Bond Formation: Synthesis of Ninhydrin-Creatinine Condensation Products”. By Penthala N. Reddy, Yerramreddy T. Reddy, Sean Parkin, and Peter A. Crooks, J. Heterocyclic Chem., 2013, 50(S1), E156-E159; DOI: 10.1002/jhet.1107. 527. “Structural Modification of Tocotrienols to Improve Bioavailability”. By Awantika Singh, Philip J. Breen, P. Sanchita Ghosh, K. Sree Kumar, Kottayil I. Varughese, Peter A. Crooks, Martin Hauer-Jensen, and Cesar M. Compadre, in Tocotrienols: Vitamin E Beyond Tocopherols, 2nd Edit., Barrie Tan, Ronald R. Watson, and Victor R. Preedy Eds., American Oil Chemists Society and Taylor and Francis, 2013, pp 359-370. 528. “Antihyperglycemic Profile of Ernidine Isolated from Hunteria umbellata Seed”. By Adejuwon Adewale Adeneye, Peter Anthony Crooks, Zaineb Fadhel-Albayati, Anne- Frances Miller, Zito S. Williams, Olufunmilayo Olaide Adeyemi, and Esther Oluwatoyin Agbaje, African J. Tradit. Complement. Altern. Med., 2013, 10(2), 189‐202; DOI: 10.4314/ajtcam.v10i2.3. 529. “rac-N-Benzylisatincreatinine (Unknown Solvate)”. By Narsimha Reddy Penthala and Peter
83
A. Crooks, Acta Crystallogr., Section E, 2013, E69(2), o29o-o291; DOI: 10.1107/1600536813000378; PMID: 23424560. 530. “Exploring the Effect of N-Substitution in nor-Lobelane on the Interaction with VMAT2: Discovery of a Potential Clinical Candidate for Treatment of Methamphetamine Abuse”. By Guangrong Zheng, David B. Horton, Narsimha Reddy Penthala, Justin R. Nickell, John P. Culver, Agripina G. Deaciuc, Linda P. Dwoskin and Peter A. Crooks, Med. Chem. Comm., 2013, 4(3), 564-568; DOI:10.1039/C3MD20374C; PMID: 23527317. 531. “N-Aroyl Indole Thiobarbituric Acids as Inhibitors of DNA Repair and Replication Stress Response Polymerases". By Grace Coggins, Leena Maddukuri, Narsimha R. Penthala, Sarah Eddy, Amit Ketkar, Peter A. Crooks, and Robert Eoff, ACS Chem. Biol., 2013, 8, 1722-1729; DOI: 10.1021/cb400305r; PMID: 23679919. 532. “Evaluation of (Z)-2-((1-Benzyl-1H-indol-3-yl) methylene)-quinuclidin-3-one Analogues as Novel, High Affinity Ligands for CB1 and CB2 Cannabinoid Receptors”. By Nikhil Reddy Madadi, Narsimha Reddy Penthala, Lisa K. Brents, Benjamin M. Ford; Paul L. Prather, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2013, 23, 2019-2021; DOI: 10.1016/j.bmcl.2013.02.025; PMID: 23466226. 533. “Effects of VMAT2 Inhibitors Lobeline and GZ-793A on Methamphetamine-induced Changes in Dopamine Release, Metabolism and Synthesis In Vivo”. By Andrew C. Meyer, Nichole M. Neugebauer, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, J. Neurochem., 2013, 127, 187-198; DOI: 10.111/jnc.12373; PMID: 23875705. 534. “Pyrrolidine Analogs of GZ-793A: Synthesis and Evaluation as Inhibitors of the Vesicular Monoamine Transporter-2”. By Narsimha Reddy Penthala, Purushothama Rao Ponugoti, Justin R. Nickell, Agripina G. Deaciuc, Linda P. Dwoskin, Peter A. Crooks, Bioorg. Med. Chem. Lett., 2013, 23, 3342-3345; DOI.org/10.1016/j.bmcl.2013.03.092; PMID: 23597792. 535. “Keap1 is a Redox Sensitive Target that Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells”. By Yong Xu, Fang Fang, Sumitra Miriyala, Peter A. Crooks, Terry D. Oberley, Luksana Chaiswing, Teresa Noel, Aaron K. Holley, Yanming Zhao, Kelley K. Kiningham, Daret St Clair, and William H. St. Clair, Cancer Research, 2013, 73, 4406-4417; DOI: 10.1158/0008-5472.CAN-12-4297; PMID: 23674500 [21 citations]. 536. “Highly Efficient Conversion of Fused 2-Amino-4-Aryl-4H-chromene-3-carbonitriles into Fused 2-Oxo-4-aryl-2H-chromene-3-carbonitriles using Vilsmeier Conditions”. By Janardhan Banothu, Ravibabu Velpula, Rajitha Gali, Rajitha Bavantula, and Peter A. Crooks, Tetrahedron Letters, 2013, 54, 3862-3864, DOI: org/1016/j.tetlet.2013.05.030. 537. “Synthesis and Evaluation of a Series of Benzothiophene Acrylonitrile Analogs as Anticancer Agents”. By Narsimha Reddy Penthala, Vijayakumar N. Sonar, Jamie Horn, Jai Shanker K. B. Yadlapalli, Markos Leggas, Peter A. Crooks, Med. Chem. Comm., 2013, 4, 1073-1078; DOI: 10.1039/C3MD00130J; PMID: 23956835 [22 citations]. 538. “Multiple Modes of α7 nAChR Non-competitive Antagonism of Control Agonist Evoked and Allosterically Enhanced Currents”. Can Peng, Matthew R. Kimbrell, Chengju Tian, Thomas F. Pack, Peter A. Crooks, E. Kim Fifer, and Roger L. Papke, Mol. Pharmacol., 2013, 84,
84
459-475, DOI: 10.1124/mol.113.0864622013; PMID: 23839567. 539. “GZ-793A, a Lobelane Analog, Interacts with the Vesicular Monoamine Transporter-2 to Inhibit the Effect of Methamphetamine”. By David B. Horton, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin, J. Neurochem., 2013, 127, 177-186; DOI: 10.111/jnc.12371; PMID: 23875622. 540. “Efficient Synthesis of cis-2,6-Di-(2-quinolylpiperidine)”. By Derong Ding, Linda P. Dwoskin, and Peter A. Crooks, Tetrahedron Letters, 2013, 54, 5211-5213; DOI: org./10.1016/j.tetlet.2013.07.067. 541. “Synthesis and Evaluation of Novel Azetidine Analogs as Potent Inhibitors of Vesicular [3H]Dopamine Uptake”. By Derong Ding, Justin R. Nickell, Agripina G. Deaciuc, Narsimha Reddy Penthala, Linda P. Dwoskin, and Peter A. Crooks, Bioorg. Med. Chem., 2013, 21, 6771-6777; DOI: pii: S0968-0896(13)00683-4.10.1016/j.bmc.2013.08001; PMID: 23993667.
542. “Poly(4-vinylpyridinium)hydrogen Sulfate Catalyzed an Efficient and Eco-friendly Protocol for the One-pot Multicomponent Synthesis of 1,8-Acridinediones in Aqueous Medium". By Janardhan Banothu, B. Rajitha and Peter A. Crooks, ISRN Journal of Chemistry, Article ID 850254, 2013, 1-6; DOI: http://dx.doi/10.1155/2013/850254. 543. "An Eco-Friendly Improved Protocol for the Synthesis of bis-(3-Indolyl)methanes using Poly(4-vinylpyridinium)hydrogen Sulfate as an Efficient, Heterogeneous and Recyclable Solid Acid Catalyst," by Janardhan Banothu, Rajitha Gali, Ravibabu Velpula, B. Rajitha and Peter A. Crooks, ISRN Journal of Chemistry, Article No. 616932, 6pp, Sept 2; 2013; PMID 24052864; DOI: 10.1155/2013/616932. 544. “Modern Instrumental Methods for Studying Mechanisms of Toxicology.” By Peter A. Crooks, Howard P. Hendrickson, David R. Worthen, Gary D. Byrd, J. Donald deBethizy, and William S. Caldwell, Invited Chapter in: Principles and Methods of Toxicology, Seventh Edition, Ed. A. Wallace Hayes, Taylor & Francis, Philadelphia, 2014, Chapter 41, pp 1959-2022. 545. “The NADH Oxidase ENOX1, a Critical Mediator of Endothelial Cell Radiosensitivity, is Crucial for Vascular Development”. By Amudhan Venkateswaran, Konjeti Sekhar, Daniel Levic, David Melville, Travis Clark, Witold Rybski, Alex Walsh, Melissa Skala, Peter Crooks, Ela Knapik, and Michael Freeman, Cancer Research, 2014, 74, 38-43; DOI: 10.1158/0008-5472.CAN-13-1981; PMID: 24247717. 546. “Synthesis of Fused Thiazolo[3,2-a]pyrimidinones: N-Aryl-2-chloroacetamides as Doubly Electrophilic Building Blocks”. By Janardhan Banothu, Srinivas Basavoju, Rajitha Bavantula, and Peter A. Crooks, Tetrahedron Letters, 2014, 55, 224-226; http://dx.doi.org/10.1016/j.tetlet.2013.11.001.
547. “An Expiditious Synthesis of Quinoxalines by Using Biodegradable Cellulose Sulfuric Acid as a Solid Catalyst”. By Suresh Kuarm, J. Venu Madhav, Peter A. Crooks, and Bavanthula Rajitha, Green Chemistry Letters and Reviews, 2013, 6, 228-232; DOI: 10.1080/17518253.2012.752041.
548. “Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse”. Peter A. Crooks,
Michael T. Bardo and Linda P. Dwoskin, In Emerging Targets and Therapeutics in the
85
Treatment of Psychostimulant Abuse, Volume 69, Chapter 13, pp 513-551; Advances in Pharmacology, Edit. Linda P. Dwoskin, Elsevier, New York, 2014; DOI: 10.1016/B978-0- 12-420118-7.00013-5.; PMID: 24484986 [18 citations]. 549. “Dimethylaminoparthenolide and Gemcitabine: A Survival Study using a Genetically Engineered Mouse Model of Pancreatic Cancer”. By Michele T. Yip-Schneider, Huangbing Wu, Keith Stantz, Narasimhan Agaram, Peter A. Crooks, and C. Max Schmidt, BMC Cancer, 2013, 13(1), 194; DOI: 10.1186/1471-2407-13-194; PMID: 23590467. 550. “Efficacy of Dimethylamino Parthenolide and Sulindac in Combination with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer”. By Michele T. Yip- Schneider, Huangbing Wu, Ralph H. Hruban, Andrew M. Lowy, Peter A. Crooks, and C. Max Schmidt, Pancreas, 2013, 42, 160-167, DOI: 10.1097/MPA.0b013e318254f455; PMID: 22699205. 551. “The Vesicular Monoamine Transporter-2 (VMAT2): An Important Pharmacological Target for the Discovery of Novel Therapeutics to Treat Methamphetamine Abuse”. By Justin R. Nickell, Kiran B. Siripurapu, Ashish Vartak, Peter A. Crooks, and Linda P. Dwoskin, In Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse, Volume 69, Chapter 2, pp 71-106; Advances in Pharmacology, Edit. Linda P. Dwoskin, Elsevier, New York, 2014; DOI: 10.1016/B978-0-12-420118-7.00002-0.; PMID: 24484975. 552. “Oral administration of GZ-793A, a VMAT2 Inhibitor, Decreases Methamphetamine Self- Administration in Rats”. By Carrie E. Wilmouth, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Pharmacol. Biochem. Behav., 2013, 112, 29- 33; DOI: pii: S0091-3057(13)00222-0.10.1016/j.pbb.2013.09.006; PMID: 24075974. 553. “13-(E)-(4-Aminophenyl)parthenolide”. By Narsimha R. Penthala, Venumadhav Janganati, Sean Parkin, Kottayil I. Varughese, and Peter A. Crooks, Acta Crystallogr., Section E, published on-line, 2013, E69, o1709-o1710; DOI: 10.1107/S1600536813028730; PMID: 24454134. 554. “Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells”. By Shanshan Pei, Mohammad Minhajuddin, Kevin P. Callahan, Marlene Balys, John M. Ashton, Sarah J. Neering, Eleni D. Lagadinou, Cheryl Corbett, Haobin Ye, Jane L. Liesveld, Kristen M. O' Dwyer, Zheng Li, Lei Shi, Patricia Greninger, Jeffrey Settleman, Cyril Benes, Fred K. Hagen, Joshua Munger, Peter A. Crooks, Michael W. Becker, and Craig T. Jordan, J. Biol. Chem., 2013, 288, 33542-33558, DOI: 10.1074/jbc.M113.511170; PMID: 24089526. [45 citations]. 555. “13-Imidazolyl-11,13-dihydromelampomagnolide B Monohydrate”. By Venumadhav Janganati, Narsimha Reddy Penthala, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, published on-line, 2013, E69, o1734o-1735 ; DOI: 10.1107/S1600536813029188; PMID: 24454194. 556. “Synthesis and Anti-proliferative Activity of Aromatic Substituted 5-((1-Benzyl-1H-indol-3- yl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione Analogs Against Human Tumor Cell Lines”. By Nikhil R. Madadi, Narsimha R. Penthala, Venumadhav Janganati, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2014, 24, 601-603; DOI: 10.1016/j.bmcl.2013.12.013; PMID 24361000 [18 citations]. 557. “13-N,N-Dimethylaminomicheliolide 0.08-hydrate”. By Shobanbabu Bommagani,
Narsimha R. Reddy, Venumadhav Janganati, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2013; E69, o1789-o1790; DOI: 10.1107/S16005368113030304; PMID: 24454230. 558. “Targeting Nucleophosmin to Radiosensitize NSCLC”. By Konjeti R. Sekhar, Mouadh Benamar, Amudhan Venkateswaran, Soumya Sasi, Narsimha R. Penthala, Peter A. Crooks, Stephen R. Hann, Ling Geng, Tarek Abbas, and Michael L. Freeman, Int. J. Radiation Oncology, Biology, Physics, 2014, 89, 1106-1114; DOI: http://dx.doi.org/10.1016/j.ijrobp.2014.04.012 PMID: 25035215. 559. “Sodium Fluoride as an Efficient Catalyst for the Synthesis of 2,4-Disubstituted-1,3- thiazoles and Selenazoles at Ambient Temperature”. By Janardhan Banothu, Krishnaiah Vaarla, Rajitha Bavantula, and Peter A. Crooks, Chinese Chemical Letters, 2014, 25, 172-175; DOI: 10.1016/j.cclet.2013.10.001. 560. “(E)13-(2-Bromophenyl)micheliolide” Narsimha Reddy Penthala, Shobanbabu Bommagani, Venumadhav Janganati, Sean Parkin and Peter A. Crooks Acta Crystallogr., Section E, 2013, E70, o251-o252; DOI: 10.1107/S1600536814002177; PMID: 24764970. 561. “Facile One-pot Synthesis of 2-Amino-6-(2-oxo-2H-chromen-3-yl)-4-arylpyridine-3- carbonitriles Using Bronsted Acidic Ionic Liquid as Catalyst Under Solvent-free Conditions”. By Janardhan Banothu, Rajitha Bavantula and Peter A. Crooks, Iranian Journal of Catalysis, 2013, 3(1), 41-47. 562. “Synthetic Stilbenoids: Novel Substrates for Human Hepatic, Renal and Intestinal UDP- Glucuronosyltransferases”. By Aleksandra K. Greer, Nikhil Madadi, Stacie M. Bratton, Sarah D. Eddy, Zofia Mazerska, Howard P. Hendrickson, Peter A. Crooks, and Anna Radominska-Pandya, Chemical Research in Toxicology, 2014, 27, 536-545; DOI: 10.1021/tx400408x; PMID: 24571610. 563. “Mono-succinate Ester of Malampomagnolide B”. By Venumadhav Janganati, Narsimha Reddy Penthala, Nikhil Reddy Madadi, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, 2014, E70, o372-o373; DOI: 10.1016/S1600536814002815; PMID: 24765054. 564. “Scientific Overview: 2013 BBC Plenary Symposium on Tobacco Addiction”. Mariella De Biasi, Ian Mclaughlin, Erika E. Perez, Peter A. Crooks, Linda P. Dwoskin, Michael T. Bardo, Paul Pentel, and Dorothy Hatsukami, Drug and Alcohol Dependence, 2014, 141, 107-117; DOI: 10.1016/j.druglcdep.2014.05.013; PMID: 2493469. 565. “Characterization of the Intrinsic Activity for a Novel Class of Cannabinoid Receptor Ligands: Indole Quinuclidine Analogues”. By Lirit N. Franks, Benjamin M. Ford, Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks and Paul L. Prather, European Journal of Pharmacology, 2014, 737, 140-148; DOI: 10.1016/j.ejphar.2014.05.007; PMID: 24858620. 566. “Heterocyclic Aminoparthenolide Derivatives Modulate G2-M Cell Cycle Progression During Xenopus Oocyte Maturation”. By Venumadhav Janganati, Narsimha Reddy Penthala, Chad E. Cragle, Angus M. MacNicol, and Peter A. Crooks, Bioorg. Med. Chem. Lett. 2014, 24, 1963-1967. DOI: 10.1016/j.bmcl.2014.02.067; PMID: 24656611. 567. “Poly(4-vinylpyridinium)hydrogen Sulfate: An Efficient Heterogeneous Catalyst for the One- pot Synthesis of Polyhydroquinolines via Unsymmetrical Hantzsch Reaction in Aqueous
Medium”. By Banothu Janardhan, Bavantula Rajitha, and Peter A. Crooks, J. Saudi Chemical Society, 2014, 18(5), 722-727; DOI: http://dx.doi.org/10.1016/j.jscs.2014.01.009. 568. “Anticancer Activity of Carbamate Derivatives of Melampomagnolide-B”. By Venumadhav Janganati, Narsimha Reddy Penthala, Nikhil Reddy Madadi, Zheng Chen, and Peter A. Crooks, Bioorg. Med. Chem. Lett. 2014, 24, 3499-3502; DOI: 10.1016/j.bmcl.2014.05.059; PMID: 24928404. 569. “Synthesis and Evaluation of a Series of Quinolyl trans-Cyanostilbene Analogs as Anticancer Agents”. By Narsimha Reddy Penthala, Venumadhav Janganati, Shobanbabu Bommagani, and Peter A. Crooks, MedChemComm, 2014, 5, 886-890; DOI: 10.1039/c4md00115j, 2014. 570. “Preparation of 4,5 Disubstituted-2H-1,2,3-triazoles from (Z)-2,3-Diaryl Substituted Acrylonitriles”. By Nikhil Reddy Madadi, Narsimha Reddy Penthala, Lin Song, Howard P. Hendrickson, and Peter A. Crooks, Tetrahedron Letters, 2014, 55, 4207-4211; DOI: 10.1016/j.tetlet.2014.05.045. 571. “Crystal Structure of (E)-13-{4-[(Z)-2-Cyano-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl}- Parthenolide Methanol Hemisolvate”. By Narsimha Reddy Penthala, Shobanbabu Bommagani, Venumadhav Janganati, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, 2014, E70, part 10, o1092-o1093; DOI: 10.1107/S1600536814019333; PMID: 25484689. 572. “Heck Products of Parthenolide and Melampomagnolide-B as Anticancer Modulators that Modify Cell Cycle Progression”. Narsimha R. Penthala, Shobanbabu Bommagani, Venumadhav Janganati, Kenzie B. MacNicol, Chad E. Cragle, Nikhil R. Madadi, Linda L. Hardy Angus M. MacNicol, and Peter A. Crooks. European Journal of Medicinal Chemistry,
2014, 85, 517-525; published on-line: http://dx.doi.org/10.1016/j.ejmech.2014.08.022 PMID: 25117652.
573. "NF-B Dependent and Independent Epigenetic Modulation Using the Novel Anti-cancer Agent DMAPT" by Harikrishna Nakshatri, Hitesh Appaiah, Manjushree Anjanappa, David Gilley, Hiromi Tanaka, Sunil Badve, Peter A. Crooks, William Matthews, Christopher Sweeney, and Poornima Bhat-Nakshatri, Cell Death and Disease, 2014, Jan 22; 6: e1608; DOI: 10.1038/cddis.2014.569; PMID: 25611383. 574. “L-Proline catalyzed one-step synthesis of 4,5-diaryl-2H-1,2,3-triazoles from cyanostilbenes via [3+2] cycloaddition of azide”. By Narsimha R. Penthala, Nikhil R. Madadi, Venumadhav Janganati, Peter A. Crooks, Tetrahedron Letters, 2014, 55, 5562-5565; DOI: 10.1016/j.tetlet.2014.08.027; PMID: 25267862. 575. “Novel Cytoprotective Inhibitors for Apoptotic Endonuclease”. By Dae Song Jang, Narsimha Penthala, Eugene Apostolov, Xaioying Wang, Peter A. Crooks, and Alexei Basnakian. DNA and Cell Biology, 2014, 34, 92-100; DOI: 10.1089/dna.2014.2530; PMID: 25401220. 576. “Synthesis of Lobeline, Lobelane, and their Analogues. A Review”. By Guangrong Zheng and Peter A. Crooks, Organic Preparations and Procedures International, invited review, 2015, 47(5), 317-337; DOI: 10.1080/00304948.2015.1066642; PMID: 26858465.
577. “Crystal Structure of 4,5-bis(3,4,5-trimethoxyphenyl)-2H-1,2,3-triazole Methanol Monosolvate”. By Nikhil R. Madadi, Sean Parkin, and Peter A. Crooks, Acta Crystallographa, Series E, 2014, E70, part 10, o1128-1129; DOI: 10.1107/S1600536814023095; PMID: 25484710. 578. “Synthesis, Anticancer Activity and Molecular Docking Studies on a Series of Heterocyclic trans-Cyano-combretastatin Analogues as Antitubulin Agents. By Narsimha Reddy Penthala, Hongliang Zong, Amit Ketkar, Nikhil Reddy Madadi, Venumadav Janganati, Robert L. Eoff, Monica L. Guzman, and Peter A. Crooks, European Journal of Medicinal Chemistry, 2014, 92, 212-220; DOI: 10.1016/j,ejmech.2014.12.050; PMID: 25557492.
579. “Synthesis and In Vivo Stability of Amino Acid Prodrugs of 6--Naltrexone for Microneedle-enhanced Transdermal Delivery”. By Joshua A. Eldridge, Mikolaj Milewski, Audra L. Stinchcomb, and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2014, 24, 5212- 5215; DOI: 10.1016/j.bmcl.2014.09.072; PMID: 25442314. 580. “Nanodelivery of Parthenolide Using Functionalized Nanographene Enhances its Anticancer Activity”. By Alokita Karmakar, Yang Xu, Thikra Mustafa, Ganesh Kannarpady, Stacie M. Bratton, Anna Radominska-Pandya, Peter A. Crooks, Alexandru S. Biris, RSC Advances, 2014, Jan. 1; 5(4), 2411-2420; DOI: 10.1039/c4ra10871j; PMID: 25574376.
581. “Novel High-Throughput Deoxyribonuclease 1 Assay”. By Dae S. Jang, Narsimha R. Penthala, Eugene O. Apostolov, Xiaoing Wang, Tariq Fahmi, Peter A. Crooks, and Alexei G. Basnakian. J. Biomol. Screen, 2014, 20, 202-211; DOI: 10.1177/1087057114555828; PMID: 25326282. 582. “Comparison of Crystal Structures of 4-(Benzo[b]thiophen-2-yl)-5-(3,4,5-trimethoxyphenyl)- 2H-1,2,3-triazole and 4-(Benzo[b]thiophen-2-yl)-2-methyl-5-(3,4,5-trimethoxyphenyl)-2H- 1,2,3-triazole”. Narsimha R. Penthala, Nikhil R. Madadi, Shobanbabu Bommagani, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Research Communications, 2014, E70(part 11), 392-395; DOI: 10.1107/S16005336814023095; PMID: 25484755. 583. “One-pot Multicomponent Synthesis of Indole Incorporated Thiazolylcoumarins and their Antibacterial, Anticancer and DNA Cleavage Studies”. By Rajitha Gali, Janardha Banothu, Ramesh Gondru, Rajitha Bavantula, Yashodhara Velivela and Peter A. Crooks, Bioorg. Med. Chem. Lett., 2014, 25, 106-112; DOI: 10.1016/j.bmcl.2014.10.100; PMID: 25435148.
584. “Synthesis and Evaluation of a Series of Resveratrol Analogs as Potent Anticancer Agents that Target Tubulin”. By Nikhil R. Madadi, Hongliang Zong, Amit Ketkar, Chen Zheng, Narsimha R. Penthala, Venumadhav Janganati, Shobanbabu Bommagani, Robert L. Eoff, Monica L. Guzman, Peter A. Crooks, MedChemComm, 2015, 6, 788-794; DOI:10.1039/C4MD00478G; PMID: 26257861.
585. “Anticancer Evaluation of 3,4,5,4’-trans-tetramethoxystilbene (DMU-212) and its Analogs Against An Extensive Panel of Human Tumor Cell Lines”. By Nikhil R. Madadi and Peter A. Crooks, Letters in Drug Design and Discovery, 2015, 12, 521-528, DOI: 10.2174/1570180812999150324163710. 586. “Pharmacologically-distinct Nicotinic ACh Receptors Drive Efferent-mediated Excitation
in Calyx-bearing Vestibular Afferents". By Joseph Holt, Kevin Kewin, Paivi Jordan, Peter Cameron, Marcin Klapczynski, J. Michael McIntosh, Peter A. Crooks, Linda P. Dwoskin, and Anna Lysakowski, Journal of Neuroscience, 2015, 35(8), 3625-3643, DOI: 10.1523/JNEUROSCI.3388-14.2015; PMID: 25716861. 587. “Nanodelivery of Gambogic Acid by Functionalized Graphene Enhances Inhibition of Cell Proliferation and Induces G0/G1 Cell Cycle Arrest in Cervical, Ovarian, and Prostate
Cancer Cells”. By L. M Saeed, M. Mahmood,Y. Xu, Z. A. Nima, G. Kannarpady, S. M. Bratton, E. Dervishi, D. Casciano, S. Ali, Peter A. Crooks, Anna Radominska-Pandya, and Alex S. Biris, RSC Advances, 2015, 5, 44022-44030; DOI: 10.1039/C5RA00833F; PMID: 588. “Organ-Specific Adaptive Signaling Pathway Activation in Metastatic Breast Cancer Cells”. By Riesa M. Burnett1, Kelly Craven, Purna Krishnamurthy, Chirayu P. Goswami, Sunil Badve, Peter A. Crooks, William P. Matthews, Poornima Bhat-Nakshatri1 and Harikrishna
Nakshatri, Oncotarget, 2015, 6, 12682-12696; published on-line at: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3707 March 30th, 2015: PMID: 25926557.
589. “Development and Validation of a Novel Assay to Identify Radiosensitizers that Target Nucleophosmin 1”. By Narsimha R. Penthala, Peter A. Crooks, Michael L. Freeman, and Sekhar Raja Konjeti, Bioorg. Med. Chem., 2015, 23, 3681-3686; DOI: 10.1016/j.bmc.2015.04.018; PMID: 25922180. 590. “Asymetric Synthesis of (S)- and (R)-Norketamine via Sharpless Asymmetric Dihydroxylat- ion/Ritter Amination Sequence”. Manfred Biermann, Guangrong Zheng, Marhaba Hojahmat, Nick V. Moskalev, and Peter A. Crooks, Tetrahedron Letters, 2015, 56, 2608- 2610; DOI: http://dx.doi.org/10.1016/j.tetlet.2015.04.050 591. “Weight Losing, Antihyperlipidemic and Cardioprotective Effects of the Alkaloid Fraction of Hunteria umbellata Seed Extract on Normal and Triton-induced Hyperlipidemic Rats”. By Adejuwon Adewale Adeneye and Peter A. Crooks, Asian Pacific Journal of Tropical Biomedicine, 2015, 5(5), 387-394. 592. “Quinolyl Analogues of Norlobelane: Novel Potent Inhibitors of Binding and [3H]Dopamine Uptake at the Vesicular Monoamine Transporter-2”. By Derong Ding, Justin R. Nickell, Linda P. Dwoskin, and Peter A. Crooks. Bioorganic. Med. Chem. Lett., 2015, 25, 2613-2616, DOI: http://dx.doi.org/10.1016/j.bmcl.2015.04.105; PMID: 24991431. 593. “Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anticancer agents”. By Narsimha R. Penthala, Shraddha Thakkar, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2763-2767; DOI: http://dx.doi.org/10.1016/j.bmcl.2015.05.019 PMID: 26022840. 594. “Synthesis and Anti-cancer Screening of Novel Heterocyclic-(2H)-1,2,3-triazoles as Potential Anti-cancer Agents”. By Narsimha R. Penthala, Leena Madhukuri, Shraddha Thakkar,Nikhil R. Madadi,Gauri Lamture, Robert L. Eoff and Peter A. Crooks, MedChemComm, 2015, 6(8), 1535-1543, DOI: 10.1039/C5MD00219B; PMID: 27066215. 595. “Comparison of the Crystal structures of 4,4'-bis-(3-(4-methylpiperidin-1-yl)prop-1-yn-1- yl)-1,1'-biphenyl and 4,4'-bis-3-(2,2,6,6-tetramethylpiperidin-1-yl)prop-1-yn-1-yl)-1,1'- biphenyl”. By Anqi Wan, Narsimha R. Penthala, Kim E. Fifer, Sean Parkin, and Peter A. Crooks, Acta Crystallogr., Section E, Research Communications, 2015, E71, 1132- 1135; DOI: 10.1107/S2056989015015352; PMID: 26594389.
596. “r-bPiDI, an 62* Nicotinic Receptor Antagonist, Decreases Nicotine-evoked Dopamine Release and Nicotine Reinforcement”. By Joshua S. Beckmann, Andrew C. Meyer, M. Pivavarchyk, David B. Horton, Guangrong Zheng, Andrew M. Smith, Thomas E. Wooters, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo and Linda P. Dwoskin, Neurochem. Res., 2015, 40, 2121-2130; DOI: 10.1007/s11064-015-1680-4; PMID: 26227997. 597. “Synthesis and Biological Evaluation of Novel 4,5-Disubstituted 2H-1,2,3-triazoles as cis-
Constrained Analogues of Combretastatin A-4”. By Nikhil R. Madadi, Narsimha R. Penthala, Kevin Howk, Amit Ketkar, Robert L. Eoff, Michael J. Borrelli, and Peter Anthony Crooks, Europ. J. Med. Chem., 2015, 103, 123-132; DOI: 10.1016/j.ejmech.2015.08.014; PMID: 26352674.
598. “Use of a Novel Bone-targeting Agent for the Enhanced Delivery of Vancomycin to Bone”. By Zaineb A. F. Albayati, Manjula Shanker, Suzannah M. Schmidt-Malan, Melissa J. Karau, Andrew J. Morris, James M. Steckelberg, Robert Patel, Philip J. Breen, Mark S. Smeltzer, Grant Talor, Kevyn E. Merten, William M. Pierce, and Peter A. Crooks, Antimicrobial Agents and Chemotherapy, 2015, 30, 1865-1868; DOI: 10.1128/AAC.01609-15; PMID: 2666918.
599. “Comparison Crystal Structure Conformations of 4,4′-bis(3-(Pyrrolidin-1-yl)prop-1-yn-1-yl)- 1,1′-biphenyl and 4,4′-bis(3-((S)-2-Methylpyrrolidin-1-yl)prop-1-yn-1-yl)-1,1′-biphenyl”. By Anqi Wan, Narsimha Reddy Penthala, E. Kim Fifer, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, Research Communications, 2015, E71, 1147-1150; DOI: 10.1107/S2056989015016163; PMID: 26594393. 600. “Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity Against Hematological and Solid Tumor Cells". By Venumadhav Janganati, Jessica Ponder, Craig Jordan, Michael Borrelli, Penthala, N. Reddy and Peter A. Crooks, J. Med. Chem., 2015, 58, 8896- 8906, DOI: 10.1021/acs.jmedchem.5b01187; PMID: 26540463. 601. “1-Benzyl-2-methyl-3-indolylmethylene Barbituric Acid Derivatives: Anticancer Agents that Target Nucleophosmin 1 (NPM1)”. By Narsimha R. Penthala, Amit Ketkar, Konjeti R. Sekhar, Michael L. Freeman, Robert L. Eoff, Ramesh Balusu, and Peter A. Crooks, Bioorganic and Medicinal Chemistry, 2015, 23, 7226-7233; DOI: 10.1016/j.bmc.2015.10.019; PMID: 26602084. 602. “13-(E)-(5-Pyrimidinyl)parthenolide”. By Shobanbabu Bommagani, Narsimha R. Penthala, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, Research Communications, 2015, E71, 1536-1538; DOI: 10.1107/S2056989015021507. Featured on the Cover of the Journal for the Month of December, 2015. 603. "In Vivo Targeting of Leukemia Stem Cells by Directing Parthenolide-loaded Nanoparticles to the Bone Marrow Niche." By Hongliang Zong, Siddhartha Sen, Guodong Zhang, David G. Gorenstein, Xuewu Liu, Mauro Ferrari, Peter A. Crooks, Zaineb Albayati, Gail J. Roboz, Haifa Shen, and Monica L. Guzman, Leukemia, 2016, 30, 1582-1586; DOI: 10.1038/leu.2015.343; PMID: 26669973. 604. “A Novel and Efficient Tributyltin Azide-mediated Synthesis of 1H-tetrazolylstilbenes from Cyanostilbenes”. By Narsimha Reddy Penthala, Shobanbabu Bommagani, Jaishankar Yadlapalli, and Peter A. Crooks, Tetrahedron Letters, 2016, 57, 1807-1810; published on-line, http://dx.doi.org/10.1016/j.tetlet.2016.03.040.
605. “Dioxol and Dihydrodioxin Analogs of 2- and 3-Phenylacetonitriles as Potent Anti-cancer Agents with Nanomolar Activity Against a Variety of Human Cancer Cells”. By Nikhil R. Madadi, Amit Ketkar, Narsimha R. Penthala, April C.L. Bostian, Robert L. Eoff, and Peter Crooks, Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2164-2169, on-line at: http://dx.doi.org/10.1016/j.bmcl.2016.03.068; PMID: 27017113. 606. “Lobelane Analogues Containing 4-Hydroxy and 4-(2-Fluoroethoxy) Aromatic Substituents: Potent and Selective Inhibitors of [3H]Dopamine Uptake at the Vesicular Monoamine Transporter-2”. By Shyam R. Joolakanti, Justin R. Nickell, Venumadhav Janganati, Guangrong Zheng, Linda P. Dwoskin and Peter A. Crooks, Bioorganic and Medicinal Chemistry, 2016, 26, 2422-2427, http://dx.doi.org/10.1016/j.bmcl.2016.03.119 PMID: 27080180. 607. “Crystal Structures of (Z)-5-[2-(Benzo[b]thiophen-2-yl)-1-(3,5-dimethoxyphenyl)ethenyl]-1H- tetrazole and (Z)-5-[2-(Benzo[b]thiophen-3-yl)-1-(3,4,5-trimethoxyphenyl)ethenyl]-1H- tetrazole”. By Narsimha Reddy Penthala, Jaishankar K. B. Yadlapalli, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, Research Communications, 2016, E72, 652- 655, http://dx.doi.org/10.1107/S2056989016005600; PMID: 27308011.
608. “Persistant Activation of NFB in BRCA1-deficient Mammary Progenitors Drives Abberant Proliferation and Accumulation of DNA Damage”. By Andrea Sau, Rosanna Lau, Miguel A. Cabrita, Emma Nolan, Peter A. Crooks, Jane Visvader, and Christine Pratt, Cell Stem Cell, 2016, 19, 1-14, July 7, http://dx.doi.org/10.1016/j.stem.2016.05.003; PMID: 27292187. 609. “Antinociceptive Effects of the 6-O-Sulfate Ester of Morphine in Normal and Diabetic Rats:
Comparative Role of - and -Opioid Receptors”. By Jai Shankar K. Yadlapalli, Benjamin M. Ford, Amit Ketkar, Anqi Wan, Narasimha R. Penthala, Robert L. Eoff, Paul L. Prather, Maxim Dobretsov, Peter A. Crooks, Pharmacological Research, 2016, 113 (Part A), 335-347; DOI: 10.1016/j.phrs.2016.09.012; PMID: 27637375.
610. “1,4-Diphenalkylpiperidines: A New Scaffold for the Design of Potent Inhibitors of the
Vesicular Monoamine Transporter-2”. By Justin R. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, , Bioorganic and Medicinal Chemistry Letters, 2016, 26(13), 2997-3000; published on-line at: http://dx.doi.org/10.1016/j.bmcl.2016.05.025 ; PMID: 27212067.
611. “Synthesis of (2R,8′S,3′E,11′E)--Tocodienol, a Tocoflexol Family Member Designed to have
a Superior Pharmacokinetic Profile than -Tocotrienol”. By Xingui Liu, Satheesh Gujarathi, Xuan Zhang, Marjan Boerma, Cesar M. Compadre, Peter A. Crooks, Martin Hauer-Jensen, Daohong Zhou, Guangrong Zheng, Tetrahedron, 2016, 72, 4001-4006; DOI: 10.1016/j.tet.2016.05.028; PMID: 612. “Synthesis and In vitro Evaluation of Water-soluble 1,4-Diphenethylpiperazine Analogs as Novel Inhibitors of the Vesicular Monoamine Transporter-2”. Justin R. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4441-4445, DOI: 10.1016/j.bmcl.2016.08.001; PMID: 27524311.
613. “Synthesis of Triazolidine-2.4-dione Derivatives: Anticancer, Antimicrobial and DNA Cleavage Studies”. By S. Vijaya Laxmi, P. Anil, G. Rajitha, Asha Jyothi Rao, and Peter A. Crooks, J. Chem. Biol., 2016, 9, 97-106; DOI: 10.1007/s12154-016-0154-8; PMID: 27698947. 614. “Targeting Enox1 in Tumor Stroma Increases the Efficacy of Fractionated Radiotherapy”. By Clayton A. Smith, Geri Traver, Konjeti R. Sekhar, Peter A. Crooks, and Michael L. Freeman, Oncotarget, 2016, manuscript No. 017133R1, accepted for publication. . 615. “Identification of Resveratrol Analogs as Potent Anti-Dengue Agents Using a Cell-based Assay”. By Ying-Shan Han, Narsimha R. Penthala, Maureen Oliveira, Thibault Mesplede, Hongtau Xu, Yudong Quan, Peter A. Crooks, and Mark. A. Wainberg, J. Med. Virol., Manuscript no. JMV-16-5421, published on-line, July, 2016. DOI: 10.1002/jmv.24660; PMID: 27509184. 616. “Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute
Myelogenous Leukemia Stem Cells”. By Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Travis Nemkov, Brett M. Stevens, Biniam Adane, Nabilah Khan, Fred K. Hagen, Vinod K. Yadav, Subhajyoti De, John M. Ashton, Kirk C. Hansen, Jonathan A. Gutman, Daniel A. Pollyea, Peter A. Crooks, Clayton Smith and Craig T. Jordan, J. Biol. Chem., manuscript M116.750653; 2016, in press: published on-line at: http://www.jbc.org/cgi/doi/10.1074/jbc.M116.750653 ; PMID: 27573247.
Manuscripts submitted for publication "A Phytochemical and Phytopharmacological Review on the Seeds of Nigella sativa L." By Alison
Anderson, Omar A. Ghosheh and Peter A. Crooks, J. Ethnopharmacol., submitted, 2014.
“Development of Guanylated Nicotine Analogs: Ligands for α42 and α7 Neuronal Nicotinic Acetylcholine Receptor Subtypes”. By Aaron J. Haubner, Emily J. Kennard, Joshua R. Ring, Agripina G. Deaciuc, May C. Fu, John M. Littleton, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem., submitted, 2014. “Preparation of 2-(Heterocyclicmethoxy)pyridines As Neuronal Nicotinic Receptor Ligands”. By
Jianghong Chen, Peter A. Crooks, Linda P. Dwoskin, and Donglu Bai, Bioorganic and Medicinal
Chemistry Letters, in preparation, 2014. “Agmatine Analogs as N-Methyl-D-Aspartate Receptor Inhibitory Modulators”. By Joshua R. Ring, Aaron J. Haubner, John M. Littleton, and Peter A. Crooks, Biorg. Med. Chem., submitted, 2014. “Preclinical Pharmacokinetic Evaluation of Z-(±)-2-(1-Benzenesulfonyl-1H-indol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-one (BSAO); a Novel Radio-sensitization Agent”. By Abeer M. Al-Ghananeem, Ahmad H. Malkawi, Zaineb F. Al-Bayati, Michael L. Freeman and Peter A. Crooks, AAPS Journal, submitted, 2014. “Bridged Amidino Nicotine Analogs: Subtype-selective, High Affinity Ligands for the Neuronal Nicotinic Receptor”. By Aaron J. Haubner, Jianhong Chen, Emily J. Kennard, Gareth Young, Roger L. Papke, Neil S. Millar, Linda P. Dwoskin and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted, 2014. “Guanylated Nicotine Analogs: Ligands for α4β2* and α7* Neuronal Nicotinic Receptor Subtypes”. By Aaron J. Haubner, Emily J. Kennard, Joshua R. Ring, May C. Fu, John M. Littleton, Linda P. Dwoskin, and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted, 2014. “Dimethylaminoparthenolide (DMAPT) is an Active In Vivo Agent for Prostate Cancer, and Cell Death is Associated with Generation of Oxidative Stress, c-Jun N-terminal Kinase Activation, and Inhibition of Nuclear Factor Kappa B (NFkB)”. By Rajasubramaniam Shanmugam, Praveen Kasumanchi, Peter A. Crooks, Craig Jordan, William Matthews, Harikrishna Nakshatri, and Christopher J. Sweeney, Clinical Cancer Research, submitted. “The Pyrrolidine Analog of nor-Lobelane, cis-2,5-di-(2-Phenethyl)-pyrrolidine Hydrochloride, Inhibits VMAT2 Function, Dopamine Release, and Methamphetamine Self-administration in Rats”. Joshua Beckmann, Kiran Siripurapu, Justin Nickell, Emily Denehy, Ashish Vartak, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo. J. Pharmacol. Exp. Ther., submitted. “CuPy2Cl2: An Efficient Recyclable Solid Acid Catalyst for the Solvent-free Synthesis of 2-Amino thiazole/selenazole-5-carboxylic Esters in the Presence of N-Bromosuccinimide”. J. Venu Madhav, Y. Thirupathi Reddy, B. Suresh Kuarm, Peter A. Crooks and B. Rajitha. Chem. Lett., manuscript in the preparation. “Design, Synthesis and Anti-proliferative Activity of Novel Parthenolide Analogs”. M. Nikhil Reddy, Srinivas Koduru, Y. Thirupathi, Reddy, P. Narsimha Reddy, Damodaran Chendil, and Peter A. Crooks. Bioorg. Med. Chem. Lett., manuscript in the preparation. “A Convenient and Scalable Synthesis of S-(-)-Nornicotine from S-(-)-Nicotine with Retention of Configuration at the Pyrrolidine-2 Carbon Utilizing Manganese Dioxide-mediated Oxidative
94
N-demethylation”. By Marhaba Hojhamat, Xiaochen Wei, and Peter A. Crooks, Chirality, submitted. “Synthesis and In Vitro Evaluation of N-Alkyl-3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)indolin-2-ones as Potential Anticancer Agents”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, M. Nikhil Reddy and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted, BMCL-D-10-00863. “Structural and Pharmacological Studies on the Antileukemic Properties of 1,2,4-Thiadiazolidine-3,5-diones: Identification of Potent and Water-soluble Derivatives”. By Shama Nasim, Monica L. Guzman, Craig T. Jordan, and Peter A. Crooks, J. Med. Chem., submitted. “Microwave-assisted Synthesis and Anti-proliferative Activity of Novel Resveratrol Analogs”. By Nikhil Reddy Madadi, Y. Thirupathi Reddy, Srinivas Koduru, P. Narsimha Reddy, Chendil Damodaran, and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted. “1-Methyl-2,6-distyrylpyridinium Iodide”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, Joshua Eldridge, Sean Parkin and Peter A. Crooks, Acta Cryst., Section E, submitted. “Synthesis and Evaluation of Chromenyl Barbiturates and Thiobarbiturates as Potential Anti- tuberculosis Agents”. By Vijaya S. Laxmi, Suresh B. Kuarm, B. Rajitha, Narsimha P. Reddy, Thirupathi Y. Reddy, and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted. “Inhibition of Vesicular Monoamine Transporter-2 Function Specifically Blocks Methamphetamine Reward in Rats”. By Joshua S. Beckmann, Emily D. Denehy, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Neuropsychopharmacology, submitted. “The Novel Nicotinic Receptor Antagonist r3,5L/3PiDDB Potently Inhibits Nicotine-evoked [3H]Dopamine Release from Rat Striatal Slices”. By Andrew M. Smith, A. C. Meyer, Marharyta Pivavarchyk, Thomas E. Wooters, David B. Horton, Zhenfa Zheng, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., submitted. “GZ-793A Selectively Inhibits Methamphetamine Effects on Dopamine Release”. By Kirin B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Neuropharmacology, in preparation. “Acyclic Lobelane Analogs Inhibit Vesicular Monoamine Transporter-2 (VMAT2) Function and Both Methamphetamine- and Nicotine-evoked Dopamine Release”. By Zach Cao, Kirin B. Siripurapu, Andrew M. Smith, David B. Horton, Guangrong Zheng, C. E. Wilmouth, A. Gabriela Deaciuc, Michael T. Bardo, Peter A. Crooks, and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., in preparation. “GZ-793A, A Novel Vesicular Monoamine Transporter-2 (VMAT2) Inhibitor that Probes Multiple Sites on VMAT2 as a Potential Treatment for Methamphetamine Abuse”. By David B. Horton, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, J. Neurochem., in review. “Oral GZ-793A Treatment Does Not Exacerbate Methamphetamine-induced Dopamine Depletions in Striatal Tissue and Striatal Vesicles Following Methamphetamine Self-administration”. By C. E. Wilmouth, Kirin B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, J. Pharmacol. Exp. Therap., in preparation.
95
“The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to the Sites of DNA Damage, Suppressing Repair of DNA Double Strand Breaks, and Enhancing Radio-sensitization”. By Konjeti R Sekhar, YT Reddy, Peter A Crooks, Amudhan Venkateswaran, Hayes, W. McDonald, Ling Geng1, Souma Sasi, Robert P. Van Der Waal, Joseph L Roti Roti, Ken J Salleng, and Michael L. Freeman, Clin. Cancer Research, submitted. “Synthesis and Evaluation of Chromenyl Barbiturates and Thiobarbiturates as Potential Antituberculosis Agents”. By S. Vijayalaxmi, Y. Thirupathi Reddy, B. Suresh Kuarm, P. Narsimha Reddy, J. Venu Madhav, Peter A. Crooks, and B. Rajitha, Bioorg. Med. Chem. Lett., submitted.
“Synthesis of 11H-Xantheno[2,1-c][1,2,5]selenadiazol-11-ones as Potent Antimicrobial Agents”. By B. Suresh Kuarm, Peter A. Crooks, and B. Rajitha, Bioorg. Med. Chem. Lett., submitted. “Synthesis of 2-(2-oxo-2H-chromen-3-yl)-3-arylquinazolin-4(3H)-ones as Potent Antimicrobial Agents”. By B. Suresh Kuarm, Peter A. Crooks and B. Rajitha, Bioorg. Med. Chem. Lett., submitted. “Xanthan Sulfuric Acid: an Efficient Biodegradable and Recyclabable Solid Acid Catalyst for the Synthesis of 14-Aryl-14H-dibenzo[a,i]xanthene-8,13-diones”. By B. Suresh Kuarm, P. Narsimha Reddy, Peter A. Crooks and B. Rajitha, Synth. Comm., submitted. “Photochemical Synthesis and Anticancer Activity of Barbituric Acid, Thiobarbituric Acid, Thio- semicarbazide and Isoniazide linked to 2-Phenyl Indole Derivatives”. By Vijaya S. Laxmi, Janardhan Banothu, Bhargavi Rajitha, Asha Rao Jyothi, and Peter A. Crooks, J. Enz. Inhibit. Med. Chem., submitted.
“GZ-793A Attenuates Acute Methamphetamine-induced Striatal Dopamine Depletions”. By Kiran B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., submitted. “GZ-793A Interacts with the Vesicular Monoamine Transporter-2 to Inhibit the Effect of Methamphetamine”. By David B. Horton, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin, J. Neurochem., submitted. “Synthesis of New Side Chain Derivatives of Thiazolidine-2,4-dione: Anticancer, Antimicrobial and DNA Cleavage Studies”. By Vijaya Laxmi, Rajitha Bahrgavi, Asha Jyothi Rao, and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted. “Assembly of N,N-Disubstituted Hydrazines and Indacenes via Copper-Catalyzed Coupling Reactions”. By Suresh Kuarm, Peter A. Crooks, and B. Rajitha, Organic Letters, submitted. “Synthesis of 11H-xantheno[2,1-c][1,2,5]selenadiazol-11-ones as Potent Antimicrobial Agents”. By B. Suresh Kuarm, Peter A. Crooks, and B. Rajitha, Bioorg. Med. Chem. Lett., submitted. “Keap1 is a Redox Sensitive Target that Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells”. By Yong Xu, Fang Fang, Sumitra Miriyala, Peter A. Crooks, Terry D. Oberley, Luksana Chaiswing, Teresa Noel, Aaron K. Holley, Yanming Zhao, Kelley K. Kiningham, Daret St Clair, and William H. St. Clair, Cancer Research, manuscript CAN-12-4297, submitted. “Effects of VMAT2 Inhibitors lobeline and GZ-793A on Methamphetamine-induced Changes in Dopamine Release, Metabolism and Synthesis In Vivo”. By Andrew C. Meyer, Nichole M. Neugebauer, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, J. Neurochem., submitted.
96
“r-bPiDI Acts Selectively at 62* Nicotinic Receptors to Decrease Nicotine-evoked Dopamine Release and Nicotine Reinforcement”. By Joshua S. Beckmann, Andrew C. Meyer, Marharyta Pivavarchyk, David B. Horton, Guangrong Zheng, Andrew M. Smith, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo and Linda P. Dwoskin, Neuropharmacology, submitted. “Oral administration of GZ-793A, a VMAT2 Inhibitor, Decreases Methamphetamine Self-Administration in Rats”. By Carrie E. Wilmouth, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, Michael T. Bardo, Psychopharmacol., in preparation. “Design, Synthesis and Anti-microbial Activity of 11H-xantheno[2,1-c][1,2,5] Selenadiazol-11-ones”. By B. Suresh Kuarm, Peter A. Crooks, and B.Rajitha, Bioorg. Med. Chem. Lett., BMCL-D-13-00394, submitted. “Effects of Non-peptide, Small-molecule, Antagonists ofNicotinic Acetylcholine Receptors in Assays of Chronic Pain in Rats”. Elzbieta P. Wala, Peter A. Crooks, Linda P. Dwoskin, J. Michael McIntosh, Joseph R. Holtman, Jr., European Journal of Pharmacology, submitted. “Poly(4-vinylpyridinium)hydrogen Sulfate Catalyzed an Efficient and Eco-friendly Protocol for the One-pot Multicomponent Synthesis of 1,8-Acridinediones in Aqueous Medium". By Janardhan Banothu, B. Rajitha and Peter A. Crooks, ISRN Journal of Chemistry, Article ID 850254, 2013, 1-6; DOI: http://dx.doi/10.1155/2013/850254. “Design, Synthesis and Anti-proliferative Activity of 5-[(1-Benzyl-1H-indol-3-yl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H]-trione Analogs Against Human Tumor Cell Lines”. By Nikhil Reddy Madadi, Narsimha Reddy Penthala, Venumadhav Janganati and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted.
“An Environmental Friendly Improved Protocol for the Synthesis of bis-(3-indolyl)methanes using Poly(4-vinylpyridinium) HydrogenSulfate as Efficient, Heterogeneous and Recyclable Solid Acid Catalyst”. By Janardhan Banothu, Rajitha Gali, Ravibabu Velpula, Rajitha Bavantula, and Peter A. Crooks, ISRN Journal of Chemistry, submitted, Manuscript No. 616932. “Novel Resveratrol-based Substrates for Human Hepatic, Renal and Intestinal UDP-Glucuronosyltransferases”. By Aleksandra K. Greer, Nikhil Madadi, Stacie M. Bratton, Sarah D. Eddy, Zofia Mazerska, Howard P. Hendrickson, Peter A. Crooks, and Anna Radominska-Pandya, Chemical Research in Toxicology, submitted, Manuscript ID tx-2013-00408x.
“The NADH Oxidase ENOX1, a Critical Mediator of Endothelial Cell Radiosensitivity, is Crucial for Vascular Development”. By Amudhan Venkateswaran, Konjeti Sekhar, Daniel Levic, David Melville, Travis Clark, Witold Rybski, Alex Walsh, Melissa Skala, Peter Crooks, Ela Knapik, and Michael Freeman, Cancer Research, submitted. “N-[Phenyl/(benzo[d]thiazol-2-yl)]-2-chloroacetamides are Doubly Electrophilic Building blocks for the Formation of Thiazolo[3,2-a]pyrimidinones”. By Janardhan Banothu, Srinivas Basavoju, Rajitha Bavantula, and Peter A. Crooks, Tetrahedron Letters, submitted. “Sodium Fluoride as an Efficient Catalyst for the Synthesis of 2,4-Disubstituted-1,3-thiazoles and Selenazoles at Ambient Temperature”. By Janardhan Banothu, Krishnaiah Vaarla, Rajitha Bavantula, and Peter A. Crooks, Journal of Molecular Catalysis A: Chemical, submitted.
97
“13-(E)-(4-Aminophenyl)parthenolide”. By Narsimha R. Penthala, Venumadhave Janganati, Sean Parkin, Kottayil I. Varuhese, and Peter A. Crooks, Acta Crystallogr., Section E, submitted for publication. “Characterization of the Intrinsic Activity for a Novel Class of Cannabinoid Receptor Lligands: Indole Quinuclidine Analogues (IQDs)”. By Lirit N. Franks, Benjamin M. Ford, Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks and Paul L. Prather, J. Pharmacol. Exp. Therap., submitted; JPET/2013/210195. “Synthesis and Evaluation of a Series of Quinolyl trans-Cyanostilbene Analogs as Anticancer Agents”. By Narsimha Reddy Penthala, Venumadhav Janganati, Shobanbabu Bommagani, and Peter A. Crooks, MedChemComm, manuscript no. MD-CAR-03-2014-000115, submitted 2014. “Heck Products of Parthenolide and Melampomagnolide-B as Anticancer Modulators that Modify Cell Cycle Progression”. Narsimha R. Penthala, Shobanbabu Bommagani, Venumadhav Janganati, Kenzie B. MacNicol, Chad E. Cragle, Nikhil R. Madadi, Linda L. Hardy Angus M. MacNicol, and Peter A. Crooks. European Journal of Medicinal Chemistry, submitted, 2014, manuscript no. EJMECH-D-14-00866. “Novel Cytoprotective Inhibitors for Apoptotic Endonuclease”. By Dae Song Jang, Narsimha Penthala, Eugene Apostolov, Xaioying Wang, Peter A. Crooks, and Alexei Basnakian. DNA and Cell Biology, submitted, 2014, Manuscript no. DNA-2014-2530. "In Vivo Targeting of Leukemia Stem Cells by Directing Parthenolide-loaded Nanoparticles to the Bone Marrow Niche." By Hongliang Zong, Siddhartha Sen, Guodong Zhang, David G. Gorenstein, Xuewu Liu, Mauro Ferrari, Peter A. Crooks, Zaineb Albayati, Gail J. Roboz, Haifa Shen, and Monica L. Guzman, Leukemia, manuscript 15-LEU-1235, submitted, 2015. “Organ-Specific Adaptive Signaling Pathway Activation in Metastatic Breast Cancer Cells”. By Riesa M. Burnett, Kelley Craven, Purna Krishnamurthy, Chirayu P. Goswami, Sunil Badve, Peter A. Crooks, William P. Mathews, Patricia S. Steeg, Poornima Bhat-Nakshatri, and Harikrishna Nakshatri, manuscript in preparation, 2014.
“4,5-bis(3,4,5-Trimethoxyphenyl)-2H-1,2,3-triazole Methanolate”. By Nikhil R. Madadi, Sean Parkin, and Peter A. Crooks, Acta Crystallographa, Series E, submitted for publication, 2014. “Comparison of Crystal structures of 4-(Benzo[b]thiophen-2-yl)-5-(3,4,5-trimethoxyphenyl)-2H-1,2,3-triazole and 4-(Benzo[b]thiophen-2-yl)-2-methyl-5-(3,4,5-trimethoxyphenyl)-2H-1,2,3-triazole”. Narsimha R. Penthala, Nikhil R. Madadi, Shobanbabu Bommagani, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Research Communications, submitted, manuscript t0c0209, 2014.
“Synthesis and Evaluation of a Series of Resveratrol Analogs as Potent Anticancer Agents that Target Tubulin”. By Nikhil R. Madadi, Hongliang Zong, Amit Ketkar, Chen Zheng, Narsimha R. Penthala, Venumadhav Janganati, Shobanbabu Bommagani, Robert L. Eoff, Monica L. Guzman, Peter A. Crooks, MedChemComm, submitted, 2014; manuscript MD-CAR-10-2014-000478. “Recent Advances on 1,2,3-Triazole Ring-containing Pharmacophores in Medicinal Chemistry”. By Nikhil Reddy Madadi and Peter A. Crooks, Current Topics in Medicinal Chemistry: Special Issue: New Developments in Medicinal Chemistry Highlighting Diverse Heterocyclic Ring Systems. Invited paper, 2014.
98
“Synthesis and Anti-cancer Activity of Novel C2 Substituted Methoxylated Resveratrol Analogs against Human Tumor Cell Lines”. Nikhil Reddy Madadi, Narsimha Reddy Penthala and Peter A. Crooks, Bioorg. Med. Chem. Lett., submitted, 2014. “Synthesis of Thiazolidine-2,4-dione Derivatives: Anticancer, Antimicrobial and DNA Cleavage Studies”. S. Vijaya Laxmi, P. Anil, G. Rajitha, Jyothi Rao Asha, Peter A. Crooks, B. Rajitha, MedChemComm, submitted 2015, manuscript MD-CAR-04-2015-000173. “2-Methyl-N-benzylindole Barbituric Acid Derivatives: Anti-cancer Agents that Target Nucleophosmin 1 (NPM1)”. By Narsimha Reddy Penthala, Amit Ketkar, Konjeti R. Sekhar, Michael L. Freeman, Robert L. Eoff, Ramesh Balusu and Peter A. Crooks, Bioorganic and Medicinal Chemistry, 2015, Manuscript No. BMC-D-15-01083R1, accepted for publication.
“Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells”. By Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Travis Nemkov, Brett M. Stevens, Biniam Adane, Nabilah Khan, Fred K. Hagen, Vinod K. Yadav, Subhajyoti De, John M. Ashton, Kirk C. Hansen, Jonathan A. Gutman, Daniel A. Pollyea, Peter A. Crooks, Clayton Smith and Craig T. Jordan, J. Biol. Chem., submitted, 2016; Manuscript No. JBC/2016/750653. “A Xenopus Oocyte Phenotypic Bioassay Screen Identifies Novel Small Chemical Regulators of Cell Cycle Progression and Stem Cell Self-Renewal”. By M.C. MacNicol, M.T.E. Montales, K. Cragle, Narsimha R. Penthala, Venumadhav Janganati, C.E. Cragle, Guangrong Zheng, L.L. Hardy, Shobanbabu Bommagani, K.B. MacNicol, Nikhil R. Madadi, B.S. Winter, A.T. Franco, Y.
Luo, Daohong Zhou, R.C.M. Simmen, Peter A. Crooks, and Angus M. MacNicol, J. Biol. Chem., submitted, 2015, manuscript No. JBC/2015/691832. “Effects of the VMAT2 Inhibitor GZ-793A on Acute and Chronic Methamphetamine-induced Dopamine Depletion in Rat Striatal Tissue”. By Kiran B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, European J. Pharmacol., submitted, 2015. “A Novel and Efficient Tributyltin Azide-mediated Synthesis of 1H-tetrazolylstilbenes from Cyanostilbenes”. By Narsimha Reddy Penthala, Shobanbabu Bommagani, Jaishankar Yadlapalli, and Peter A. Crooks, Tetrahedron Letters, submitted, 2016, manuscript No. TETL-D-16-00306. “(Z)-2-(Benzo[d][1,3]dioxol-5-yl) and (Z)-2,3-Dihydrobenzo[b][1,4]dioxin-6-yl Analogs of 2- and 3-Phenylacetonitriles as Potent Anti-cancer Agents with Nanomolar Activity Aagainst a Variety of Human Cancer Cells”. By Nikhil R. Madadi, Amit Ketkar, Narsimha R. Penthala, April C.L. Bostian, Robert L. Eoff, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, submitted, 2016. “Antinociceptive Effects of the 6-O-Sulfate Ester of Morphine in Normal and Diabetic Rats: Comparative Role of - and -Opioid Receptors”. By Jai Shankar K. Yadlapalli, Benjamin M. Ford, Amit Ketkar, Anqi Wan, Narasimha R. Penthala, Robert L. Eoff, Paul L. Prather, Maxim Dobretsov, Peter A. Crooks, Pharmacological Research, submitted, 2016. “Lobelane Analogues Containing 4-Hydroxy and 4-(2-Fluoroethoxy) Aromatic Substituents: Potent and Selective Iinhibitors of [3H]Dopamine Uptake at the Vesicular Monoamine Transporter-2”. By Shyama R. Joolakanti, Justin R. Nickell, Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, submitted, 2016.
“Crystal Structures of (Z)-5-(Benzo[b]thiophen-2-yl)-1-(3,5-dimethoxyphenyl)vinyl-1H-tetrazole and
99
(Z)-5-(Benzo[b]thiophen-3-yl)-1-(3,4,5-trimethoxyphenyl)vinyl-1H-tetrazole”. By Narsimha Reddy Penthala, Jaishankar K.B. Yadlapalli, Sean Parkin and Peter A. Crooks, Acta Crystallogr., Section E, Research Communications, Submitted, 2016. “1,4-Diphenalkylpiperidines: A New Scaffold for the Design of Potent Inhibitors of the Vesicular Monoamine Transporter-2”. By Justin R. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, , Bioorganic and Medicinal Chemistry Letters, submitted, 2016.
“Synthesis of Thiazolidine-2,4-dione Derivatives: Anticancer, Antimicrobial and DNA Cleavage Studies". By Vijaya Laxmi Somarapu, Rajitha Gali, Anil Pommodi, Rajitha Bhavantula, Asha Jyothi, and Peter A. Crooks, Monatshefte fur Chemie, manuscript MCCM-D-16-00227, submitted for publication, 2016. “Synthesis and In vitro Evaluation of Water-soluble 1,4-Diphenethylpiperazine Analogs as Novel Inhibitors of the Vesicular Monoamine Transporter-2”. Justin R. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Linda P. Dwoskin, and Peter A. Crooks, Bioorganic and Medicinal Chemistry Letters, submitted, 2016. “Identification of Resveratrol Analogs as Potent Anti-Dengue Agents Using a Cell-based Assay”. By Ying-Shan Han, Narsimha R. Penthala, Maureen Oliveira, Thibault Mesplede, Hongtau Xu, Yudong Quan, Peter A. Crooks, and Mark. A. Wainberg, J. Med. Virol., Manuscript no. JMV-16-5421, submitted, 2016. “Targeting Enox1 in Tumor Stroma Increases the Efficacy of Fractionated Radiotherapy”. By Clayton A. Smith, Geri Traver, Konjeti R. Sekhar, Peter A. Crooks, and Michael L. Freeman, submitted, Oncotarget, 2016, manuscript No. 017133. “GZ-793A Selectively Inhibits Neurochemical Effects of Methamphetamine”. By Justin R. Nickell, Kiran B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin, J. Pharmacol. Exp. Therap., submitted, 2016. “Effects of Varenicline and GZ-793A on Methamphetamine and Food Self-Administration Under a Multiple Schedule of Reinforcement in Rats”. By Megan M. Kangiser, Linda P. Dwoskin, Guangrong Zheng, Peter A. Crooks and Dustin J. Stairs, submitted, 2016. “A Small-molecule Inhibitor of DNA Polymerase Eta Sensitizes Cells to Cisplatin”. By Maroof K. Zafar, Leena Maddukuri, Narsima R. Penthala, Amit Ketkar, Sarah D. Eddy, Megan R. Reed, Peter A. Crooks, and Robert L. Eoff, J. Amer. Chem. Soc., submitted, 2016, manuscript no. ja-2016-09055z.
100
Symposium Abstracts
1. "Formation of an Alpha-Pyridone Metabolite of Metyrapone by Rat Hepatic Soluble
Enzymes". Lyaquatali A. Damani, and Peter A. Crooks, 41st International Congress of
Pharmaceutical Sciences of the Federation of International Pharmacists, Proc. 41st. Int.
2. "Conformation Requirements for Selectivity of Agonists at Post Synaptic Alpha 2-
Receptors". Peter Hicks, Christopher Waldron, Peter Burn, and Peter A. Crooks,
Proceedings of the British Hypertension Society, September, 1982, Oxford, UK; (Abstract
No. 53).
3. "Inhibition of Bacterial DNA Methylation by Synthetic Analogs of S-Adenosyl-L-
homocysteine", Peter A. Crooks, Malcolm J. Tribe, and Richard J. Pinney, American
Pharmaceutical Association Academy of Pharmaceutical Sciences, 33rd National
Meeting, November 1982, San Diego, CA, USA; Proc. Acad. Pharm. Sci., 1982, 12 (2),
151 (Abstract No. 18).
4. "Synthesis of Novel Nucleosides as Potential Inhibitors of mRNA Guanine 7-
Methyltransferase," Eric Benghiat, and Peter A. Crooks, American Pharmaceutical
Association Academy of Pharmaceutical Sciences, 33rd National Meeting, November,
1982, San Diego, CA, USA; Proc. Acad. Pharm. Sci., 1982, 12 (2), 152 (Abstract No. 20).
5. "High-Performance Liquid-Chromatographic Determination of the In Vivo N-Methylation of 14C-nicotine in the Guinea Pig", Kenneth C. Cundy, and Peter A. Crooks, American
Pharmaceutical Association Academy of Pharmaceutical Sciences, 33rd National
Meeting, November, 1982, San Diego, CA, USA; Proc. Acad. Pharm. Sci., 1982, 12 (2),
151 (Abstract No. 19).
6. "In Vitro Methylation of Nicotine in the Guinea Pig." C. Steven Godin, and Peter A.
Crooks, 35th National Meeting of the Academy of Pharmaceutical Sciences, American
Pharmaceutical Association, Miami Beach, Florida, Nov., 1983; Proc. Acad. Pharm. Sci.,
1983, 13(2), 174 (Abstract No. 8).
7. "Unexpected Phenomenon in the High-Performance Liquid-Chromatography of
Radiolabeled Nicotines-Separation of Enantiomers in an Achiral System". Kenneth C.
Cundy, and Peter A. Crooks, 35th National Meeting of the Academy of Pharmaceutical
Sciences, American Pharmaceutical Association, Miami Beach, Florida, November, 1983;
Proc. Acad. Pharm. Sci., 1983, 13(2), 177 (Abstract No. 20).
8. "Pulmonary Metabolism of Enkephalins," Peter A. Crooks, Jerzy Krechniak, Jack W.
Olson, Ralph J. Altiere, and Mark N. Gillespie, American Physiological Society, 35th
21. "Depletion of S-Adenosylhomocysteine Levels in Guinea Pig Lung After Chronic In Vivo
Exposure to S-(-)-Nicotine". C. Steven. Godin, Abdulghani A. Houdi, and Peter A.
Crooks, 39th National Meeting and Exposition of the Academy of Pharmaceutical
Sciences, American Pharmaceutical Association, Minneapolis, Minnesota, October, 1985;
Proc. Acad. Pharm. Sci., 1985, 15(2) 122 (Abstract No. 6).
22. "Stereospecific Synthesis and Structural Analysis, Using 1H-, 13C- and Auto-correlated 2-
Dimensional NMR Spectroscopy, of a Conformationally Defined, Rigid Analogue of
Dopa". Everett J. Horn, W. John Layton, Stanford L. Smith and Peter A. Crooks, 39th
National Meeting and Exposition of the Academy of Pharmaceutical Sciences, American
Pharmaceutical Association, Minneapolis, Minnesota, October, 1985; Proc. Acad. Pharm.
Sci., 1985, 15(2), 124 (Abstract No. 12).
23. "Determination of Quaternary Ammonium Metabolites by Mass Spectrometric Analysis",
William F. Pool, Peter A. Crooks, Roger J. Greathead, and R. Parillo, Society of
Toxicology, Annual National Meeting, New Orleans, March, 1986; The Toxicologist, 1986,
6(1), 305 (Abstract No. 1026).
24. "Quantitation of Polar Urinary Metabolites of Nicotine Enantiomers in the Guinea Pig",
Chukwuemeka G. Nwosu, C. Steven Godin, and Peter A. Crooks, Society of Toxicology,
Annual National Meeting, New Orleans, March, 1986; The Toxicologist, 1986, 6(1), 249
(Abstract No. 1002). 25. "N-Methyl-N'-Oxonicotinium Ion - a New Metabolite of R-(+)-Nicotine", William F. Pool,
and Peter A. Crooks, Society of Toxicology Annual National Meeting, New Orleans,
March, 1986; The Toxicologist, 1986, 6(1), 14 (Abstract No. 53).
26. "Formation of MPP+ from 4-Phenylpyridine by Rabbit Tissue Cytosolic Preparations", C.
Steven Godin, and Peter A. Crooks, First National Meeting and Premiere Exposition of
the American Association of Pharmaceutical Scientists, Washington, DC, November,
1986; Pharm. Research, 1986, 3(5)(Supplement), 136S (Abstract 152). 27. "Structural Analysis of N-Methyl-N'-Oxonicotinium Ion, a New Stereoselectively Formed
Metabolite of R-(+)-Nicotine in the Guinea Pig", William F. Pool, W. John Layton, and Peter A. Crooks, First National Meeting and Premiere Exposition of the American Assocation of Pharmaceutical Scientists, Washington, DC, November, 1986; Pharm. Research, 1986, 3(5)(Supplement), 124S (Abstract 102).
28. "Comparative Metabolism of Radiolabeled [3H-N'-CH3]-Nicotine Enantiomers in Rat and
Guinea Pig", Chukwuemeka G. Nwosu, Peter A. Crooks, First National Meeting and
Premiere Exposition of the American Association of Pharmaceutical Scientists,
(Abstract 248). 29. "Synthesis of Novel 5'-Substituted-5'-deoxyadenosines Designed as Mechanism- Based
Enzyme Inhibitors", Samira F. Hassan, Peter A. Crooks, First National Meeting and Premiere Exposition of the American Assocation of Pharmaceutical Scientists, Washington, DC, November, 1986; Pharm. Research, 1986, 3(5)(Supplement), 22S (Abstract 7).
30. "Kinetics and Mechanism of Chlorination of Aliphatic Amino Acids by Chloramine-T",
Anwar A. Hussain, and Peter A. Crooks, First National Meeting and Premiere Exposition
of the American Assocation of Pharmaceutical Scientists, Washington, DC, November,
80. "Nornicotine and Other Minor Tobacco Alkaloids Release [3H] Dopamine from
Superfused Rat Striatal Slices", Peter A. Crooks, Alain Ravard, Niranjan Deo, Li Hong
Teng, and Linda P. Dwoskin, 8th Annual Meeting and Exposition of the American
Association of Pharmaceutical Scientists, November, 1993, Orlando, Florida; Pharm.
Research, 1993, 10 (10) (Supplement),
81. "Novel Prodrugs of Indomethacin: Synthesis and Stability Studies", Robert M. Riggs,
Shyamala Chandrasekaran, Paul Ashton, and Peter A. Crooks, 8th Annual Meeting and
Exposition of the American Association of Pharmaceutical Scientists, November, 1993,
Orlando, Florida; Pharm. Research, 1993, 10 (10) (Supplement), 82. "The Effect of Surface Active Agents on the Stability of Aspartame". Anwar A. Hussain,
Jonan Jona, and Peter A. Crooks, 8th Annual Meeting and Exposition of the American
Association of Pharmaceutical Scientists, November, 1993, Orlando, Florida; Pharm.
Research, 1993, 10 (10) ( Supplement),
83. "Kinetics and Mechanism of the Reaction of Chloramine-T with Model Amino Acids",
Anwar A. Hussain, Peter A. Crooks, Lewis Dittert, Riad Awad, and Jonan Jona, 8th
Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists,
from Rat Striatal Slices”, Sairam Krishnamurthy, Peter A. Crooks, Guangrong Zheng, and
Linda P. Dwoskin, Frontiers in Addiction Biology-Genomics and Beyond, Vanderbilt
University Summer Conference, Nashville, TN, June, 2004.
295. “The Unsaturated N-n-Alkylnicotinium Analog, NONB3t, is a Potent and Selective
Antagonist at Nicotinic Receptors (62*) Mediating Nicotine- Evoked [3H]Dopamine Release from Rat Striatal Slices”, Sangeetha P. Sumithran, Jun Zhu, A.Gabriela Deaciuc, Rui Xu, Peter A. Crooks and L.P. Dwoskin, Frontiers in Addiction Biology-Genomics and Beyond, Vanderbilt University Summer Conference, Nashville, TN, June, 2004.
296. “In Vivo Evaluation of 3-O-Alkyl Ester Prodrugs of Naltrexone for Transdermal Delivery”,
Audra L. Stinchcomb, D. C. Hammell, K. S. Paudel, S. Valiveti, Mohamed O. Hamad, and Peter A. Crooks, Controlled Release Society Annual Meeting, Honolulu, HI, June, 2004.
133
297. “The PLP-dependent Arginine Decarboxylase from Yersinia pestis: a Link Between
Polyamine Biosynthesis and Biofilm Formation”. Chandra N. Patel, Korie G. Sell, Brian
Wortham, Paul Balbo, Robert S. Adcock, Peter, A. Crooks, Isaac Wong, Jacqueline
Fetherston, Robert D. Perry and Marcos A. Oliveira, Gordon Research Conference:
Enzymes Co-enzymes and Metabolic Pathways, Kimball Union Academy, Meriden, NH,
July, 2004.
298. “Arginine Decarboxylase a Target for the Design of Novel Biodefense Agents”, Chandra
N. Patel, Korie G. Sell, Robert S. Adcock, Paul Balbo, Peter, A. Crooks, Jacqueline D.
Fetherston, Robert D. Perry, and Marcos A. Oliveira, American Crystallographic
Association Meeting, August, 2004.
299. “Bis-Quinolinium and bis-Isoquinolinium Quaternary Ammonium Analogs Potently Inhibit
Nicotinic Receptors Mediating Nicotine-Evoked Striatal Dopamine Release”, Sangeetha P. Sumithran, Peter A. Crooks, A. Gabriela Deaciuc, Joshua T. Ayers and Linda P. Dwoskin, Soc. Neurosci. Abstr., 2004, 34, Abstract 918.12-W. San Diego, CA, October, 2004.
300. “The Effects of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB), a Novel
Nicotinic Receptor Antagonist, on Nicotine-induced Behaviors”, Nichole M. Neugebauer, Joshua T. Ayers, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, 10th Annual Duke Nicotine Research Conference, Durham, NC, October, 2004.
301. “Preparation and Purification of Amino Derivatives of Dehydrocostus Lactone and their
Antileukemic Activities Against Primary Human Acute Myelogenous Leukemia Cells in Culture”, Marlene Cotto, Xiaochen Wei, Monica Guzman , Craig Jordan, and Peter A. Crooks, The 2004 Annual Biomedical Research Conference for Minority Students, November, 2004, Dallas, TX, Abstract No. 190. A134.
302. “A Gas Chromatography and Mass Selective method for the Determination of Fentanyl in
Plasma at Subnanogram Levels”, Ahmad Malkawi, Abeer Al Ghananeem, Peter A. Crooks, Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, November, 2004, Baltimore, MD., Abstract T2039, p68.
303. “Synthesis and Development of Rapid Assay Probes for Derived from Bacteriophage”,
Sundar Neelakantan, I. Surjawan, H. Karacelik, Clair L. Hicks, Peter A. Crooks, Annual
Meeting and Exposition of the American Association of Pharmaceutical Scientists,
357. “Parthenolide Selectively Sensitizes Prostate Cancer Cells but not Normal Prostate
Epithelial Cells to Radiation Treatment through Inhibition of NF-KB Activation”. Yulan
Sun, Graham Warren, Daret St. Clair, Peter A. Crooks, and William St. Clair, Annual
Meeting of the Free Radical Research Society, 2005, 39, S169.
358. “Effects of Novel N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide on Acute Nicotine-
140
Induced Changes in Brain Dopamine Function”, S. Rahman, Nicole M. Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Soc. Neurosci. Abstr., 2005, 35, Abstract 158.15, Washington, DC, November, 2005.
359. “Sulfate Esters of Lobeline: Interaction at Neurotransmitter Transporters and Nicotinic
Receptors”, David B. Horton, Marhaba Hojahmat, Seth D. Norrholm, G.Kaprit Dhawan, Peter A. Crooks, and Linda P. Dwoskin, Soc. Neurosci. Abstr., 2005, 35, Abstract 227.11, VV80, Washington, DC, November, 2005.
360. “Effect of Lobeline Analogs to Inhibit Nicotine- and Methamphetamine-Evoked Dopamine
Overflow from Rat Striatal Slices: Novel Therapeutic Agents with Potential for the Treatment of Psychostimulant Abuse”. Linda P. Dwoskin, G. Kaprit Dhawan, Guangrong Zheng, A. Gabriela Deaciuc, S. Krishnamurthy, and Peter A. Crooks, Soc. Neurosci. Abstr., 2005, 35, Abstract 681.17, Washington, DC, November, 2005.
361. “The Novel Nicotinic Receptor Antagonists N,N’-Dodecane-1,12-diyl-bis-3-picolinium
Dibromide Inhibits Nicotine-Evoked [3H]Norepinephrine Overflow from Superfused Rat Hippocampal Slices”. Sangeetha P. Sumithran, G. Kaprit Dhawan, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Soc. Neurosci. Abstr., 2005, 35, Abstract 961.17, Washington, DC, November, 2005.
362. “The Effect of S(-)-Norketamine on Oxycodone Analgesia in Rats”. By Elzbieta P. Wala,
Peter A. Crooks, J. K. Johnson, and Joseph R. Holtman, Jr., Soc. Neurosci. Abstr., 2005, 35, Abstract 49.10, Washington, DC, November, 2005.
363. “Synergistic Radiosensitization of Lung Cancer Cells Using Parthenolide and Low Dose
Combinations of Proteasome or Cycloxygenase Inhibitors”. Graham W. Warren, K. R. Grimes, Peter A. Crooks, and William H. St. Clair, Int. J. Radiat. Oncol. Biol. Phys. 2005, 63: S391, Abstract 2275.
364. “A Novel Drug for Chronic Pain”. Joseph R. Holtman, Jr., Peter A. Crooks, Elzbieta P.
Wala, Postgraduate Assembley in Anesthesiology, New York State Society of Anesthesiologists, December, 2005, New York, NY.
365. “Development of Novel Nicotinic receptor Antagonists as Treatments for Nicotine Addiction”. Linda P. Dwoskin. Peter A. Crooks, Michael T. Bardo, Roger L. Papke, Davis D. Allen, and Paul R. Lockman, National Cooperative Drug Discovery Groups for Nicotine Addiction: NIDA Symposium Meeting, Orlando, FL, February, 2006. 366. “Differing Activity Profiles of Nicotine and its CNS metabolite and Tobacco alkaloid, Nornicotine”. Roger L. Papke, Linda P. Dwoskin, and Peter A. Crooks, Society for Research on Nicotine and Tobacco, Twelth Annual Meeting, Orlando, FL, February, 2006. 367. “The Effect of S-Norketamine on the Development of Tolerance to Opioids in Rats”. By Joseph R. Holtman, Wendell G. Griffin, Peter A. Crooks, and Elzbieta P. Wala, International Anesthesia Research Association Annual Meeting, Abstract S-224, San Fransisco, CA, March, 2006. 368. “Sulfate Esters of Lobeline: Interaction at Neurotransmitter Transporters and Nicotinic
Receptors”, David B. Horton, Marhaba Hojahmat, Seth D. Norrholm, G.Kaprit Dhawan,
141
Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the the Society for Neyroscience, Lexington, KY, March, 2006.
369. “Water-soluble Analogue of Parthenolide LC-1 Influences Apotosis in Bladder Cancer
Cell Lines by Modulating Pro-Apoptotic Genes and promotes p21 Activity”. Rajasubramaniam Shanmugam, Sundar Neelakantan, Vetrichelvan Jayaprakasan, Peter A. Crooks, Harikrishna Nakshatri, and Christopher Sweeney, Ninety Seventh Annual Meeting of the American Association for Cancer Research, Abstract 06-AB-3393-AACR, Washington, DC, April1st-5th, 2006.
370. “Synthesis of New Water Soluble Parthenolide Analogs as Potential Antitumor Agents”.
Daneli Lopez, Peter A. Crooks, and Sundar Neelakantan, Proceedings of the 231st American Chemical Society National Meeting, March 26-30, 2006, Atlanta, GA, Abstract No. MEDI-292.
371. “Effects of Novel N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide on Nucleus
Accumbens Dopamine Release in Rats Sensitized to Nicotine”. Shafiq Rahman, Nicole
M. Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T.
Bardo, Sixty Eighth Annual Meeting of the College on Problems of Drug Dependence,
Abstract 45, p5, Scottsdale, AZ, June, 2006.
372. “Synergistic Design of Polar bis-Pyridinium Analogs Containing a 1,4-Di-(1- butynyl)phenylenediyl Linker: Interaction with Both Nicotinic Receptors and the Blood- Brain Choline Transporter”. Zhenfa Zhang, A. Gabriela Deaciuc, Paul R. Lockman, David D. Alllen, Linda P. Dwoskin, and Peter A. Crooks, Sixty Eighth Annual Meeting of the College on Problems of Drug Dependence, p17, Scottsdale, AZ, June, 2006. 373. “Novel Trivalent Antagonists with Selectivity for Alpha7 Type Nicotinic Acetylcholine Receptors”. By Roger L. Papke, Guangrong Zheng, C. J. Burkle, Peter A. Crooks, and Linda P. Dwoskin, Sixty Eighth Annual Meeting of the College on Problems of Drug Dependence, Abstract 23, p27, Scottsdale, AZ, June, 2006. 374. “New Leads for the Treatment of Nicotine Addiction: Discovery of Novel bis-Quaternary Ammonium Antagonists at Neuronal Nicotinic Receptors Mediating Nicotine-Evoked Dopamine Release”. Guangrong Zheng, Sangeetha P. Sumithran, A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Sixty Eighth Annual Meeting of the College on Problems of Drug Dependence, Abstract 24, p27, Scottsdale, AZ, June, 2006. 375. “New Leads for the Treatment of Nicotine Addiction: Discovery of Novel tris-Quaternary Ammonium Antagonists at Neuronal Nicotinic Receptors Mediating Nicotine-Evoked Dopamine Release”. Sangeetha P. Sumithran, Guangrong Zheng, A. Gabriela Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Sixty Eighth Annual Meeting of the College on Problems of Drug Dependence, Abstract 25, p27, Scottsdale, AZ, June, 2006. 376. “A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells”. Monica L. Guzman, Randall M. Rossi, Xiaojie Li, Cheryl Corbett, Duane C. Hassane, Timothy Bushnell, Martin Carroll, Edmund Sullivan, Sundar Neelakantan, Peter A. Crooks, and Craig T. Jordan, Forty Eighth Annual Meeting of the American Society of Hematology, Abstract # 553723, Orlando, FL, December, 2006. 377. “Nornicotine, the Tobacco Alkaloid and CNS Metabolite of Nicotine, Differentially Activates
142
Brain Nicotinic Receptors”. Roger L. Papke, Linda P. Dwoskin, and Peter A. Crooks, Annual Meeting of the Society for Neuroscience, Atlanta, GA, October, 2006; Neuroscience Abstracts, 2006, 36, Abstract 524.11/C74. 378. “Lobeline and meso-Transdiene Analogs: Interaction at Neurotransmitter Transporters and Nicotinic Receptors”. David B. Horton, Marhaba Hojahmat, A. Gabriela Deaciuc, John P. Culver, Seth D. Norrholm, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Atlanta, GA, October, 2006; Neuroscience Abstracts, 2006, 36, Abstract 591.1/PP67. 379. “Parthenolide and its Water Soluble Analog LC-1 as Potent Anti-tumor Agents”. Sundar
Neelakantan, Rajasubramaniam Shanmugam, Zhu Wei, Vetrichelvan Jayaprakasan, Poornima Bhat-Nakshatri, Harikrishna Nakshratri, Christopher J. Sweeney, and Peter A. Crooks, Fourth Annual Kentucky Lung Cancer Research Program Scientist’s Meeting, Abstract No. 7, Frankfort, KY, October, 2006,
380. “Facilitated Distribution of the Charged Nicotinic Receptor Antagonist bis-[dodecane-1,12- diyl]-3-picolinium Dibromide (bPiDDB) Across the Blood-Brain Barrier”. Paul R. Lockman, Peter A. Crooks, F. Thomas, Linda P. Ddwoskin, and David D. Allen, Annual Meeting of the Society for Neuroscience, Atlanta, GA, October, 2006; Neuroscience Abstracts, 2006, 36, Abstract 460.12/EE10. 381. “Determination of Novel Nicotinic Receptor Antagonist Binding to the Blood-Brain Barrier Choline Transporter: a Potential Mechanism for Brain Entry”. Paul R. Lockman, V. K. Manda, C. J. Van Der Schyf, J. A. Egbert, Linda P. Dwoskin, Peter A. Crooks, and David D. Allen, Annual Meeting of the Society for Neuroscience, Atlanta, GA, October, 2006; Neuroscience Abstracts, 2006, 36, Abstract 460.13/EE11. 382. “Development and Validation of an HPLC Analytical method for the Quantitation of Nornicotine in Rat Plasma, and its Application to Pharmacokinetic Studies”. Buchi Nalluri, Zaineb Fahdel, Marhaba Hojahmat and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1010. 383. “A Highly Sensitive Method for 5-Fluorouracil in Plasma and Vitreous Humor by Liquid Chromatography-Mass Spectrometry”. Ahmad Malkawi, Abeer Al-Ghananeem, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1037. 384. “Brain/Plasma Bioavailability of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB), a Novel Nicotinic Receptor Antagonist”. Zaineb Albayati, Nicole Neugebauer, Michael T. Bardo, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1091. 385. “Synthetic Approaches Towards Analogs of Lobeline: Discovery of novel Treatments foe Psychostimulant Abuse”. Ashish Vartak, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1093.
386. “Carbonate Ester Prodrugs of 6--Naltrexol for Transdermal Delivery”. Mohamed Hamad,
143
Audra Stinchcomb, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1097. Bristol-Myers Squibb Award for Outstanding Poster Presentation. 387. “Sub-type Selective, Guanylated Nicotine Analogs; Functionally Active Non-competitive Agonists and Antagonists at the Neuronal Nicotinic Receptor”. Aaron Haubner, John M. Littleton, Neil Millar, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1098. 388. “Synthesis, Solubility, and Hydrolytic Stability of Hydroxybupropion Prodrugs”. Mohamed Hamad, Paul Kiptoo, Audra Stinchcomb, and Peter A. Crooks. Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1099. 389. “A Water-Soluble Analog of Parthenolide LC-1 as a Potent Anti-tumor Agent”. Sundar Neelakantan, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1104. 390. “Synthesis and Evaluation of a Series of New Water-soluble Aromatic Amine Parthenolide Analogs as Anti-leukemic Agents”. Shama Nasim, Sundar Neelakantan, Craig Jordan, Monica Guzzman, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1114. Bristol-Myers Squibb Award for Outstanding Poster Presentation. 391. “Synergistic Design of Polar bis-Pyridinium Analogs Containing a Conformationally Restricted 1,4-Di-(butynyl)phenylenediyl Linker: Interaction with both Nicotinic Receptors and the Blood-Brain Barrier Choline Transporter”. Zhenfa Zhang, Sangitha Sumithran, A. Gabriela Deaciuc, Paul R. Lockman, David D. Allen, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1116. 392. “Synthesis of Novel Arylideneamino-gaunidine Hydrochlorides as Potential Antagonists of the N-Methyl-D-aspartate Receptor (NMDAR) Complex”. Thirupathi Yerramreddy, Vijayakumar Sonar, John M. Littelton, Robert Holley, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1117.
393. “Prediction of the Affinity of N-n-Alkyl Nicotinium Salts as Antagonists at the α42* Nicotinic Acetylcholine Receptor (nAChR) Subtype by Computational Neuronal Network Analysis”. Fang Zheng, A. Gabriela Deaciuc, Guangrong Zheng, Chang-Guo Zhan, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1128. 394. “Synthesis and Pharmacological Studies on Novel tris-Quaternary Ammonium Salts: Interaction with Nicotinic Acetylcholine Receptors and Inhibition of Nicotine-Evoked Dopamine Release”. Guangrong Zheng, Sangeetha Sumithram, Roger L. Papke, Linda P. Dwoskin, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1130.
144
395. “Scopolamine Sublingual Spray: An Alternative Route of Delivery for the Treatment of Motion Sickness”. Abeer Al-Ghananeem, Ahmad Malkawi, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1221.
396. “Nasal Delivery of 9-Tetrahydrocannabenol-Loaded Bioadhesive Chitosan Gels in Rabbits”. Abeer Al-Ghananeem, Ahmad Malkawi, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1222. 397. “In Vivo Evaluation of Transdermal Delivery of 6-Beta-Naltrexol Hydrochloride after Microneedle Treatment of Hairless Guinea Pigs”. Stan Banks, Mohamed Hamad, R. Pinninti, H. Gill, Peter A. Crooks, amd Audra Stinchcomb, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract M1302. 398. “Absolute Configuration, Resolution and Chiral HPLC Separation of Norketamine Enantiomers: a Potential Analgesic Agent for Neuropathic Pain”. Marhaba Hojahmat, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract T2003. 399. “In Vitro/In Vivo Correlation of a Transdermal Codrug of 6-Beta-Naltrexol Linked to Hydroxybupropion in Hairless Guinea Pigs”. Paul Kiptoo, K. Paudel, Donna Hammell, Mohamed hamad, Peter A. Crooks, and Audra Stinchcomb, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract T2210. 400. “Tablet Formulation Studies on Nimesulide and Meloxicam-Cyclodextrin Binary Systems”. Buchi Nalluri, C. Kora, R. Murthy, G. Becket, and Peter A. Crooks, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract T3246. 401. “The Blood-Brain Barrier Choline Transporter Facilitates Brain Entry of the Polar Nicotinic Receptor Antagonist, bis-[Dodecane-1.12-diyl]-3-picolinium Dibromide (bPiDDB)”. Paul R. Lockman, Peter A. Crooks, V. Manda, J. Egbert, F. Thomas, Linda P. Dwoskin, and David D. Allen, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract W5337. 402. “Molecular Modeling of Semi-rigid bis-Quaternary Ammonium Compounds at the Blood- Brain Barrier Choline Transporter”. W. Geldenhuys, V. Manda, Paul R. Lockman, J. Egbert, Peter A. Crooks, Linda P. Dwoskin, and David D. Allen, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract W5344. 403. “Affinity of Nicotinic Receptor Antagonists for the Blood-Brain Barrier Choline Transporter: a Potential Vector for Brain Access”. V. Manda, J. Egbert, Peter A. Crooks, Linda P. Dwoskin, David D. Allen, and Paul R. Lockman, Twentieth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2006, San Antonio, TX, Abstract W5345. 404. “Lobeline Analogs as Potent and Selective VMAT2 Antagonists”. Peter A. Crooks,
145
Guangrong Zheng, Agripina G. Deaciuc, and Linda P. Dwoskin, Proceeding of the 45th Annual Meeting of the American College of Neuropsychopharmacology, December, 2006, Hollywood, FL, Neuropsychopharmacology, 2006, 31(Supplement 1), S29. 405. “NMDA Receptor for Chronic Pain; Can We Do Better than Ketamine?”. By Joseph R. Holtman, Jr., Peter A. Crooks, J. K. Johnson, and Elzbieta P. Wala, 30th Meeting of the Midwest Pain Soc, Abstract, June, 2006, Chicago, IL. 406. “S(-)-Norketamine-Morphine Combination Therapy for Treatment of Neuropathetic Pain”. By Joseph R. Holtman, Jr., J.K. Johnson, Peter A. Crooks, and Elzbieta Wala, Annual Meeting of the American Pain Society, Abstract # 768, San Antonio, TX, 2006. 407. “S(-)-Norketamine Inhibits Morphine and Oxycodone Tolerance in Rats”. By Elzbieta Wala, W. Griffitn, Peter A. Crooks, and Joseph R. Holtman, Jr., Annual Meeting of the American Pain Society, Abstract # 764, San Antonio, TX, 2006.
408. “Suppression of Manganese Superoxide Dismutase Induction Reveals a Transcriptional- based Mechanism for the Selective Radiosensitization of Prostate Cancer Cells by
Parthenolide”. William St. Clair, Yulan Sun, Daret St. Clair, I. Batinic-Haberle, F. Fang, M. Kudrimoti, Graham Warren, and Peter A. Crooks, Int. J. Radiat. Oncol. Biol. Phys., 2006, 66: S592.
409. “A Pharmacokinetic Study on Z-()-2-(1-Benzylindole-3-yl-methylene)azabicyclo[2.2.2]-
octane-3-ol; a Novel Radio-sensitization Agent”. Abeer M. Al-Ghananeem, Zaineb Al-
Beyati, Ahmad Malkawi, Vijayakumar N. Sonar, Buck Rogers, Michael L. Freeman and
Peter A. Crooks. 7th Joint American Association for Cancer Research – Japanese Cancer
Society Conference; In the Forefront of Basic and Translational Cancer Research,
January, 2007, Kona, HI.
410. “Effect of Celecoxib and Novel Agent LC1 in a Hamster Model of Lung Cancer”. By Reid
C. Vegeler, Michelle T. Yip-Schneider, Mathew Ralsten, Peter A. Crooks, and C. Max
Schmidt, 2nd Annual Academic Surgical Congress of the Association for Academic
Surgery of the Society of University Surgeons, Abstract 11, 2007, February, 2007,
Phoenix, AZ.
411. “Brain/Plasma Bioavailability of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide
(bPiDDB), a Novel Nicotinic Receptor Antagonist”. By Zaineb A. Fadhel Albayati, Nichole
Negebauer, Michael T. Bardo, Linda P. Dwoskin, and Peter A. Crooks, International
Scholars Poster Session, Office of International Affairs, University of Kentucky, Abstract
2, page 2, February, 2007, Lexington, KY.
412. “An HPLC Method for the Simultaneous Determination of Neurotoxic Dipyridyl Isomers in
Human Plasma”. By Ahmad H. Malkawi, Abeer M. Al-Ghananeem, Shama Naseem, Jose
de Leon, and Peter A. Crooks, International Scholars Poster Session, Office of
International Affairs, University of Kentucky, Abstract 23, page 24, February, 2007,
Lexington, KY. 413. “Norketamine in Combination with Morphine for Inflammatory Pain”. J. K. Johnson, Elzbieta P. Wala, Peter A. Crooks, L. M. Dorfling, and Joseph R. Holtman, Jr., Experimental Biology Annual Meeting, FASEB Meeting, Abstract 563.6, April, 2007, Washington, DC.
146
414. “Norketamine (NKET) Enantiomers in Combination with Morphine (MOR) for Neuropathic Pain”. Elzbieta P. Wala, J. K. Johnson, Peter A. Crooks, L. M. Dorfling, and Joseph R. Holtman, Jr., Experimental Biology Annual Meeting, ASPET Meeting, Abstract No. 563.7, April, 2007, Washington, DC. 415. “Novel Chemical Enhancers of Heat Shock Increase Thermal Radiosensitization through a Mitotic Catastrophe Pathway”. By Konjeti R. Sekhar, Vijayakumar N. Sonar, Venkatraj Muthusamy, Andrei Laszlo, Joseph L. Roti Roti, Michael L. Freeman, Thirteenth International Congress of Radiation Research, July, 2007, San Franscisco, CA. 416. “Preclinical Development and Mechanistic Evaluation of Parthenolide and its Water-
Soluble Analogue, Dimethylaminoparthenolide (DMAPT) as a New Treatment for Prostate Cancer”. By Christopher Sweeney; Rajasubramaniam Shanmugam; Praveen Kusumanchi, Marc Mendonca, Peter A. Crooks, and Harikrishna Nakshatri, Department of Defence IMPACT Meeting, Atlanta, GA, September, 2007. 417. “Lobeline and meso-Transdiene Analogs: Interaction at Neurotransmitter Transporters and Nicotinic Receptors”. David B. Horton, Marhaba Hojahmat, A. Gabriela Deaciuc, John P. Culver, Seth D. Norrholm, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society of Neuroscience, March, 2007, Lexington, KY, 418. “Drugability Case Study: Exploration of Structural Modifications and Their Impact on Oral
Bioavailability of Novel Radiosensitization Agents (A): Z-()-2-(1-Benzylindole-3-yl-
bicyclo[2.2.2]octane-3-one, (C): Z-()-2-[1-(4-Chlorobenzy)lindole-3-yl-methylene]aza- bicyclo[2.2.2]octane-3-ol”. By Abeer M. Al-Ghananeem, Zaineb Al-Beyati, Ahmad H.
Malkawi, Michael Freeman, and Peter A. Crooks. Proceedings of the 233rd American
Chemical Society National Meeting, March, 2007, Chicago, IL, Abstract No. MEDI-99.
419. “Synthesis and Evaluation of Quinuclidine-Incorporated Lobelane Analogs as Vesicular
Monoamine Transporter Ligands”. By Guangrong Zheng, Linda P. Dwoskin, Agripina G.
Deaciuc, and Peter A. Crooks, Proceedings of the 233rd American Chemical Society
National Meeting, March, 2007, Chicago, IL, Abstract No. MEDI-267.
420. “Cytotoxicity of Parthenolide Analogs against Leukemia Cells In Vitro”. By Shama Nasim
and Peter A. Crooks, Proceedings of the 233rd American Chemical Society National
Meeting, March, 2007, Chicago, IL, Abstract No. MEDI-170.
421. “Design and Synthesis of Lobelane Analogs Targetting the Vesicular Monoamine
Transporter (VMAT2) as a Potential Treatment for Methamphetamine Abuse”. John P.
Culver, Agripina G. Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Proceedings of the
233rd American Chemical Society National Meeting, March, 2007, Chicago, IL, Abstract
No. MEDI-268.
422. “Computational Neural Network Analysis of the Affinity of Lobelane and Tetrabenazine
Analogs for the Vesicular Monoamine Transporter-2”. By Fang Zheng, Guangrong Zheng,
A. Gabriela Deaciuc, Chang-Guo Zhan, Linda P. Dwoskin, and Peter A. Crooks.
Proceedings of the 233rd American Chemical Society National Meeting, March, 2007,
Chicago, IL, Abstract No. MEDI-269.
147
423. “Design, Synthesis and Pharmacological Evaluation of Novel Analogs of the Anti-
AddictiveAlkaloid, Lobeline”. By Ashish P. Vartak, Agripina G. Deaciuc, Linda P. Dwoskin,
and Peter A. Crooks, Proceedings of the 233rd American Chemical Society National
Meeting, March, 2007, Chicago, IL, Abstract No. MEDI-454.
424. “Targeting Cell Cycle and Apoptopic Machinery of Bladder Cancer Cells Through a Novel
NF-кB inhibitor LC-1”. By Rajasubramanium Shanmugam, Suresh Kumar, Sundar
Neelakantan, Peter A. Crooks, Christopher J. Sweeney, and Harikrishna Nakshatri, Flight
Attendant Medical Research Institute Annual Meeting, May, 2007, Miami, FL, Abstract
No. xxx.
425. “Structural Evolution of Simple N, N’-Alkylnicotinium Analogs: A Novel Class of Nicotinic
Receptor Agonists Inhibiting Nicotine-Evoked Neurotransmitter Release”. By Peter A.
Crooks, NIDA-Supported National Cooperative Drug Discovery Groups
Symposium. Building Translational Research in Medication Development in Academia:
Issues, Strategies and Tactics, Quebec City, Canada, June, 2007.
426. “Effects of Novel tris-Quaternary Ammonium Nicotinic Antagonists on Locomotor Activity and
Nicotine-Induced Hyperlocomotion in Rats”. By Jason T. Ross, Zhenfa Zang, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Sixty Ninth Annual Meeting of the College on Problems of Drug Dependence, Abstract 22, p78, Quebec City, Canada, June, 2007.
427. “Paclitaxel-loaded Cross-linked Hyaluronidase Nanoparticles for Breast Cancer Therapy”. By
Abeer M. Al-Ghananeem, Penni Black, Justin M. Balko, jabar Faraj, Ahmad Malkawi, Patrick DeLuca, Peter A. Crooks, and Edward Romond, Sixteenth International Symposium on Microencapsulation, Abstract 216, p11, Lexington, KY, September, 2007.
428. “The Search for More Selective Neuronal Nicotinic Acetylcholine Receptor Antagonists
as Smoking Cessation Agents”. Invited speaker, Symposium on Molecular Diversity in
Drug Design, Discovery and Delivery, University of South Florida, Abstract 13, p20,
Tampa, FL, October, 2007.
429. “Antinociceptive Effects of Nornicotine in Rodents”. Joseph R. Holtman, Peter A. Crooks, Jamie Johnson, Marhaba Hojhamat, and Elzbieta P. Wala, Annual Meeting of the Society for Neuroscience, Abstract No. 182.21/009, San Diego, CA, November, 2007.
In a Relapse Paradigm and Following Restraint Stress in Rodents”. B. Lewis, J. M. Farook, K. A. Wellman, Peter A. Crooks, John M. Littleton, and Susan Barron, Annual Meeting of the Society for Neuroscience, Abstract No. 63.6/X17, San Diego, CA, November, 2007. 431. “Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors as Potential Treatments for Methamphetamine Abuse: 3, 5-Disubstituted Meso-transdiene Analogs of Lobeline” .A. Gabi Deaciuc, David B. Horton, Marhaba Hojahmat, John P. Culver, Seth D. Norrholm Peter A. Crooks, and Linda P. Dwoskin. Annual Meeting of the Society for Neuroscience, Abstract No. 814.4/AA16, San Diego, CA, November, 2007. 432. “Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors as Potential Treatments for Methamphetamine Abuse: Constrained Lobeline Analogs Inhibit VMAT2 Binding and
148
Function”. J. Chagkutip, Ashish P. Vartak, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 65.2/Y13, San Diego, CA, November, 2007. 433. “Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors as Potential Treatments for Methamphetamine Abuse: Interaction of meso-Transdiene and Lobelane Analogs at Neurotransmitter Transporters”. David B. Horton, Guangrong Zheng, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 815.AA17, San Diego, CA, November, 2007. 434. “Discovery of Novel Nicotinic Receptor Antagonists for the Treatment of Nicotine Addiction: 1-Trimethylammonium-10-[1-(3-picolinium0]decane (TMPD) Inhibits Nicotine-Evoked Dopamine Release from Rat Striatal Slices and Decreases Nicotine Self-administration”. By B. Matt Joyce, Guangrong Zheng, J. T. Ross, Michael T. Bardo, Roger L. Papke, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 781.10, San Diego, CA, November, 2007. 435. “Investigation of the Selectivity of Phenyl Ring-substituted Lobelane Analogs for VMAT2 in the Development of Novel Therapies for Methamphetamine Abuse”. By J. R. Nickell, A. Gabi Deaciuc, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 65.16/Y27, San Diego, CA, November, 2007. 436. “Tetrakis Quaternary Ammonium Salts: Novel Nicotinic Receptor Antagonists which Inhibit Nicotine-evoked [3H]Dopamine Overflow from Superfused Rat Striatal Slices”. By Marharyta Pivavarchyk, Zhenfa Zhang, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 78.12/F12, San Diego, CA, November, 2007. 437. “The Identification of Selective Competitive and Noncompetitive nAChR Antagonists Using Alpha6 Nicotinic Acetylcholine Receptor Chimeras”. By Clair Stokes, Linda P. Dwoskin, Peter A. Crooks, L. B. Jacobs, J. Michael McIntosh, and Roger L. Papke, Annual Meeting of the Society for Neuroscience, Abstract No. 574.4/J9, San Diego, CA, November, 2007. 438. “Pharmacokinetics of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB), a Novel Nicotinic Receptor Antagonist”. By Zaineb F. Albayati, Linda P. Dwoskin, Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, November, 2007, San Diego, CA, 439. “Synthesis and Evaluation of 3,5-Disubstituted Piperidine Analogs Related to Lobeline as Vesicular Monoamine Transporter Ligands”. By Marhaba Hojahmat, David B. Horton, A. Gabi Deaciuc, John P. Culver, Linda P. Dwoskin, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA,
440. “Prediction of Channel Blocking Effect of 5-n-Alkyloctahydro Indolizine Analogs at the
α4β2* nAChR Subtype”. By Fang Zheng, X. Huang, Linda P. Dwoskin, Chang-Guo Zhan and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 441. “Synthesis and Evaluation of Homologous Analogs of Lobelane at the Vesicular Monamine
149
Transporter (VMAT2)”. By Guangrong Zheng, Linda P. Dwoskin, A. Gabi Deaciuc, and Peter A. Crooks. Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA.
442. “Tetrakis-quaternary Ammonium salts: Novel bPiDDB Analogs as Selective Neuronal
Nicotinic Receptor Antagonists for Subtypes Mediating Nicotine-evoked Dopamine Release”. By Zhenfa Zheng, Maharyta Pivavarchyk, A. Gabi Deaciuc, Linda P. Dwoskin, Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 443. “Synthesis and Evaluation of a Series of Acrylonitriles as Polyamine Site Antagonists at the NMDA Receptor Complex”. By Vijayakumar N. Sonar, Robert Holley, John H. Littleton, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 444. “Synthesis of Novel Substituted (Z)-2-(N-Benzylindol-3-ylmethylene)-quinuclidin-3-one and (Z)-2-(N-Benzylindol-3-ylmethylene)-quinuclidin-3-ol Derivatives as Potent Radiosensitizing Agents”. By Vijayakumar N. Sonar, Thirupathi R. Yerramreddy, Rajasekhar Konjeti, Michael Freeman, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 445. “Design and Synthesis of Bone-Targeted Analogs of Estradiol for Osteoporosos”. By Shama Nasim, Grant Taylor, William Pierce, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 446. “Local Perfusion of the Novel Nicotinic Receptor Antagonist N,N-dodecane-1,12-diyl-bis-3- picolinium Dibromide (bPiDDB) into the Ventral Tegmental Area (VTA) or the Nucleus Accumbens (NAcc), differentially regulates Nicotine-Induced Increases in Extracellular Dopamine”. By Shafiq Rahman, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 447. “Extraction and Quantitation of Parthenolide from Tancetum Parthenium (feverfew plant), Followed by Direct Derivitization to the Antitumor Drug, LC-1”. By Sundar Neelakantan and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 448. “Synthesis of Lobeline Analogs Targeting the Vesicular Mononamine transporter-2 (VMAT2)”. By John P. Culver, Agripina Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA.
449. “A Pharmacokinetic Study on Z-(-2-(1-Benzylindole-3-yl-methylene)azabicyclo[2.2.2] octane-3-ol; a Novel Radiosensitization Agent”. By Abeer M. Al-Ghananeem, Ahmad H. Malkawi, Zaineb Al-Beyati, Vijayukumar N. Sonar, Michael Freeman, and Peter A. Crooks Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 450. “In Vitro Human Skin Permeation: Effects of Bioconversion and Moleculer Weight”. By Paul
150
K. Kiptoo, Peter A. Crooks, and Audra L. Stinchcomb, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 451. “Simultaneous Determination of Nitrogen Mustard [2-Chloro-N-(2-chloroethyl)-N-methyl- ethanamine] and its Potential Half Mustard metabolite, [2-Hydroxy-N-(2-chloroethyl)-N- methyl-ethanamine] in Human Blood”. By Vipin P. Nair, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 452. “An HPLC Method for the Simultaneous Determination of Neurotoxic Dipyridyl Isomers in Human Plasma”. By Ahamd H. Malkawi, Shama Naseem, Abeer M. Al-Ghananeem, Jose de Leon, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 453. “Does the Use of Warmed Water for Injection Accelerate the Reconstitution of the Sparingly Water-Soluble Drug Dantrolene Sodium?”. By Abeer M. Al-Ghananeem, Ahmad H. Malkawi, George A. Digenis, Patrick P. Deluca, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 454. “Kinetic Studies on Dantrolene Sodium”. By Abeer M. Al-Ghananeem, Ahmad H. Malkawi, George A. Digenis, Patrick P. Deluca, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 455. “Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry
(LC/MS/MS) Method for the Determination of the Novel Radiosensitization Agent: Z-()-2- (1-Benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol (BMABO)”. By Abeer M. Al- Ghananeem, Ahmad H. Malkawi, Vijayukumar N. Sonar, John May, Buck Rogers, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 456. “Effect of Oral Norketamine in the Rat Formalin Pain Model”. By Joseph Holtman, Jr., Jaime Johnson, Lize-Mari Dorfling, Marhaba Hojahmat, Mark Klevin, and Peter A. Crooks, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 457. “Differential Inhibition of Ach-evoked Responses of Neuronal Nicotinic Receptors in Rat Brain Slices by Selective nAChR Antagonists”. By G. Y. Lopez, J. S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Roger L. Papke, Satelite Meeting, Twenty First Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October, 2007, San Diego, CA. 458. “NMDA Receptor Antagonists for Pain-Can We Do Better Than Ketamine?” By Joseph L. Holtman, Jr., Peter A. Crooks, Jamie K. Jameson, and Elzbieta P. Wala, Postgraduate
Assembly in Anesthesiology, New York State Society of Anesthesiologists, December, 2007, New York, NY.
459. “The NF-B-PTEN Axis Enhances Radiation Sensitivity of Prostate Cancer Cells”. William St. Clair, Yulan Sun, Daret St. Clair, F. Fang, Graham Warren, V. Rangnekar, and Peter A.
151
Crooks, Int. J. Radiat. Oncol. Biol. Phys. Abstract 2007, 69: S611. 460. “Opioid Combination Drug Therapy for Neuropathic Pain”. By Joseph R. Holtman, Jr., Peter
A. Crooks, Jaime K. Johnson, Marhaba Hojahmat, and Elzbieta P. Wala, American Academy of Pain Medicine: Twenty Fourth Annual Meeting, Abstract xxx, February, 2008, Orlando, FL.
461. “A Water-soluble Analogue of Parthenolide has Anti-Cancer In Vitro and In Vivo Activity by
Generation of Reactive Oxygen Species and Inhibition of Nuclear Factor Kappa B. By Christopher Sweeney, R. Shanmugam, P. Kusumanchi, Sundar Neelakantan, William Matthews, Craig T. Jordan. Peter A. Crooks, and Harikrishna Nakshatri, The Genitourinary Cancers Symposium, an ASCO, ASTRO and SUO Co-sponsored Symposium, Abstract 08-AB-202292-ASCOGU, February, 2008, San Franscisco, CA.
462. “Water-Soluble Parthenolide Analog LC-1 as a Potent Anti-tumor Agent”. By Sundar Neelakantan, Rajasubramaniam Shanmugam, Vetrichelvan Jayaprakasan, Harikrishna Nakshatri, Christopher J. Sweeney, and Peter A. Crooks, Fifth Annual Meeting of the Kentucky Lung Cancer Research Program (KLCRP), February, 2008, Frankfort, KY. 463. “Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors as Potential Treatments for Methamphetamine Abuse: Interaction of meso-Transdiene and Lobelane Analogs at Neurotransmitter Transporters”. David B. Horton, Guangrong Zheng, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society for Neuroscience, March, 2008, Lexington, KY. 464. “An Orally Bioavailable Parthenolide Analogue Inhibits Both Subcutaneous and Metastatic Xenograft Growth in Lung and Bladder Cancer Cell Lines and is Independent of p53 Status”. By Rajasubramaniam Shanmugam, Praveen Kusumanchi, Peter A. Crooks, James Klaunig, Craig T. Jordan, Harikrishna Nakshatri, and Christopher Sweeney, Annual Meeting of the American Association for Cancer Research, April, 2008, San Diego, CA 465. “Dimethylaminoparthenolide (DMAPT) Anti-cancer Activity is Mediated by ROS
Generation and Inhibition of Nuclear Factor κ B”. By Praveen Kusumanchi,
Rajasubramaniam Shanmugam, Peter A. Crooks, Craig T. Jordan, Harikrishna Nakshatri, and Christopher Sweeney, Annual Meeting of the American Association for Cancer Research, April, 2008, San Diego, CA. 466. “LC-1: A Water Soluble Parthenolide Analog and Potent Anti-tumor Agent can be Isolated Directly from Tanacetum parthenium (feverfew) Green Plant”. By Sundar Neelakantan, Maelor Davies, Orlando Chambers, William Mathews, and Peter A. Crooks, Sixth Annual Ohio Valley Affiliates for Life Sciences (OVALS) Symposium, Transformational Research: A Bridge to Building Economies, Louisville, KY, April, 2008 (Award for Outstanding Poster Presentation). 467. “Oral Efficacy of S-Norketamine in Preclinical Rodent Pain Models”. By Joseph R. Holtman,
Peter A. Crooks, Mark S. Klevin, Marhaba Hojahmat, Jamie K. Johnson, Katelyn Etscheidt and Elzbieta P. Wala, Twenty Seventh Annual Meeting of the American Pain Society, May, 2008,Tampa, FL.
468. “DMAPT (LC-1), Parthenolide Analogue, as Epigenetic Therapy for Bladder Cancer”. By
Nikhail R. Collins, Praveen Kusumanchi, Rajasubramanium Shamugam, Sunil Badve,
152
Sundar Neelakantan, Peter A. Crooks, Christopher J. Sweeney, and Harikrishna
Nakshatri, Flight Attendant Medical Research Institute Annual Meeting, May, 2008,
Boston, MA, Abstract No. 895.
469. “LC-1: A Synthetic Water-soluble Parthenolide Analog and Potent Anti-tumor Agent can be Obtained Directly from Tanacetum parthenium (Feverfew) Green Plant”. By Sundar Neelakantan, Maelor H. Davies, Orlando D. Chambers, and Peter A. Crooks, Thirty Fifth Annual MALTO Conference, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2008.
470. “Oral Bioavailability and Pharmacokinetics of N,N’-Dodecane-1,12-diyl-bis-3-picolinium
Dibromide (bPiDDB), a Novel Nicotinic Receptor Antagonist, in Rats”. By Zaineb A.
Fadhel Albayati, Linda P. Dwoskin and Peter A. Crooks, Thirty Fifth Annual MALTO
Conference, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2008.
471. “GC-NPD-MS Dual Detection for Stability Profiling of a Nitrogenous Drug in a Topical Formulation”. Vipin D. P. Nair, Nicole Henderson, David R. Worthen, Peter A. Crooks, Roger Buchanan and Robyn Hannigan, Pharmforum ’08; 7th Annual Southern Regional Discussion Group Meeting, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2008.
472. “Inhibition of Nicotine-evoked Dopamine Release from Superfused Rat Striatal Slices by Novel Quaternary Ammonium Salts Containing an N-5-(3-Biphenyl)pentyl-1-yl Substituent”. By Peter A. Crooks, Guangrong Zheng, Marharyta Pivavarchyk, and Linda P. Dwoskin, 70th Annual Meeting of the College on Problems of Drug Dependence, Abstract
No. 87, p14, San Juan, Puerto Rico, June, 2008. 473. “Effects of the Novel Nicotinic Acetylcholine Receptor Antagonist, N,N’-Decane-1,10-diyl-bis-
3-picolinium Diiodide (bPiDI), on Nicotine Self-administration and Food-maintained Responding in Rats”. By Tim Wooters, John T. Ross, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, 70th Annual Meeting of the College on Problems of Drug Dependence, Abstract No.75, p13, San Juan, Puerto Rico, June, 2008.
474. “Indolizidine 235B’ Potently Inhibits Nicotine-evoked Dopamine Release from Superfused Rat Striatal Slices”. By Linda P. Dwoskin, Marharyta Pivavarchyk, Hiroshi Tsuneki, Naoki Toyooka, Zhenfa Zhang, Peter A. Crooks, 70th Annual Meeting of the College on
Problems of Drug Dependence, Abstract No. 86, p14, San Juan, Puerto Rico, June, 2008. 475. “The Novel NMDA Receptor Modulator JR220 is Positive in an Entire Anti-relapse Screening Hierarchy”. By John M. Littleton, Peter A. Crooks, Joshua Ring, Vijayakumar N. Sonar, and Susan Barron, Joint Meeting of the Research Association on Alcoholism and the International Society for Biomedical Research on Alcoholism, June, 2008, Washington DC. 476. “Differential Inhibition of Nicotinic Responses in the Ventral Temental Area by Subtype- Selective Antagonists” By Gretchen Y. López-Hernández, Jeffrey S. Thinschmidt, Linda Cortés, Clare Stokes, Peter A. Crooks, Linda P. Dwoskin, and Roger L. Papke. XIII International Symposium on Cholinergic Mechanisms. Neuronal and Non-Neuronal Cholinergic Systems: Molecular and Translational Significance, August, 2008, Foz do Iguaçu, Brazil, Abstract No. xxx. 477. “Opiod-Nicotinic Antinociceptive Interactions in Rodent Pain Models”. By Joseph R.
153
Holtman, Jr., Peter A. Crooks, Jamie K. Johnson, Marhaba Hojhamat, and Elzbieta P. Wala, World Congress on Pain 2008, August, 2008, Glasgow, Scotland. 478. “Use of Gas Chromatography-Nitrogen/Phosphorus Detection-Mass Spectroscopy Dual Detection in the Stability Profiling of a Nitrogenous Drug in an Aqueous Gel Formulation”. By Vipin D. P. Nair, Nicole Henderson, David R. Worthen, Peter A. Crooks, Roger Buchanan and Robyn Hannigan, Proceedings of the 235th American Chemical Society National Meeting, Abstract No. ANYL-098, August, 2008, Philadelphia, PA. 479. ”Radiation-mediated Tumor Control Using (Z)-2-(1-benzylindol-3-ylmethylene)-1- azabicyclo[2.2.2]octane-3-ol to Target Endothelial Cell proliferation and Morphogenesis”. By Ling Geng, Girish Rachakonda, D. James Morre, Peter A. Crooks, Vijayakumar N. Sonar, Joseph L. Roti Roti, Buck Rogers, Suellan Greco, Soumya Sasi, Michael L. Freeman, and Konjeti R. Sekhar, 54th Annual Meeting of the Radiation Research Society (RRS) in conjunction with the American Society for Therapeutic Radiology and Oncology (ASTRO), September, 2008, Boston, MA. 480. “JR220, A Novel Polyamine Antagonist, Reduces Ultrasonic Vocalization Deficits In Infant Rat Pups Following “3RD Trimester” Ethanol Exposure”. By Kristen A. Wellmann, B. Lewis, A.H. Kehrberg, M. Carter, John M. Littleton, Peter A. Crooks, and Susan Barron, Joint Meeting of the International Society for Biomedical Research on Alcoholism (ISBRA) and the Research Society on Alcoholism (RSA), Washington DC, June, 2008. 481. “A Novel Compound, JR-220, Reduces Ethanol Withdrawal-induced Neurotoxicity in Organotypic Hippocampal Slice Cultures. By A. Hutton Kehrberg, L. Carter, K. A. Wellmann, Mark A. Prendergast, Peter. A. Crooks, John M. Littleton, and Susan Barron, Annual Meeting of the Society for Neuroscience, Abstract 315.5/AA15, Washington, DC, November, 2008. 482. “A Novel Compound, JR-220, Reduces Voluntary Alcohol Consumption in a Limited-Access "Drinking in the Dark" Paradigm”. By B. Lewis, J. M. Farook, K. Wellmann, Peter A. Crooks, John M. Littleton, and Susan Barron, Annual Meeting of the Society for Neuroscience, Abstract 257.16/Z33, Washington, DC, November, 2008. 483. “JR-220, A Novel Compound, Reduces Spatial Memory Deficits in Adolescent Rat Pups Following “3RD Trimester” Ethanol Exposure”. By K.A. Wellmann, B. Lewis, A.H. Kehrberg, M. Carter, L. Carter, John M. Littleton1, Peter A. Crooks, and Susan Barron, Annual Meeting of the Society for Neuroscience, Abstract 158.7/DD28, Washington, DC, November, 2008. 484. “Effects of bis-3-Picolinium Nicotinic Receptor Antagonists on Somatic Indices of Withdrawal in Nicotine-dependent Rats: Comparison to Mecamylamine”. By Thomas E. Wooters, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Annual
Meeting of the Society for Neuroscience, Washington, DC, November, 2008. 485. “Differential Inhibition of Nicotinic Responses in the Ventral Tegmental area by nAChR Subtype-selective Antagonists”. By G. Y. López, J. S. Thinschmidt1, L. Cortés1, Claire Stokes1, Peter A. Crooks, Linda P. Dwoskin, and Roger L. Papke, Annual Meeting of the Society for Neuroscience, Abstract No. 328.13/C43, Washington, DC, November, 2008. 486. “tkPIQB Inhibits Nicotine-evoked [3H]Dopamine Release from Rat Striatal Slices via
154
Surmountable Allosteric Antagonism of 62-Containing Nicotinic Receptors”. By Marharyta Pivavarchyk, Zhenfa Zhang, J. Michael McIntosh, Peter A. Crooks and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract 328.15/C45, Washington, DC, November, 2008. 487. “Water-soluble Analogs of Lobelane as Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors and Potential Treatments for Methamphetamine Abuse.” By David B. Horton, Guangrong Zheng, K. B. Siripurapu, A.Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract 660.5/GG24, Washington, DC, November, 2008. 488. “N,N’-Dodecane-1,12-diyl-bis-3-picolinium dibromide Inhibits Nicotine-evoked Norepinephrine Release Through an Allosteric Mechanism of Action”. By Andrew M. Smith, G. K. Dhawan, Zhenfa Zhang, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract 258.12/AA15, Washington, DC, November, 2008. 489. “Development of Lobelane Isomers Targeting the Vesicular Monoamine Transporter-2 (VMAT2)”. By John P. Culver, Linda P. Dwoskin, A. Gabi Deaciuc, J. Chagkutip, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6126, p141, November, 2008, Atlanta, GA.
490. “Microneedle-enhanced Transdermal Delivery of Naltrexone Prodrugs”. By Mikolaj Milewski, Y. Thirupathi Reddy, Harvinder S. Gill, Mark R. Prausnitz, Peter A. Crooks, Audra L. Stinchcomb, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3057, p103, November, 2008, Atlanta, GA.
491. “Stability-Indicating HPLC Method for an Oral Formulation of the Novel Anti-Tumor Agent LC-1.” By Sundar Neelakantan and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5027, p126, November, 2008, Atlanta, GA. 492. “Synthesis of Novel Substituted N-Benzyl Alysinopsin Analogs as Potent Radio-sensitizing Agents”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, Konjeti R. Sekhar, Michael L. Freeman, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6076, p140, November, 2008, Atlanta, GA. 493. “Design and Synthesis of Novel 3-O-Pegylated Carboxylated and 3-O-Pegylated Carbamate Naltrexone Prodrugs for Transdermal Delivery”. By Thirupathi Reddy Yerramreddy, Mikolaj Milewski, Audra L. Stinchcomb, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6085, p140, November, 2008, Atlanta, GA. 494. “Preclinical Pharmacokinetic Evaluation of Z-()-2-(1-Benzenesulfonyl-1H-indol-3-yl- methylene)-1-azabicyclo[2.2.2]octan-3-one (BSAO); a Novel Radio-sensitization Agent” By Abeer M. Al-Ghananeem, Ahmad H Malkawi, Zaineb F Al-Beyati, Michael L. Freeman,
Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American
Association of Pharmaceutical Scientists, Abstract No. T3239, p108, November, 2008, Atlanta, GA.
155
495. “Studies on the Interaction of Mechlorethamine Hydrochloride with Topical Excipients”. By Vipin D. P. Nair, David R. Worthen and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1179, p83, November, 2008, Atlanta, GA. 496. “Simultaneous Determination of Mechlorethamine HCl Nitrogen and a Proposed Monohydroxyl Degradant in a Model Topical Formulation”. By Vipin D. P. Nair, David R. Worthen and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5025, p1127, November, 2008, Atlanta, GA. 497. “An Improved Synthesis of Bone-Targeted Analogs of Estradiol”. By Shama Nasim, William M. Pierce, K. Grant Taylor and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R36075, p140, November, 2008, Atlanta, GA. 498. “Stability of Mechlorethamine HCl Nitrogen Mustard in Diethylene Glycol Monoethyl Ether”. By David R. Worthen, Vipin D. P. Nair and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3083, p104, November, 2008, Atlanta, GA. 499. “A Novel Drug Hybrid of Codeine and S-(-)-Nornicotine as a Potent Analgesic”. By Ujjwal Chakraborty, Joseph R. Holtman, Elzbieta P. Wala and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6070, p139, November, 2008, Atlanta, GA. 500. “Preparation of a Synergistic Codrug of Codeine and Δ9-THC as a Potent Antinociceptive Agent”. By Harpreet K. Dhooper, Joseph Holtman and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6071, p139, November, 2008, Atlanta, GA. 501. “Pharmacological Mimickry of Lobelane by Substituted Pyrrolidines in the Inhibition of of the Vesicular Monoamine Transporter 2 (VMAT2)”. By Ashish P. Vartak, Jaturaporn Chagkutip,
Agripina G. Deaciuc, Linda P. Dwoskin and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5067, p128, November, 2008, Atlanta, GA.
502. “A Novel, Practical, Enantioselective Synthesis of (+)- and (-)-Lofexidine”. By Ashish P. A. Vartak, Abeer Al-Ghananeem, George A. Digenis and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6099, p140, November, 2008, Atlanta, GA. 503. “Nicotine Exposure can be Detected in Cerebrospinal Fluid of Active and Passive Smokers, Including Infants and Neonates of Smoking Mothers”. By Ahmad H Malkawi, Abeer M. Al- Ghananeem, Jose de Leon, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1026, P78, November, 2008, Atlanta, GA. 504. “Brain/Plasma Bioavailability and Protein Binding Behavior of N,N’-Dodecane-1,12-diyl-bis- 3-picolinium Dibromide (bPiDDB), a Novel Nicotinic Receptor Antagonist”. By Zaineb A. Fadhel Albayati, Linda P. Dwoskin, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5050, p127, November, 2008, Atlanta, GA.
156
505. “Biotinylated 2,4-Disubstituted 1,2,4-thiadiazolidine-3,5-diones as Mechanistic Probes for the Study of TDZD-mediated Leukemia-Specific Cell Death”. By Shama Nasim, Monica L. Guzman, Craig T. Jordan and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5058, p127, November, 2008, Atlanta, GA. 506. “Synthesis and Hydrolysis Studies of a (-)-Cytisine-Naltrexone Carbamate Codrug for Transdermal Drug Delivery”. By Joshua A. Eldridge, Audra L. Stinchcomb and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6072, p139, November, 2008, Atlanta, GA. 507. “Synthesis and Antileukemic Activities of 2,4-Disubstituted 1,2,4-Thiadiazolidine-3,5-dione Analogs”. By Shama Nasim, Monica L. Guzman, Craig T. Jordan and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5059, p128, November, 2008, Atlanta, GA. 508. “The Environmental Pollutant 2, 2’ Dipyridyl is Present in the Plasma of Healthy Human Volunteers”. By Ahmad H Malkawi, Abeer M. Al-Ghananeem, Jose de Leon, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1027, p78, November, 2008, Atlanta, GA. 509. “Synthesis and Evaluation of a Series of Acrylonitrile Analogs as Antitumor Agents”. By Vijayakumar N. Sonar, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6125, p141, November, 2008, Atlanta, GA. 510. “Synthesis and Pharmacological Evaluation of N-Substituted Lobelane Analogs at the Vesicular Monoamine Transporter (VMAT2)”. By Guangrong Zheng, David B. Horton, Agripina G. Deaciuc, Linda P. Dwoskin, Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6133, p141, November, 2008, Atlanta, GA. 511. “Synergystic Design of Polar bis-Pyridinium Analogs Containing a Conformationally Restricted Linker Unit with Activity at Both Nicotinic Receptors and the Blood-brain Choline Transporter (BBBCT)”. By Zhenfa Zheng, Linda P. Dwoskin, and Peter A. Crooks, Twenty Second Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6132, p141, November, 2008, Atlanta, GA.
512. “Dimethylaminoparthenolide (DMAPT) in Multiple Myeloma”. By Colin D. Crean, Genglin Zhang, Karen E. Pollok, Anthony L. Sinn, Peter A. Crooks, Sherif Farag, and Attaya Suvannasankha, Fifitieth American Society of Hematology Meeting and Exposition, Abstract No. 14001, San Francisco, CA, December, 2008. 513. “Decamethonium Analogs as Brain Deliverable Neuronal Nicotinic Acetylcholine Receptor
Antagonists for Nicotinic Addiction”. Invited speaker, Fourteenth International
Pharmaceutical Technology Symposium: Overcoming Biological Barriers in Innovative
514. “Effect of the Lobeline Analog AV-1-228 on Methamphetamine Self-administration in Rats”. By Josh Beckmann, Emily Denehy, Ashish Vartak, Peter A. Crooks, Linda P. Dwoskin and Michael T. Bardo, Southeastern Association for Behavior Analysis Conference, Atlanta, GA, 2008. 515. “Design and Synthesis of Novel Water-soluble Amino and AminoPhosphonate Derivatives
157
of Parthenolide as Posiible Anti-leukemic Agents”. By Nikhil Reddy Madadi, Thirupathi Reddy Yerramreddy, and Peter A. Crooks, National Symposium on Recent Trends in Organic and Medicinal Chemistry, Abstract #1, National Institute of Technology, January, 2009, Warangal, India. 516. “Dipyridine Cobalt Chloride as a Mild and Efficient Catalyst for the One-Pot Synthesis of 3,4- Dihydropyrimidine-2(1H)-ones under Solvent-free Conditions”. By B. Suresh Kuarm, S. Vijaya Laxmi, J. Venu Madhav, B. Rajitha, Y. Thirupathi Reddy, and Peter A. Crooks, National Symposium on Recent Trends in Organic and Medicinal Chemistry, Abstract #22, National Institute of Technology, January, 2009, Warangal, India. 517. “Synthesis and Anticonvulsant Activity of Novel Substituted (Z)-5-((N-Benzyl-1H-indol-3-yl) methylene)imidazolidine-2,4-diones and 5-((N-Benzyl-1H-indol-3-yl)methylene)pyrimidine- 2,4,6 (1H, 3H, 5H)-triones”. By Thirupathi Reddy Yerramreddy, Narsimha Reddy Penthala, James P. Stables, and Peter A. Crooks, National Symposium on Recent Trends in Organic and Medicinal Chemistry, Abstract #32, National Instute of Technology, January, 2009Warangal,India. 518. “Synthesis of Novel Substituted N-Benzyl Indolyl Barbiturates as Potential Radio-Sensitizing Agents”. By Thirupathi Reddy Yerramreddy, Narsimha Reddy Penthala, Konjeti R. Sekhar, Michael L. Freeman, and Peter A. Crooks, National Symposium on Recent Trends in Organic and Medicinal Chemistry, Abstract #57, National Institute of Technology, January, 2009, Warangal, India. 519. “Water-soluble Analogs of Lobelane as Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors and Potential Treatments for Methamphetamine Abuse.” By David B. Horton, Guangrong Zheng, K. B. Siripurapu, A.Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society of Neuroscience, March, 2009, Lexington, KY. 520. “Water-soluble Analogs of Lobelane as Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors and Potential Treatments for Methamphetamine Abuse.” By David B. Horton, Guangrong Zheng, K. B. Siripurapu, A.Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, University of Kentucky Center for Clinical and Translational Sciences (CCTS) Spring Conference,March, 2009, Lexington, KY. 521. “Using the Principles of Hyperthermia to Design Small Molecule Radiation Sensitizers”. By Konjeti R. Sekhar, Vijayakumar N. Sonar, Thirupathi R. Yerramreddy, Narsimha R. Penthala, Peter A. Crooks, and Michael L. Freeman, Annual Meeting of the Society for Thermal Medicine, Tucson, Arizona, April, 2009. 522. “Novel Opioid-Nicotinic Combination Drug Therapy for Pain”. By Joseph R. Holtman Jr., Peter A. Crooks, Jaime Johnson-Hardy, Ujjwal Chakraborty, and Elzbieta P. Wala, Twenty Eighth Annual Meeting of the American Pain Society, San Diego, CA, May, 2009. 523. “An Epigenetics Therapy for Bladder Cancer”. By Nikhail R. Collins, Christopher
Sweeney, Craig T. Jordan, By Peter A. Crooks, Sundar Neelakantan, William Matthews,
and Harikrishna Nakshatri, Flight Attendant Medical Research Institute Annual Meeting,
Abstract No. 895, May, 2009, Boston, MA.
524. “Brain/Plasma Bioavailability of N,N’-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB) and N,N′-Decane-1,10-diyl-bis-3-reduced-picolinium Hydrochloride (GZ- 541a),Two Novel Nicotinic Receptor Antagonists, in Rats. By Zaineb A. Fadhel Albayati, Thomas E. Wooters, Michael T. Bardo, Linda P. Dwoskin and Peter A.
158
Crooks, Thirty Sixth Annual MALTO Conference, University of Memphis, College of Pharmacy, May, 2009, Memphis, TN. 525. “Influence of pH on the Stability of Naltrexone Prodrugs Designed for Transdermal Delivery Using Microneedles”. By Priyanka Ghosh, Mikolaj Milewski, Yerramreddy T. Reddy, Peter A. Crooks and Audra L. Stinchcomb, Gordon Conferences: Barrier Function of Mammalian Skin, June, 2009, NH. 526. “Lobelane Analogs with Varying Methylene Linker Lengths as Novel Ligands for the Vesicular Monoamine Transporter-2”. By Zheng Cao, Guangrong Zheng, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Post-graduate Student Research Meeting, Purdue University, IN, June, 2009. 527. “JR220, A Novel Compound, Reduces Social, Locomotor, Balance and Memory Deficits in Rats Following “3rd Trimester” Ethanol Exposure”. By Kristen A. Wellman, B. Lewis, L. Carter, A. Hutton Kehrberg, John M. Littleton, Peter A. Crooks, and Susan Barron, 2009 Annual Scientific Meeting of the Research Society on Alcoholism, San Diego, CA, June, 2009. Winner of the Gordis Award for best poster presentation. 528. “(R)-cis-N-(2,3-Dihydroxypropyl)-2,6-di-(4-methoxyphenylethyl)piperidine hemisulfate (UK- 793A) Selectively Blocks Methamphetamine reinforcement without producing Tolerance in Rats”. By Joshua Beckmann, David B. Horton, Kirin B. Siripurapu, E. Denehy, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, 71st Annual Meeting of the College on Problems of Drug Dependence, Reno/Sparks, NV, June, 2009. 529. “Indolyl-quinuclidinols Inhibit ENOX Activity and Endothelial Cell Morphogenesis while
Enhancing Radiation-mediated Control of Tumor Vasculature”. By Ling Geng, Girish Rachakonda, D. James Morre, Dorothy M. Morre, Peter A. Crooks, Vijayakumar N. Sonor, Joseph L. Roti Roti, Buck E. Rogers, Fei Ye, Michael L. Freeman, Konjeti R. Sekhar, 55th Annual Meeting of the Radiation Research Society, Savannah, GA, October, 2009.
530. “GZ556A and ZZ204G are Novel Small Molecule Antagonists of α9α10 nAChRs and are Analgesic in rats”. By J. Michael McIntosh, Jr., Linda P. Dwoskin, Peter A. Crooks, and Joseph R. Holtman, Nicotinic Acetylcholine Receptors as Therapeutics Targets: Emerging Fronitiers in Basic Research and Clinical Science: Satellite Meeting, Annual Meeting of the Society for Neuroscience, Abstract 4.5, Biochemical Pharmacology, 2009, 78, 921, Chicago, IL, October, 2009. 531. “Inhibition of Nicotine-Evoked [3H]Dopamine Overflow from Superfused Rat Strital Slices By Tertiary Amino Analogs”. By Marharyta Pivavarchyk, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, and Linda P. Dwoskin, NIDA Satellite Symposium. Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Fronitiers in Basic Research and Clinical Science. Annual Meeting of the Society for Neuroscience, October, 2009, Chicago, IL.
532. “Discovery of b3,5L/3PiDDB and r-b3,5L/3PiDDB: Novel 62* Subtype-Selective Nicotinic Receptor Antagonists”. By Andrew M. Smith, Marharyta Pivavarchyk, Tom E. Wooters, Zhenfa Zhang, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, NIDA Satellite Symposium. Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Fronitiers in Basic Research and Clinical Science. Annual Meeting of the Society for Neuroscience. October, 2009, Chicago, IL.
159
533. “N-Substituted Methamphetamine Derivatives as Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors”. By David B. Horton, Guangrong Zheng, Joshua S. Beckmann, A. Gabi Deaciuc, Michael T. Bardo, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience; Abstract 554.6/AA6, October, 2009, Chicago, IL. 534. “[3H]Dihydrotetrabenazine Binding and [3H]Doapamine Uptake Inhibitory Activity of a Series of Pyrrolidine Analogs at the Vesicular Monoamine Transporter-2”. By Justin Nickell, Ashish Vartak, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience; Abstract 554.6/AA7, October, 2009, Chicago, IL. 535. “Chemical Derivitives of the Anti-Leukemis Stem Cell Compound 4-Benzyl-2-memthyl- 1,2,4-thiadiazolidine-3,5-dione (TDZD-8) with Imptoved Activity.” By Monica L. Guzman, Shama Nasim, Marlene Bayls, Cheryl Corbett, Peter A. Crooks and Craig T. Jordan, Annual Meeting of the American Society of Hematology, Abstract 3764, New Orleans, LA, December, 2009. 536. “Chemical Genomics Screening Reveals that PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide”. By Duane C. Hassane, Siddhartha Sen, Cheryl A. Corbett, Peter A. Crooks, Monica L. Guzman and Craig T. Jordan, Annual Meeting of the American Society of Hematology, Abstract 388, New Orleans, LA, December, 2009. 537. “Analysis of the Anti-Leukemia Mechanism of Parthenolide”. By Shanshan Pei, Monica L. Guzman, Shama Nasam, Peter A. Crooks, and Craig T. Jordan, Annual Meeting of the American Society of Hematology, Abstract 2734, New Orleans, LA, December, 2009. 538. “In Vivo Pharmacokinetic Comparison of Transdermal S-(-)-Nornicotine (S-NN) and S-(-)- Nicotine in Male Yucatan Minipigs”. By Zaineb Albayati, Buchi Nalluri, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1107, p66, November, 2009, Los Angeles, CA. 539. “Design and Synthesis of Selective 3-O-Phosphate Analogs of Estradiol prodrugs for Bone Targetting”. By Shama Nasim, William M. Pierce, Jr., Grant Taylor , and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1141, p67, November, 2009, Los Angeles, CA. 540. “Synthesis and In Vivo Cytotoxicity of Substituted (Z)-2-Amino-5((1-benzyl-1H-Indol-3- yl)methylene-1-methyl-1H-imidazol-4(5H)-ones”. By Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1155, p68, November, 2009, Los Angeles, CA. 541. “Stability of the Oral Formulation of the Novel Antitumor Agent LC-1 in Various Soft Beverages”. By Sundar Neelakantan and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T2025, p80, November, 2009, Los Angeles, CA. 542. “The Presence of the Environmental Pollutant, 2,2’-Dipyridyl is Directly Correlated to Cotinine Levels in the Plasma of Smokers”. By Ahmad Malkawi, Jose De Leon, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T2071, p82, November, 2009, Los Angeles, CA.
160
543. "A Novel Drug Hybrid of 3-O-Acetylmorphine and S-(-)-Nornicotine as a Potent Analgesic”. By Ujjwal Chakraborty, Elzbieta Wala, Joseph Holtman, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3193, p105, November, 2009, Los Angeles, CA.
544. “Pharmacokinetic Profile of a Codeine-9-tetrahydrocannabinol Hybrid Drug for Pain Management”. By Harpreet Dhooper, Zaineb Albayati, Jamie Horn, Joseph Holtman, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3194, p105, November, 2009, Los Angeles, CA. 545. “Development of a Stability-indicating HPLC method for the Analysis of S-(-)-Nornicotine Difumarate”. Marhaba Hojahmat and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4007, P116, November, 2009, Los Angeles, CA. 546. “Azaheterocyclic Modulators of the Vesicular Monoamine Transporter 2 (VMAT2)”. By Ashish Vartak, Justin Nickell, Agripina G. Deaciuc, Jaturaporn Chagkutip, Linda P. Dwoskin, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4186, p123, November, 2009, Los Angeles, CA. 547. “Predictive Screening Model for Potential Vector-Mediated Transport of Cationic Substrates at the Blood-Brain Choline Transporter”. By Cornelius J. Van der Schyf, Paul Lockman, David Allen, Rajender Mittapalli, Vamshi Manda, Linda P. Dwoskin and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4191, p123, November, 2009, Los Angeles, CA. 548. “Synthesis and Evaluation of Analogs of Lobelane Targetting the Vesicular Monoamine Transporter-2 (VMAT2)”. By John Culver, Justin Nickell, Agripina G. Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4197, p123, November, 2009, Los Angeles, CA. 549. “Design and Synthesis of Novel Mono- and Duplex Pegylated Aminoparthenolide Derivatives as Water soluble Antileukemic Agents”. By Nikhil Madadi, Thirupathi Reddy Yerramreddy, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4199, p123, November, 2009, Los Angeles, CA. 550. “Second Generation Analogs of 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) as Potent, Selective and Drugable Antileukemic Agents”. By Shama Nasim, Monica Guzman, Craig Jordan, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4200, p123, November, 2009, Los Angeles, CA. 551. “Design, Synthesis and Antiproliferative Activity of Novel Resveratrol Analogs”. By Nikhil Madadi, Thirupathi Reddy Yerramreddy, Narsimha Reddy Penthala, Srinivas Kodura, Damodaran Chendil, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5187, p1, November, 2009, Los Angeles, CA.
161
552. “Synthesis and Antiproliferative Activity of Novel Substituted (Z)-5-(N-Benzyl-1H-indol-3- yl)methyleneimidazolidin-2,4-diones”. By Thirupathi Reddy Yerramreddy, Narshima Reddy Penthala, Srinivas Kodura, Damodaran Chendil, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5188, p140, November, 2009, Los Angeles, CA.
553. “Synthesis of Amino Acid Ester Prodrugs of 6-Naltrexone for Microneedle-enhanced Transdermal Delivery”. By Josh Eldridge, Mikolaj Milewski, Audra Stinchcomb and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5197, p141, November, 2009, Los Angeles, CA. 554. “N-Substituted Methamphetamine Derivatives as Inhibitors of Dopamine Uptake at the Vesicular Monoamine Transporter (VMAT2)”. By Guangrong Zheng, David Horton, Agripina G. Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Twenty Third Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. R6166, P156, November, 2009, Los Angeles, CA. 555. “GZ-793A Selectively Inhibits Methamphetamine-induced Neurochemical Effects”. By Kirin B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society for Neuroscience, March, 2010, Lexington, KY. 556. “N-Substituted Methamphetamine Derivatives as Novel Vesicular Monoamine Transporter (VMAT2) Inhibitors”. By David B. Horton, Guangrong Zheng, Joshua S. Beckmann, A. Gabi Deaciuc, Michael T. Bardo, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society for Neuroscience, March, 2010, Lexington, KY. 557. “Novel tris-Quaternary Ammonium Antagonists at Neuronal Nicotinic Acetylcholine Receptors Mediating Nicotine-evoked Dopamine Release”. Guangrong Zheng, Sangeetha P. Sumithran, Roger L. Papke, Linda P. Dwoskin, and Peter A. Crooks, Kentucky Lung Cancer Research Program, University of Kentucky-University of Louisville Lung Cancer Retreat, Abstract No. 2, March 27th, 2010, Lexington, KY. 558. “New Leads for the Treatment of Nicotine Addiction: Novel bis-, tris-, and tetrakis-Tertiary Amino Analogs as Antagonists at Neuronal Nicotinic Receptors that Mediate Nicotine- evoked Dopamine Release”. Guangrong Zheng, Zhenfa Zhang, Marharyta Pivavarchyk, Andrew Smith, A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks, Kentucky Lung Cancer Research Program, University of Kentucky-University of Louisville Lung Cancer Retreat, Abstract No. 3, March 27th, 2010, Lexington, KY. 559. “Inhibition of Nicotine-evoked [3H]Dopamine Overflow from Superfused Rat Striatal Slices by Tertiary Amino Antagonists”. Marharyta Pivavarchyk, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, and Linda P. Dwoskin, Kentucky Lung Cancer Research Program, University of Kentucky-University of Louisville Lung Cancer Retreat, Abstract No. 4, March 27th, 2010, Lexington, KY.
560. “Discovery of b3,5L/3PiDDB and r-b3,5L/3PiDDB: Novel 62* Subtype-selective Nicotinic Receptor Antagonists”. Andrew Smith, Marharyta Pivavarchyk, Zhenfa Zhang, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, and Linda P. Dwoskin, Kentucky Lung Cancer Research Program, University of Kentucky-University of Louisville Lung Cancer Retreat, Abstract No. 5, March 27th, 2010, Lexington, KY.
162
561. “Effects of Novel N,N’-Dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on Nucleus Accumbens Dopamine Release in Rats Sensitized to Nicotine”. Shafiqur Rahman, Nichole M. Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Kentucky Lung Cancer Research Program, University of Kentucky-University of Louisville Lung Cancer Retreat, Abstract No. 6, March 27th, 2010, Lexington, KY. 562. “Effects of the Novel Nicotinic Acetylcholine Receptor Antagonists N,N’-Decane-1,10-diyl- bis-3-picolinium diiodide (bPiDI) on Nicotine Self-administration and Food-maintained Responding in Rats”. Kentucky Lung Cancer Research Program, University of Kentucky- University of Louisville Lung Cancer Retreat, Abstract No. 7, March 27th, 2010, Lexington, KY. 563. “Novel Small Molecule Alpha9 Alpha10 Nicotinic Receptor Antagonists for Pain Management”. Joseph R. Holtman Jr., Linda P. Dwoskin, Elzbieta P. Wala, Peter A. Crooks, and J. Michael McIntosh. 29th Annual Scientific Meeting of the American Pain Society, May, 2010, Baltimore, MD; E20: Non-Opioid Analgesics, Abstract 228, The Journal of Pain, 11(4), Suppl. 1, S33, 2010. 564. “Developing Radiation Sensitizers from Small Molecule Thermal Enhancers”. Konjeti R. Sekhar, Y. Thirupathi Reddy, Vijayakumar N. Sonar, Peter A. Crooks, and Michael L. Freeman, Annual Meeting of the Society of Thermal Medicine, April, 2010, Clearwater Beach, FL. 565. “A Stability-indicating Liquid Chromatographic method for the Simultaneous Determination of Dantrolene Sodium Drug Substance and its Related Degradation Products”. By Ahmad Malkawi, Abeer Al-Ghananeem, and Peter A. Crooks, Fifth National Analytical Chemistry Congress, Ataturk University, Erzurum, Turkey, June, 2010. 566. “Solubility, Stability and Minipump Efflux Studies on BT777, a New Bone-targetting Agent”. By Yucel Kadioglu, Zaineb A. F. Albayati, and Peter A. Crooks, Fifth National Analytical Chemistry Congress, Ataturk University, Erzurum, Turkey, June, 2010. 567. “Quantification of Vancomycin in Rat Bone and Plasma Using a Novel LC/MS/MS Method”. By Zaineb A. Fadhel Albayati, Yucel Kadioglu, and Peter A. Crooks, Fifth National Analytical Chemistry Congress, Ataturk University, Erzurum, Turkey, June, 2010. 568. “A Novel Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS Method to Determine the Pharmacokinetics (PK), and Bioavailability of GZ-793A, a lead N-(R)- 2,3-dihydroxypropyl Analog”. Zaineb A. Fadhel Albayati, Joshua Beckmann, Michael T. Bardo, Linda P. Dwoskin and Peter A. Crooks, Thirty Seventh Annual MALTO Meeting, May, 2010, Oxford, MS. 569. “Acyclic Lobelane Analogs as Novel Ligands foe the vesicular Monoamine Transporter-2”. By Zheng Cao, Guangrong Zheng, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Post-graduate Student Research Meeting, Purdue University, IN, June, 2010. 570. “Identification and Screening of Novel and Known Compounds for Neuroprotective and Anti- Relapse Efficacy”. B. Lewis, K.A. Wellmann, M.L. Carter, J.M. Farook, A.H. Kehrberg, Peter
A. Crooks, John M. Littleton, and Susan Barron, Thirty Third Annual Meeting of the Research Society on Alcoholism (RSA), June, 2010, San Antonio, TX.
571. “Effect of a Novel Nicotinic receptor Antagonist r-b3,5L/3PiDDB on Nicotine- and Food-
163
maintained Self-administration”. By A. C. Meyer, Thomas E. Wooters, Zhenfa Zhang, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Micheal T. Bardo, College on Problems of Drug Dependence, Abstract 118, June, 2010, Scottsdale, AZ. 572. “GZ-793A, a Diol Analog of Lobelane, Selectively Blocks the Effects of Methamphetamine on Dopamine Release and Specifically Blocks Methamphetamine Self-administration”. Joshua S. Beckmann, Kristin M. Alvers, E. D. Denehy, Kirin B. Siripurapu, Justin R. Nickell, David B. Horton, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, International Conference on Translational Research in Psychiatry, July, 2010, Innsbruk, Austria. 573. “GZ-793A, a Diol nor-lobelane analog, Inhibits the Neurochemical Effects of Methamphetamine and Specifically Decreases Methamphetamine Self-administration and Reinstatement”. Linda P. Dwoskin, Joshua S. Beckmann, David B. Horton, Kristin M. Alvers, Kirin B. Siripurapu, Justin R. Nickell, M. R. Kilbourn, Guangrong Zheng, Peter A. Crooks and Michael T. Bardo, Conference on Translational Research in Methamphetamine Addiction, July, 2010, Pray, MT. 574. “Effects of a Lobeline Derivative on [11C]-DTBZ Binding to VMAT2”. Michael J. Kilbourn, P. Sherman, C. Quesada, Ashish P. Vartak, Peter A. Crooks, and Linda P. Dwoskin, International Symposium on Functional Neuroreceptor Mapping of the Living Brain: Neuroreceptor Mapping Congress, Abstract P012, July, 2010, Glasgow, Scotland. 575. “Effects of a Lobeline Analog on [11C]-DTBZ Binding to the VMAT2”. Michael J. Kilbourn, P. Sherman, C. Quesada, Ashish P. Vartak, Peter A. Crooks, and Linda P. Dwoskin, PacifiChem 2010, International Chemical Congress of Pacific Basin Societies, Abstract BIOL-248, December, 2010, Honolulu, HI. 576. “GZ-793A, A Novel Vesicular Monoamine Transporter-2 (VMAT2) inhibitor that probes Multiple Sites on VMAT2 as a Potential Treatment for Methamphetamine Abuse” David B. Horton, Guangrong Zheng, A. Gabriela Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, University of Kentucky College of Pharmacy Symposium on Drug Discovery and Development, 2010, Lexington, KY. 577. “Acyclic Lobelane Analogs as Novel Inhibitors of the Vesicular monoamine Transporter-2”. Zack Cao, Guangrong Zheng, A. Gabriela Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, L. University of Kentucky College of Pharmacy Symposium on Drug Discovery and Development, 2010, Lexington, KY. 578. “GZ-793A, A Selective and Potent VMAT2 Inhibitor, Attenuates Both Methamphetamine- and Cue-induced Reinstatement”. Kristin M. Alvers, Joshua S. Beckmann, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Annual Meeting of the Society for Neuroscience; November, 2010, San Diego, CA. 579. “GZ-793A Selectively Inhibits methamphetamine-induced Neurochemical Effects”. Kirin B. Siripurapu, David B. Horton, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience; November, 2010, San Diego, CA. 580. “GZ-793A, A Novel Vesicular Monoamine Transporter-2 (VMAT2) Inhibitor that Probes Multiple Sites on VMAT2 as a Potential Treatment for Methamphetamine Abuse”. David B.
164
Horton, Guangrong Zheng, A. Gabriela Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience; November, 2010, San Diego, CA.
581. “Preclinical Evaluation of r-b3,5L/3PiDDB: an Allosteric 62* Subtype-selective Nicotinic Receptor Antagonist that Specifically Decreases Nicotine Self-administration”. By Andrew M. Smith, Andrew C. Meyer, Marharyta Pivavarchyk, Thomas E. Wooters, Zhenfa Zhang, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, John P. WyattSymposium on Environmental Health and Disease, Research Abstract, November, 2010, Lexington, KY. 582. “A Comparison of BT2-peg2-vancomycin and Vancomycin Levels in Plasma and Bone after Intraperitoneal Administration to Albino Wistar Male Rats. S. M. Schmidt, Zaineb F. Albayati, M. J. Karau, M. S. Rouse, J. M. Steckelberg, M. Sunkara, A. Pearson, Peter A. Crooks, and Robin Patel, General Meeting of the American Society of Microbiology; May, 2011, New Orleans, LA. 583. “Synthesis and Anti-microbial Activities of Novel Substituted 3-[Benzimidazo- and Benzothiadiazole-[1,2-c]quinazolin-5-yl]-2H-chromene-2-one Analogs”. Rajitha Bavanthula, Suresh Kuarm, Thiraputhi Yerramreddy, J. Venu Madhav, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1021, p98, November, 2010, New Orleans, LA. 584. “Design, Synthesis and Biological Evaluation of Novel Lobelane Analogs”. Derong Ding, Linda P. Dwoskin, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1025, p99, November, 2010, New Orleans, LA. 585. “Synthesis and In Vivo Cytotoxicities of Novel Substituted N-Benzyl Indolyl Hydantoin Analogs”. Thirupathi Reddy Yerramreddy, Narsimha Reddy Penthala, and Peter A. Crooks, Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1043, p99, November, 2010, New Orleans, LA.
586. “Amino Acid Ester Prodrugs of Naltrexone and 6--Naltrexone as Candidates for Microneedle-enhanced Transdermal Delivery”. Joshua T. Eldridge, Mikolaj Milewski, Audra L. Stinchcomb, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1138, p104, November, 2010, New Orleans, LA. 587. “Novel Drug Hybrids of Morphine and S-(-)-Nornicotine as Potent Analgesics”. Ujjwal Chakraborty, Joseph R. Holtman, Elzbieta T. Wala, Zaineb A. Fadhel Albayati, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T2008, p122, November, 2010, New Orleans, LA. 588. “Synthesis and Evaluation of Structurally Diverse Analogs of Lobelane Targeting the
165
Vesicular Monoamine Transporter-2 (VMAT2)”. John P. Culver, Linda P. Dwoskin, Justin Nickell, A. Gabi Deaciuc, and Peter A. Crooks, Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3020, p146, November, 2010, New Orleans, LA. 589. “Synthesis and In Vitro Cytotoxicity Evaluation of Isatin Creatininies as Novel Anticancer Agents”. Narsimha Reddy Penthala, Thiraputhi Reddy Yerramreddy, and Peter A. Crooks, Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3028, p147, November, 2010, New Orleans, LA. 590. “Pyrrolidine Analogs of Lobelane: Synthesis and Evaluation as Inhibitors of the Vesicular Monoamine Transporter-2 (VMAT2)”. Purushothama Rao Ponugoti, Narsimha Reddy Penthala, Justin Nickell, A. Gabi Deaciuc, Linda P. Dwoskin, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3029, p147, November, 2010, New Orleans, LA. 591. “New Leads for the Treatment of Nicotine Addiction: Novel bis-, tris-, and tetrakis-Tertiary Amino Analogs as Antagonists at Neuronal Nicotinc Receptors that Mediate Nicotine-evoked Dopamine Release”. Guangrong Zheng, Zhenfa Zhang, Marharyta Pivavarchyk, Andrew M. Smith, A. Gabi Deaciuc, Linda P. Dwoskin, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3031, p147, November, 2010, New Orleans, LA. 592. “Anti-leukemic Activity of a Hybrid Drug: TDZD-8-Parthenolide”. Shama Nasim, Monica Guzman, Craig Jordan, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4446, p189, November, 2010, New Orleans, LA. 593. “Design, Synthesis and Anti-proliferative Activity of Novel Reseveratrol Analogs”. Nikhil Reddy Madadi, Thirupathi Reddy Yerramreddy, Narsimha Reddy Penthala, Srinivas Koduru, D. Chendil Damadaran, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5023, p194, November, 2010, New Orleans, LA. 594. “Quantification of Vancomycin in Rat Bone and Plasma Using a Novel LC/MS/MS Method”. Zaineb A. Fadhel Albayati, Yucel Kadioglu, and Peter A. Crooks. Pharmaceutical Sciences World Congress 2010, and Joint Meeting of the International Pharmaceutical Federation (FIP) and the Twenty Fourth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5308, p207, November, 2010, New Orleans, LA. 595. “Chemical Genomics Screening Reveals that P13K/mTOR Inhibition Enhances Activity of the Anti-Leukemic Stem Cell Compound Parthenolide”. Duane Hassane, Siddhartha Sen, Cheryl A. Corbett, Marlene Balys, Randall M. Rossi, Peter A. Crooks, Monica Guzman, and
166
Craig T. Jordan, Fifity First Annual Meeting and Exposition of the Americam Hematology Society, December, 2011, New Orleans, LA.
596. “Novel Small Molecule 910 Nicotinic Receptor Antagonist Prevents and Reverses Chemotherapy-evoked Neuropathic Pain in the Rat”. Elzbieta P. Wala, Peter A. Crooks, J. Michael McIntosh, Mitchell Elliott, Jonathan Walter, and Joseph R. Holtman Jr., American Pain Society Annual Meeting, May, 2011, Austin, TX. 597. “GZ-793A, A Novel Vesicular Monoamine Transporter-2 (VMAT2) Inhibitor that Probes Multiple Sites on VMAT2 as a Potential Treatment for Methamphetamine Abuse”. David B. Horton, Guangrong Zheng, A. Gabriela Deaciuc, Peter A. Crooks, and Linda P. Dwoskin, Bluegrass Chapter of the Society for Neuroscience; March, 2011, Lexington, KY, 598. “Development of a Novel HPLC Method for the Determination of Fluridone in Untreated Rat Plasma Spiked With Fluridone”. By Zaineb F. Albayati, Narsimha P. Reddy, Yerram T. Reddy, and Peter A. Crooks, 50th Anniversary Annual Society of Toxicology Meeting and ToxExpo, Abstract 2925, Poster Board #201, March, 2011, Washington, DC. 599. “In Vivo Pharmacokinetic Comparison of Transdermal S-Nornicotine (S-NN) and Nicotine in Male Yucatan Minipigs”. By Zaineb A. F. Albayati, Nalluri N. Buchi, and Peter A. Crooks, Markey Cancer Center Research Day, University of Kentucky, Abstract 3, March 2011, Lexington, KY. 600. “Design, Synthesis and Anti-proliferative Activity of Novel Resveratrol Analogs”. By Nikhil Reddy Madadi, Thirupathi Reddy Yerremreddy, Narsimha Reddy Penthala, Srinivas Koduru, Damodaran Chendil, and Peter A. Crooks, Markey Cancer Center Research Day, University of Kentucky, Abstract 18, March, 2011, Lexington, KY. 601. “Synthesis and In Vitro Cytotoxicity Evaluation of N-Alkyl-3-hydroxy-3-(2-imino-3-methyl-5- oxoimidazolin-4yl)indolin-2-ones as Novel Anticancer Agents”. By Peter A. Crooks, Narsimha Reddy Penthala, and Thirupathi Reddy Yerramreddy, Markey Cancer Center Research Day, University of Kentucky, Abstract 50, March, 2011, Lexington, KY. 602. “Cassette Dosing and Pharmacokinetic Screening of Lobelane and Lead Lobelane Analogs in Rats”. By Zaineb A. F. Albayati, Linda P. Dwoskin and Peter A. Crooks, 12th National Spectroscopy Congress with International Participation, Antalya, Turkey, May, 2011. 603. “An Epigenetic Therapy for Bladder Cancer”. By Hitesh N. Appaiah, Nikhail Collins, Sunil Badve, Hiroma Tanaka, Peter A. Crooks, William Matthews, and Harikrishna Natshaktri, Cancer Research Day, Melvin and Bren Simons Cancer Center, Indiana University, Abstract No. 20, May, 2011, Indianapolis, IN.
604. “Chemoprevention and Chemotherapy in HER2/NEU Overexpressing Mice with an NF-B Inhibitor”. By Riesa Burnett, Hitesh Appaiah, Poornima Bhat-Nakshatri, Peter A. Crooks, William Matthews, and Harikrishna Nakshatri, Cancer Research Day, Melvin and Bren Simons Cancer Center, Indiana University, Abstract No. 22, May, 2011, Indianapolis, IN. 605. “Preclinical Evaluation of GZ-793A as a Pharmacotherapy for Methamphetamine Abuse”. By Linda P. Dwoskin, Joshua Beckmann, David Horton, Kirin. Siripurapu, K. Alvers, Guangrong Zheng, Peter A. Crooks, and Michael T. Bardo”, 73rd Annual Meeting of the College on Problems of Drug Dependence, Research Abstract no. 191, p 48, June, 2011, Hollywood,
167
FL. 606. “1,4-Diphenethyl-based Lobelane Analogs: Potent and Competitive Inhibition of the Vesicular Monoamine Transporter-2. Justin R. Nickell, John P. Culver, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience; November, 2011, Washington, DC. Society for Neuroscience, Abstract no. xxx, 2011.
607. “Oral Administration of GZ-793A, a VMAT2 Inhibitor, Selectively Attenuates Methamphet - amine Self-administration”. C. E. Wilmouth, E. D. Denehy, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, Annual Meeting of the Society for Neuroscience, November, 2011, Washington, DC. Society for Neuroscience, Abstract no. xxx, 2011.
608. “Acyclic Lobelane Analogs as Novel Inhibitors of Vesicular Monoamine Transporter-2 Function. Zack Cao, Guangrong Zheng, David B. Horton, A. Gabi Deaciuc, Peter A. Crooks, and Linda P. Dwoskin. Annual Meeting of the Society for Neuroscience, November, 2011, Washington, DC. Society for Neuroscience, Abstract no. xxx, 2011.
609. “Design, Synthesis and Antiproliferative Activity of Novel Resveratrol Analogs”. By Nikhil Madadi, Thirupathi Yerramreddy, Narsimha Penthala and Peter A. Crooks, Twenty Fifth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T2041, p85, October, 2011, Washington, DC.
610. “Design, Synthesis and In Vitro Screening of 5-((1-Aroyl-1H-indol-3-yl)methylene-2-thioxodihydropyrimidine-4,6-(1H,5H)-diones as Anticancer Agents”. By Narsimha Penthala, Thirupathi Yerramreddy, and Peter A. Crooks, Twenty Fifth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4068, p118, October, 2011, Washington, DC.
611. “Synthesis and Evaluation of a Series of Acrylonitrile Analogs as Antileukemic Agents”. By Narsimha Penthala, Vijayakumar Sonar, H. Zong, Monica Guzman, and Peter A. Crooks, Twenty Fifth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4069, p118, October, 2011, Washington, DC.
612. “Acyclic Lobelane Analogs as Inhibitors of Dopamine Uptake at the Vesicular Monoamine Transporter (VMAT2)”. By Guangrong Zheng, Zack Cao, Linda P. Dwoskin, and Peter A. Crooks, Twenty Fifth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4079, p118, October, 2011, Washington, DC.
613. “Cassette Dosing and Pharmacokinetic Screening of Lobelane and Lead Lobelane Analogs in Rats”. By Zaineb Albayati, Linda P. Dwoskin, and Peter A. Crooks, Twenty Fifth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W4081, p118, October, 2011, Washington, DC.
614. “Small Molecule Antitubulin Drugs that Evade Multiple Drug Resistance Mechanisms”. By Markos Leggas, Eleftheria Tsakalozou, Tamer Ahmed, Kuei-Ling Kuo, Jamie Horn,
Narsimha Penthala, and Peter A. Crooks, Combined Meeting of the American Association for Cancer Research, the National Cancer Institute, and the European Organization for Research and Treatment of Cancer: Molecular Targets and Cancer Chemotherapeutics , Abstract 11-A-986-AACR, November, 2011, San Francisco, CA.
615. “The Acrylonitrile Analog, VJ-289 Ablates Acute Myelogenous Leukemia Blast, Progenitor and Stem Cell Populations by Inducing Tubulin Acetylation and Caspase Activation”. By Hongliang Zong, Narsimha Reddy Penthala, Siddhartha Sen, Sarah Brennan, Vijayakumar Sonar, Peter A. Crooks, and Monica L. Guzman, Annual Meeting of the American Society of Hematology, December, 2011, San Diego, CA.
168
616. “In Vitro and In Vivo Characterization of a (-)-Cytisine-Naltrexone Codrug. Josh Eldridge, Zaineb A. F. Albayati, Manjula, Sunkara, Andrew J. Morris and Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P16, p55, Monroe, LA. May, 2012.
617. “In Vitro Stability of Morphine-6-O-sulfate Sodium in Rat Plasma and Simulated Gatric and Intestinal Fluids. Jai Shankar K.B. Yadlapalli, Zaineb A. F. Albayati, Howard P. Hendrickson, Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P19, p58, Monroe, LA. May, 2012.
618. “Design, Synthesis and In Vitro Screening of (Z)-2-Aryl-3-(quinolyl)acrylonitriles as Anticancer Agents. Narsimha Reddy Penthala, Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P20, p59, Monroe, LA. May, 2012.
619. “Design and Synthesis of Active Indole Quinuclidones as Novel Cannabinoid Ligands. Narsimha R. Penthala, Lisa K. Brents, Paul L. Prather, and Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P9, p48, Monroe, LA. May, 2012.
620. “A Study of Pharmacokinetic Parameters and Distribution of BT-2 in Plasma and Bone Samples in BT-2-Treated Rats. Zaineb A. F. Albayati, Manjula, Sunkara, Andrew J. Morris and Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P17, p56, Monroe, LA. May, 2012.
621. “Synthesis and Anti-proliferative Activity of Novel Resveratrol Analogs. Nikhil Reddy Madadi and Peter A. Crooks, 39th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P13, p52, Monroe, LA. May, 2012
622. “Synthetic Stilbenoids: Novel Substrates for Human Hepatic, Renal and Intestinal UDP- Glucuronyl Transferases”. Aleksandra K. Greer, Nikhil Reddy Madadi, Sarah Eddy, Stacie M. Bratton, Howard P. Hendrickson, Peter A. Crooks, and Anna Radominska-Pandya, 19th International Symposium on Microsomes and Drug Oxidation and the 12th European Meeting of the International Society for the Study of Xenobiotics, Abstract P22, Noordwijk aan Zee, the Netherlands, June, 2012.
623. “Modeling the Channel Blocking Effect of Frog Toxin (-)-235B' at α4β2 Nicotinic Acetylcholine Receptors (nAChRs)”. Fang Zheng, X. Huang, Linda Dwoskin, Peter A. Crooks, and Chang-Guo Zhan, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3011, p31, October, 2012, Chicago, IL.
624. “Pharmacokinetics and Left Tibia Uptake of BT-2 - a Bone Targeting Agent in Rats”. Zaineb Albayati, Manjula Sunkara, Anthony Morris, and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3012, p31, October, 2012, Chicago, IL.
625. “A (-)-Cytisine-naltrexone Codrug for Treatment of Alcohol Abuse and Nicotine Addiction”. Joshua Elidridge, Zaineb Albayati, Manjula Sunkara, Anthony Morris, and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3040, p32, October, 2012, Chicago, IL.
626. “Design, Synthesis and Stability Studies of Melampomagolide-B Prodrugs”. Zhang Chen, Guangrong Zheng, Zaineb Albayati, and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3045, p32, October, 2012, Chicago, IL.
169
627. “Design, Synthesis and Anti-cancer Activity of Novel Resveratrol Analogs”. Nikhil Madadi and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3059, p33, October, 2012, Chicago, IL.
628. “Design, Synthesis and In Vitro Screening of Quinolinyl Combretastatins as Potent Anticancer Agents”. Narshima Penthala and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3062, p32, October, 2012, Chicago, IL.
629. “Design and Synthesis of Potent and Selective Indolequinuclidins as Novel Cannabinoid Receptor Ligands.” Narshima Penthala, L. Brents, Paul Prather and Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3063, p32, October, 2012, Chicago, IL.
630. “Analytical Method Development and In Vitro Stability of Morphine-6-O-Sulfate Sodium Salt in Simulated Gastric and Intestinal Fluids and Rat Plasma”. Jaishankar Yadlapalli, Zaineb Albayati, Howard Hendrickson, Peter A. Crooks, Twenty Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3073, p32, October, 2012, Chicago, IL.
631. “Lobelane Analogs Interact with Vesicular Monoamine Transporter-2 to Inhibit the Effect of Methamphetamine”. Zach Cao, Guangrong Zheng, Peter A. Crooks, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract No. 142.18/C70, October, 2012, New Orleans, LA.
632. “Targeting the High-conductance Ca++-activated K+ Channel as Vasodilator Therapy for Pulmonary hypertension”. By Sujay V. Kharade, Rachel J. Versluis, Sung W. Rhee, Peter A. Crooks, and Nancy J. Rusch, Experimental Biology Annual Meeting, ASPET Meeting, Abstract No. xxx.x, April, 2013, Boston, MA. 633. “Novel High-throughput DNASE 1 Assay”. D. S. Jang, E.O. Apostolov, Narshima Penthala, Guangrong Zheng, Peter A. Crooks, and Alexei G. Basnakian”, Experimental Biology Annual Meeting, ASPET Meeting, Abstract No. A161-663.16, April, 2013, Boston, MA. The FASEB Journal, 2013; 27, 663.16 634. “The Analgesic Effects of Novel Opioid Analgesic Morphine 6-O-sulfate Sodium in Rat Models of Pain”. By Jai Shankar K. B. Yadlapalli, Maxim Dobretsov, and Peter A. Crooks,
40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P2, p45, University of Arkansas for Medical Sciences, Little Rock, AR, 2013.
635. “Design, Synthesis and In Vitro Stability Studies of Melampomagnolide-B Prodrugs”. By Zheng Chen and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P3, p46, University of Arkansas for Medical Sciences, Little Rock, AR, 2013.
636. “Determination of the Pharmacokinetic Profile of Lead Prodrugs for the Treatment of Leukemia”. By Zaineb A. F. Albayati, Philip J. Breen, and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P4, p47, University of Arkansas for Medical Sciences, Little Rock, AR, 2013.
637. “The Synthesis of Parthenolide Derivatives which are Active as Progesterone-dependent Oocyte Maturation Modulators”. By Venumadhav Jaganati, Narsimha R. Penthala, and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P14, p57, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2013.
170
638. “Design and Synthesis of Novel Indomethacin Analogs as Inhibitors of Human Y-Family DNA Polymerases”. Narsimha R. Penthala, Grace E. Coggins, Leena Maddukuri, Sarah Eddy, Robert L. Eof, and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P16, p59, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2013.
639. “3,4-Methylenedioxy-substituted Stilbenes as Selective and High Affinity Ligands for CB1 and CB2 Cannabinoid Receptors”. By Nikhil R. Madadi, Paul L. Praither, and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P17, p60, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2013.
640. “Synthesis of Sesquiterpene Lactones as Anticancer Modulators which Modify Cell Cycle Progesterone Utilizing a Novel Xenopus Assay”. By Narsimha R. Penthala, Venumadhav Jaganati, Angus M. MacNicol, and Peter A. Crooks, 40th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P28, p71, University of Arkansas for Medical Sciences, Little Rock, AR, May, 2013.
641. “Transporter-targeted Approach to Improve Tocotrienol Bioavailability”. Awantika Singh, Philip J. Breen, Shradda Thakkar, Guangrong Zheng, Mahmoud Kiaei, Peter A. Crooks, Kottayil I. Varughese, Martin Hauer-Jensen, and Cesar M. Compadre, PharmForum’13, Nanomedicine and Translational Experimental Therapeutics: Going Small and Aiming Big!, University of Arkansas for Medical Sciences, Little Rock AR, May, 2013.
642. “Characterization of the Intrinsic Activity for a Novel Class of Indole Quinuclidine Analogs (IQDs) Exhibiting High Nanomolar Affinity for CB1 and CB2 Cannabinoid Receptors”. By L. N. Franks, B. M. Ford, Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks, Paul L. Prather, Annual Meeting of the Society for Neuroscience, Abstract No. xxxxxxxxx, November, 2013, San Diego, CA. 643. “3,4-Methylenedioxy Substituted Stilbenes and Cyanostilbenes as Selective and High Affinity Ligands for CB1 and CB2 Cannabiniod Receptors”. By Nikhil R. Madadi, Paul Prather, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1019, November, 2013, San Antonio, TX. 644. “Design and Synthesis of 5-((1-aroyl-1H-indole-3-yl)methylene)-2-thioxodihydro- pyrimidine-4,6(1H, 5H)-diones as Inhibitors of the Human Y-Family of DNA Polymerases”. By Narsimha R. Penthala, Grace Coggins, Leena Maddukurri, Sarah Eddy, Robert Eoff, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3031, November, 2013, San Antonio, TX. 645. “Design and Synthesis of Novel Indomethacin Analogs as DNA-Endonuclease G Inhibitors”. Narsimha R. Penthala, Nikhil R. Madadi, Jang Song, Alexei Basnakian, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3023, November, 2013, San Antonio, TX. 646. “Synthesis and In Vitro Stability Studies of Melampomagnolide-B Prodrugs”. By Zheng Chen, Venumadhav Janganati, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3017, November, 2013, San Antonio, TX. 647. “Determination of Analgesic Effect of Novel Opiod Analgesic Morphine 6-O-sulfate Sodium”. By Jai S. Yadlapalli, Maxim Dobretsov, Peter A. Crooks, Twenty Seventh
171
Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3040, November, 2013, San Antonio, TX. 648. “Development of Lead Prodrugs for Treatment of Leukemia”. By Zaineb Albayati, Philip Breen, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1004, November, 2013, San Antonio, TX. 649. “Synthesis and Identification of Novel Indole Analogs as Inhibitors of NS3 Helicase”. By Narsimha R. Penthala, Suja Aarattuthodiyil, Kevin Raney, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3030, November, 2013, San Antonio, TX. 650. “The Synthesis of Melampomagnolide-B Derivatives and their Anti-leukemic Activity”. By Venumadhav Janganati, Craig T. Jordan, Angus Macnicol, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3020, November, 2013, San Antonio, TX. 651. “Synthesis of Sesquiterpene Analogs as Anticancer Modulators which Modify Cell Cycle Progression Utilizing a Novel Xenopus Bioassay”. By Narsimha R. Penthala, Venumadhav Janganati, Angus Macnicol, and Peter A. Crooks, Twenty Seventh Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No.T3029, November, 2013, San Antonio, TX.
652. “Identification and Characterization of Novel Small Molecule Inhibitors of the Human Y- family of DNA polymerases”, By Amit Ketkar, Maroof K. Zafar, Leena Maddukuri, Narsimha R. Penthala, Peter A. Crooks, Grace E Coggins, R. Stephen Lloyd, and Robert L. Eoff, Experimental Biology Annual Meeting, ASPET Meeting, Abstract No. 543.1, April, 2013, Boston, MA. The FASEB Journal. 2013, 27, 543.1. 653. “Development of New Oral Medications for the Treatment of Methamphetamine Addiction.” Guangrong Zheng, David B. Horton, Justin R. Nickell, Josh S. Beckmann, Nichole M. Neugebauer, Andrew C. Meyer, Carrie E. Wilmouth, Kristin M. Alvers, Emily D. Denehy, Kiran B. Siripurapu, Agripina Deaciuc, Michael T. Bardo, Linda P. Dwoskin,
and Peter A. Crooks. UAMS College of Medicine Showcase of Medical Discoveries: A Focus on Substance Abuse, Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, December, 2013. 654. “Targeting NPM1 for the Radiosensitization of NSCLC”. By Konjeti R. Sekhar, Mouadh Benamar, Amudhan Venkateswaran, Narsimha R. Penthala, Peter A. Crooks, Stephen R. Hann, Ling Geng, Ramesh Balusu, Tarek Abbas, and Michael L. Freeman, Abstract 14-A- 1910-AACR, Annual Meeting of the American Association of Cancer Research, San Diego, April, 2014. 655. “NPM1 as a Target for Radiosensitization of NSCLC Using a Genetic Model and Inhibitor
YTR107”. By Clayton A. Smith, Konjeti R. Sekhar, Mouadh Benamar, Amudhan Venkateswaran, Soumya Sasi, Narsimha R. Penthala, Peter A. Crooks, Stephen R. Hann, Ling Geng, Tarek Abbas, Michael L. Freeman, 2014 American Society for Radiation Oncology (ASTRO) Meeting, Abstract # 222, September 14-17th, 2014, San Francisco, LA; Int. J. Radiat. Oncol. Biol. Phys., Suppl. pp S103-S104, Sept 1st, 2014.
656. “Morphine 6-O-Sulfate: A Novel Opioid Analgesic Alternative Evaluated in a Rat Model of Diabetic Neuropathy”. By Jai Shanker K. B. Yadlapalli, Navdeep Dogra, Bejamin Ford, Paul L. Prather, Maxim Dobretsov, and Peter A. Crooks, 41st Annual MALTO Medicinal
172
Chemistry-Pharmacognosy Meeting, Abstract No. O-3, p17, University of Tennessee, Memphis, TN, May, 2014.
657. “Synthesis and Biological Evaluation of 4,5-Disubstituted-2H-1,2,3-triazoles as Combretatstatin Analogs”. By Nikhil Reddy Madadi, Narsimha Reddy Penthala, and Peter A. Crooks, 41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. O-8, p22, University of Tennessee, Memphis, TN, May, 2014.
658. “Comparative Toxicity and Stability Studies with Parthenolide and Melampomagnolide B against Walker-256 hepatocellular Cancer Cells In Culture”. By Zheng Chen, Lin Song, Michael J. Borrelli, and Peter A. Crooks, 41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. O-13, p23, University of Tennessee, Memphis, TN, May, 2014.
659. “In Vivo Evaluation of Vancomycin and BT-2-minipeg-2-vancomycin in Rat Plasma and Bone Tissue after i.p. Administration”. By Zaineb A. F. Albayati, Manjula Shanker, Andrew J. Morris, Philip Breen, and Peter A. Crooks, 41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-15, p62, University of Tennessee, Memphis, TN, May, 2014.
660. “Design, Synthesis and Anticancer Activity of 4-Heteroaryl-5-aryl-2H-1,2,3-triazoles”. By Narsimha R. Penthala, Nikhil R. Madadi, Leena Maddukuri, Robert L. Eoff, and Peter A. Crooks, 41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-17, p64, University of Tennessee, Memphis, TN, May, 2014.
661. “Anti-cancer Activity of Carbamate Derivatives of Melampomagnolide B”. By Venumadhav Janganati, Narsimha Reddy Penthala, and Peter A. Crooks, 41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-18, p65, University of Tennessee, Memphis, TN, May, 2014.
662. “Morphine 6-O-Sulfate Sodium: A Novel Opioid Analgesic Alternative Evaluated in a Rat Model of Diabetic Neuropathy”. By Navdeep Dogra, Jaishanker J. K. Yadlipalli, Maxim Dobretsov, and Peter A. Crooks, Abstract No. S-214, Annual Meeting of the International Anesthesia Research Society, May, 2014, Montreal, Canada [Resident Abstract Awards Finalist].
663. “Morphine 6-O-sulfate: A Novel Opioid Analgesic alternative Evaluated in a Rat Model od Diabetic Neuropathy”. By Jai Shanker, K. B. Yadlapalli, Navdeep Dogra, Benjamin Ford, Paul Prather, Maxim Dobretsov, and Peter A. Crooks, Abstract 008, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
664. “The Synthesis of Novel Melampomagnolide B Derivatives and their Antileukemic Activity”. By Venumadhav Janganati, Carig T. Jordan, and Peter A. Crooks, Abstract 012, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
665. “Therapeutic Potential of New Parthenolide Analogs for the Treatment of Glioblastoma Multiforme”. By Curtis Lee Lowery III, Michael Borrelli, and Peter A. Crooks, Abstract 017, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
666. “Cassette Dosing and Pharmacokinetic Screening of Lobelane and Lead Lobelane Analogs in Rats”. By Zaineb A. F. Albayati, Manjula Sunkara, Andrew J. Morris, Philip J. Breen, Linda P. Dwoskin, and Peter A. Crooks, Abstract 018, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
667. “Inhibition of Translational DNA Polymerases in Cancer”. By Leena Maddukuri, Amit Ketkar, Grace E. Coggins, maroof K. Zafar, Narsimha R. Penthala, Peter A. Crooks, and Robert L.
173
Eoff, Abstract 030, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
668. “Design, Synthesis and Anticancer Activity of Heteroaryl-2H-1,2,3-triazoles”. By Narsimha R. Penthala, Nikhil R. Maddadi, Leena Maddukuri, Robert L. Eoff, and Peter A. Crooks, Abstract 034, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
669. “Synthesis and Biological Evaluation of 4,5-disubstituted-2H-1,2,3-trazoles as Combretastatin Analogs”. By Nikhil Reddy Maddadi and Peter A. Crooks, Abstract 037, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
670. “Comparative Toxicity and Stability Studies with Parthenolide and Malampomagnolide-B against Walker-256 Hepatocellular Cancer Cells in Culture”. By Zheng Chen, Michael Borrelli, and Peter A. Crooks, Abstract 049, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
671. “Investigating the Idea of Thermal Protection against Motor Neuron Degeneration in ALS”. By Shilpi Yadav, Azemat Jamshidi Parsian, Robert J. Griffin, Peter A. Crooks, Michael J. Borrelli, Usha Ponnappan, and Mahmoud Kiaei, Abstract 053, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
672. “Combination DMAPT and YTR107 Synergistically Radiosensitize 9L Glioma Cells In Vitro”. By Kevin Howk, Jackob Szwedo, Peter A. Crooks, and Michael Borrelli, Abstract 055, Drug Discovery and Development Colloquium 2014, Little Rock, AR, June, 2014.
673. “Preclinical Evaluation of JPC-141 as a Novel Treatment for methamphetamine Abuse”. By Justin R. Nickell, Emily D. Denehy, John P. Culver, Peter A. Crooks, Michael T. Bardo and Linda P. Dwoskin, Abstract 522, p. 131 76th Annual Meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico, June, 2014. Drug and Alcohol Dependence, 2014, 140, 160e-161e; DOI: http://dx.doi.org/10.1016/j.drugalcdep.2014.02.453.
674. “Weight Losing and Antihyperlipidemic Activities of the Alkaloid Fraction of Hunteria
Umbellata Seed in Experimental Hyperlipidemia”. By Adejuwon Adewale Adeneye,
Olufunmilayo Olaide Adeyemi, Esther Oluwatoyin Agbaje, and Peter A. Crooks,
Proceedings of The Physiological Society, Obesity, London, UK, June, 2014, Proc.
Physiol. Soc., (2014), 32, PC023. 675. “p38 MAPK Is the Key Modulator of Sensitivity to Microtubule Inhibition In AML”. Hongliang Zong, Narsimha R. Penthala, Matthew S. Sung, Vijayakumar Sonar, Paraskevi Giannakakou, Gail J. Roboz, Peter A. Crooks and Monica L. Guzman, American Society of Hemotology 56th Annual Meeting and Exposition, San Francisco, CA, December, 2014. 676. “The In Vitro Effects of Actinomycin D and DMAPT on Panc-1 Pancreatic Cancer Cells”. By Gauri Lamture, Peter A. Crooks and Michael Borrelli, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1240, November, 2014, San Diego, CA. 677. “Morphine 6-Sulfate Sodium: A Novel Opioid Therapeutic Alternative Evaluated in a Rat Model of Diabetic Neuropathy, It’s Pharmacological Characterization and Blood Brain Barrier Permeability”. By Jai Shankar Yadlapalli, Navdeep Dogra, Benjamin Ford, Anqi Wan, Paul Prather, Maxim Dobretsov, and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T2011, November, 2014, San Diego, CA.
678. “The vesicular Momoamine Transporter-2 (VMAT-2: An Important Pharmacological Target for the Discovery of Novel Targets for the Discovery of Novel Therapeutics to Treat Methamphetamine Abuse“. By Shyamsunder Joolakanti, Clint Kilts, and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract T3007, November, 2014, San Diego, CA. 679. “Design and Synthesis of Bioactive Analogues of Melampomagnolide B”. By Shobanbabu Bommagani, Narsimha Penthala, Brett Stevens, Shanshan Pei, Craig Jordan, and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3021, November, 2014, San Diego, CA. 680. “The Design and Synthesis of Succinic Amide Derivatives of Melampomagnolide B and their Anti-leukemic Activity”. By Peter A. Crooks, Venumadhav Janganati, Craig Jordan, and Narsimha Reddy Penthala, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3024, November, 2014, San Diego, CA. 681. “Design, Synthesis and Anticancer Activity of 4,5-Disubstituted-2H-1,2,3-triazoles as Combretatstatin A4 Analogs”. By Nikhil Madadi and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3027, November, 2014, San Diego, CA. 682. “Design, Synthesis and Anticancer Activity of Heteroaryl-2-1,2,3-Triazoles”. By Narsimha Reddy Penthala, Nikhil Madadi, Leena Maddukuri, Robert Eoff, and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3029, November, 2014, San Diego, CA. 683. “Comparative Toxicity and Stability Studies with Parthenolide and Melampomagnolide-B Against Walker-256 Hepatocellular Cells in Culture”. By Zheng Chen, Michael Borrelli, and Peter A. Crooks, Twenty Eighth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. T3031, November, 2014, San Diego, CA. 684. “Inhibition of Alternative NF-B Activity Prevents the Expansion of Genetically Unstable Progenitor cells in BRCA1-deficient Mammary Glands”. By Andrea Sau, Rosanna Lau, Emma Nolan, Peter A. Crooks, Jane E. Visvader, and Chritine M. A. Pratt, Thiryt-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium, Abstract P5-11-04, December, 2014, San Antonio, TX; Cancer Res., 2015, 75, p5-11-04; DOI: 10.1158/1538- 7445.SABCS14-P5-11-04 685. "Analgesic Profile of Morphine-6-O-sulfate Sodium: a Mixed mu/delta Agonist in the Treatment of Diabetic Neuropathic Pain". By Jai Shanker Yadlapalli, Navdeep Dogra, Benjamin Ford, Zaineb Albayati, Narasimha Reddy Penthala, Paul L. Prather, Maxim Dobretsov, and Peter A. Crooks, 34th Annual Scientific Meeting of the American Pain Society, Abstract 434, May, 2015, Palm Springs, CA; J. Pain, 2015, 16(4), page S84; DOI: http://dx.doi.org/10.1016/j.jpain.2015.01.353. 686. “Dimethyaminoparthenolide Exhibits Selective Toxicity and Chemosensitization for Liver Tumor Cells:. By Michael J. Borrelli, Zheng Chen, and Peter A. Crooks, Society for Interventional Radiology Annual Meeting, Abstract 22, Atlanta, GA, 2015; J. Interventional Radiology, 2015, 26(2), Issue 2, Supplement, pp S16-S17; DOI: http://dx.doi.org/10.1016/j.jvir.2014.12.051.
687. “Preclinical Evaluation of JPC-141 as a Novel Treatment for Methamphetamine Abuse”. By Justin R. Nickell, Emily D. Denehey, John P. Culver, Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, Annual Meeting of the Society for Neuroscience, Abstract XXX, January, 2015; Drug and Alcohol Dependence, 2015, 146, e51; DOI: http://dx.doi.org/10.1016/j.drugalcdep.2014.09.509. 688. “A non-peptide α9α10 nAChR antagonist for pain management: an in vivo study”. By Anqi Wan, Jai Shankar K. Yadlapalli, Maxim Dobretsov and Peter A. Crooks, Behavior, Biology, and Chemistry: Translational Research in Addiction, San Antonio, Texas, March, 2015. 689. “Non-Peptide α9α10 nAChRs Antagonist for Pain Management: in vivo Study”. By Anqi Wan, Jai Shankar K Yadlapalli, Maxim Dobretsov and Peter A. Crooks, 2015 UAMS Graduate Student Association Symposium, Little Rock, AR, March, 2015. 690. “The in vitro effects of Dimethylaminoparthenolide and Actinomycin D on Panc-1 Pancreatic Cancer Cells”. By Gauri Lamture, Michael J. Borrelli and Peter A. Crooks, 2015 UAMS Graduate Student Association Symposium, Little Rock, AR, March, 2015. 691. “Toxicity Studies with Parthenolide and DMAPT against Hepatocellular Cancer Cells”. By
Zheng Chen, Michael J. Borrelli and Peter A. Crooks, 2015 UAMS Graduate Student Association Symposium, Little Rock, AR, March, 2015.
692. “Morphine 6-O-sulfate is a Novel Mixed m/d Opioid Therapeutic for Diabetic Neuropathy: Pharmacology, Pharmacokinetics and Blood Brain Barrier Permeability”. By Jai Shankar K.B. Yadlapalli, Zaineb Albayati, Amit Ketkar, Anqi Wan, Benjamin M Ford, Narasimha Penthala Robert Eoff, Paul L Prather, William E Fantegrossi, Maxim Dobretsov, Peter A Crooks, 2015 UAMS Graduate Student Association Symposium, Little Rock, AR, March, 2015. POSTER AWARD; 1st PLACE. 693. “ZZ204G, an 910 nAChr Anatagonist for Pain Management: an In Vivo Study”. By Anqi Wan, Jai Shankar K. Yadlapalli, Maxim Dobretsov and Peter A. Crooks, University of Arkansas for Medical Sciences Student Research Day, Poster 21, Little Rock, AR, April 15th, 2015. 694. “The Inhibitory Effects of Dimethylaminoparthenolide and Actinomycin D on Panc-1 Pancreatic Cancer Cells”. By Gauri Lamture, Michael Borrelli, and Peter A. Crooks, University of Arkansas for Medical Sciences Student Research Day, Poster 6, Little Rock, AR, April 15th, 2015. 695. “Analgesic Profile of Morphine 6-O-Sulfate Sodium: a Mixed Mu/Delta Agonist in the Treatment of Diabetic Neuropathic Pain”. By Jai Shankar Yadlapalli, Maxim Dobretsov and Peter A. Crooks, University of Arkansas for Medical Sciences Student Research Day, Poster 49, Little Rock, AR, April 15th, 2015. 696. “Targeting Acute Myelogenous Leukemia with Novel Combretastatin Analogs and Development of Predictors of Response”. By Hongliang Zong, Narsimha R. Penthala, Vijayakumar N. Sonar, Paraskevi Giannakakou, Gail J. Roboz, Peter A. Crooks, and Monica L. Guzman, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Abstract 1667, Philiadelphia, PA, April, 2015. 697. “The Study of Inhibitory Effects of Dimethylaminoparthenolide and Actinomycin-D on PANC-1 Pancreatic Cancer Cells”. By Gauri Lamture, Michael J. Borrelli, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No.
P-9, p52, University of Mississippi, Oxford, MS, May, 2015.
176
698. “An In Vivo Study of a Novel Analgesic Agent ZZ204G”. By Anqi Wan, Jai Shanker K. Yadlapalli, Maxim Dobretsov, Kim E. Fifer, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-17, p60, University of Mississippi, Oxford, MS, May, 2015.
699. “Pharmacology, Pharmacokinetis and Therapeutic Implications of Morphine-6-O-sulfate Sodium in Diabetic Neuropathy”. By Jai Shanker K. Yadlapalli, Zaineb A. F. Albayati, Benjamin Ford, Anqi Wan, Narsimha Reddy Penthala, Paul L. Prather, William E. Fantegrossi, Maxim Debretsov, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-18, p61, University of Mississippi, Oxford, MS, May, 2015.
700. “Detection and Determination of Parthenolide (PTL) in Plasma and Bone Samples from MSV-PTL-Treated AML-PDX Mice”. By Zaineb A. F. Albayati, Hongliang Zong, Siddhartha Sen, Guodong Zhang, David G. Gorenstein, Xuewu Liu, Mauro Farrari, Peter A. Crooks, Gail J. Roboz, Haifa Shen, and Monica L. Guzman, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-19, p62, University of Mississippi, Oxford, MS, May, 2015.
701. “Synthesis of Malampomagnolide B Esters as Anticancer Agents”. By Shobanbabu Bommagani, Jessica Ponder, Craig T. Jordan, and Peter A. Crooks. 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-22, p65, University of Mississippi, Oxford, MS, May, 2015.
702. “Synthesis of Carbamate and Carbonate Derivatives of Melampomagnolide B and their Evaluation as Potent Anti-Cancer Agents”. By Venumadhav Janganati, Jessica Ponder, Craig T. Jordan, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-25, p68, University of Mississippi, Oxford, MS, May, 2015.
703. “Design and Synthesis of Lobelane Analogues as Treatments for Methamphetamine Abuse”. Shyam R. Joolakantin, Justin R. Nickell, Linda P. Dwoskin, Guangrong Zheng, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-26, p69, University of Mississippi, Oxford, MS, May, 2015.
704. “Synthesis and Anti-cancer Activity of Indole-3-yl-2-oxoacetate Derivatives of the Sesquiterpene Lactone MMB”. By Narsimha Reddy Penthala, Craig T. Jordan, Jessica Ponder, and Peter A. Crooks, 42nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, Abstract No. P-28, p71, University of Mississippi, Oxford, MS, May, 2015.
705. “Oral JPC-077 and JPC-141, Vesicular Monoamine Transporter-2 Inhibitors, Reduce Methamphetamine Self-administration and Methamphetamine-induced Reinstatement in Rats”. By A. George Wilson, Justin P. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, 77th Annual Meeting of the College on Problems of Drug Dependence, Research Abstract no. 678, p 170, June, 2015, Phoenix, AZ. 706. “Use of a Novel Bone-targeting Agent for the Enhanced Delivery of Vancomycin to Bone”. By
Zaineb A. F. Albayati, Manula Sunkara, Suzannah M. Schmidt-Malan, Melissa J. Karau, Andrew J. Morris, James M. Steckelberg, Robin Patel, Philip J. Breen, Mark S. Smeltzer, K. Grant Taylor, Kevyn E. Merten, William M. Pierce, And Peter A. Crooks, Showcase of Medical Discoveries: Infectious Diseases and the Microbiome. Winthrop P. Rockefeller Cancer Institute, UAMS College of Medicine, Little Rock, AR, September 2015.
707. “Design and Synthesis of Carbamate and Carbonate Dimers of Sesquiterpene Lactones
177
and their Evaluation as Potent Anti-cancer Agents”. By Venumadhav Janganati, Jessica Ponder, Craig Jordan, and Peter A. Crooks, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1026, November, 2015, Orlando, FL, October, 2015. 708. “Synthesis and Antioxidant Activity of -Tocoflexol and -Tocotrienol Analogs Designed to Have Improved Pharmacokinetic Profile”. By Xingui Liu, Lijian Shao, Satheesh Gujarathi, Cesar Compadre, Martin Hauer-Jensen, Peter A. Crooks, Daohong Zhou, and Guangrong Zheng, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1028, Orlando, FL, October, 2015.
709. “Synthesis of Bioactive Analogues of Melampomagnolide B as Potent Anticancer Agents”. By Shobanbabu Bommagani, Narsimha Reddy Penthala, Peter A. Crooks, Craig Jordan, and Jessica Ponder, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1032, Orlando, FL, October, 2015.
710. “Synthesis and Evaluation of Anti-tumor Activity of Indole-3-yl-2-oxoacetates of Sesquiterpene Lactone MMB”. By Narsimha Reddy Penthala, Jessica Ponder, Craig Jordan, and Peter A. Crooks, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1033, Orlando, FL, October, 2015.
711. “Pharmacology, Pharmacokinetics and Side Effect Profile of Morphine-6-O-sulfate and Therapeutic Implications in Diabetic Neuropathy”. By Jai Shankar Yadlapalli, Zaineb Albayati, Benjamin Ford, Anqi Wan, Narasimha Reddy Penthala, Paul Prather, William Fantegrossi, Maxim Dobretsov, and Peter A. Crooks, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. M1037, Orlando, FL, October, 2015.
712. “Enhancement in Radiosensitivity through the Concurrent Inhibition of Separate DNA Repair Pathways”. By Kevin Howk, Narsimha Penthala, Peter A. Crooks and Michael Borrelli, Twenty Ninth Annual Meeting and Exposition of the American Association of
713. “LC/MS/MS Quantitation of Parthenolide (PTL) in Plasma and Bone Samples from AML- PDX Mice after IV Injection of MSV-PTL-Nanoparticles”. By Zaineb Albayati, Hongliang Zong, Siddhartha Sen, Guodong Zhang, David Gorenstein, Xuewu Liu Liu, Mauro Ferrari, Peter A. Crooks, Gail Roboz, Haifa Shen and Monica Guzman, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical
714. “Novel 910 Nicotinic Acetylcholine Receptor Antagonist ZZ204G for Pain Management in Normal and Diabetic Rats”. By Anqi Wan, Jai Shankar Yadlapalli, Espero Fifer, Maxim Dobretsov and Peter A. Crooks, Twenty Ninth Annual Meeting and Exposition of the
American Association of Pharmaceutical Scientists, Abstract No. T3018, Orlando, FL, October, 2015.
715. “Apoptopic Cell Death in PANC-1 Pancreatic Cancer Cells with Irreversible Electroporation”. By Gauri Lamture, Jackob Szwedo, Wolf Heberlein, Michael Borrelli,
178
and Peter A. Crooks, Twenty Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Abstract No. W5205, Orlando, FL, October, 2015.
716. “Targeting Translesion DNA Polymerases for Inhibition in Cancer”. By Robert L. Eoff, Maroof K. Zafar, Leena Maddukuri, Sarah Eddy, Amit Ketkar, Narsimha Penthala, and Peter A. Crooks, 67th Southeast/71st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, November, 2015.
717. “LC/MS/MS Quantitation of Parthenoide (PTL) in Plasma and Bone Samples from AML- PDX Mice after I.V. Injection of MSV-PTL-nanoparticles”. By Zaineb A. F. Albayati, Hongliang Zong, Siddhartha Sen, Guodong Zhang, David G. Gorenstein, Xuewu Liu, Mauro Farrari, Peter A. Crooks, Gail J. Roboz, Haifa Shen, and Monica Guzman, Nanotechnology for Health Care, The Winthrop Rockefeller Conference, Petit Jean Mountain, AR, December, 2015.
718. “Oral JPC-077, a Vesicular Monoamine Transporter-2 Inhibitor, Reduces Methamphetamine Self-administration across Repeated Treatments”. By A. George Wilson, Na-Ra Lee, Justin R. Nickell, John P. Culver, Venumadhav Janganati, Guangrong Zheng, Peter A. Crooks, Linda P. Dwoskin, and Michael T. Bardo, 78th Annual Meeting of the College on Problems of Drug Dependence, Research Abstract no. xxx, p xx, June, 2016, Palm Springs, CA. 719. “Enantiomers of (±)-GZ-888 Potently and Selectively Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-stimulated Locomotor Activity”. By Na-Ra Lee, Guangrong Zheng, Seth M. Mayfield, Emily Denehy, Justin R. Nickell, Zheng Cao, Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, 78th Annual Meeting of the College on Problems of Drug Dependence, Research Abstract no. xxx, p xx, June, 2016, Palm Springs, CA. 720. “F10 Fraction of Terminalia arjuna (TA) Bark Aqueous Extract Exerts a Positive Inotropic Effect on Adult Ventricular Myocytes”. By Shi J. Liu, Guangrong Zheng, and Peter A. Crooks, Joint Meeting with 16th Annual International Conference on the Science of Botanicals (ICSB) & 5th Interim American Society of Pharmacognosy (ASP), Abstract PB27, April, 2016, Oxford, MS. Planta Medica, 2016, 82, pB27, DOI: 10.1055/s-0036-1578675. 721. “Effects of Small-molecule Drugs on Protein Aggregation and Paralysis in a C. elegans Strain Expressing Aβ1–42 in Muscle”. By Samuel Kakraba, Narsimha R. Penthala, Peter A. Crooks, Robert J. Shmookler Reis, and Srinivas Ayyadevara, Mid-South Computational Biology and Bioinformatics (MCBIOS) XIII Annual Conference, Little Rock, AR, March, 2016. 722. “Synthesis and Evaluation of Anti-tumor Activity of Benzyl and Phenethyl Carbamates of Melampomagnolide”. By Narsimha R. Penthala, Craig T. Jordan, Jessica Ponder, and Peter A. Crooks, 43nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature,
Abstract No. P-23 PD, p73, University of Houston, Houston, TX, May, 2016.
723. “Determination of the Pharamcokinetic Profile of Lead Compounds for Treatment of Leukemia”. By Zaineb A. F. Albayati, Venumadhav Janganati, and Peter A. Crooks, 43nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature, Abstract No. P-24 PD, p74, University of Houston, Houston, TX, May, 2016.
179
724. “Design and Synthesis of Amide Derivatives of Melampomagnolamine and their Anticancer Activities”. By Venumadhav Janganati, Jessica Ponder, Ctraig T. Jordan, and Peter A. Crooks, 43nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature, Abstract No. P-28 PD, p78, University of Houston, Houston, TX, May, 2016.
725. “Synthesis of Heterocyclic Esters of Melampomagnolide B as Anticancer Agents”. By Shobanbabu Bommagani, Jessica Ponder, Craig T. Jordan, Michael J. Borrelli, and Peter A. Crooks, 43nd Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature, Abstract No. P-29 PD, p79, University of Houston, Houston, TX, May, 2016.
726. "Identifying Y-family DNA Polymerase Inhibitors to Improve Anti-Cancer Drugs." By Maddukuri, Leena, Maroof Khan Zafar, Narsimha Penthala, Peter A. Crooks, and Robert L. Eoff. Annual Experimental Biology Meeting, San Diego, CA, April, 2016; The FASEB Journal 30, no. 1 Supplement (2016): 1052-6.
727. "Investigation of Structure-Activity Relationships for Small-Molecule Inhibitors of Human DNA Polymerase Eta." Zafar, Maroof K., Leena Maddukuri, Sarah Eddy, Amit Ketkar, Narsima R. Penthala, Peter A. Crooks, and Robert L. Eoff. Annual Experimental Biology Meeting, San Diego, CA, April, 2016; The FASEB Journal 30, no. 1 Supplement (2016): 1052-3.
728. “Transarterial Embolization with Parthenolide in a Rat Liver Tumor Model Induces Tumor Regression Without any Detectable Liver or Systemic Toxicity”. By Zheng Chen, Peter A. Crooks, and Michael J. Borrelli. Showcase of Medical Discoveries: A Focus on Natural Products. Winthrop P. Rockefeller Cancer Institute, UAMS College of Medicine, Little Rock, AR, June, 2016.
729. “Comparative Pharmacokinetics of S-(-)-Nornicotine and S-(-)-Nicotine after Transdermal Application”. By Zaineb A. F. Albayati, Buchi Nalluri, Philip J. Breen, and Peter A. Crooks, Showcase of Medical Discoveries: A Focus on Natural Products. Winthrop P. Rockefeller Cancer Institute, UAMS College of Medicine, Little Rock, AR, June, 2016.
730. “Rapid Pharmacokinetic Screening ofLobelane and Lead Lobelane Analogs in Rats via Cassette Dosing”. By Zaineb A. F. Albayati, Manjula Sunkara, Andrew J. Morris, Linda P. Dwoskin, and Peter A. Crooks. Showcase of Medical Discoveries: A Focus on Natural Products. Winthrop P. Rockefeller Cancer Institute, UAMS College of Medicine, Little Rock, AR, June, 2016.
731. “Development of Oral Medications for the Treatment of Methamphetamine Addiction”. By Venumadhav Janganati, Guangrong Zheng, John Culver, Justin R. Nickell, Josh S. Beckmann, George Wilson, Na-Ra Lee, Nichole M. Neugebauer, Andrew C. Meyer, Carrie E. Wilmouth, Kristin M. Alvers, Emily D. Denehy, Kiran B. Siripurapu, Agripina Deaciuc, Michael T. Bardo, Linda P. Dwoskin, and Peter A. Crooks, UAMS/UTHSC Research in Substance Abuse Mini-Symposium, Little Rock, AR, June, 2016. 732. “Cassette Dosing and Pharmacokinetic Screening of Lobelane and Lead Lobelane Analogs in Rats”. By Zaineb A. F. Albayati, Manjula Sunkara, Andrew J. Morris, Linda P. Dwoskin, and Peter A. Crooks, UAMS/UTHSC Research in Substance Abuse Mini-Symposium, Little Rock, AR, June, 2016. 733. “Potential Anticancer Activity of a Novel Sesquiterpene Dimer, JVM-355, in PANC-1 Pancreatic Cancer Cells”. By Gauri Lamture, Venumadhav Janganati, Michael Borrelli, and Peter A. Crooks, Drug Discovery and Development Colloquium 2016, Birmingham, AL, June, 2016.
180
734. “Acute and Chronic Studies of ZZ204G for Pain Management in Normal and Diabetic Rats”. By Anqi Wan, Jai SHanker K. Yadlapalli, E. Kim Fifer, Maxim Dobretsov, and Peter A. Crooks, Drug Discovery and Development Colloquium 2016, Birmingham, AL, June, 2016. 735. “Targeting ENOX1 Impairs Repair of DNA DSBs in Endothelial Cells and Increases Survival of Tumor-Bearing Mice”. By Clayton A. Smith, Konjeti Sekhar, Peter A. Crooks, G. L. Traver, Michael L. Freeman, 58th Annual Meeting of the American Society for Radiation Oncology, Abstract 176, September, 2016, Boston, MA; Int J Radiat Oncol Biol Phys, 2016, 96(2S), S78; DOI: 10.1016/j.ijrobp.2016.06.198; PMID: 27676016. 736. “Targeting NPM1 for the Radiosensitization of Non-Small Cell Lung Cancer”. By M. Ofori, Konjeti Sekhar, Peter A. Crooks, Narsimha R. Reddy, Michael L. Freeman, 58th Annual Meeting of the American Society for Radiation Oncology, Abstract 36, September, 2016, Boston, MA; Int J Radiat Oncol Biol Phys, 2016, 96(2S), S17. DOI: 10.1016/j.ijrobp.2016.06.055; PMID: 27675696. 737. “Two Clinical Candidates for Treatment of Acute Myelogenous Leukemia”. By Zaineb A. F. Albayati, Venumadhav Janganati, and Peter A. Crooks, Arkansas Stem Cell Coalition Conference, October, 2016, Little Rock, AR.
"The Synthesis of Some 5-Aza- and 5, 7-Diazaindoles with Potential Oncolytic Activity". Peter A.
Crooks, M.Sc. Thesis, University of Manchester, UK, 1967.
"Alkaloids of Tabernaemontana Pachysiphon var. Cumminsii, and Cinchona Ledgeriana". Peter
A. Crooks, Ph.D. Thesis, University of Manchester, UK, 1970.
“The Medicinal Chemistry of Nicotine, Lobeline and Structurally Related Analogues:
Development of Treatments for Drug Abuse”. Peter A. Crooks, D.Sc. Thesis, University of
Manchester, UK, 2011.
Book Reviews
"Introductory Medicinal Chemistry", J. B. Taylor, P. D. Kennewell, Halstead Press, New York,
1981. Reviewed by Peter A. Crooks, J. Medicin. Chem., 1983, 26, 458.
"Surfactant Systems - Their Chemistry, Pharmacy and Biology", David Attwood and Andrew T.
Florence, Chapman and Hall, New York, 1983. Reviewed by Peter A. Crooks,
J. Medicin. Chem., 1984, 27, 1754.
"Terpenoids and Steroids, Vol.12 Specialist Periodical Reports, Royal Society of Chemistry", J.
R. Hanson, Adlard and Sons, Ltd., 1983. Reviewed by Peter A. Crooks, J. Pharm. Sci., 1985,
74, 801-802.
"Biosynthesis, Vol. 7 Specialist Periodical Reports, Royal Society of Chemistry", R. B. Herbert
and T. J. Simpson, Adlard and Sons, Ltd., 1983. Reviewed by Peter A. Crooks, J. Pharm. Sci.,
1985, 74, 702. "Environmental Chemistry, Vol. 3 Specialist Periodical Reports, Royal Society of Chemistry", H.
J. M. Bowen. Whitstable Litho Ltd., 1984. Reviewed by Peter A. Crooks, J. Pharm. Sci., 1985,
74, 906-907.
"Biological Methylation and Drug Design," Edit. Ronald T. Borchardt, C.R. Creveling, and P.M.
Ueland, Humana Press, Clifton, New Jersey, U.S.A., 1986. Reviewed by Peter A. Crooks, J.
Pharm. Sci., 1988, 77, 94.
182
Patent Activity 1. "Co-Drugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks,
Tadeusz Cynkowski, Grazyna Cynkowska, Robert M. Riggs, and Hong Guo, Canadian Patent No. CA 2,182,228AA, February 17, 1994 (Licensed).
2. "Co-Drugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Robert M. Riggs, and Hong Guo, Australian Patent No. AU 6,254,594A, August 15th, 1995 (Licensed).
3. "Co-Drugs as a Method of Controlled Drug Delivery". Paul Ashton, Peter A. Crooks,
Tadeusz Cynkowski, Grazyna Cynkowska, Robert M. Riggs and Hong Guo, International Patent, WO 95/20,567A1, August 3, 1995 (Licensed).
4. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks,
Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Australian Patent No. AU 6,254,4594A1, August 15, 1995.
5. "Co-Drugs as a Method of Controlled Drug Delivery". Paul Ashton, Peter A. Crooks,
Tadeusz Cynkowski, Grazyna Cynkowska, Robert M. Riggs, and Hong Guo, European Patent, No. 94-909643.2-2103, February 2, 1996 (Licensed).
"Preparation of 2-azabicyclo[2.2.1]hept-5-ene and 2-azabicyclo[2.2.2]oct-5-ene; Compounds of Use in Pharmaceutical Compositions for the Prevention and Treatment of Central Nervous System Disorders". By Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello, Peter A. Crooks, Balwinder S. Bhatti, Niranjan M. Deo, and Alain Ravard, International Patent, WO 96/36637A1, November 21, 1996 (Licensed).
6. "Pharmaceutical Compositions for Prevention of Central Nervous System Disorders". By
Peter A. Crooks, William S. Caldwell, Gary M. Dull, and Balwinder S. Bhatti, Australian Patent No. AU 4,645,596A1, July 24, 1996.
7. "Codrugs as a Method of Controlled Delivery" By Paul Ashton, Peter A. Crooks, Robert
M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Guo Hong, European Patent EP 740,650A1, November 6, 1996.
8. "Polynucleotide Analogs Based Upon Sulfonate and Sulfonamide Internucleoside
Linkages". John A. Secrist, John A. Montgomery and Peter A. Crooks, U.S. Patent No. 5, 561,225, October 1, 1996 [93 citations].
"Use of L-Canavanine as a Chemotherapeutic Agent for the Treatment of Pancreatic Cancer." By Peter A. Crooks and Gerald A. Rosenthal, U.S. Patent No. 5,552,440, September 3, 1996 [20 citations].
9. "Pharmaceutical Compositions for the Prevention and Treatment of Central Nervous
System Diseases". By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, International Patent, WO 96/20,929A1, July 11, 1996 (Licensed).
10. "Pharmaceutical Compositions for the Prevention and Treatment of Central Nervous
System Diseases". By Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello, Peter A. Crooks, Balwinder S. Bhatti, Naranjan M. Deo, Alain Ravard, International Patent, WO 96/36,637A1, November 21, 1996 (Licensed).
183
11. "Pharmaceutical Compositions for the Prevention and Treatment of Central Nervous System Disorders". By Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello, Peter A. Crooks, Balwinder S. Bhatti, Naranjan M. Deo, Alain Ravard, Australian Patent No. AU 5383196, November 29, 1996 (Licensed).
12. "Permeable, Non-Irritating Prodrugs of Non-Steroidal and Steroidal Agents". By Paul
Ashton, Thomas J. Smith, Peter G. Glavinos, John D. Conklin, Jr., Peter Anthony Crooks, Robert Mack Riggs, Tadeusz Cynkowski and Grazyna Cynkowska, U.S. Patent No. 5,681,964, October 28, 1997 (Licensed) [20 citations].
13. "Nicotinic Receptor Antagonists in the Treatment of Neuropharmacological Disorders".
By Peter A. Crooks, Linda P. Dwoskin and Alain Ravard, U.S. Patent No. 5,691,365, November 25, 1997 (Licensed) [19 citations].
14. "Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System
Disorders". By Peter A. Crooks, William S. Caldwell, Gary M. Dull, and Balwinder S. Bhatti, European Patent EP 801,646A1, October 22, 1997.
15. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks,
Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, and Hong Guo, Japanese Patent No. JP 9,509,151TZ, September 16, 1997 (Licensed).
16. "Compounds Which are Useful for Prevention and Treatment of Central Nervous System
Disorders". By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Niranjan M. Deo, Alain Ravard, U.S. Patent No. 5,616,707, April 1, 1997 (Licensed) [26 citations].
17. "Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System
Disorders." By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, European Patent No. EP0801646A1, October 22, 1997 (Licensed).
18. "Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System
Disorders." By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Niranjan M. Deo and Alain Ravard, U.S. Patent No. 5,726,316, March 10, 1998 (Licensed) [15 citations].
19. "3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders". By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M. Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, Canadian Patent No. CA 2,294,990, April 22, 1998.
20. "Lobeline Compounds as a Treatment for Psycho Stimulant Abuse and Withdrawal, and
for Eating Disorders". By Peter A. Crooks and Linda P. Dwoskin, U.S. Patent No. 5,830,904, November 3, 1998. (Licensed) [14 citations].
21. "Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System
Disorders." By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, European Patent No. EP0801646A4, March 25th, 1998 (Licensed).
22. "Nornicotine Enantiomers for Use as a Treatment for Dopamine-Related Conditions and
Disease States". By Peter A. Crooks, Linda P. Dwoskin and Michael T. Bardo, U.S. Patent No. 5,776,957, July 8, 1998.
184
23. "Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System Disorders". By Peter A. Crooks, William S. Caldwell, Gary M. Dull, and Balwinder S. Bhatti, European Patent EP 801,646A4, March 25, 1998.
24. "Compounds which are Useful for Prevention and Treatment of Central Nervous System
Disorders". By Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Niranjan M. Deo, Alain Ravard, Japanese Patent No. JP 11501294T, February 2, 1999 (Licensed).
25. "3-Pyridyl-1-azabicycloalkane Derivatives for Prevention and Treatment of CNS
Disorders." By William S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, Balwinder S. Bhatti, Niranjan M. Deo, and Alain Ravard, International Patent, WO 99/00,385A1, January 7th, 1999 (licensed).
26. "Azatricyclic Compounds." By Peter A. Crooks and Niranjan M. Deo, International Patent,
WO 99/51,601A1, October 14th, 1999 (licensed).
27. "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists".
By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, Canadian Patent No. CA 2,334,923, June 3, 1999.
28. "Azatricyclo[3.3.1.1]Decane Derivatives and Pharmaceutical Compositions Containing
Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, International Patent, WO 99/51,602A1, October 14th, 1999 (licensed).
29. "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists". By
William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, International Patent, WO 99/65,876A1, December 23rd, 1999.
30. "Pharmaceutical Compositions and Methods for Effecting Dopamine Release". By
William S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, Balwinder S. Bhatti, Niranjan M. Deo, and Alain Ravard, Canadian Patent Application, CA 2,294,990, December 20, 1999.
31. "Canavanine Analogs and Their Use as Chemotherapeutic Agents". By Peter A. Crooks
and Gerald A. Rosenthal, U.S. Patent No. 5,859,295, January 12, 1999. 32. "Pharmaceutical Compositions and Methods for Use". By Peter A. Crooks, Haeil Park,
Gary M. Dull, Patrick M. Lippiello, Merouane Bencherif, Balwinder S. Bhatti, and William S. Caldwell, Canadian Patent No. CA 2,317,567, October 10th, 1999.
33. "Pyridyl-Bridgehead Derivatives and their Analogs, Pharmaceutical Compositions and
their Use as Inhibitors of Nicotinic Cholinergic Receptors". By Gary M. Dull, Jeffrey D. Schmitt, and Peter A. Crooks, Canadian Patent No. CA 2,317,025, August 31, 1999.
34. "Azatricyclic Compounds". By Niranjan M. Deo, and Peter A. Crooks, Canadian Patent No. CA 2,317,570, February 26, 1999.
35. "Azatricyclo[3.3.1.1]Decane Derivatives and Pharmaceutical Compositions Containing Them." By Haeil Park, Gary M. Dull, William S. Caldwell, Balwinder S. Bhatti,
185
Patrick M. Lippiello, Peter A. Crooks, and Merouane Bencherif, Canadian Patent No. CA 2,317,567, March 3, 1999.
36. "Pharmaceutical Compositions and Methods for Use". By Peter A. Crooks and Niranjan
M. Deo, U.S. Patent No. 5,986,100, November 16, 1999 (Licensed).
37. "Azatricyclo[3.3.1.1]decane Derivatives and Pharmaceutical Compositions
Containing Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, German Patent No. DE 69,907,894D, October 14th, 1999.
38. "Azatricyclo[3.3.1.1]decane Derivatives and Pharmaceutical Compositions
Containing Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Danish Patent No. DK 1,068,208T, October 14th, 1999.
39. "3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders". By William S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, Balwinder S. Bhatti, Niranjan M. Deo, and Alain Ravard, Australian Patent No. AU 7,149,798A1, January 19, 1999.
40. "Azatricyclic Compounds". By Peter A. Crooks and Niranjan M. Deo, Australian Patent
No. AU 2,794,899A1, October 25th, 1999. 41. "Means to Achieve Sustained Release of Synergistic Drugs By Conjugation". Paul
Ashton, Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Robert M. Riggs and Hong Guo, U.S. Patent No. 6,051,576, April 18th, 2000 (Licensed) [146 citations].
42. "Use of Lobeline Compounds in the Treatment for Central Nervous System Diseases
and Pathologies." By Peter A. Crooks and Linda P. Dwoskin, U.S. Patent No. 6,087,376, July 11, 2000.
43. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks,
Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Guo Hong, European Patent EP 740,650A4, April 19, 2000.
44. "3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders". William S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, Balwinder S. Bhatti, Niranjan M. Deo, and Alain Ravard, European Patent EP 994,875A1, April 26, 2000.
45. "Certain 1-Aza-tricyclo[3.3.1-13,7]decane Compounds". By Peter A. Crooks, Haeil Park,
Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, U.S. Patent, 6,057,446, May 2, 2000.
46. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A. Crooks,
Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Australian Patent No. AU 705,226B2, May 20, 2000.
47. "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists".
By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B.
186
Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, Australian Patent No. AU 4,230,799, January 5, 2000.
48. "Pyridyl-Bridgehead Derivatives and their Analogs, Pharmaceutical Compositions and their Use as Inhibitors of Nicotinic Cholinergic Receptors". By Jeffrey D. Schmitt, Peter A. Crooks, and Gary M. Dull, European Patent No. EP 1,053,236, June 15th, 2000.
49. "Agmatine and Agmatine Analogs In the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, US Provisional Patent No. 60/211,532, June 15th, 2000.
50. "Use of Bacteriophage Peptides to Manufacture Markers for Rapid Assays, and for
Specific Cell Delivery of Antibiotics." By Clair L. Hicks and Peter A. Crooks, Submitted to the Office of Intellectual Properties, University of Kentucky (UKRF Case No. 999), September, 20th, 2000, filed as a US provisional patent.
51. "Pyridyl-Bridgehead Derivatives and their Analogs, Pharmaceutical Compositions and
their Use as Inhibitors of Nicotinic Cholinergic Receptors". By Jeffrey D. Schmitt, Peter A. Crooks, and Gary M. Dull, Australian Patent No. AU 5,699,399, June 26th, 2000.
52. "Permeable Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents with Oxaalkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, International Patent No. WO 067,801A2, November 16th, 2000 (Licensed).
53. "Thermal Vaporizing Device for Drug Delivery". By Peter A. Crooks, S. George Kottayil, and David Riggs, Provisional US Patent Application No. 60/243,404, October 27, 2000.
54. "Compounds Useful for the Treatment of CNS Pathologies." By Peter A. Crooks, Linda P.
Dwoskin, Rui Xu, and Vladimir Grinevich, (Docket No. 50229-193), U.S. Patent Application No. 60/228,766, August 30th, 2000.
55. "Pyridyl-Bridgehead Derivatives and their Analogues, Pharmaceutical Compositions and
Their Use as Inhibitors of Nicotinic Cholinergic Receptors." By Jeffrey D. Schmitt, Peter A. Crooks, and Gary M. Dull, International Patent No. WO 034,276A1, June 15, 2000.
56. "Azatricyclo(3.3.1.1)decane Derivatives and Pharmaceutical Compositions Containing
Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Australian Patent No. AU 2,892,999A1, May 2, 2000.
59. "Derivados de Azatriciclo(3.3.1.1)decano e Composicoes Farmaceuticas Contendo-
Os." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Brazilian Patent No. BR 9,907,172A, October 10, 2000.
60. "Derivados de Cabeca de Ponte de Piridila e Seus Analogos, Composicoes
Farmaceuticas e Seus Empregos Como Inibidores de Receptores Colinergicos Nicotinicos." By Jeffrey D. Schmitt, Peter A. Crooks, and Gary M. Dull, Brazilian Patent No. BR 9,907,169, October 17, 2000.
187
61. "Pharmaceutical Compositions and Methods for Use". By Niranjan M. Deo and Peter A. Crooks, Canadian Patent No. CA 2,317,570, June 29th, 2000. 62. "Compostos Azatriciclicos". By Peter A. Crooks and Niranjan M. Deo, Brazilian Patent No. BR 9907191A, December 26th, 2000. 63. "Permeable Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents with Oxaalkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, Australian Patent No. AU 4703700, November 16th, 2000 (Licensed). 64. “3-Pyridyl-1-aza-bicyclo-alkanderative zur Behandlung von ZNS-Erkrankungen”. By William
S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, Balwinder S. Bhatti, Niranjan M. Deo, Alain Ravard, European Patent No. EP 0994875, May 31st, 2000.
65. "Agmatine and Agmatine Analogs In the Treatment of Epilepsy, Seizure, and
Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, Australian Patent No. AU 6,842201, June 15th, 2000.
66. "Use of the Naturally Occurring Quinones, Thymoquinone and Dithymoquinone, as
Antineoplastic and Cytotoxic Agents". Peter A. Crooks, David R. Worthen, and Omar Ghosheh. U.S. Patent No. 6,218,434, April 17, 2001.
67. "Boron-Containing Nicotine Analogs for Use in the Treatment of CNS Pathologies." By
Peter A. Crooks, Linda P. Dwoskin, Rui Xu, Vladimir Grinevich, and Roger L. Papke, (Docket No. 50229-249), U.S. Patent Application No. 60/261,822, May, 2001.
68. "Azatricyclic Compounds". By Peter A. Crooks and Niranjan M. Deo, European Patent
No. EP 1,066,287A1, January 10, 2001. 69. "Azatricyclo(3.3.1.1)decane Derivatives and Pharmaceutical Compositions Containing
Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, European Patent No. EP 1,068,208A1, January 17, 2001.
70. "Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, International Patent No. WO 01/08678A1, February 8, 2001.
71. "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists".
By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, European Patent No. EP 1,086,082A1, March 28, 2001.
72. "Pharmaceutical Compositions and Methods for Use". By Peter A. Crooks and
Niranjan M. Deo, U.S. Patent No. 6,211,372, April 3, 2001. 73. "Aminas Olefinicas Substituidas com Arila e o seu uso como Agonistas de Receptores
Colinergicos." By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishalikumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks,
188
Patrick M. Lippiello, and Merouane Bencherif, Brazilian Patent No. BR 9,911,325, April 3, 2001.
74. "Agmatine and Agmatine Analogs In the Treatment of Epilepsy, Seizure, and
Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, US Patent Application No. US 9/881,215, June 15th, 2001.
75. "Permeable Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents with
Oxaalkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, International Patent No. WO 0067801 A3, August 2nd, 2001 (Licensed).
76. "Prodrugs of Chemotherapeutic Agents with Oxaalkanoic Acids." By Peter A. Crooks,
Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, European Patent No. EP 928,867, December 12, 2001.
77. "Agmatine and Agmatine Analogs In the Treatment of Epilepsy, Seizure, and
Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, International Patent No. WO 01/95897, December 20, 2001.
78. "Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use In the Treatment
of CNS Pathologies." By Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Joshua Ayers, Provisional U.S. Patent No. US 60/342,120, filed December 26th, 2001.
79. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents
with Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Paul Ashton, and Hong Guo, Canadian Patent No. CA 2,368,831, November 5th, 2001.
80. “Aza-Aminotetralin Compounds for Use in the Treatment of CNS Pathologies.” By
Peter A. Crooks, Linda P. Dwoskin, and Rui Xu, submitted to the Office of Intellectual Properties, University of Kentucky, (UK Case No. 1069, Docket No. 50229-281). July, 8, 2001,
81. “Analgesics and Methods of Use”. By Richard Smith-Carliss, Frank S. Caruso, Peter
A. Crooks, Kenneth J. Keller, and Yingxian Xiao, U.S. Patent Application No. 60/315,530, August 29th, 2001.
82. “bis-Pyridino Containing Compounds for Use in the Treatment of CNS Pathologies.”
By Peter A. Crooks, Linda P. Dwoskin, and Joshua Ayers, submitted to the Office of Intellectual Properties, University of Kentucky, (UK Case No. 1101). November 12th, 2001.
83. “Thermal Vaporizing Device for Drug Delivery”. By Peter A. Crooks, George S. Kottayil, Ram Murty, and David Riggs, Australian Patent Application No. AU 2002246500, October 1st, 2001. 84. “Azatricyclo[3.3.1.1]decanderivate und diese Enthaltende Pharmazeutische Zubereitungen“. By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, Gary M. Dull, European Patent No. EP 1068208, February 2nd, 2001. 85. "Bridged Nicotine Compounds for Use In the Treatment of CNS Pathologies". By
Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Vladimir Grinevich, International Patent No. WO 02/17922, March 7, 2002.
189
86. "Agmatine and Agmatine Derivatives for Use in the Treatment of Epilepsy, Seizure and Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, U.S. Patent Application No. 09/881,215, filed June 15, 2000, Publication No. US 2002/0065323 A1, Pub. Date May 30, 2002.
87. "Compounds for Use in the Treatment of Epilepsy, Seizure and Electroconvulsive
Disorders.” By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, Provisional U.S. Patent Application No. US 2002/0065323 A1, May 30th, 2002.
88. "Agmatine and Agmatine Analogs In the Treatment of Epilepsy, Seizure, and
Electroconvulsive Disorders". By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, USPatent No. WO 01/95897, December 20, 2001.
89. "Cis-2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine Receptor
Mediated Neurotransmitter Release and Neurotransmitter Uptake and Storage". By Peter A. Crooks, Guangrong Zheng, Dennis K. Miller, Seth Norrholm, Vladimir P. Grinevich, and Linda P. Dwoskin, U.S. Patent Application No. US 10/163,633, June 7th, 2002.
90. “Morphine-6-O-sulfate Analogues and Their Use for the Treatment of Pain”. By Peter
A. Crooks, Abdulghani A. Houdi, Santosh G. Kottayil, and D. Allan Butterfield, U.S. Patent No. 6,403,602, June 11th, 2002.
91. “Pharmaceutical Compositions and Methods for Use”. By Peter A. Crooks, Haeil Park,
Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, U.S. Patent No. 6,417, 359, July 9th, 2002.
92. “Boron-Containing Nicotine Analogs for Use in the Treatment of CNS Pathologies”. By
Peter A. Crooks, Linda P. Dwoskin, Vladimir P. Grinevich, and Rui Xu, International Patent No. WO 02/057275, July 25th, 2002.
93. "3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders". By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M. Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, Japanese Patent No. JP 2002511090, April 9th, 2002.
94. “Thermal Vaporizing Device for Drug Delivery”. By S. George Kottayil, Peter A. Crooks,
David Riggs, and Ram Murty, International Patent No. WO 02/056932, July 25th, 2002. 95. “Pharmaceutical Compositions and Methods for Use”. By Jeffrey D. Schmitt, Peter A.
Crooks, and Gary M. Dull, U.S. Patent No. 6,432,975, August 13th, 2002. 96. “Analgesics and Methods of Use”. By Richard Smith-Carliss, Frank S. Caruso, Peter
A. Crooks, Kenneth J. Keller, and Yingxian Xiao, International Patent Application, PCT Serial No. PCT/US/27936, filed August 29th, 2002.
97. “Pharmaceutical Compositions and Methods for Use”. By Jeffrey D. Schmitt, Peter
Crooks, and Gary M. Dull, Japanese Patent No. JP 2002531564T T, September 24th, 2002.
98. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents
with Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, European Patent No. EP 1,233,789A August 28th, 2002.
190
99. “Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, U.S. Patent No. 6,455,543, September 24th, 2002.
100. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, and Peter A. Crooks, U.S. Patent Application No. 09/973,411, filed October 9, 2001, Publication No. US 2002/0052497 A1, Publication Date, May 2nd, 2002.
101. "Thermal Vaporizing Device for Drug Delivery". By Peter A. Crooks, S. George Kottayil,
and David Riggs, U.S. Patent Application No. 09/984,294, filed October 29, 2001, Publication No. US 2002/0117175 A1, Publication Date August 29th, 2002.
102. “Bridged Nicotine Compounds for Use in the Treatment of CNS Pathologies”. By
Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Vladimir P. Grinevich, U.S. Patent Application No. 09/941,926, filed August 30, 2001, Publication no. US 2002/0099069 A1, Publication Date July 25th, 2002.
103. “Lobeline and Other Gag Reflex-Inducing Bitter Alkaloids in Combination with
Opioids in Extended Release Formulations to Deter Targeted Chewing by Recreational or Addicted Drug Abusers”. By Richard D. Smith-Carliss and Peter A. Crooks, to be filed as a U.S. Provisional Patent, October, 2002.
104. “Bridged Nicotine Compounds for Use in the Treatment of CNS Pathologies”. By Peter A.
Crooks, Linda P. Dwoskin, Rui Xu, and Vladimir P. Grinevich, Australian Patent No. AU 8,687501, July 25th, 2002.
105. "Prodrugs of Chemotherapeutic Agents with Oxaalkanoic Acids." By Peter A. Crooks,
Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, European Patent No. EP 1,233,789, August 28th, 2002.
106. “Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, Australian Patent No. AU 6,386700, September 24th, 2002.
107 “Analgesic Uses of Norketamine and Ketamine/Norketamine”. By Peter A. Crooks, and
Miguel Rivera, U.S. Provisional Application No. 60/426,793, November 18th, 2002.
108. "Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use In the treatment of CNS Pathologies." By Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Joshua Ayers, U.S. Patent Application No. 10/328,192, filed December 26th, 2002.
109. “Pharmaceutical Compositions and Methods for Use.” By Peter A. Crooks and Naranjan M. Deo, Japanese Patent No. JP 2002510689T, April 9th, 2002. 110. "Azatricyclo[3.3.1.1]decane Derivatives and Pharmaceutical Compositions Containing Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Japanese Patent No. JP 2002510690T, April 9th, 2002. 111. “Analgetic Pyrroline Derivatives”. By Frank S. Caruso, Peter A. Crooks, Kenneth J.
191
Kellar, Richard Smith-Carliss, and Yingxian Xiao, Australian Patent Application No. AU 2002326806, August 29th, 2002. 112. “Boron-containing Nicotine Analogs for use in the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Vladimir P. Grinevich, and Rui Xu, Australian Patent Application No. AU 2002241900, January 17th, 2002. 113. “Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, U.S. Patent Application, No. 10/231,156, August 30th, 2002.
114 "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists". By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, Japanese Patent No. JP 2002518373T T, June 25th, 2002. 115. “Analgetic Pyrroline Derivatives”. By Richard Smith-Carliss, Frank S. Caruso, Peter A. Crooks, Kenneth J. Keller, and Yingxian Xiao, European Patent Application No. EP 02,761,550.9-2123, filed August 29th, 2002. 116. “Bridged Nicotine Compounds for Use in the Treatment of CNS Pathologies.” By
Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Vladimir P. Grinevich, U.S. Patent No. 6,503,922, January 7th, 2003.
117. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents
with Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, Japanese Patent No. JP 2003513884T T, April 15th, 2003.
118. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, U.S. Patent Application No. 10,263,083 filed October 2nd, 2002. Publication No. US 2003/0125345 A1, Publication Date July 3rd, 2003.
119. “Pharmaceutical Compositions and Methods for Effecting Dopamine Release”. By William
S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, and Patrick M. Lippiello, U.S. Patent No. 6,525,065, February 25th, 2003.
120. “Pharmaceutical Compositions and Methods for Use.” By Jeffrey D. Schmitt, Peter
A. Crooks, and Gary M. Dull, U.S. Patent Application, Publication No. US 2003/0045523 A1, Publication Date March 6th, 2003.
121. “Analgesics and Methods of Use.” By Richard Smith-Carliss, Frank S. Caruso, Peter
A. Crooks, Kenneth J. Keller, and Yingxian Xiao, International Patent No. WO 03018004 A2, Publication date March 6th, 2003.
122. “Opiate Agonist and Antagonist Duplex Prodrugs for Transdermal Delivery”. By
Peter A. Crooks, Mohamed O. Hamad, and Audra L. Stinchcomb, UK Disclosure No. 1183, Docket No. 50229-337, filed as a U.S. Provisional Patent Application, No. 60/489,183, July 23rd, 2003.
123. "Azatricyclo[3.3.1.1]decane Derivatives and Pharmaceutical Compositions
Containing Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks,
192
Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, European Patent No. EP 1068208 B1, May 14th, 2003.
124. “Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, U.S. Patent Application, Publication No. US 2003/0100547 A1, Publication date May 29th, 2003.
125. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents.” By
Peter A. Crooks, Xiachem Wei and Craig Jordan, filed as a Provisional U.S. Patent Application No. 60/486,171, July11th, 2003.
126. "Azatricyclo[3.3.1.1]decanderivate und Diese Enthaltende Pharmazeutische
Zubereitungen" By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Austrian Patent No. AT 24,0331T, May 15th, 2003.
127. "Thermal Vaporizing Device for Drug Delivery". By Peter A. Crooks, S. George
Kottayil, Ram Murty and David Riggs, International Patent Application No. WO 02056932 A3, August 7th, 2003.
128. "Thermal Vaporizing Device for Drug Delivery". By Peter A. Crooks, S. George
Kottayil, Ram Murty and David Riggs, International Patent Application No. WO 02056932 A9, May 1st, 2003.
129. “Pharmaceutical Compositions for Treating and/or Preventing CNS Disorders.” By
Peter A. Crooks, Gary M. Dull, William S. Caldwell, Balwinder S. Bhatti, Naranjan M. Deo, and Alain Ravard, U.S. Patent No. 6,624,173 B1, September 23rd, 2003.
130. “Azatrizyclische Verbindungen.” By Niranjan M. Deo and Peter A. Crooks,
Austrian Patent No. AT 248,839T, September 15th, 2003. 131. "Azatricyclic Compounds". By Peter A. Crooks and Niranjan M. Deo, European Patent
No. EP 1066287 B1, September 3rd, 2003. 132. "Compounds of Use in the Treatment of Epilepsy, Seizure and Electroconvulsive
Disorders.” By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, U.S. Patent Application No. US 2003/0,186,942, publication date October 2nd, 2003.
133. “Pharmaceutical Compositions and Methods for Use.” By Peter A. Crooks and
Naranjan M. Deo, German Patent No. DE 6,991,099D, October 10th, 2003. 134. "Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use In the
Treatment of CNS Pathologies." By Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Joshua Ayers, U.S. Patent Application No. US 2003/0225142A1, December 4th, 2003.
135. “Analgetic Pyrroline Derivatives”. By Richard Smith-Carliss, Frank S. Caruso, Peter
A. Crooks, Kenneth J. Keller, and Yingxian Xiao, Canadian Patent Application No. CA 2,458,015, filed March 3rd, 2003.
193
136. “bis-Pyridino-containing Compounds for Use in the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers, and Vladimir Grinevich, Provisional U.S. Patent Application No. 60/533,213, Decmber 31st, 2003.
137. “Derivados do Azatriciclo 3.3.1.1 Decano e Composicoes Farmaceuticas Contendo
os Mesmos.” By Peter A. Crooks, Haeil Park, and Gary M. Dull, Portuguese Patent No. PT 1,068,208T, September 30th, 2003.
138. “Analgesics and Methods of Use.” By Richard Smith-Carliss, Frank S. Caruso, Peter
A. Crooks, Kenneth J. Keller, and Yingxian Xiao, International Patent No. WO 03018004 A3, May 22nd, 2003.
139. “Aryl Substituted Olefinic Amines and their Uses as Cholinergic Receptor Antagonists”. By
Merouane Bencherif, Balwinder S. Bhatti, William S. Caldwell, Peter A. Crooks, Patrick Lipiello, Gary M. Dull, Jared M. Wagner, Srishailkumar B. Hadimani, and Haeil Park, Australian Patent Application No. AU 2003236404, August 21st, 2003.
140. “Pharmaceutical Compositions and Methods for Use.” By Peter A. Crooks and Naranjan
M. Deo, Danish Patent No. DK 1,066,287T, January 19th, 2004. 141. “2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine Receptor
Mediated Neurotransmitter Release, Uptake and Storage.” By Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P. Grinevich, Seth D. Norrholm, and Guangrong Zheng, U.S. Patent Application No. US 2004/0019081 A1, January 29th, 2004.
142. “2,6-disubstituted Piperidines as Modulators of Nicotinic Acetylcholine Receptor Mediated
Neurotransmitter Release, Uptake and Storage.” By Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P. Grinevich, Seth D. Norrholm, and Guangrong Zheng, U.S. Patent No. US 6,703,406, March 9th, 2004.
143. “Bioactive Peptide-based Probes.” By Clair L. Hicks and Peter A. Crooks (Docket No.
434-286, UKRF Disclosure No. 999), U.S. Patent Application No. 10/795,174, filed March 5th, 2004.
144. “Disubstituted Piperidine and Piperazine Compounds”. By Peter A. Crooks, Linda P.
Dwoskin, Guangrong Zheng, Marlon Jones, Dennis K. Miller, Seth Norrholm, and Sairam Krishnamurthy (Docket No. 64684-024), U.S. Patent Application, filed April 1st, 2004.
145. “2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine Receptor
Mediated Neurotransmitter Release, Uptake and Storage.” By Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P. Grinevich, Seth D. Norrholm, and Guangrong Zheng, U.S. Patent Application No. US 2004/0019081, January 29th, 2004.
146. “3-Pyridyl-1-Azabicycloalkan-Derivate Zur Behandlung Von ZNS-Erkrankungen.” By
Niranjan M. Deo, Alain Ravard, William S. Caldwell, Merouane Bencherif, Gary M. Dull, Peter A. Crooks, Patrick M. Lippiello, and Balwinder S. Bhatti, Austrian Patent No. AT 261443T, March 15th, 2004.
147. “Azatricyclo[3.3.1.1]decane Derivatives and Pharmaceutical Compositions
Containing Them." By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, and Gary M. Dull, Spanish Patent No. ES 2,199,561T, February 16th, 2004.
194
148. “Compostos Azatricilicos.” By Peter A. Crooks and Niranjan M. Deo, Portuguese Patent No. PT 1,066,287T, January 30th, 2004.
149. “Kombinierte Wirkstoffe als Methode Zur Gezieten Wirkstoffe-Freisetzung”. By Paul
Ashton, Peter A. Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Austrian Patent No. AT 267,798T, June 15th, 2004.
150. “Analgesic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter A.
Crooks and Miguel Rivera, International Patent No. WO 2004/045601, June 3rd, 2004.
151. “Pharmaceutical Compounds and Methods for Use”. By Peter A. Crooks and Naranjan M. Deo, Spanish Patent No. ES 2,205,778T, May 1st, 2004. 152. “Method for Treatment of Cancer”. By Peter A. Crooks and Robert Alonso, U.S.
Patent Application (Docket No. YAUP-3920), filed July 8th, 2004. 153. “3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders”. By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M. Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, Danish Patent No. DK 994,875, June 26th, 2004.
154. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents with
Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, U.S. Patent No. US 6,765,019 July 20th, 2004.
155. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A.
Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, German Patent No. DE 69,433,818D, July 1st, 2004.
156. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A.
Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, European Patent No. EP 0,740,650 B1, May 26th, 2004.
157. "Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists".
By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, European Patent No. EP 1,086,082 B1, August 18th, 2004.
158. “Pharmaceutical Compounds and Methods for Use”. By Peter A. Crooks and Naranjan M.
Deo, German Patent No. DE 69,910,993T, July 22nd, 2004. 159. “Analgetic Pyrroline Derivatives”. By Richard Smith-Carliss, Frank S. Caruso, Peter A.
Crooks, Kenneth J. Keller, and Yingxian Xiao, European Patent Application No. EP 1420781 A2, May 26th, 2004.
160. “3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders”. By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M. Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, German Patent No. DE 69,822,300D, May 15th, 2004.
161. “3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders”. By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M.
195
Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, European Patent No. EP 0994,875 B1, March 10th, 2004.
162. “Derivados De 3-Piridil-1-aza-biciclo-alcano Para A Prevencao E Tratamento De
Desordens Do SNC”. By By Alain Ravard, Balwinder S. Bhatti, Niranjan M. Deo, Patrick M. Lippiello, Peter A. Crooks, William S. Caldwell, Merouane Bencherif, and Gary M. Dull, Portuguese Patent No. PT 994875T, June 30th, 2004.
163. “Arylsubstituierte Olefinische Amine und Ihre Verwendung als Cholinergische
Rezeptoragonisten” By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti,
William S. Caldwell, and Haeil Park, Austrian Patent No. AT 273,956T, September 15th, 2004. 164. “Co-Farmacos Como um Metodo de Administracao Controlada de Farmacos”. By
Peter A. Crooks, Paul Ashton, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Portuguese Patent No. PT 740650T, October 10th, 2004.
165. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents.” By Peter A. Crooks, Xiachem Wei and Craig Jordan, U.S. Patent Application No. 10/888,274, July 9th, 2004. 166. "Codrugs as a Method of Controlled Drug Delivery". By Paul Ashton, Peter A.
Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Danish Patent No. DK 740650T, September 27th, 2004.
167. “Analgesic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter A.
Crooks and Miguel Rivera, Australian Patent No. AU 2003,291,037, June 15th, 2004.
168. “Analgesic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter A. Crooks
and Miguel Rivera, Canadian Patent No. CA 2,506,615, June 3rd, 2004. 169. “Azatricyclo[3.3.1.1]decanderivate und diese Enthaltende Pharmazeutische Zubereitungen“. By Merouane Bencherif, Patrick M. Lippiello, Peter A. Crooks, Haeil Park, Balwinder S. Bhatti, William S. Caldwell, Gary M. Dull, German Patent No. DE 69907894T2, November 3rd, 2004. 170. “3-Pyridyl-1-Aza-Bicyclo-Alkane Derivatives for Prevention and Treatment of CNS
Disorders”. By Gary M. Dull, Patrick M. Lippiello, Merouane Bencherif, Balwinder S. Bhatti, William S. Caldwell, and Peter A. Crooks, Spanish Patent No. ES 2,214,707T, September 16th, 2004.
171. “2,6-Disubstituted Piperidines and Piperazine Compounds”. By Peter A. Crooks,
Linda P. Dwoskin, Marlon D. Jones, Dennis K. Miller, Seth D. Norholm, Guangrong Zheng, and Sairam Krishamurthy, U.S. Patent Application No. 10/813,647, March 31st, 2004.
172. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents
with Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, U.S. Patent No. US 2004/0214784, October 28th, 2004.
173. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park,
196
Jared M. Wagner, and Peter A. Crooks, U.S. Patent No. US 2004/0214835, October 28th, 2004.
174. “Arylsubstituerede Olefiiske Aminer og deres Anvendelse som Cholinerge
Receptoragonister”. By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, Danish Patent No. DK 1,086,082T, November 22nd, 2004.
175. “Analgesic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter
A. Crooks and Miguel Rivera, U.S. Patent No. US2004/0248964 A1, December 9th, 2004.
176. “Compounds of Use in the Treatment of Epilepsy, Seizer, and Electroconvulsive
Disorders”. By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, U.S. Patent No. US2004/0266737, December 30th, 2004.
177. “2, 6-Disubstituted Piperidines and Piperazine Compounds”. By Peter A. Crooks,
Linda P. Dwoskin, Guangrong Zheng, Dennis K. Miller, Seth D. Norholm, Krishnan Sairam, and Marlon D. Jones, U.S. Patent No. US2004/0266824, December 30th, 2004.
178. “bis-Pyridino-containing Compounds for Use in the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers, and Vladimir Grinevich, U.S. Patent Application No. 11/027, 675, January 3rd, 2005.
179. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, International Patent No.
WO2005007103, January 27th, 2005. 180. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter
A. Crooks, Craig T. Jordan, and Xiaochen Wei, U.S. Patent Application No. US 2005/0032886, February 10th, 2005.
181. “Novel Oral Bioavailable prodrugs”. By Peter A. Crooks, Mohamed O. Hamad, and
Audra L. Stinchcomb, International Patent No. WO 2005/009377 A2, February 3rd, 2005.
182. “2,6-Disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, and Marlon D. Jones, U.S. European Patent No. EP1513513, March 16th, 2005.
183. “Scopolamine Sublingual Spray for the Treatment of Motion Sickness”. By Peter A.
Crooks, Abeer M. Al Ghananeem, and Ahmad Malkawi, U.S. Patent Application, No. US60/656,359 filed February 25th, 2005.
184. “Lofexidine Enantiomers for Use as a Treatment for CNS Diseases and
Pathologies”. By George A. Digenis, Peter A. Crooks, and Abeer M. Al Ghananeem, U.S. Patent Application No. US60/661,525, filed March 14th, 2005.
185. “Sublingual Oxycodone for Acute Pain Management”. By Peter A. Crooks, Abeer M. Al
Ghananeem, and Ahmad Malkawi, U.S. Patent Application No. 60/666,060, filed March 29st, 2005.
197
186. “Use of 3-Aryl/Heteroaryl-2-thiophene-3-yl-acrylonitriles as Anticancer Agents”. By Peter A. Crooks and Vijayakumar Sonar, U.S. Patent Application, submitted to the University of Kentucky Intellectual Propertied Committee, Case No. 1338, March 22nd, 2005.
187. “Use of Substituted N’-(1H-Indol-3-ylmethylene)-N-alkyl-N-phenylhydrazines as
Anticancer Agents”. By Peter A. Crooks and Vijayakumar Sonar, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1339, March 23rd, 2005.
188. “Use of N’-Indol-3-ylmethylene)- and N-alkyl-N’-benzo[b]thiophen-3-ylmethylene-N-
phenylhydrazines as Antitubercular Agents”. By Peter A. Crooks and Vijayakumar Sonar, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1342, March 25th, 2005.
189. “Use of 3-(2-Nitrovinyl)- and 3-(2-Nitropropenyl)indoles as Anticancer Agents”. By
Peter A. Crooks and Vijayakumar Sonar, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, March 29th, 2005.
190. “Codrugs as a Method of Controlled Drug Delivery”. By Paul Ashton, Peter A.
Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, Danish Patent No. DK 740650T, September 27th, 2004. Spanish Patent No. ES 2,222,455T, February 1st, 2005.
191. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, and Peter A. Crooks, U.S. Patent No. US 2005/0131034, June 16th, 2005.
192. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif, U.S. Patent No. US 2005/0148611, July 7th, 2005.
193. “Novel Oral Bioavailable Prodrugs”. By Peter A. Crooks, Mohamed O. Hamad, and
Audra L. Stinchcomb, U.S. Patent No. US 2005/0154002, July 14th, 2005. 194. “bis-Pyridino-containing Compounds for Use in the Treatment of CNS Pathologies”. By
Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers, Vladimir Grinevich, and Sangeetha P. Sumithran, International Patent No. WO 2005/066129 A2, July 27th, 2005.
195. “Analgesic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter
A. Crooks and Miguel Rivera, European Patent No. EP 1567145, August 31st, 2005.
196. “Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant Abuse and
Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies." By Linda P. Dwoskin, Peter A. Crooks, and Marlon D. Jones, U.S. Patent No. US 6,943,177, September 13th, 2005.
197. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Use Thereof”. Peter
A. Crooks, and Robert Alonso, U.S. Patent Application, Docket No. YAUPON-4248US1, December, 2005.
198
198. “Use of Parthenolide Derivatives as AntiLeukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, Continuation in Part of U.S. Patent Application No. US 2005/0032886 (February 10th, 2005), Docket No. 75812.010200, Serial No. 11/31,315, January 7th, 2005.
199. ”R(+)- and S(-)-Nornicotine for the Treatment of Pain”. By Joseph R. Holtman,
Peter A. Crooks, and Linda P. Dwoskin, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1377. November 17th, 2005.
200. “Synergistic Enhancement of Opiod Analgesia by Combination with S(-)-Nornicotine
or R(+)-Nornicotine”. By Joseph R. Holtman, and Peter A. Crooks, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1379. November 17th, 2005.
201. “Synergistic Enhancement of Opioid Analgesia and Attenuation of Opiod Tolerance
and dependence by Combination with Racemic, S-(-)- and R(+)-Norketamine”. By Joseph R. Holtman, and Peter A. Crooks, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1380. November 17th, 2005.
202. “Nicotine Sublingual Spray for Smoking Cessation”. By Peter A. Crooks, Abeer M.
Al Ghananeem, and Ahmad Malkawi, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, November 17th, 2005.
203. “Analgesics and methods of Use”. By Richard Smith-Carliss, Frank S. Caruso,
PeterA. Crooks, Kenneth J. Keller, and Yingxian Xiao, People’s Republic of China Patent Application No. CN 1,612,732, May 4th, 2005.
204. “Substituted Arylidenamino Guanidines for Use as Selective NMDA Receptor
Inhibitory Modulators”. By Peter A. Crooks, John L. Littleton, Joshua R. Ring, and Sundar Neelakantan, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, November 5th, 2005, Case No. 1374, filed as a U.S. Provisional patent, 2005.
205. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary
M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif, U.S. Patent No. US 6,958,399, October 25th, 2005.
206. “bis-Pyridino-containing Compounds for the Use in the Treatment of CNS Pathologies”.
By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers, Vladimir Grinevich, and Sangeetha P. Sumithran, U.S. Patent Application No. US2005/0261334 A1, November 24th, 2005.
207. “Synergistic Enhancement of Opioid Analgesia and Attenuation of Opioid Tolerance and
Dependence by Combination with Racemic (+/-) Norketamine, S(-)-Norketamine and R(+)-Norketamine”. By Joseph R. Holtman and Peter A. Crooks, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1380.November 17th, 2005,
208. “Novel Synergistic Opioid-Cannabinoid Codrug Combinations for Pain Management.” By
Joseph R. Holtman and Peter A. Crooks, U.S. Patent Application, submitted to the
199
University of Kentucky Intellectual Properties Committee, Case No. 1392, December 8th, 2005.
209. “Novel tris-Quaternary Ammonium Salts that Interact with Neuronal Nicotinic Receptors”.
By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, Sangeetha Sumithran, U.S. Patent Application, US 60/753,970, December 12th, 2005.
210. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary
M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif, U.S. Patent No. US 6,979,695 B2, December 27th, 2005.
211. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, Australian Patent Application No. AU 2004257696, January 27th, 2005.
212. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, Canadian Patent Application No. CA 2,532,229, January 27th, 2005.
213. “Derivados de Azatriciclo[3.3.1.1]decano y Composiciones Farmaceuticas que los
Contienen" By Peter A. Crooks, Mexican Patent No. MX PA 00009634 A, June 20th, 2005.
214. “Co-Pharmaka als ein verfarhane des Kontrollierten Arzneimittel Transportes“. By Paul
Ashton, Peter A. Crooks, Robert M. Riggs, Tadeusz Cynkowski, Grazyna Cynkowska, and Hong Guo, German Patent No. DE 69433818T2, June 16th, 2005
215. “Arylsubstituierte Olefinische Amine und ihre Verwendung als Cholinergische
Rezeptoragonisten“. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, German Patent No. DE 69919537T2, August 9th, 2005.
216. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, International Patent Application No. WO 2005/007103 A2, January 27th, 2005.
217. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell,
Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, U.S. Patent Application No. US 2005/0282846 A1, December 22nd, 2005.
218. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, U.S. Patent Application No. US2005-0272716 A1, December 8th, 2005.
219. “R(+)- and S(-)-Nornicotine for the treatment of Pain”. By Joseph R. Holtman, Peter A.
Crooks, Linda P. Dwoskin, and Elzbieta P. Wala, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, November 17th, 2005, Case No. 1377 filed as a U.S. Provisional Patent No. US 60/859,488, November 17th, 2006 .
220. “Synergistic Enhancement of Opioid Analgesia Combination with S(-)- and R(+)-
Nornicotine”. By Joseph R. Holtman and Peter A. Crooks, U.S. Patent Application,
200
submitted to the University of Kentucky Intellectual Properties Committee, November 17th, 2005, Case No. 1379 filed as a U.S. Provisional Patent No. US 60/xxx,xxx, December 11th, 2006.
221. “bis-Quaternary Ammonium Compounds that Interact with Neuronal Nicotinic Receptors”.
By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, and Sangeetha Sumithran, UK Case No. 1401; U.S. Patent Application, US 60/758,622, January 13th, 2006.
222. “Method for Treatment of Cancer”. By Peter A. Crooks and Robert Alonso, U.S.
Patent Application No. US2006/0009468, January 12th, 2006. 223. “mono-Quaternary Ammonium Compounds that Interact with Neuronal Nicotinic
Receptors”. By Peter A. Crooks, Guangrong Zheng, Zhenfa Zhang, Linda P. Dwoskin, and Sangeetha Sumithran, U.S. Patent Application, US 60/814,423, July 14th, 2006.
224. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, European Patent Application No. EP 4,777,849.3-2123, February 2nd, 2006.
225. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, European Patent Application No. EP 1643984, April 4th, 2006.
226. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By
Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, Canadian Patent No. CA2600468, September 9th, 2006.
227. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, and Peter A. Crooks, U.S. Patent No. 7,045,538, May 16th, 2006. 228. “Enhancing Transdermal Delivery of Opioid Antagonists and Antagonists Using Codrugs
Linked to Bupropion or Hydroxybupropion” Peter A. Crooks, Audra L. Stinchcomb, Mohamed O. Hamad, and Paul K. Kiptoo, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, Case No. 1426 (docket no. 1028750-000274), May 25th, 2006.
229. “bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Receptors” By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa
Zhang, Sangeetha Sumithran, David D. Allen, and Paul Lockman, UK Case No. 1429, U.S. Provisional Patent Application, US 60/799811, May 12th, 2006.
230. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park,
Jared M. Wagner, and Peter A. Crooks, Canadian Patent Application No. CA 2,501,335, April 4th, 2006.
231. "Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use in the Treatment of CNS Pathologies." By Peter A. Crooks, Linda P. Dwoskin, Rui Xu, and Joshua T. Ayers, U.S. Patent No. US 7,091,357 B2, August 15th, 2006. 232. “Scopolamine Sublingual Spray for the treatment of Motion Sickness.” By Peter A.
Crooks, Abeer Al-Ghananeem, and Ahmad H. Malkawi, U.S. Patent Apllication No.
201
US2006/0193784 A1, August 31st, 2006. 233. “Scopolamine Sublingual Spray for the treatment of Motion Sickness.” By Peter A. Crooks, Abeer Al-Ghananeem, and Ahmad H. Malkawi, International Patent Application No. WO 2006/093786, September 8th, 2006. 234. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof.” By Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, U.S. Patent Application No. US2006/0205694 A1, September 14th, 2006. 235. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof.” By Peter A. Crooks, Stuart R. Lessin, Mark A. Pimley, Robert Alonso and Abeer Al- Ghananeem, International Patent Application No. WO 2006/099385A3, September 21st, 2006. 236. “Novel Synergistic Opioid-Cannabinoid Codrug for Pain Management.” By Joseph R. Holtman and Peter A. Crooks (Docket No. 13177N/060236), U.S. Patent Application No. US60,828,960, October 10th, 2006. 237. “Lofexidine Enantiomers for Use as a Treatment for CNS Diseases and
Pathologies”. By George A. Digenis, Peter A. Crooks, and Abeer M. Al Ghananeem, U.S. Patent Application No. 11,376,710, filed March 14th, 2006.
238. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, Korean Patent Application No. KR 1020060037340, May 3rd, 2006. 239. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, and Peter A. Crooks, U.S. Patent Application No. US 2006/0264445 A1, November 23rd,
2006. 240. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, and Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif, U.S. Patent Application No. US 2006/0293289 A1, December 28th, 2006. 241. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof.” By Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, Australian Patent Application No. AU2006223076 September 21st, 2006. 242. “Sublingual Spray for the Treatment of Pain.” By Peter A. Crooks, Abeer Al-Ghananeem, and Ahmad H. Malkawi, International Patent No. WO 2006/105205, October 5th, 2006.
243. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park,
Jared M. Wagner, and Peter A. Crooks, U.S. Patent No. 7,060,826, June 13th, 2006.
244. “bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Zhenfa Zhang, Linda P. Dwoskin, Sangeetha Sumithran, and Marharyta Pivavarchyk, UK Case No. 1439; U.S. Provisional Patent Application 60/814640, May 31, 2007.
202
245. “Use of Substituted (Z)/(E)-2-(1H-Indole-3-ylmethylene)azabicyclo[2.2.2]octane-3- ones and Related Compounds as Radiosensitization Agents”. By Peter A. Crooks, Vijayakumar N. R. Sonar, Michael L. Freeman, Sekhar R. Konjeti, and Joseph L. Roti Roti, U.S. Patent Application, submitted to the University of Kentucky Intellectual Properties Committee, November 17th, 2005, Case No. 1475, filed as a U.S. provisional patent No. US60/879,895, January 11th, 2007.
246. “Use of Substituted (Z)- and (E)-2-(1-Benzyl-1H-indol-3-yl)azabicyclo[2.2.2]octan-3-ols and Related Compounds as Radio-sensitizing Agents with Synergystic Antiangiogenic Properties.” By Peter A. Crooks, Vijayakumar N. R. Sonar, Michael L. Freeman, Sekhar R. Konjeti, and Joseph L. Roti Roti, U.S. Patent Application, submitted to the University of Kentucky, Intellectual Properties Committee, September 5th, 2006, Case no. 1458, filed as a U.S. provisional patent No. US60/878,735, January 5th, 2007. 247. “tetrakis-Quaternary Ammonium Compounds that Interact with Neuronal Nicotinic Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zheng, Zhenfa, Marharyta Pivavarchyk, submitted to the University of Kentucky Intellectual Properties Office, Case No. 1494, April, 2007, filed as a US Provisional Patent No. 61/001,196. October 31, 2007. 248. “bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic
Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, and Sangeetha Sumithran, UK Case No. 1401; filed as a U.S. Utility Patent Application January 12th, 2007.
249. “bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Zhenfa Zhang, Linda P. Dwoskin, Sangeetha Sumithran, and Marharyta Pivavarchyk, UK Case No. 1439; filed as a U.S. Utility Patent Application May 31, 2007. 250. “bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha Sumithran, David D. Allen, and Paul Lockman, UK Case No. 1429, Filed as a U.S. Utility Patent Application, May 12th, 2007.
251. “Permeable, Water Soluble, Non-Irritating Prodrugs of Chemotherapeutic Agents with Alkanoic Acids”. By Peter A. Crooks, Tadeusz Cynkowski, Grazyna Cynkowska, Hong Guo, and Paul Ashton, U.S. Patent No. US 7,214,710, May 8th, 2007. 252. “Synergistic Combinations of Norketamine and Opiate Analgesics”. By Joseph R. Holtman and Peter A. Crooks, U.S. Patent Application No. US 11/558,782, November
10th, 2007. 253. “Compounds of Use in the Treatment of Epilepsy, Seizure and Electroconvulsant Disorders”. By Peter A. Crooks, Aimee K. Bence, and David R. Worthen, U.S. Patent No. 7,226,949, June 5th, 2007. 254. “Method for Enantioselectively Forming R-(+)-Nornicotine or S-(-)-Nornicotine”. By Marhaba Hojahmat, Xiaochen Wei and Peter A. Crooks, Docket No. Yaup-1960, Filed as a U.S. Provisional Patent, May, 2007. 255. “Synergistic Combinations of Norketamine and Opioid Analgesics”. By Joseph R. Holtman and Peter A. Crooks, International Patent No. WO 2007/059445 A2, May 24th, 2007.
203
256. “Analgesics and Methods of Use”. By Richard Smith-Carliss, Frank S. Caruso, Peter A. Crooks, Kenneth J. Kellar, and Yingxian Xiao, U.S. Patent Application No. US 2007/0129434 A1, June 7th, 2007.
257. “tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, and Sangeetha Sumithran, International Patent No. WO 2007/076112 A2, July 5th, 2007. 258. “Analgetic Pyrroline Derivatives”. By Yingxian Xiao, Peter A. Crooks, Richard Smith-Carliss,
Kenneth J. Kellar, Frank S. Caruso, Australian Patent Application No. AU 2002326806 B, July 19th, 2007.
259. “bis-Quaternary Ammonium Salts and methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, and Sangeetha Sumithran, International Patent No. WO 2007/094912, August 23rd, 2007. 260. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, US Patent Application No. 11/908,531, September 13th, 2007. 261. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, European Patent Application No. EP06738150.9-1211, October 19th, 2007. 262. “Novel Synergystic Opioid-Cannabinnoid Codrugs for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Harpreet Dhooper, US Patent Application No. US 11/973,818, October 10th, 2007. 263. “bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha Sumithran, David D. Allen, and Paul Lockman, UK Case No. 1429, International Patent No. WO 2007/133614, November 22nd, 2007. 264. “Opioid-Norketamine Codrug Combinations for Pain Management”. By Joseph R. Holtman and Peter A. Crooks, UK Case No.1555, U.S. Provisional Patent Application No. 61/072090, March 27th, 2008. 265. “Opioid-Nornicotine Codrug Combinations for Pain Management”. By Joseph R. Holtman and Peter A. Crooks, UK Case No.1554, U.S. Provisional Patent Application No. 61/072091, March 27th, 2008. 266. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, and Abeer M. Al Ghananeem, European Patent No. EP1858864, November 28th, 2007. 267. “Use of Lobeline Diastereomers in the Treatment of Central nervous System Diseases, Pathologies, and Drug Abuse”. By Peter A. Crooks, Linda P. Dwoskin, and David R. Worthen, U.S. Provisional Application No. 60/985,189, November 2nd, 2007. 268. “Substituted Arylidenamino Guanidines for Use as Selective NMDA Receptor Inhibitory Modulators”. By Peter A. Crooks, John L. Littleton, Joshua R. Ring, and Sundar Neelakantan, U.S. Patent Application No. 60/884,365, January 10th, 2007.
204
269. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Peter A. Crooks, Mark A. Pimley and Robert Alonso, European Patent No. EP1858864A2, November 28th, 2007. 270. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, U.S. Patent No. US 7,307,092, December 11th, 2007. 271. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.
Crooks, Craig T. Jordan, and Xiaochen Wei, U.S. Patent No. US 7,312,242, December 25th, 2007. 272. “Extraction and Quantitation of Parthenolide from Tanacetum parthenium (Feverfew Plant), Followed by Direct Derivitization to the Antitumor Drug, LC-1”. By Peter A. Crooks and Sundar Neelakantan, U.S. Patent Application, submitted to the University of Kentucky, Intellectual Properties Committee, UK Case No. 1552, December 13th, 2007. 273. “mono-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acertylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, angeetha Sumithran, and Zhenfa Zhang, International Patent No. WO 2007/149392, December 27th, 2007. 274. “Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zhenfa, Zheng Guangrong Zheng, Sangetha and Marharyta Pivavarchyk, International Patent No. WO 2007/149163, December 27th, 2007. 275. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin and Abeer M. Al Ghananeem, Korean Patent No. KR 2007/0120163, December 21st, 2007. 276. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Same”. By Robert Alonso, Peter A. Crooks, Barry M. Walker, and David R. Worthen, Docket No. Yaupon 2010, Continuation-in-part, Provisional US Patent Application 61/039,840, March 27th, 2008. 277. “Novel Synergistic Opiod-Cannabinnoid Codrug for Pain Management”. By Joseph R. Holtman and Peter A. Crooks, International Patent No. WO2008/045556, April 17th, 2008. 278. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Peter A. Crooks, Mark A. Pimley and Robert Alonso, European Patent No. EP1858864A4, April 30th, 2008. 279. “2,6-Disubstituted Piperidines and Piperazine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Dennis K. Miller, Seth D. Norholm, Krishnan Sairam, and Marlon D. Jones, U.S. Patent No. 7,368,443, May 6th, 2008. 280. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By
Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Stuart R. Lessin, Chinese Patent No. CN 101175735, May 7th, 2008.
205
281. “Nornicotine for the Treatment of Pain”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and Elzbieta P. Wala, International Patent No. WO 2008/063556, May 29th, 2008. 282. “Synergistic Combinations of Norketamine and Opiod Analgesics”. By Joseph R. Holtman and Peter A. Crooks, US Patent Application No. 2008/0132531 A1, June 5th, 2008. 283. “Synergisitic Effects of Combinations of Nornicotine and Opioids for Treatment of Pain”. By Joseph R. Holtman and Peter A. Crooks, International Patent No. WO 2008/073381, June 19th, 2008. 284. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, and Peter A. Crooks, US Patent Application 2008/0139809, June 12th, 2008. 285. “Synergistic Combinations of Norketamine and Opioid Analgesics”. By Joseph R. Holtman and Peter A. Crooks, Australian Patent Application No. AU 2006/315201, May 24th, 2007. 286. “bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, and Sangeetha Sumithran, U.S. Patent Application No. US 12/160,713, July 11th, 2008. 287. “tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, and Sangeetha Sumithran, U.S.Patent Application No. 12,158,192, June 19th, 2008. 288. “Novel Synergistic Opioid-Cannabinnoid Codrug for Pain Management”. By Joseph R. Holtman, Peter A. Crooks and Dhooper Harpreet, U.S. Patent Application Patent No. US2008/0176885, July 24th, 2008. 289. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Threof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin and Abeer M. Al Ghananeem, U.S. Patent Application No. US2008/0194699, August 14th, 2008. 290. “Analgetic Uses of Norketamine and Ketamine/Norketamine Prodrugs”. By Peter A. Crooks and Miguel Rivera, New Zealand Patent Application No. NZ5440282, June 30th, 2008. 291. “Synergistic Combinations of Norketamine and Opioid Analgesics”. By Joseph R. Holtman and Peter A. Crooks, Canadian Patent Application No. CA 2629347, May 24th, 2007. 292. “Synergistic Combinations of Norketamine and Opioid Analgesics”. By Joseph R. Holtman and Peter A. Crooks, European Patent Application No. EP 1962589, September 3rd, 2008. 293. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, and Peter A. Crooks, US Patent Application 2008/0214628 A1, September 4th, 2008. 294. “Use of Substituted 5-((N-Benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-
triones and (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and Related
206
Compounds as Radiation Sensitizing Agents with Synergistic Anti-Angiogenic Properties”. By Peter A. Crooks, Thirapathi R.Y. Reddy, Narisimha R. Penthala, Michael L. Freeman and Raja S. Konjeti, Docket No. PAC-0001, US Provisional Patent Application No. 61/194,754, filed September 30th, 2008.
295. “Method for the Enantioselective Synthesis of (+)- and (-)-2-[1-(2,6-Dichlorophenoxy)- ethyl]-1,3-diazacyclopent-2-ene”. By Peter A. Crooks and Ashish P. Vartak, Docket No. PAC-0002, US Provisional Patent Application No. 61/195,309, filed October 6th, 2008. 296. “Pyrrolidine Based Analogs for the Inhibition of Dopamine Uptake by the Vesicular Monoamine Transporter 2 (VMAT2) Protein”. By Peter A. Crooks, Ashish P. Vartak,
Jaturaporn Chagkutip, Agripina G. Deaciuc, and Linda P. Dwoskin, Docket No. PAC 0003, US Provisional Patent Application No. 61/xxx,xxx, filed October 6th, 2008.
297. “Unsaturated Thiadiazolidinone Derivatives as Antileukemic Agents”. By Peter A. Crooks, Shama Nasim, Monica Guzman and Craig T. Jordan, Docket No. PAC 0004, US
Provisional Patent Application No. 61/195,554, filed October 8th, 2008. 298. “Use of tris-Quaternary Ammonium Salts as Pain Modulating Agents”. Peter A. Crooks, Joseph R. Holtman, Linda P. Dwoskin, and J. Michael McIntosh, Docket No. PAC 0005, US Provisional Patent Application No. 61/195,824, filed October 10th, 2008. 299. “Differential Inhibition of Acetylcholine-evoked Responses of Neuronal Nicotinic Receptors in Rat Brain Slices by Selective nAChR Antagonists”. By Gretchen Y. López, Jeffrey S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, and Roger L. Papke, Docket No. PAC 0006, US Provisional Patent Application No. 61/195,820, filed October 10th, 2008. 300. “tetrakis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zheng, Zhenfa, Marharyta Pivavarchyk, US Patent Application No. US 12/260,502, filed October 29th, 2008. 301. “Aryl Substituted Olefinic Amines and Their Use As Cholinergic Receptor Agonists". By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner,
Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, Japanese Patent No. JP 2008/255122 A, October 30th, 2008.
302. “Process Development for the Synthesis of Bupropion Hydrochloride and Hydroxybupropion via Efficient Bromination using N-Bromosuccinimide”. By Peter A. Crooks, Thirapathi R.Y. Reddy, Narisimha R. Penthala, Nikhil R. Madadi, and Rajitha Bavanthula, Docket No.
PAC 0007, US Provisional Patent Application No. 61/198,802, filed November 10th, 2008. 303. “bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng,
Sangeetha Sumithran, David D. Allen, Zhenfa Zheng, and Paul Lockman, US Patent Application No. US 12/300,197, filed November 20th, 2008.
304. “bis-Pyridino Containing Compounds for the Use in the Treatment of CNS Pathologies”. By
Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, and Sangeetha Sumithran, US Patent Application No. 2008/0287490, November 20th, 2008.
305. “Use of tetrakis-Quaternary Ammonium Salts as Pain Modulating Agents”. By Peter A.
207
Crooks, Joseph R. Holtman, Linda P. Dwoskin, and J. Michael McIntosh, Docket No. PAC 0008, US Provisional Patent Application No. 61/200,969, filed December 5th, 2008.
306. “bis-Tertiary Amines and Methods for Modulating Neuronal Nicotinic Acetylcholine
Receptors”. By Peter A. Crooks, Ph.D., Linda P. Dwoskin, Zhenfa Zhang, Marharyta Pivavarchyk, and Andrew Smith, Docket No. PAC 0010, US Provisional Patent Application No. 61/212,162, filed December, 2008.
307. “bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, and Sangeetha Sumithran, U.S. Patent Application No. US 12/304,948, December 15th, 2008. 308. “mono-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, and Zhenfa Zhang, U.S. Patent Application No. US 12/304955, December 15th, 2008. 309. “tris- and tetrakis-Tertiary Amines and Methods for Modulating Neuronal Nicotinic
Acetylcholine Receptors”. By Peter A. Crooks, Ph.D., Linda P. Dwoskin, Zhenfa Zhang, and Marharyta Pivavarchyk, Docket No. PAC 0011, US Provisional Patent Application No. 61/212,187, filed April 8th, 2009.
310. “Lofexidine Enantiomers for Use as a Treatment for CNS Diseases and
Pathologies and its Chiral Synthesis”. By George A. Digenis, Peter A. Crooks, and Abeer M. Al Ghananeem, U.S. Patent Application No. US 2008/319041 A1, December 25th, 2008.
311. “Aryl-substituted Olefinic Amines and Aryl-substituted Olefinic Amines Cholinergic Receptor Agonists". By Patrick M. Lippiello, Merouane Bencherif, Peter A. Crooks, Jared M. Wagner, Srishailkumar B. Hadimani, Gary M. Dull, Balwinder S. Bhatti, William S. Caldwell, and Haeil Park, Japanese Patent No. JP 2008/260774 A, October 30th, 2008. 312. “Enhancing Transdermal Delivery of Opioid Antagonists and Agonists Using Codrug Links to Bupropion or Hydroxybupropion”. By Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, and Paul Kiptoo, US Patent Application No. 2009/0017102, January 15th, 2009. 313. “Synthesis and Hydrolysis Studies of a (-)-Cytisine-Naltrexone Carbamate Codrug for Transdermal Drug Delivery”. By Peter A. Crooks, Joshua Eldridge, and Audra Stinchcomb, UK Intellectual Properties Committee, UK Case No. 1643, February 10th, 2009. 314. “Analgesic Uses of Norketamine and Ketamine/norketamine Prodrugs”. By Peter A. Crooks and Miguel L. Rivera, European Patent No. EP 2027854 A1, February 25th, 2009. 315. “N-2,3-Dihydroxypropyl Analogs of nor-Lobelane and Related Compounds for the Treatment of Psychostimulant Abuse and Withdrawal, Eating Disorders, and Central Nervous System Diseases and Pathologies”. Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Ashish P. Vartak, and David B. Horton, Docket No. PAC-0012, US Provisional Patent Application No., 61,268,472, filed June 12th, 2009. 316. “An Economical Synthesis of Fluridone”, Peter A. Crooks, Ashish P. Vartak, and L. Jeffry
208
Lawrence. Docket No. Profix-001, US Provisional Patent Application No. 61/215,057, filed May 1st, 2009. 317. “Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases,
Pathologies, and Drug Abuse”. Peter A. Crooks and Linda P. Dwoskin, US Patent Application No. US2009/118331 A, May 7th, 2009.
318. “Sublingual Spray for the Treatment of Pain”. Peter A. Crooks, Abeer Al-Ghananeem, and Ahmad Malkawi, US Patent Application No. US2009/117054 A1, May 7th, 2009. 319. “Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases,
Pathologies, and Drug Abuse”. Peter A. Crooks and Linda P. Dwoskin, International Patent No. WO2009/059,260A, May 7th, 2009.
320. “Nornicotine for the Treatment of Pain”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and Elzbieta P. Wala, US Patent Application No. 12/515,152, May 15th, 2009. 321. “tetrakis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zheng, Zhenfa, Marharyta Pivavarchyk, US Patent Application No. US 2009/143424, June 4th, 2009. 322. “Analgetische Verwendung von (S)-Norketamin”. By Peter A. Crooks and Miguel Rivera, Austrian Patent No. AT432697, June 15th, 2009. 323. “Synergistic Effects of Combinations of Nornicotine and Opioids for Treatment of Pain”. By Joseph R. Holtman, and Peter A. Crooks, US Patent Application No. 12/518,562, June 10th, 2009. 324. “1-[3’-(trifluoromethyl)phenyl]-3-phenyl propanone”. By Ashish P. Vartak, Jeffry Lawrence and Peter A. Crooks Docket No. Profix-002, US Provisional Patent Application No. 61/xxx.xxx, filed June 30th, 2009. 325. “Analgesic Uses of (S)-Norketamine”. By Peter A. Crooks and Miguel L. Rivera, European Patent No. EP 1567145 B1, June 6th, 2009. 326. “Opioid-nornicotine Codrugs for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, International Patent No. WO2009/121018, October 1st, 2009. 327. “Analgesic Uses of (S)-Norketamine”. By Peter A. Crooks and Miguel L. Rivera, Hong Kong Patent No. HK 1079461, August 14th, 2009. 328. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, International Patent No. WO 2009/120493, October 1st, 2009. 329. “Indole Compounds and Their Use as Radiation Sensitizing Agents and Chemotherapeutic Agents”. By Peter A. Crooks, Thirupathi R. YerramReddy, Narsimha R. Reddy, Michael L. Freeman and Narsimha R. Penthala, Michael L. Freeman, and Sekhar R. Konjeti, US Patent Application No. US 12/571,425, September 30th, 2009. 330. “Enantioselective Synthesis of (+)- and (-)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diaza- cyclopent-2-ene”. By Peter A. Crooks and Ashish P. Vartak, US Patent Application No.
209
US 12/574,578, filed October 6th, 2009. 331. “Use of Tris-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, US Patent Application No. US 12/576,300, October 9th, 2009. 332. “bis-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, US Provisional Patent Application No. 61/xxx.xxx, filed October 15th, 2009. 333. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, Mark Pimley, Stuart Lessin, and Peter A. Crooks, US Patent Application No. 12/549,258, August 27th, 2009. 334. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent Application No. US20090247645, October 1st, 2009. 335. “Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, International Patent Application No. WO 2009/131794 A1, October 29th, 2009. 336. “Indole Compounds and Their Use as Radiation Sensitizing Agents and Chemotherapeutic Agents”. By Peter A. Crooks, Therapathi R. Yerramreddy, Narshima R. Penthala, Michael L. Freeman, and Sekhar R. Konjeti, US Patent Application No. 12/571,425, September 30th, 2009. 337. “Use of Tetrakis-Quaternary Ammonium Salts as Pain Modulating Agents”. Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin and J. Michael McIntosh, US Patent Application No. US12,632,339, December 7th, 2009. 338. “Aryl Substituted Olefinic Amines and Their Use as Cholinergic Receptor Antagonists”. By Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Balwinder S. Bhatti, Peter A. Crooks, Patrick M. Lippiello, Gary M. Dull, William S. Caldwell, and Merouane Bencherif, Canadian Patent No. CA 2677519, December 23rd, 1999. 339. “Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, and Sangeetha Sumithran, US Patent Application N0. US 2009/0318503 A1, December 24th, 2009.
340. “Lofexidine Enantiomers for use as a Treatment for CNS Desease and Pathologies and its Chiral Synthesis” George A. Digenis, Peter A. Crooks, Abeer Alghananeem, and Ahmad Malkawi, International Patent Application, WO 2010016844, February 11th, 2010.
341. “Stabilized Compositions of Alkylating Agents and Methods of Using the Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent Application No. US 2010/0029783 A9, February 4th, 2010. 342. “Stabilized Compositions of Alkylating Agents and Methods of Using Therof”. By Robert Alonso. Peter A. Crooks, US Patent Application No. US2010/041767 A1, February 18thm 2010. 343. “Synergistic Effects of Combinations of Nornicotine and Opioids for Treatment of Pain”. By Joseph R. Holtman and Peter A. Crooks, US Patent Application No. US 2010/048605,
210
February 25th, 2010. 344. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan and Xiaochen Wei, U.S. Patent No. US 7,678,904, March 16th, 2010. 345. “Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha Sumithran, and Marharyta Pivavarchyk, US Patent Application No. US 2010/069432 A1, March 18th, 2010. 346. “Indole Compounds and Their Use as Radiation Sensitizing Agents and Chemo- therapeutic Agents”. By Peter A. Crooks, Therapathi R. Yerramreddy, Narshima R. Penthala, Michael L. Freeman, and Sekhar R. Konjeti, US Patent Application No. 2010/081678 A1, April 1st, 2010. 347. “Enantiomeric Synthesis of (+) and (-)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diazacyclo-
pent-2-ene”, By Peter A. Crooks and Ashish P. Vartak, US Patent Application No. US2010/087657 A1, April 8th, 2010.
348. “mono-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acertylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, and Zhenfa Zhang, U.S. Patent Application No. US 2010/113511 A1, May 6th, 2010. 349. “Use of Tris-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, US patent Application No. US2010/120857, May 13th, 2010. 350. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, U.S. Patent Application No. US2010/1211061 A1, May 13th, 2010. 351. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alsonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, David R. Worthen, US Patent Application No. US2010/152300 A1, June 17th, 2010. 352. “bis-Pyridino Containing Compounds for the Use in the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, and Sangeetha Sumithran, U.S. Patent Application No. US2010/152237 A1, June 17th, 2010. 353. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, Peter A. Crooks, U.S. Patent Application No. US2010/1160390 A1, June 24th, 2010. 354. “Use of Tetrakis-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, US Patent Application No. US2010/173937 A1, July 8th, 2010. 355. “Use of a Novel Alpha-7 nAChR Antagonist to Supress Pathogenic Signal Transduction in Cancer and Aids”. By Roger L. Papke, Peter A. Crooks, Linda P. Dwoskin, Hernandez G. Lopez, Zhenfa Zhang, Jeffrey S. Thinschmidt, and Guangrong Zheng, US Patent Application
211
No. US2010/179186 A1, July 16th, 2010. 356. “Bioactive Peptide-based Probes”. By Clair L. Hicks and Peter A. Crooks, US Patent No. 7,759,468, July 20th, 2010. 357. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan and Xiachen Wei, US Patent Application No. US2010/184745 A1, July 22nd, 2010. 358. “Oral Bioavailable Prodrugs”. By Peter A. Crooks, Hamad Mohamed, and Audra L. Stinchcomb, US Patent No. US 7,759,358, July 20th, 2010. 359. “Compounds Capable of Activating Cholinergic Receptors”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Hael Park, Jared M. Wagner, and Peter A. Crooks, U.S. Patent Application No. US2010/204481 A1, August 12th, 2010. 360. “Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse”. Peter A. Crooks and Linda P. Dwoskin, European Patent No. EP 2217236 A1, August 18th, 2010. 361. “Use of Tetrakis-Quaternary Ammonium Salts as Pain Modulating Agents”. Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin and J. Michael McIntosh, US Patent Application No. US2010/0173937 A1, July 8th, 2010. 362. “Herbal Compositions of Lupanine, Lupeol and 13-S-HODE for the Treatment of Atopic Dermatitis, Keratosis Pilaris, Acne, Mild Burns and Related Skin Conditions”. By Mikail D. Antoun, Robert A. Newman, Ilia I. Oquendo, and Peter A. Crooks, US Patent Application No. 61/401,645, August 17th, 2010. 363. “Nornicotine for the Treatment of Pain”. By Joseph R. Holtman, Jr., Peter A. Crooks, and Linda P. Dwoskin, US Patent Application No. 2010/216847 A1, August 26th, 2010. 364. “Bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, David D. Allen, Zhenfa Zhang, and Paul Lockman, US Patent Application No. US 2010/222377 A1, September 2nd, 2010. 365. “Compounds Capable of Activating Cholinergic Receptors”. William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner and Peter A. Crooks, US Patent Application No. US 2010/222395 A1, September 2nd, 2010. 366. “Compounds Capable of Activating Cholinergic Receptors”. William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner and Peter A. Crooks, US Patent No. US 7,790,757 B2, September 7nd, 2010. 367. “Aryl-substituted Olefinic Amines and Use of Aryl-substituted Olefinic Amines as Cholinergic Receptor Agonists”. By William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, and Merouane Bencherif, Japanese Patent Application No. JP 2010229149 (A), October 10th, 2010. 368. “Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders”. By Peter A. Crooks, Aimee K. Bence, and David R.
212
Worthen, US Patent No. US 7,816,407, October 19th, 2010. 369. “Use of Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents”. Peter A.Crooks, Craig T. Jordan, ShanShan Pei, and Shama Nasim, Provisional US Patent Application No. 61/405,978, October 20th, 2010. 370. “Stabilized Compositions of Volatile Alkylating Agents and metods of Using Therof”. By Robert Alonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, and David R. Worthen, US Patent Application No. 12/948,593, November 17th, 2010. 371. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, and Abeer M. Al-Ghananeem, US Patent No. US 7,838,564, November 23rd, 2010. 372. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Therof”. By Robert Alonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, Stuart R. Lessin, and David R. Worthen, New Zealand Patent No. NZ561268A, December 24th, 2010. 373. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Therof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent No. 7,872,050 B2, January 18th, 2011. 374. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, European Patent No. EP2273876 A2, January 19th, 2011. 375. “Lofexidine Enantiomers for use as a Treatment for CNS Desease and Pathologies and
its Chiral Synthesis” George A. Digenis, Peter A. Crooks, Abeer Alghananeem, and Ahmad Malkawi, US Patent Application No. US20110015246, January 20th, 2011.
376. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Therof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent Application No. US
2011/0065803 A1, March 17th, 2011. 377. “Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, and Sangeetha Sumithran, U.S.Patent Application No. 20110105556, May 5th, 2011. 378. “Opioid-nornicotine Codrugs Combinations for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, US Patent Application No. 2011/0112130 A1, May 12th, 2011. 379. “Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, US Patent Application No. 2011/0112131 A1, May 12th, 2011. 380. “Lofexidine Enantiomers for use as a Treatment for CNS Desease and Pathologies and
its Chiral Synthesis” By George A. Digenis, Peter A. Crooks, Abeer Alghananeem, and Ahmad Malkawi, European Patent Application No. EP2334297 (A1), June 22nd, 2011.
381. “bis-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, US Patent Application No. 2011/0166177, July 7th, 2011.
213
382. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan and Xiachen Wei, European Patent No.1643984B1, July 6th, 2011. 383. “Verwendung von Parthenolid-derivaten als Antileukamische und Zytotoxische Mittel. By Peter A. Crooks, Craig Jordan, and Xiaochen Wei, Austrian Patent No. AT515262 (T), July 15th, 2011. 384. “Use of Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents”. Peter A.Crooks, Craig T. Jordan, ShanShan Pei, and Shama Nasim, US Patent Application No. 13/279,038, October 21st, 2011. 385. “Method for Using Parthenolide Derivative as Antileukemic and Cytotoxic Agent”. By Peter A. Crooks, Craig T. Jordan and Xiachen Wei, Japanese Patent No. 2011137036, July 14th, 2011. 386. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan and Xiachen Wei, Danish Patent No. DK1643984 (T3), October 24th, 2011. 387. “Enantiomeric Synthesis of (+) and (-)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diazacyclo-
pent-2-ene”, By Peter A. Crooks and Ashish P. Vartak, US Patent No. 8,101,779 January 24th, 2012.
388. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiachen Wei, US Patent No. 8,124,652, February 28th, 2012. 389. “Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha Sumithran, and Marharyta Pivavarchyk, US Patent No. 8,178,678, February 28th, 2012 390. “Methods for making Tocoflexols and Analogues Thereof”. By Guangrong Zheng, Cesar M. Compadre, Philip Breen, Martin Hauer-Jensen, and Peter A. Crooks, US Provisional Patent Application No. 61/650,021, UAMS Reference No. 2012-22, Filed March 13th, 2012. 391. “Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A.Crooks, Craig T. Jordan, ShanShan Pei, and Shama Nasim, US Patent Application No. US20120122943, May 17th, 2012. 392. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using the Thereof”. By Peter A. Crooks, and Stuart R. Lessin, Australian Patent No. AU2012202164(A1), May 3rd, 2012. 393. “Indole Compounds and Their Use as Radiation Sensitizing Agents and Chemotherapeutic Agents”. By Peter A. Crooks, Thirupathi R. YerramReddy, Narsimha R. Reddy, Michael L. Freeman and Narsimha R. Penthala, Michael L. Freeman, and Sekhar R. Konjeti, US Patent Application No. US 12/571,425; Notice of Allowance, July 2nd, 2012. 394. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent Application No. US20120165308 A1, June 28th, 2012.
214
395. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using the Thereof”. By Peter A. Crooks, Mark A. Pimley, and Robert Alonso, European Patent No. EP1,858,864, July 4th, 2012. 396. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using the Thereof”. By Peter A. Crooks, and Stuart R. Lessin, New Zealand Patent No. NZ589188, June 29th, 2012. 397. “tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, and Sangeetha Sumithran, US Patent Application 12/158,192 Notice of Allowance, June 26th, 2012. 398. “Radiation Sensitizing Methods and Agents”. By Michael L. Freeman, Sekhar R. Konjeti, and Peter A. Crooks, US Provisional Patent Application No. 61/708,482, October 1st, 2012. 399. “Compounds Capable of Activating Cholinergic Receptors”. William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner and Peter A. Crooks, US Patent No. US 8,288,420 B2, October 16th, 2012. 400. “Indole Compounds and Their Use as Radiation Sensitizing Agents and Chemotherapeutic Agents”. By Peter A. Crooks, Thirupathi R. YerramReddy, Narsimha R. Penthala, Michael L. Freeman, and Sekhar R. Konjeti, US Patent No. US 8,304,421, November 6th, 2012. 401. “Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Roger Papke, Guangrong Zheng, and Sangeetha P. Sumithran, US Patent No. US 8,299,253, October 30th, 2012. 402. “Methods and Compounds for Use in Treating Cancer and Inflammation”. By Peter A. Crooks and Narsimha R. Penthala, U.S. Provisional Application No. 61/746,884; UAMS Reference No. 2013-20; January 2nd, 2013. 403. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Peter A. Crooks and Narsimha R. Penthala, U.S. Provisional Application No. 61/748,242; UAMS Reference No. 2013-20 P2; January 2nd, 2013. 404. “tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P. Dwoskin, Roger Papke, and Sangeetha Sumithran, US Patent Application No. US20130030018 A1, January 31st, 2013. 405. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John P. Culver, Guangrong Zheng, and Justin R. Nickell, US Provisional Patent Application No. 61/793,281, Docket No. 104072.65440US, March 15th, 2013. 406. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using the Thereof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent Application No. 13/735,710, January 7th, 2013. 407. “Parthenolide Compounds and their Uses as Anticancer Modulators Utilizing Novel Xenopus Bioassays to Screen for Compounds that Modify Cell Cycle Progression”. By Narsimha Penthala, Peter A. Crooks, Angus MacNicol, and Janganati Venumadhav, U.S. Provisional Patent Application No. 61/814,020; UAMS Reference No. 2013-24 P2 (Web
215
ID #323). 408. “Amphibian Oocyte or Embryo Bioassay”. By Angus Macnicol, Narsimha R. Penthala, Peter A. Crooks, and Venumadhave Janganati. Provisional U.S. Patent Application No. 61/866,872, August, 16th, 2013. 409. “A Series of Combretastatin Heterocyclic Analogs as Anticancer Agents”. By Narsimha Penthala, Peter A. Crooks, Vijayakumar Sonar, U.S. Provisional Application No. 61/814,028; UAMS Reference No. 2013-25 P2 (Web ID #324). 410. “Identification of Substituted N-Alkyl and N-Aroyl-1H-indol-3-yl)methylene)-barbiturates or 2- Thiobarbiturates as DNA Polymerase Inhibitors Targeted Against DNA Repair and Replication Stress Response Enzymes”. By Narsimha Penthala, Peter A. Crooks, Robert Eoff, Grace Coggins, Leena Maddukuri, and Jessica Hartman, U.S. Provisional Application No. 61/815,063; UAMS Reference No. 2013-27 P2 (Web ID #326). 411. “Methods for Making Tocoflexols and Analogues Thereof”. By Philip Breen, Cesar Compadre, Peter A. Crooks, Martin Hauer-Jensen, and Guangrong Zheng, PCT Application No. PCT/US2013/030862, March 13th, 2013. 412. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, Abeer Al-Ghananeem, US Patent No. 8,450,375 B2, May 28th, 2013. 413. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent Application No. 13, 911,282, June 6th, 2013. 414. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent Application No. 13, 911,217, June 6th, 2013. 415. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent Application No. 13, 930,535, June 28th, 2013. 416. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent No. 8,470,875 B2, June 25th, 2013. 417. “Use of Dehydroleucodine and its Analogues as Antileukemic and Cytotoxic Agents”. By Cesar Compadre; Darin E. Jones and Peter A.Crooks, US Provisional Patent Application No. 61/845,214, July 11, 2013. 418. “Disease Modifying Treatments For Neurodegenerative or Metabolic Diseases”. By Robert
Alonso, Peter A. Crooks, and John G. Geisler, US Provisional Patent Application No. 61/859,829, July 30, 2013. 419. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent No. 8,501,817 B2, August 6th, 2013. 420. “Combretastatin Heterocyclic Analogs”. By Narsimha Reddy Penthala, Peter A. Crooks and
216
Vijayakuma Sonar, US Provisional Patent Application No. 61/868,878, August 16th, 2013. 421. “Nucleic Acid Polymerase Inhibitors and Methods Thereof”. By Grace Coggins, Peter A. Crooks, Robert Eoff, Jessica H. Hartman, , Leena Maddukuri, Narsimha R. Reddy, US Provisional Patent Application No. 61/868,879, August 22nd, 2013. 422. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimley, and David R. Worthen, US Patent No. 8,501,818 B2, August 6th, 2013. 423. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent No. 8,501,819 B2, August 6th, 2013. 424. “Identification of Substituted Arylideneaminoguanidine Compounds as Endonuclease Inhibitors”. By Narsimha R. Penthala, Jang Dae Song, Alexei Basnakian, and Peter A. Crooks, UAMS No. 2014-03 (Web ID #336), Provisional US Patent Submission, August 16th, 2013. 425. “Parthenolide Derivatives and their Modulation of Processes Controlled by Regulated Translation”. By Peter A. Crooks, Venumadhav Janganati, and Narsimha Reddy Penthala, US Provisional Patent Application No. 61/871,657, March 29th, 2013. 426. “Stabilized Compositions of Volatile Alkylating Agents and Methods for Using Thereof”. By Peter A. Crooks, Pimley, Mark A. and Robert Alsonso, Japanese Patent No. JP2013091643A, May 16th, 2013. 427. “Method of Treating Neuropathic Pain”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, J. Michael McIntosh, Elzbieta Pogonowska Wala, US Patent Application No. 14,019,709, September 6th, 2013. 428. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, European Patent No. EP2,273, 876A4, September 16th, 2013. 429. “Endonuclease Inhibitors and Methods of Using Thereof”. By Narsimha R. Penthala, Jang Dae Song, Alexei Basnakian, and Peter A. Crooks, UAMS No. 2014-02 (Web ID #335), Provisional US Patent Application No. 61/901,715, November 8th, 2013. 430. “Use of a Novel Alpha-7 nAChR Antagonist to Supress Pathogenic Signal Transduction in Cancer and Aids”. By Roger L. Papke, Peter A. Crooks, Linda P. Dwoskin, Hernandez G. Lopez, Zhenfa Zhang, Jeffrey S. Thinschmidt, and Guangrong Zheng, US Patent Application No. US2013/0231366 A1, September 5th, 2013. 431. “bis-Pyridino Containing Compounds for the Use in the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, and Sangeetha Sumithran, US Patent No. 8,546,415 B2, October 1st, 2013. 432. “Quinolyl Cyancombretastatin Analogs”. By Narsimha R. Penthala and Peter A. Crooks, UAMS No. 2014-14 (Web ID #349), US Provisional Patent Application No. 61/901,710, November 8th, 2013.
217
433. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Narsimha R. Penthala, Peter A. Crooks, UAMS No. 2014-12 (Web ID #346), US Provisional Patent Application No. 61/901,714, November 8th, 2013. 434. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent Application No. US20130288371 A1, October 31st, 2013. 435. “Inhibition of Viral Helicase Activity”. By Narsimha R. Penthal, Kevin Raney, and Peter A. Crooks, UAMS No. 2013-31, US Provisional Patent Application No. 61/901,708, November 8th, 2013. 436. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof”. By Robert Alonso, Peter A. Crooks, Mark A. Pimley, Abeer Al-Ghananeem, US Patent application No. US 2013/0310461 A1, November 21st, 2013. 437. “Methods for Making Tocoflexols and Analogues Thereof”. By Guangrong Zheng, Cesar M. Compadre, Philip Breen, Martin Hauer-Jensen, and Peter A. Crooks, PCT International Patent Application No. WO 2013/176745 A1, filed November 28th, 2013. 438. “Methods and Compounds for use in Treating Cancer and Inflammation”. By Peter A. Crooks and Narsimha Reddy Penthala, PCT Application No. PCT/US2013/077812, December 26th, 2013. 439. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, European Patent Application No. EP20130868363, December 26th, 2013. 440. “Methods of Treating Neuropathic Pain”. Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, J. Michael McIntosh, and Elzbieta P. Wala, US Patent Application No. US2014/0011836 A1, January 9th, 2014. 441. “tetrakis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zheng, Zhenfa, Marharyta Pivavarchyk, US Patent No. 8,629,163 B2, January 14th, 2014. 442. “Enhancing Transdermal Delivery of Opioid Antagonists and Agonists using Codrugs Linked to Bupropion or Hydroxybupropion”. By Audra Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, and Paul K. Kiptoo, US Patent No. 8,653271 B2, February 18th, 2014. 443. “Bis-quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, David D. Allen, Zhenfa Zhang, and Paul Lockman, US Patent No. 8,653275 B2, February 18th, 2014. 444. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Thereof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent No. 8,664,278 B2, March 4th, 2014. 445. “Combretastatin Analogues”. By Peter A. Crooks, Narsimha Reddy Penthala, and Vijayakumar Sonar, International Patent, PCT Application No. PCT/US2014/034185, March, 2014.
218
446. “4,5-Disubstituted-2H-1,2,3-triazoles as Anticancer Agents”. By Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks, Leena Maddukuri and Robert Eoff, US Provisional Patent Application No. 61/972,938, March 10th, 2014. 447. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John P. Culver, Guangrong Zheng, and Justin R. Nickell, US Patent Application No. 14,776,306, March 14th, 2014. 448. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John P. Culver, Guangrong Zheng, and Justin R. Nickell, International Patent, PCT Application No. PCT/US2014/028315 A1 March 14th, 2014. 449. “Bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, David Allen, Zhenfa Zhang, and Paul Lockman, US Patent Application No. US2014/0080859 A1, March 20th, 2014. 450. “Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By By Peter A. Crooks, Linda P. Dwoskin, Roger Papke, Guangrong Zheng, and Sangeetha Sumithran, US Patent Application No. US2014/0080866 A1, March 20th, 2014. 451. “Parthenolide Derivatives and their Modulation of Processes Controled by Regulated Translation”. By Peter A. Crooks, Venumadhav Janganati, and Narsimha Reddy Penthala, PCT Application No. PCT/US2014/034605, April 18th, 2014. 452. “Amphibian Oocyte or Embryo Bioassay”. By Peter A. Crooks, Venumadhav Janganati, Angus MacNicol, and Narsimha Reddy Penthala, PCT Application No. PCT/US2014/034604, April 18th, 2014. 453. “Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By By Peter A. Crooks, Linda P. Dwoskin, Roger Papke, Guangrong Zheng, and Sangeetha Sumithran, US Patent No. 8,703,803 B2, April 22nd, 2014. 454. “Polymerase, Endonuclease, and Helicase Inhibitors and Methods of Using Thereof”. By Suja Aarattuthodiyil, Alex Basnakian, Grace Coggins, Peter A. Crooks, Robert Eoff, Jessica H. Hartman, Dae Song Jang, Leena Maddukuri, Narsimha Reddy Penthala, and Kevin Raney, PCT Application No. PCT/US2014/035169, April 23rd, 2014. 455. “Opioid-nornicotine Codrugs Combinations for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, US Patent No. 8,710,069 B2, April 29th, 2014. 456. “Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management”. By Joseph R. Holtman, Peter A. Crooks, and Ujjwal Chakraborty, US Patent No. 8,710,070 B2, April 29th, 2014. 457. “Substituted Arylideneaminoguanidine Compounds”. By Narsimha Reddy Penthala, Dae Song Jang, Alexei G. Basnakian, and Peter A. Crooks, US Provisional Patent Application No. 61/983,703, April 24th, 2014.
219
458. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent No. 8,716,329 B2, May 6th, 2014. 459. “Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors, By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, and Zhenfa Zhang, US Patent Application No. 12,304,955, Notice of
Allowance, May 8th, 2014. 460. “Stabilized Compositions of Alkylating Agents and Methods of Using Same”. By Robert Alonso, Barry R. Walker, and Peter A. Crooks, US Patent Application No. US
2014/0142193 A1, May 22nd, 2014. 461. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Therof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimely, US Patent Application No. US
2014/0155491 A1, June 5th, 2014. 462. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Same”. By
Robert Alonso, Martin Stogniew, Peter A. Crooks, Mark A. Pimely, and David R. Worthen, US Patent Application No. US 2014/0187810 A1, July 3rd, 2014.
463. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, WIPO Patent Application No. WO/2014/105957A1, July 3rd, 2014. 464. “Stabilized Compositions of Volatile Alkylating Agents and Methods of Using Therof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimely, US Patent Application No. US
2014/0194526 A1, July 10th, 2014. 465. “Anticancer Activity of Melampomagnolide B Dimers”. By Venumadhav Janganati, Peter A. Crooks, Narshima R. Penthala and Craig Jordan, US Provisional Patent Application, UAMS No. 2015-05 (Web ID #394), September 5th, 2014. 466. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines and 1,3-disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John Culver, Justin R. Nickell, and Guangrong Zheng,WIPO International Patent Application No. WO 2014/144064 A2, September 18th, 2014. 467. “Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, and Zhenfa Zheng, US Patent No. 8,846,937 B2, September 30th, 2014. 468. “Parthenolide Derivatives and their Modulation of Processes Controlled by Regulated Translation”. By Peter A. Crooks, Venumadhav Janganati, Narsimha R. Penthala, WIPO International Patent Application No. WO 2014/172608 A2, October 23rd, 2014. 469. “Amphibian Oocyte or Embryo Bioassay”. By Angus Macnicol, Peter A. Crooks, Venumadhav Janganati, Narsimha R. Penthala, WIPO International Patent Application No. WO 2014/172607 A1, October 23rd, 2014. 470. “Combretastatin Analogs”. By Narsimha R. Penthala, Peter A. Crooks, Venumadhav Janganati, WIPO International Patent Application No. WO 2014/172363 A2, October 23rd,
220
2014. 471. “Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, ShanShan Pei, and Shama Nasim, US Patent No. 8,884,027. November 11th, 2014. 472. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Narsimha R. Penthala, Peter A. Crooks, and Craig T. Jordan, US Patent Application No: 14,537,389, November 10th, 2014. 473. “Polymerase, Endonuclease and Helicase Inhibitors and Methods of Using Thereof”. By Narsimha R. Reddy, Peter A. Crooks, Robert Eoff, Grace Coggins, Leena Maddukuri, Jessica H. Hartman, Dae Song Jang, Alexei Basnakian, Suja Aarattuthodiyil, and Kevin Raney, WIPO International Patent Application No. WO 2014/176351 A1, October 30th, 2014. 474. “Melampomagnolide-B Dimers”. By Venumadhav Janganati, Peter A. Crooks, Narsimha R. Penthala, Craig T. Jordan, and Jessica Ponder. US Provisional Patent No. 62/086,864, December 3rd, 2014. 475. “Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, and Zhenfa Zhang, US Patent Application (published) US 2014/0371266 A1, December 18th, 2014. 476. “Dehydroleucodine Derivatives and Uses Therof”. By Cesar Compadre, Paola Ordenez, Monica Guzman, Darin Jones, Omar Malagon, Giovanni Vidari, and Peter A. Crooks, WIPO Patent Apllication No. WO/2015/006715 A1, January 15th, 2015. 477. “Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors”. Peter A. Crooks, Linda P. Dwoskin, Roger Papke, Guangrong Zheng, Sangeetha Sumithran, US Patent No. 8,940,774 B2, January 27th, 2015. 478. “Methods for Making Tocoflexols and Analogues Thereof”. Guangrong Zheng, Cesar Compadre, Martin Hauer-Jensen, Peter A. Crooks, and Philip Breen, US Patent Application No. US 2015/0087033 A1, March 26th, 2015. 479. “Disubstituted Triazole Analogs”. By Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks, Leena Maddkuri, Robert Eoff, PCT Application No. PCT/US2015/026328, March 31st, 2014. 480. “Use of Parthenolide Derivatives as Antileukemic and Cytoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US patent Application No. 2015/0099731 A1, April 9th, 2015. 481. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Peter A. Crooks, Narsimha R. Penthala, Craig T. Jordan, and Jessica Ponder. US Patent Application No. 14,676,537, April 1st, 2015. 482. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Narsimha R. Penthala, Peter A. Crooks, and Craig T. Jordan, US Patent Application Pub. No: US 2015/0133444 A1, May 14th, 2015. 483. “Use of Parthenolide Derivatives as Antileukemic and Cytoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent No. 9,045490 B2, June 2nd, 2015.
221
484. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, U.S. Patent Application No. 14,651,113, June 30th, 2015; UAMS Reference No. 2013-20 US/NAT. 485. “Melampomagnolide B Derivatives”. By Shobanbabu Bommagani, Peter A. Crooks, Narsimha Reddy Penthala, Venumadhav Janganati, Craig T. Jordan, and Jessica Ponder, US Patent Application Pub. No: US 2015/0203508 A1, July 23rd, 2015. 486. “bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha Sumithran, David D. Allen, and Paul Lockman, US Patent Application No. 14,829,527, August 18th, 2015. 487. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines and 1,3-disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John Culver, Justin R. Nickell, and Guangrong Zheng,US Patent Application No. 14/776,306, September 14th, 2015. 488. “Use of Parthenolide Derivatives as Antileukemic and Cytoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US patent Application Publication No. 2015/029356 A1, September 17th, 2015. 489. “Combretastatin Analogs”. By Narshima R. Penthala, Peter A. Crooks and Vijayakumar Sonar, Mexican National Patent Application (2013-25MX) Based on PCT International Application No. PCT/US2014/034185, September 25th, 2015. 490. “Preparation of Disubstituted Triazole Derivatives as Anti-cancer Agents”. By Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks, Leena Maddukuri, and Robert Eoff, WIPO International Patent Application No. WO 2015/153635 A1, October 8th, 2015. 491. “Disubstituted Triazole Analogs”. By Nikhil R. Madadi, Narsimha R. Penthala, Peter A. Crooks, Leena Maddkuri, and Robert Eoff, WIPO Patent Application No.WO/2015/153635 A1, October 8th, 2015. 492. “Use of Tris-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, peter A. Crooks, Linda P. Dwoskin and J. Michael McIntosh, US Patent No. 9,155,733 B2, October 13th, 2015. 493. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, European Patent Application No. EP2938342A1, November 4th, 2015. 494. “Amphibian Oocyte or Embryo Bioassay”. By Angus Macnicol, Peter A. Crooks, Venumadhav Janganati, Narsimha R. Penthala, US Patent Application No. 14,785,196 A1, November 10th, 2015. 495. “Polymerase, Endonuclease and Helicase Inhibitors and Methods of Using Thereof”. By Narsimha R. Reddy, Peter A. Crooks, Robert Eoff, Grace Coggins, Leena Maddukuri, Jessica H. Hartman, Dae Song Jang, Alexei Basnakian, Suja Aarattuthodiyil, and Kevin Raney, US Patent Application No. 14,786,331 A1, November 10th, 2015. 496. “Parthenolide Derivatives and their Modulation of Processes Controlled by Regulated Translation”. By Peter A. Crooks, Venumadhav Janganati, Narsimha R. Penthala, US Patent
222
Application No. 14,785,183, November 10th, 2015. 497. “Combretastatin Analogs”. By Narsimha R. Penthala, Peter A. Crooks, Vijayakumar Sonar, US Patent Application No. 14,785,381 A1, November 10th, November 10th. 2015. 498. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, US Patent Application No. US 2015/0328216, December 26th, 2015. 499. “Bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, David Allen, Zhenfa Zhang, and Paul Lockman, US Patent Application Publication No. US 2015/0352088 A1, December 10th, 2015. 500. “Melampomagnolide B Dimers”. By Venumadhav Janganati, Peter A. Crooks, Narsimha Reddy Penthala, Craig T. Jordan, Shobanbabu Bommagani, and Jessica Ponder, PCT Application No. PCT/US2015/063792, December 3rd, 2015. 501. “Triazole Derivatives of Melampomagnolide B and Methods of Use Thereof”. By Venumadhav Janganati, Peter A. Crooks, Craig T. Jordan, and Jessica Ponder, Docket No. 052592- 510198 (UAMS No. 2016-14); Provisional US Patent Application No. 62,289,017, January 29th, 2016. 502. “Tetrazole Combretastatin Analogs and Methods of Use Thereof”. By Shobanbabu Bommagani, Narsimha R. Penthala, Nikhil R. Madadi, Monica L. Guzman and Peter A. Crooks, US Provisional Patent Application No. 62,262,114, December 2nd, 2015; Docket No. 052592-503563 (UAMS No. 2016-09). 503. “1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines and 1,3-Disubstituted Pyrrolidine Compounds”. By Peter A. Crooks, Linda P. Dwoskin, John Culver, Justin R. Nickell, and Guangrong Zheng, US Patent Application Publication No. 2016/0031840 A1, February 4th, 2016. 504. “Combretastatin Analogs”. By Narsimha R. Penthala, Peter A. Crooks, Venumadhav Janganati, European Patent Application No. EP 2,986,596 A2, February 24th, 2016. 505. “Polymerase, Endonuclease, and Helicase Inhibitors and Methods of Using Thereof”. By Narsimha R. Reddy, Peter A. Crooks, Robert Eoff, Grace Coggins, Leena Maddukuri, Jessica H. Hartman, Dae Song Jang, Alexei Basnakian, Suja Aarattuthodiyil, and Kevin Raney, European Patent Application No. EP 2,988,598 A1, March 2nd, 2016. 506. “DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, and/or Metabolic Disease”. By Peter A. Crooks, Narsimha R. Penthala, and Zaineb Albayati, US Provisional Patent Application No. 62/304,584, March 7th, 2016. 507. “Combretastatin Analogs”. By Narsimha R. Penthala, Peter A. Crooks, Vijayuakumar Sonar, US Patent Application Publication No. US2016/0068506 A1, March 10th, 2016. 508. “Amphibian Oocyte or Embryo Bioassay”. By Angus Macnicol, Narsimha R. Penthala, Peter A. Crooks, and Venumadhav Janganati, US Patent Application Publication No. US 2016/0077084 A1, March 17th, 2016. 509. “Polymerase, Endonuclease and Helicase Inhibitors and Methods of Using Thereof”. By Narsimha R. Reddy, Peter A. Crooks, Robert Eoff, Grace Coggins, Leena Maddukuri,
223
Jessica H. Hartman, Dae Song Jang, Alexei Basnakian, Suja Aarattuthodiyil, and Kevin Raney, US Patent Application Publication No. US20160075689 A1, March 17th, 2016. 510. “Parthenolide Derivatives and their Modulation of Processes Controlled by Regulated Translation”. By Narsimha R. Penthala, Peter A. Crooks, and Venumadhav Janganati, US Patent Application Publication No. US20160083397, March 24th, 2016. 511. “Methods for Making Tocoflexols and Analogues Thereof”. Guangrong Zheng, Cesar Compadre, Martin Hauer-Jensen, Peter A. Crooks, and Philip Breen, US Patent No. US 9,309,547 B2, April 12th, 2016. 512. “Vesicular Monoamine Transporter-2 Ligands and their Use in the Treatment of Psychostimulant Abuse”. By Peter A. Crooks, Guangrong Zheng, Justin R. Nickell and Linda P. Dwoskin, US Provisional Patent no. 62/325,875, April 21st, 2016. 513. “Dehydroleucodine Derivatives and Uses Thereof”. By Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidan, and Peter
A. Crooks, European Patent Application No. EP3019165 A1, May 18th, 2016. 514. “Melampomagnolide B Dimers”. By Venumadhav Janganati, Peter A. Crooks, Narsimha Reddy Penthala, Craig T. Jordan, Shobanbabu Bommagani, and Jessica Ponder, WIPO Patent Application No. WO/2016090166, June 9th, 2016. 515. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Peter A. Crooks, Narsimha R. Penthala, Craig T. Jordan, and Jessica Ponder. US Patent Application No. 14,676,537, Notice of Allowance, June 16th, 2016. 516. “Indole Compounds for Use in Treating Inflammation and Cancer”. By Narsimha R. Penthala and Peter A. Crooks, US Patent Application No. US 2015/0328216, December 26th, 2015. 517. “Dehydroleucodine Derivatives and Uses Thereof”. By Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, and Peter
A. Crooks, European Patent Application No. EP2938342A4, June 23rd, 2016. 518. “Stabilized Compositions of Volatile Alkylating Agents and Methods Therof”. By Robert Alonso, Peter A. Crooks, and Mark A. Pimley, US Patent No. 9,382,191 B2, July 5th, 2016. 519. “Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents”. By Peter A. Crooks, Craig T. Jordan, and Xiaochen Wei, US Patent No. 9,447,112 B2, September 20th, 2016. 520. “bis-Quaternary Ammonium Salts as Pain Modulating Agents”. By Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, and J. Michael McIntosh, Elzbieta Pogonowska Wala, US Patent Application No. 2016/0279119 A9, September 29th, 2016. 521. “Melampomagnolide B Derivatives”. By Venumadhav Janganati, Narsimha R. Penthala, Peter A. Crooks, and Craig T. Jordan, US patent No. US 9,469,650 B2, October 18th, 2016.
224
XIII Grant Activity and Research Su pport
1970-1974 "Semi-Rigid Heterocyclic Compounds with Potential Analgesic Activity", Imperial Chemical
Industries, Alderely Park, England, 1972-1975, $18,000 (approximate U.S. equivalent) (P.I. Peter
A. Crooks).
Pharmaceutical Society of Great Britain Award for Graduate Student Support for the Project -
"Synthesis and Pharmacological Profile within the CNS of Some Rigid and Semi-Rigid
Analogues of Phenylethylamines", 1972, $14,000 (approximate U.S. equivalent) (P.I. Peter A.
Crooks).
Pharmaceutical Society of Great Britain Award for Graduate Student Support for the Project -
"Synthesis of Novel Enkephalin Analogues", 1974, $15,000 (approximate U.S. equivalent) (P.I.
Peter A. Crooks).
Pharmaceutical Society of Great Britain Award for Graduate Student Support for the Project -
"Conformationally Defined Analogues of Dopamine, Tyramine and Phenylethylamine", 1974,
$15,000 (approximate U.S. equivalent) (P.I. Peter A. Crooks).
1975-1979 "Novel, Rigid Phenethylamine Analogues", Imperial Chemical Industries, Alderely Park, England,
1975-1976, $8,000 (approximate U.S. equivalent) (P.I. Peter A. Crooks). "Rigid Analogues of Dopamine", The Wellcome Foundation, United Kingdom, 1978-1979, $8,000
(approximate U.S. equivalent) (P.I. Peter A. Crooks). Science Research Council Award for Graduate Student Support for the Project - "Development
of Transition - State Analogue Inhibitors of DNA Adenine N6-Methyltransferase", 1979, $15,000
(approximate U.S. equivalent) (P.I. Peter A. Crooks).
"Synthesis of Novel Heterocycles from Ninhydrin", British Council - CNR (Italy), Academic Links
Scheme, 1979-80, $6,000 (approximate U.S. equivalent) (P.I. Peter A. Crooks).
1980-1984
Science Research Council Award for Graduate Student Support for the Project - "Synthesis of
Mechanism - Based Inhibitors of RNA Guanine 7-Methyltransferase", 1980, $15,000
(approximate U.S. equivalent) (P.I. Peter A. Crooks).
"Synthesis and Evaluation of Methyltransferase Inhibitors", Science Research Council,
1981-1982, $12,000 (approximate U.S. equivalent) (P.I. Peter A. Crooks).
"Role of Methylation in Nicotine Toxicity", Tobacco and Health Research Institute, 1982-1983,
$65,101 (P.I. Peter A. Crooks).
"The Role of Methylation in Nicotine Toxicity", Tobacco and Health Research Institute, June
1982-December 1985, $11,799 (P.I. Peter A. Crooks).
225
"Laboratory Equipment for Research", Biomedical Research Support Grant, 1982, $2,124 (P.I.
Peter A. Crooks) - funded.
"Role of Methylation in Nicotine Toxicity", (2nd year renewal) Tobacco and Health Research
Institute, 1983-1984, $59,677 (P.I. Peter A. Crooks).
"Alterations of Rat Trachea and Lung Polyamine Biosynthesis by Cigarette Smoke Components",
Tobacco and Health Research Institute, 1983-1984, $56,379 (P.I. J. Olson, Co-Investigator,
Peter A. Crooks).
"Synthesis and Evaluation of Multisubstrate Adducts as Selective Inhibitors of
Phenylethanolamine-N-methyltransferase", Isabell Kirscher Research Award, 1983-1984,
$5,000.00 (P.I. Peter A. Crooks).
"Development of Irreversible Inhibitors of Aminoalkyltransferases", University of Kentucky
Research Foundation Research Project Award, 1983-1984, $1,500 (P.I. Peter A. Crooks). "Role of Methylation in Nicotine Toxicity (3rd year renewal), Tobacco and Health Research
Institute, 1984-1985, $66,426 (P.I. Peter A. Crooks).
"Closed-System Metabolic Cages", Tobacco and Health Research Institute - Special Equipment
Award, 1984, $4,598 (P.I. Peter A. Crooks).
"A Campus Facility for the Packing of High-Pressure Liquid Chromatographic Columns", UKMC
Major Equipment Award, 1984, $3,017 (P.I. Peter A. Crooks).
"Metabolic Fate of Dichloroacetonitrile",University of Kentucky Medical Center Research Award,
1984-1985, $4,230 (P.I. Peter A. Crooks).
1985-1989
"An In Vivo Study of the Effect of Chronic Nicotine Administration on Tissue and Plasma Levels
of Histamine", Tobacco and Health Research Institute, 1985, $19,917 (P.I. Peter A. Crooks).
"Role of Methylation in Nicotine Toxicity - Potential Toxicity of N-Methylnicotinium Ion", Tobacco
and Health Research Institute, January 1986 - December 1986, $24,382 (P.I. Peter A. Crooks).
"Chromatographic Resolution of (± )-[14C-2']-Nicotine", R.J. Reynolds Tobacco Company, 1987-
1988, $14,748 (P.I. Peter A. Crooks).
"(± )-[14C-2']-Nicotine", R.J. Reynolds Tobacco Company, 1987, supplied as a gift (value
$33,780) (P.I. Peter A. Crooks).
"Nicotine Methylation Studies", Tobacco and Health Research Institute, January 1 to June 1987,
$11,748 (P.I., Peter A. Crooks).
"Super HPTLC System", University of Kentucky Bond Issue Equipment Proposal, 1987, $50,000
(P.I. Peter A. Crooks).
226
"Metabolism and Pharmacology of Triazoline Anticonvulsants", National Institutes of Health,
1987-1990, $170,493 (P.I. Pankaja K. Kadaba, Co-Investigator, Peter A. Crooks).
"Liquid Chromatography Flow-Through Optical Activity Detector", University of Kentucky Bond
Issue Equipment Proposal, 1987, $20,158 (P.I. Peter A. Crooks).
"Diode Array Flow-Through Rapid Spectrum Detector", University of Kentucky Bond Issue
Equipment Proposal, 1987, $18,900 (P.I., Peter A. Crooks).
"Gradient High Performance Liquid Chromatography System", University of Kentucky Bond Issue
Equipment Proposal, 1987, $10,222 (P.I. Peter A. Crooks).
"Research Personnel Support Grant", Tobacco and Health Research Institute, July, 1987, $1,500
(P.I. Peter A. Crooks).
"Development of New Antiviral Agents", Faculty Development Program Support, 1988, $4,500
1990-1994 "Practical Approaches to Enhancing the Stability of Aspartame in Aqueous Solutions", The Nutrasweet Company, 1990-1991, $50,625, (P.I. Anwar A. Hussain, Co-P.I. Peter A. Crooks). "Development of Novel Antisense Oligonucleotides", UKMC Major Equipment Research Fund, January 1990 to December 31, 1990, $19,352 (P.I. Peter A. Crooks, Co-Investigator, R.M. Riggs). "Synthesis of Glucuronide Conjugates of Nicotine, Cotinine and 3'-Hydroxycotinine", R.J.
Reynolds Tobacco Company, $25,080, 1990-1992 (P.I. Peter A. Crooks).
"Development of Antisense Oligonucleotides with Potential Chemotherapeutic Value in the
Treatment of AIDS", Biomedical Research Support Grant, NIH, $3,900, 1990-1991 (P.I. Peter A.
Crooks).
"Pharmaceutical Preparations for Addiction Treatment," National Institutes of Health, NIDA,
1991-1996, $1,936,422, (P.I. Rajinder Matharu, Co-P.I., Peter A. Crooks).
"CNS Pharmacology of Nicotine and Its Metabolites", Tobacco and Health Research Institute,
1991-1992, $54,000 (P.I. Linda Dwoskin, Co-P.I. Peter A. Crooks).
"Synthesis of Compounds as Therapeutic Agents in Alzheimer's Disease", R.J. Reynolds
Tobacco Company, 1992-1993, $83,000 (P.I. Peter A. Crooks).
227
"CNS Pharmacology of Nicotine and Its Metabolites", Tobacco and Health Research Institute,
1992-1993, $56,442, 2nd year renewal (P.I.s Linda Dwoskin, Peter A. Crooks).
"Nasal Absorption of Oxymetazoline, Azatadine Hydrochloride and Chlorpheniramine Maleate in
Rats Using In-Vivo In-Situ Technique", Schering-Plough Health Care Products, 4-1-92 to 10-1-
92, $44,000 (P.I's. Dr. Anwar Hussain, Dr. Peter A. Crooks).
"Synthesis of Compounds as Therapeutic Agents in Alzheimer's Disease", R.J. Reynolds
Tobacco Company, 1993-1994, $130,000, 2nd year renewal (P.I. Peter A. Crooks).
"Synthesis of Prodrugs for Ophthalmic Delivery", Control Delivery Systems, Inc., 1993-1994,
$71,520, (P.I. Peter A. Crooks, Co-P.I. Robert M. Riggs).
"Synthesis of dl-NAM and Related Amino Acid Nitrogen Mustards", NIH, National Institute on
Aging, 1993-1996, $50,000, for contract synthesis (P.I., Peter A. Crooks).
"CNS Pharmacology of Nicotine and its Metabolites", Tobacco and Health Research Institute,
1993-1994, $63,692, 3rd year renewal, (P.I.'s Linda Dwoskin, Peter A. Crooks).
"Synthesis of Prodrugs for Ophthalmic Delivery", Control Delivery Systems, Inc., 1994-1995,
$86,058, 2nd year renewal (P.I. Peter A. Crooks).
"Synthesis of Compounds as Therapeutic Agents in Alzheimer's Disease", R.J. Reynolds
Tobacco Company, 1994-1995, $130,000, 3rd year renewal (P.I. Peter A. Crooks).
"CNS Pharmacology of Nicotine and its Metabolites", Tobacco and Health Research Institute,
1994-1995, $71,639 (P.I.'s Linda Dwoskin and Peter A. Crooks), fourth year renewal.
"Enantioselective Synthesis of Nornicotine", UKMC Research fund, 1994-1995, $9,500 (P.I.
Peter A. Crooks).
1995-1999
"Synthesis of Prodrugs for Ophthalmic Delivery", Control Delivery Systems, Inc., 1995-1996,
$107,100, 3rd year renewal (P.I. Peter A. Crooks).
"Synthesis of Compounds as Therapeutic Agents in Alzheimer's Disease", R.J. Reynolds
Tobacco Company, 1995-1996, $131,000, 4th year renewal (P.I. Peter A. Crooks).
"CNS Pharmacology of Nicotine and its Metabolites", Tobacco and Health Research Institute,
$79,705, 7/01/95 to 6/30/96 (Co P.I.s Linda Dwoskin and Peter A. Crooks), fifth year renewal.
"Acylated Amino Acids and Peptides: Use as Antioxidants and Emulsifiers in Foods",
NRICGP/CSRS/USDA, $137,236.75, 9/15/95 to 9/30/96, (P.I. Clair L. Hicks, Co.P.I., Peter A.
Crooks).
"Synthesis of Prodrugs for Ophthalmic Delivery", Control Delivery Systems, Inc., 3/1/96 - 2/28/97,
$124,220, 4th year renewal (P.I. Peter A. Crooks).
228
"CNS Pharmacology of Nicotine and its Metabolites", Tobacco and Health Research Institute,
$83,466, 7/01/96 to 6/30/97 (Co P.I.'s Linda Dwoskin and Peter A. Crooks), sixth year renewal.
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity", Tobacco and Health
Research Institute, Collaborative In-House Project, $155,500, 7/1/96 - 6/30/97, P.I.ís Peter A.
Crooks, Abdulghani Houdi and John Littleton.
"Synthesis of Compounds as Therapeutic Agents in Alzheimer’s Disease," R.J. Reynolds
Tobacco Company, 1996-1997, $181,303, 5th year renewal (P.I.Peter A. Crooks).
"Nornicotine Contribution to the CNS Effect of Nicotine", National Institutes of Health, $421,000
4/01/97 to 3/30/00 (Co P.I.s Linda Dwoskin and Peter A. Crooks).
"Development of Selective Nicotinic Receptor Antagonists", National Institutes of Health,
$989,051, 12/1/97 to 11/30/01 (Co P.I.s Linda Dwoskin and Peter A. Crooks).
"Synthesis of Prodrugs for Ophthalmic Delivery", Control Delivery Systems, Inc., 3/01/97-
2/28/98, $144,900, 5th year renewal (P.I.Peter A. Crooks).
“CNS Pharmacology of Nicotine and its Metabolites", Tobacco and Health Research Institute,
$52,000, 7/01/97-6/30/98 (Co-P.I.s Linda Dwoskin and Peter A. Crooks), seventh year renewal.
"Synthesis of Compounds as Therapeutic Agents in Alzheimer’s Disease." R.J. Reynolds
Tobacco Company, 6/01/97 – 6/30/00, $195,000, (P.I. Peter A. Crooks).
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity." Tobacco and Health
Research Institute, Collaborative In-House Project, $175,000, 7/1/97 – 6/30/98 (P.I.s Peter A.
Crooks, Deane Falcone, and John Littleton), second year renewal.
"Synthesis of Prodrugs for Ophthalmic Delivery." Control Delivery Systems, Inc., 3/01/98 –
2/28/99, $152,680, 6th year renewal, (P.I. Peter A. Crooks).
"CNS Pharmacology of Tobacco Alkaloids." Tobacco and Health Research Institute, $93,792,
7/01/98 – 6/30/99 (CoP.I.s Linda Dwoskin and Peter A. Crooks), eighth year renewal.
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity." Tobacco and Health
Research Institute, Collaborative In-House Project, $163,985, 7/1/98 – 6/30/99 (P.I.s Peter A.
Crooks, Deane Falcone, and John Littleton), third year renewal.
"Research Training in Drug Abuse Behavior." NIDA T32 DA 07304-01, $782,836, 7/1/98-6/30/03
(P.I. Tim F. Garrity, P.G.F. Peter A. Crooks, 5% effort).
"Synthesis of Prodrugs for Ophthalmic Delivery.", Control Delivery Systems, Inc., 3/01/99 –
2/28/03, $172,179, 7th year renewal, (P.I. Peter A. Crooks).
"CNS Pharmacology of Tobacco Alkaloids.", Tobacco and Health Research Institute, $80,000,
7/01/99 – 6/30/00 (Co P.I.s Linda Dwoskin, Peter A. Crooks, Michael Bardo), ninth year renewal.
229
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity." Tobacco and Health
Research Institute, Collaborative In-House Project, $175,000, 7/1/99 – 6/30/00 (P.I.s Peter A.
Crooks, Deane Falcone, and John Littleton), fourth year renewal.
"Preparation of Analgesic Molecules." Endo Pharmaceuticals, Inc. $20,000, 3/01/99-9/30/99.
(P.I.Peter A. Crooks).
"Development of Nicotinic Receptor Antagonist Molecules." Layton Biosciences, Inc. $103,000,
10/1/99 - 9/30/01 (P.I. Peter A. Crooks, CoP.I. Linda Dwoskin).
"Development of Screens for Drugs in Alcohol Dependence." NIH RFA-AA-99-004 (In Vivo
Medication Development for Alcohol–Related Conditions) $2,709,686, 9/30/99-8/31/04 (P.I. J.
Littleton, Co P.I. Peter A. Crooks, 10% effort).
2000-2004
"Enhanced Glycolysis for Hypothermic Heart Preservation." NIH R01 $1,388,298, 7/1/00-6/30/05
(P.I. S. Chien, Co P.I. Peter A. Crooks, 5% effort).
"Development of Novel Therapies for Methamphetamine Abuse." NIDA RO1 $1,158,800,
7/15/00-6/14/04 (P.I. Linda P. Dwoskin, Co. P.I. Peter A. Crooks, 15% effort).
"Graduate Training in Environmental Toxicology" NIEHS $871,302, 7/1/00-6/30/05 (P.I. Mary
Vore, P.G.F. Peter A. Crooks, 5% effort).
"CNS Pharmacology of Tobacco Alkaloids.", Tobacco and Health Research Institute, $60,000,
7/01/00 – 6/30/01 (Co P.I.s Linda Dwoskin, Peter A. Crooks, Michael Bardo), tenth year renewal.
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity." Tobacco and Health
Research Institute, Collaborative In-House Project, $180,000, 7/1/00 – 6/30/01 (P.I.s Peter A.
Crooks, Deane Falcone, and John Littleton), fifth year renewal.
"Preparation of Analgesic Molecules." Endo Pharmaceuticals, Inc. $30,000, 8/01/00-9/30/01.
(P.I.Peter A. Crooks).
"Lobeline Analogs as a Potential Treatment for Drug Abuse." $36,120, 6/15/00-6/14/01, NIH
Predoctoral Fellowship awarded to Marlon D. Jones (1 F31 DA06061), sponsor: Peter A. Crooks.
"CNS Pharmacology of Lobelia inflata Alkaloids and Related Compounds.", Tobacco and Health
Research Institute, $50,345, 7/01/01 – 6/30/02 (Co P.I.s Linda Dwoskin, Peter A. Crooks,
Michael Bardo).
"Genetic Manipulation of Tobacco Plants to Produce Molecular Diversity." Tobacco and Health
Research Institute, Collaborative In-House Project, $191,153, 7/1/01 – 6/30/02 (P.I.s Peter A.
Crooks, Deane Falcone, and John Littleton), sixth year renewal.
"Novel Nicotine Analogs" Targacept, Inc., 2/01/02 – 1/31/03, $149,167, (P.I. Peter A. Crooks,
Audra Stinchcomb, Co. P.I. Peter A. Crooks, 10% effort).
"Transdermal Codrugs for Treatment of Alcohol Abuse ", NIH (NIAAA; RFA-AA-02-004, “New Approaches to Developing Pharmacotherapy for Alcoholism”), $1,149,167, 7/1/02 - 6/30/06 (P.I. Audra Stinchcomb, Co P.I. Peter A. Crooks, 10% effort).
"Development of Bioactive Probes Derived from Bacteriophage", KSEF, $15,000 annual diect
costs, 1/1/02 - 12/31/02 (P.I. Clair Hicks, Co P.I. Peter A. Crooks, 3.5% effort).
"Drug Development Research-Product Development and Formulation", Kentucky Science and
“Parthenolides as Potential Treatments for Lung Cancer”, KLCRP; $209,998, 1/1/04-1/31/07,
(P.I. Peter A. Crooks, 2% effort).
231
“Development of Screens for Drugs in Alcohol Abuse”, NIH-NIAAA; $1,886,380 direct costs,
5/1/04-4/30/08, (P.I. John M. Littleton, CoP.I. Peter A. Crooks, 10% effort).
“Training in Drug Abuse Related Research”, NIH/NIDA-K; $1,147,537, 6/1/04-5/31/09. (P.I. Louis
Hersh, P.G.F. Peter A. Crooks, 5% effort).
“Radiosensitization by the Cellular Heat Shock Response”, PPG NIH/NCI; $11,044,020, 7/1/04-
6/30/09, (Program Director, Joseph Roti-Roti) $352,061, 7/1/04-6/30/09, subcontract with the
University of Washington, (P.I. Peter A. Crooks, 2% effort).
“Polyamine Inhibition: a Target for Biodefense in Y. pestis” NIH/SERCEB, $230,000, 10/1/04-
2/28/06. (P.I. Marcos Oliviera, 5% effort).
2005-2009 “Molecular Mechanisms of Toxicity” NIEHS $917,110, 7/1/05-6/30/10 (P.I. Mary Vore, P.G.F.
Peter A. Crooks, 5% effort).
“Nornicotine as a Treatment for Nicotine Abuse”, STTR Phase 2/NIH/NIDA; $166,369, 11/1/05-
10/30/06. (P.I. Peter A. Crooks, 5% effort).
"Bone-Targeting and Bone Anabolic Compounds", KSTC, 1/1/05-12/31/06 (P.I. William M.
Pierce, CoP.I. Peter A. Crooks, subcontract, $79,200, 1.5% effort).
“Development of Novel Therapies for Methamphetamine Abuse”, NIH/NIDA; $3,101,858,
12/01/05-11/30/10 (P.I. Linda Dwoskin, Co P.I. Peter A. Crooks, 15% effort).
“Pharmacokinetic Studies”. NCI/Vanderbilt University (Subcontract), $31,330, 12/1/05-11/31/06;
(P.I. Peter A. Crooks, 1% effort).
“Naltrexone Prodrugs for Transdermal Delivery”, R01NIH/NIDA; $1,326,306, 7/1/05-30/6/11
(P.I. Audra Stinchcomb, Co P.I. Peter A. Crooks, 10% effort).
“Norketamine for Treatment of Pain” STTR Phase 2/NIH/NIDA, $1,151,689, 3/1/06-2/28/08.
(P.I. Joseph Holtman, CoP.I. Peter A. Crooks, 10% effort).
“Nornicotine Enantiomers for Treatment of Pain”, STTR Phase 1/NIH/NIDA, $216,583, 7/1/06-
6/30/07 (P.I. Joseph Holtman, CoP.I. Peter A. Crooks, 10% effort).
“Subtype-selective Drugs for Nicotinic Receptors from Kentucky Native Plants”, KTDRC
Program, $120,000, 7/1/06-6/30/08 (P.I. John Littleton, CoP.I. Peter A. Crooks, 2% effort).
“Lobeline Epimer Ratio Determination Study”, Yaupon Therapeutics, Inc., $16,406, 4/1/06 to
12/31/07 (P.I. Peter A. Crooks, 0.3% effort).
“Novel Bone Targetting Agents”, Pradama, Inc., $101,811, 7/31/06 to 5/22/08 (P.I. Peter A.
Crooks, 1% effort).
232
“Subtype-selective Drugs for Nicotinic Receptors from Kentucky Native Plants”, KTRDC, $130,000, 7/1/06 to 6/30/07 (CoP.I. Peter A. Crooks, 2% effort).
”LC-1: A Water-Soluble Parthenolide Analog from Tanacetum parthenium (Feverfew) as a Potent
Anti-tumor Agent”, UK Natural Product Alliance: Cross-Disciplinary Research program in Natural
Products, $43,655, 1/1/07-12/31/07 (P.I. Peter A. Crooks, 3% effort).
“API 2000TM LC/MS/MS System Coupled to a Shimadzu Binary HPLC System”, UK Major
Research Equipment Grant, $134,939, submitted 12/15/06 (P.I. Patrick McNamara; CoP.I. Peter
A. Crooks).
“Water-jacketed CO2 Incubator, Celliject Duo Electroporator, and Inverted Microscope”, UK Major
Research Equipment Grant, $22,101.40, submitted 12/15/06 (P.I. Linda Dwoskin; CoP.I. Peter A.
Crooks).
“A Novel Thiadiazolidine-dione Targets Human Leukemia Stem Cells”, The Leukemia and
Lymphoma Society, $599,780, 10/1/07-30/9/11 (P.I. Craig Jordan, University of Rochester; P.I.
Peter A. Crooks, sub-contract, University of Kentucky), total sub-contract costs: $249,140.
“Support Formulation Development and Clinical Manufacturing of API and Dosage Form”,
Leuchemix, Inc., $54,990, 5/06/07-10/31/07 (P.I. Peter A. Crooks).
“Nornicotine as a Treatment for Nicotine Abuse”, STTR Phase 2 (3rd year)/NIH/NIDA; $150,000,
6/1/08-12/31/08. (P.I. Peter A. Crooks, 15% effort).
“Development of Small Molecule Radiation Sensitizers”. R01/NIH/NCI subcontract, 12/01/09-
11/30/14, (P.I. Peter A. Crooks), $2,250,592 total direct costs, $638,831 total indirect costs;
subcontract $414,517 total direct costs, $201,041 total indirect costs (P.I. Peter A. Crooks, 5%
effort).
“Development of Novel Therapies for Methamphetamine Abuse”, NIH/NIDA Supplemental ARRA
Grant Program, $383,682.16, total direct $719,103.35, total direct and indirect $1,036,831.80,
12/01/09-11/30/11 (P.I. Linda Dwoskin, Co P.I. Peter A. Crooks, 10% effort).
2010-2015
“Alpha-7 Nicotinic Acetylcholine Receptor Antagonists as Novel Chemotherapeutic Agents for Treating Human Non-Small Cell Cancer”, Kentucky Lung Cancer Research Program, Cycle 10 Application, $300,000 (total direct and 10% indirect costs), 1/1/11 to 31/12/11 (P.I. Peter A. Crooks, 7% effort) funded.
“Novel Melampomagnolide B–based prodrugs for the Treatment of Leukemia”, R01/NIH/NCI,
$1,905,250 (total direct and indirect costs), $1,250,000 (total direct costs); 7/1/11 to 6/30/16 (PI
Peter A. Crooks, 15% effort), funded.
“Development of Novel Therapies for Methamphetamine Abuse” R01/NIH/NIDA, $3,158,238
(total direct and indirect costs), $2,126,761 (total direct costs); 7/1/12 to 6/30/17 (PI Linda
Dwoskin, Co.PI Peter A. Crooks, subcontract, 10% effort), funded.
233
“Oxidative Stress Mediates Differential Effects of Radiation-Induced Tissue Injury” R01/NIH/NCI,
$2,345,944 (total direct and indirect costs), $1,579,760 (total direct costs); 12/01/2011 to
11/30/2016 (PI Daret St Clair, Co. PI Peter A. Crooks, 10% effort), pending.
Arkansas Research Alliance Scholars Program, $666,666 direct costs, 7/1/11 to 6/30/15 (PI
Peter A. Crooks, 10% effort), funded.
“Cardiac Actions of Terminalia arjuna Bark”; R01 AT007015, Liu (PI), pending. Role: CoPI, $250,000 annual direct costs, $1,250,000 total direct costs, 0.6 calendar month effort. “Oxidative Stress Mediated Differential Effect of Radiation-induced Tissue Injury”; R01 CA (no grant # assigned yet), St Clair (PI). pending. Role: PI, UAMS Subcontract with University of Kentucky, $94,846 annual direct, total direct costs $474,230, 1.2 calendar months effort. “Mechanisms for Novel Anticancer Stem Cell Activity of A-Type Proanthocyanidines”; R01 CA (no grant # assigned yet), Guzman (PI). pending. Role: PI, UAMS Subcontract with Cornell University, $73,000 annual direct, $367,500 total direct costs, 1.2 calendar months effort.
CURRENT AND PENDING SUPPORT Current Support Title: Enhancing the Prevention and Treatment of Orthopaedic Infections Associated with Traumatic Injury Smeltzer (PI) Crooks (Co-I) 10% Supporting Agency: Department of Defense Contracting/Grants Officer: Performance Period: 10/1/2015-09/30/18 Level of Funding: $391,396 direct annual Overarching Goals: The focus in this proposal is on the development and optimization of two additional means of maximizing the efficacy of immediate, point-of-injury antibiotic therapy in the context of the prevention and treatment of post-traumatic osteomyelitis, both which could be used in the context of both systemic and local antibiotic therapy. Aim 1: Comprehensively evaluate and prioritize existing antibiotics in the specific context of biofilm-associated bone infection. Aim 2: Identify small molecule inhibitors of S. aureus biofilm formation and the pathogenesis and therapeutic recalcitrance of orthopaedic infections. Aim 3: Evaluate the therapeutic efficacy of our optimized delivery methods in the context of bone infection. Title: EPSCoR Proposal: RII Track-1: Arkansas ASSET Initiative III Borrelli (PD) Crooks (PI-Project) 10% effort Supporting Agency: Arkansas Science & Technology Authority/National Science Foundation Contracting/Grants Officer: Dr. Gail McClure (501) 683-4407 [email protected] Performance Period: 07/01/2015-06/30/2020 Level of Funding: $117,915 direct annual
234
Overarching Goals: CASE will use existing and proposed infrastructure to integrate research expertise and provide a platform for the following overarching goals: Goal 1. Advance Multifunctional, Tunable Surfaces Research: enable world class research at the frontiers of surface engineering and their applications, facilitate cross-campus and cross-discipline collaborations, and acquire needed infrastructure to fill current gaps; Goal 2. Diversify and Expand the Statewide STEM Workforce: build on the Arkansas Track-3 model to increase the number of underrepresented students transitioning to graduate school, and develop a sustainable STEM workforce by creating a pipeline of STEM-trained students, educators, and workers with skill sets necessary to sustain industries that can utilize CASE’s research; Goal 3. Enhance External Engagement and Industry Impact: use internships, an industry advisory board, social and published media outlets, and researcher/public interaction to strengthen ties with industry, external institutions, and the public and to increase the relevance of research to industry needs. Title: 4-Dinitrophenol (DNP) and DNP Prodrug Pharmacokinetic Studies in Rats and Prodrug Syntheses Crooks (PI) 1% effort Supporting Agency: Mitochon Pharmaceuticals Contracting/grants officer: Robert Alonso, CEO. 259 Radnor Chester Rd, Suite 210, Radnor, PA 19087, 215-313-3905 Performance Period: 4/1/2015-3/31/2016 Level of Funding: $35,926 direct annual Goals: Synthesis of a new prodrug of DNP and its structural characterization and in vivo bioavailability. Aim: 1. DNP and DNP produrg Pharmacokinetic Study to determine the in vivo pharmacokinetic profile of DNP and DNP prodrugs. Aim 2: To determine stability of DNP prodrug in the GI tract and susceptibility to enzymatic hydrolysis to the parent drug in plasma. Title: Novel Melampomagnolide B-based Prodrugs for the Treatment of Leukemia 5R01CA158275 Crooks (PI) 10% effort Supporting Agency: NIH/Nat Cancer Institute Contracting/Grants Officer: Jaime L. Montes, [email protected] Performance Period: 07/01/2011-06/30/2016 Level of Funding: $253,322 direct annual Goals: The long term objective of this proposal is to develop a novel class of anti-cancer agents structurally related to the naturally–occurring sesquiterpene parthenolide (PTL). This goal is based on the remarkable properties of PTL, which appears to function via a unique molecular mechanism, and has reported activity towards nearly every major form of cancer. Specific Aim 1: Synthesis of Novel Orally Bioavailable Melampomagnolide B Prodrugs. Specific Aim 2: Pharmacokinetic and Biological Efficacy studies. Specific Aim 3: Molecular and cellular characterization of melampomagnolide B. Title: Arkansas Research Alliance Scholars Award Crooks (PI)
235
10% effort Supporting Agency: Arkansas Research Alliance Contracting/Grants Officer: Jerry Adams, Pres/CEO, [email protected] Performance Period: 07/01/2011 – 06/30/2016 Level of Funding: $333,000 direct annual Goals/Aims: This award is for supporting basic research in the discovery of novel anticancer agents and pain-modulating treatments by recruiting Dr. Peter Crooks to lead a research team to discover and develop new drug entities to treat lymphomas, leukemias, and other cancers; to develop novel radio -sensitization agents to improve patient outcomes after radiation therapy; and to develop new pain - relieving drugs for use in cancer patients and patients with other types of acute and chronic pain. Title: Development of Novel Therapies for Methamphetamine Abuse U01 DA13519-10 Dwoskin (PI) Crooks (subaward PI) 10% effort Supporting Agency: NIH/Nat. Inst. on Drug Abuse Contracting/Grants Officer: Pamela Fleming 301-253-8729 Performance Period: 09/01/2000 – 08/31/2017 Level of Funding: $98,305 direct annual Goals: This project focuses on determining lobeline analog interaction with neurotransmitter transporters and nicotinic receptors, and effects on methamphetamine reward. Aim 1: Replace the two phenyl rings in GZ-793A with heterocyclic rings. Aim 2: Incorporate a polar moiety into the piperidine N-substituent of GZ-793A. Aim 3: Replace the piperidine ring in GZ-793A with a morpholine or a piperizine ring. Title: COBRE Center for Studies of Host Response to Cancer Therapy (Martin Hauer-Jensen, PD/PI, Peter Crooks, Mentor) 5% effort Supporting Agency: NIH/National Institute of General Medical Sciences Contracting/Grants Officer: Yankping Liu Email: [email protected] Performance Period: 12/01/2014 – 11/30/2019 Level of Funding: $2,131,279 Year 1; 5-year funding: $11,128,345 Goals: The objectives of the Center for Studies of Host Response to Cancer Therapy are to (1) help junior investigators with a common research focus on side effects of cancer treatment establish themselves as independent scientists and (2) form a self-sustaining center within the University of Arkansas for Medical Sciences (UAMS). Specific Aim 1: Provide an environment for young investigators to succeed as independent scientists. Specific Aim 2: Strengthen the overall research infrastructure at UAMS and the Cancer Institute. Specific Aim 3: Ensure that the Center for Studies of Host Response to Cancer Therapy becomes self-sustaining. Title: Early Events in Alzheimer Pathogenesis 2P01AG012411-17A1 Griffin (PI) Crooks (CORE 3 Director) 20% effort Supporting Agency: NIH/NIA Contracting/grants officer: Performance Period: 9/30/2016- 9/29/2021
236
Level of Funding: $209,274 direct annual Goals: The overall function of Core D is to act as a resource and provide support for individual investigators in Projects 1-3, in the area of drug discovery and early preclinical drug development of putative anti-inflammatory and anti-aggregation agents. Core D will act as a resource for all of the proposed research Projects. Aim 1: Design and synthesize novel molecular entities as anti-Alzheimer agents that have the ability to interact with the potential therapeutic targets emerging from Projects 1-3; Aim 2: Identify lead compounds resulting from initial structure-activity relationship studies generated from data obtained in the target assays developed in the various projects, and to afford more potent and selective analogs as potential clinical candidates; Aim 3: Synthesize subsequent quantities (scale-up) of the most promising second generation compounds for evaluation in subsequent in vitro and in vivo experiments; and Aim 4: Provide in silico ADMET information, and QSAR and molecular modeling to further inform synthesis and direction in the design of druglike clinical candidates. Pending Support Title: Targeted Nanodrugs Exploiting Co-drug Synergy against Primary and Metastatic Disease R01 Griffin and Crooks (PIs) 10% Effort Supporting Agency: NIH/NCI Contracting/Grants Officer: Sharon Gubanich Performance Period: 04/01/17 – 03/31/22 Level of Funding: $291,310 direct annual Goals: This research employs the concept of synergistic codrug loading, combined with a dual targeted nanorod approach to develop a clinically viable modality for cancer nanomedicine in controlling primary and metastatic myeloma or breast cancer lesions.
Aim 1: Determine in vitro activity of codrug loaded, dual targeted (TNF and galectin-1) nanorods. Aim 2: Determine targeting ability in vitro and in vivo of nanoformulated codrugs. Aim 3: Demonstrate primary tumor and antimetastatic effects of targeted nano-codrug therapy.
![Notes on the Dynamics of Disorder On the ... - Gavin E. Crooks · Jarzynski equality: Jarzynski (1997)[50]. Crooks fluc-tuation theorem: Crooks (1999)[75]. Hatano-Sasa fluctuation](https://static.documents.pub/doc/80x56/60770f743369d13f85533931/notes-on-the-dynamics-of-disorder-on-the-gavin-e-crooks-jarzynski-equality.jpg)
